0000950170-24-12872710-Q Akari Therapeutics Plc 20241119202411191648291648291648291

3100015411 57aktx:EquityIncentivePlan2014Member2024-09-300001541157us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001541157us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMembersrt:MaximumMember2023-07-012023-09-300001541157us-gaap:ConvertibleDebtMembersrt:MaximumMember2024-09-300001541157us-gaap:CommonStockMember2024-04-012024-06-300001541157aktx:EquityIncentivePlan2023And2014Membersrt:MinimumMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-01-012024-09-300001541157us-gaap:RetainedEarningsMember2023-04-012023-06-300001541157us-gaap:RetainedEarningsMember2023-01-012023-03-310001541157aktx:SeriesBWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2024-09-300001541157aktx:SeriesBWarrantsMemberus-gaap:MeasurementInputSharePriceMember2023-12-310001541157us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMemberus-gaap:ForeignPlanMember2024-01-012024-09-300001541157us-gaap:MeasurementInputPriceVolatilityMemberaktx:SeriesWarrantsMember2023-12-310001541157us-gaap:FairValueInputsLevel3Member2024-09-300001541157dei:AdrMemberaktx:SeriesCWarrantsMember2024-05-310001541157us-gaap:ConvertibleDebtMember2024-01-012024-09-300001541157aktx:EquityIncentivePlan2023Memberus-gaap:SubsequentEventMembersrt:MaximumMember2024-11-070001541157aktx:EquityIncentivePlan2023And2014Member2023-01-012023-12-310001541157aktx:EquityIncentivePlan2023Membersrt:MaximumMember2023-06-300001541157us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001541157us-gaap:RelatedPartyMembersrt:MaximumMember2024-09-3000015411572022-12-310001541157us-gaap:MeasurementInputExercisePriceMemberaktx:SeriesWarrantsMember2023-12-310001541157sic:Z8880aktx:PlacementWarrants2019Member2023-12-310001541157sic:Z8880aktx:InvestorWarrants2019Member2024-09-300001541157 2024-09-30 2024-11-150001541157us-gaap:AdditionalPaidInCapitalMember2024-09-30xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:GBPxbrli:sharesiso4217:USD

Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-36288 Â Akari Therapeutics, Plc (Exact name of Registrant as specified in its Charter) Â Â England and Wales 98-1034922 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 22 Boston Wharf Road, FL 7Boston, Massachusetts 02210 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (929) 274-7510 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on which registered American Depositary Shares, each representing 2,000 Ordinary Shares, par value $0.0001 per share Â AKTX Â The NasdaqÂ Capital Market Ordinary Shares, $0.0001 par value per share* Â Â Â The NasdaqÂ Capital Market * Trading, but only in connection with the American Depositary Shares. Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Â Â Â Â Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Â Â Emerging growth company Â â˜ Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES â˜ NO â˜’ The number of shares of Registrantâ€™s Ordinary Shares outstanding as of November 15, 2024 was 49,517,115,523. Â Â Â Â TABLE OF CONTENTS Â Page PART I FINANCIAL INFORMATION 1 Item 1. Financial Statements (Unaudited) 1 Â Condensed Consolidated Balance Sheets 1 Â Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Â Condensed Consolidated Statements of Shareholders' (Deficit) Equity 3 Â Condensed Consolidated Statements of Cash Flows 5 Â Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Quantitative and Qualitative Disclosures About Market Risk 34 Item 4. Controls and Procedures 35 PART II OTHER INFORMATION 36 Item 1. Legal Proceedings 36 Item 1A. Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 3. Defaults Upon Senior Securities 36 Item 4. Mine Safety Disclosures 36 Item 5. Other Information 36 Item 6. Exhibits 37 Â SIGNATURES 38 Â Â i Â GENERAL INFORMATION Â Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q ("Form 10-Q") to â€œAkari,â€ the â€œcompany,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ â€œourâ€ or similar designations refer to Akari Therapeutics, Plc and its subsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, trade names or registered marks of their respective owners. Â Statements made in this Quarterly Report on Form 10-Q concerning the contents of any agreement, contract or other document are summaries of such agreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements, contracts or documents as exhibits to this Quarterly Report on Form 10-Q or to any previous filing with the Securities and Exchange Commission (â€œSECâ€), you may read the document itself for a complete understanding of its terms. ii Â NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q and the documents we incorporate by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). All statements, other than statements of historical fact, included or incorporated in this report regarding, among other things, our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our industry, the timing or likelihood of regulatory actions, filings and approvals for our current and future drug candidates, and the benefits related to the Merger Agreement (as defined below) and the plans and objectives of management are forward-looking statements. The words â€œbelieves,â€ â€œanticipates,â€ â€œestimates,â€ â€œplans,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œcould,â€ â€œshould,â€ â€œpotential,â€ â€œlikely,â€ â€œprojects,â€ â€œintend,â€ â€œcontinue,â€ â€œwill,â€ â€œschedule,â€ â€œwould,â€ â€œaim,â€ â€œcontemplate,â€ â€œestimate,â€ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we will actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may be beyond our control, and which may cause the actual results, performance, or achievements of the Company to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated or implied by forward-looking statements. These important factors include those set forth under Part I, â€œItem 1A. Risk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023 (our â€œForm 10-Kâ€) and Part II â€œItem 1A. Risk Factorsâ€ of this Form 10-Q and in our other disclosures and filings we have made with the SEC. These factors and the other cautionary statements made in this Form 10-Q and the documents we incorporate by reference should be read as being applicable to all related forward-looking statements whenever they appear in this Form 10-Q and the documents we incorporate by reference. In addition, any forward-looking statements represent our estimates only as of the date that this Form 10-Q is filed with the SEC and should not be relied upon as representing our estimates as of any subsequent date. All forward-looking statements included in this Form 10-Q are made as of the date hereof and are expressly qualified in their entirety by this cautionary notice. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law. Â iii Â PART Iâ€“FINANCIAL INFORMATION Item 1. Financial Statements. AKARI THERAPEUTICS, PLC Â Condensed Consolidated Balance Sheets (Unaudited, in U.S. dollars) Â Â Â September 30, Â Â December 31, Â (In thousands, except share and per share amounts) Â 2024 Â Â 2023* Â ASSETS Â Â Â Â Current assets: Â Â Â Â Cash Â $ 2,246 Â Â $ 3,845 Â Prepaid expenses Â Â 396 Â Â Â 299 Â Other current assets Â Â 92 Â Â Â 197 Â Total current assets Â Â 2,734 Â Â Â 4,341 Â Patent acquisition costs, net Â Â â€“ Â Â Â 14 Â Total assets Â $ 2,734 Â Â $ 4,355 Â Â Â Â Â Â Â Â LIABILITIES AND SHAREHOLDERSâ€™ DEFICIT Â Â Â Â Current liabilities: Â Â Â Â Accounts payable Â $ 4,782 Â Â $ 1,671 Â Accrued expenses Â Â 2,605 Â Â Â 1,566 Â Convertible notes, related party Â Â 1,000 Â Â Â â€“ Â Warrant liability Â Â 725 Â Â Â 1,253 Â Other current liabilities Â Â 316 Â Â Â 94 Â Total current liabilities Â Â 9,428 Â Â Â 4,584 Â Â Â Â Â Â Â Â Commitments and contingenciesÂ (Note 9) Â Â Â Â Â Â Â Â Shareholdersâ€™ deficit: Â Â Â Â Â Share capital of $0.0001Â par value Â Â Â Â Â Authorized: 45,122,321,523Â ordinary shares atÂ Â Â September 30, 2024 and December 31, 2023, respectively;Â Â Â issued and outstanding: 24,289,231,523Â and 13,234,315,298Â atÂ Â Â September 30, 2024 and December 31, 2023, respectively Â Â 2,430 Â Â Â 1,324 Â Additional paid-in capital Â Â 183,088 Â Â Â 174,754 Â Capital redemption reserve Â Â 52,194 Â Â Â 52,194 Â Accumulated other comprehensive loss Â Â (926) Â Â (1,040) Accumulated deficit Â Â (243,480) Â Â (227,461) Total shareholdersâ€™ deficit Â Â (6,694) Â Â (229) Total liabilities and shareholders' deficit Â $ 2,734 Â Â $ 4,355 Â Â â€“â€“â€“â€“â€“â€“ * The condensed balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date. Â The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Â AKARI THERAPEUTICS, PLC Â Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited, in U.S. dollars) Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â (In thousands, except share and per share amounts) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 143 Â Â $ (314) Â $ 5,736 Â Â $ 2,941 Â General and administrative Â Â 1,709 Â Â Â 2,821 Â Â Â 6,616 Â Â Â 8,775 Â Merger-related costs Â Â 992 Â Â Â â€“ Â Â Â 2,290 Â Â Â â€“ Â Restructuring and other costs Â Â 83 Â Â Â â€“ Â Â Â 1,723 Â Â Â â€“ Â Loss from operations Â Â (2,927) Â Â (2,507) Â Â (16,365) Â Â (11,716) Other income (expense): Â Â Â Â Â Â Â Â Â Â Â Â Interest income Â Â 3 Â Â Â 16 Â Â Â 7 Â Â Â 75 Â Interest expense Â Â (69) Â Â â€“ Â Â Â (120) Â Â â€“ Â Change in fair value of warrant liability Â Â 30 Â Â Â (258) Â Â 528 Â Â Â 5,889 Â Foreign currency exchange gain (loss), net Â Â 68 Â Â (100) Â Â (67) Â Â (72) Other expense, net Â Â â€“ Â Â Â (22) Â Â (2) Â Â (46) Total other income (expense), net Â Â 32 Â Â Â (364) Â Â 346 Â Â Â 5,846 Â Net loss Â $ (2,895) Â $ (2,871) Â $ (16,019) Â $ (5,870) Â Â Â Â Â Â Â Â Â Â Â Â Net loss per share â€“ basic and diluted Â $ (0.00) Â $ (0.00) Â $ (0.00) Â $ (0.00) Weighted-average number of ordinary shares used in computing net loss per share â€“ basic and diluted Â Â 24,386,005,523 Â Â Â 10,116,903,598 Â Â Â 18,911,928,794 Â Â Â 10,119,421,200 Â Â Â Â Â Â Â Â Â Â Â Â Comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (2,895) Â $ (2,871) Â $ (16,019) Â $ (5,870) Other comprehensive income, net of tax: Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustment Â Â (177) Â Â (3) Â Â 114 Â Â Â (58) Total other comprehensive income, net of tax Â Â (177) Â Â (3) Â Â 114 Â Â Â (58) Total comprehensive loss Â $ (3,072) Â $ (2,874) Â $ (15,905) Â $ (5,928) Â The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Â AKARI THERAPEUTICS, PLC Â Condensed Consolidated Statements of Changes in Shareholdersâ€™ Equity (Deficit) (Unaudited, in U.S. dollars) Â Â Â Nine Months Ended September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â

Â Â 3,503 Â Â Â Â Â Â Â Â Â Â Effect of exchange rates on cash Â Â (5) Â Â 1 Â Â Â Â Â Â Â Â Â Â Net decrease in cash Â Â (1,599) Â Â (8,519) Cash at beginning of period Â Â 3,845 Â Â Â 13,250 Â Cash at end of period Â $ 2,246 Â Â $ 4,731 Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: Â Â Â Â Â Â Financing costs in accrued expenses Â $ 72 Â Â $ â€” Â Non-cash seller-financed purchases Â $ 1,105 Â Â $ â€” Â Payroll taxes on share-based compensation in accrued expenses Â $ 193 Â Â $ â€” Â SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFO: Â Â Â Â Â Â Â Â Cash paid during the period for interest Â $ 120 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Â AKARI THERAPEUTICS, PLC Â Notes to the Condensed Consolidated Financial Statements (Unaudited) Note 1. Description of BusinessBusiness OverviewAkari Therapeutics, Plc, (the â€œCompanyâ€ or â€œAkariâ€) is incorporated in the United Kingdom. The Company is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (â€œC5â€) and leukotriene B4 (â€œLTB4â€) pathways. The Companyâ€™s activities since inception have consisted of performing research and development activities and raising capital.The Company is subject to a number of risks similar to those of preclinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with preclinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies.To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities.Merger with Peak BioAs further described in Note 10, on November 14, 2024, the Company closed the previously announced merger with Peak Bio, Inc. (â€œPeak Bioâ€). As a result, the Company expanded its pipeline of assets spanning early and late development stages with the addition of Peak Bioâ€™s antibody drug conjugate (â€œADCâ€) toolkit with novel payload and linker technologies as well as the Peak Bio PHP-303 small molecule selective and reversible neutrophil elastase inhibitor. By combining chemotherapy with immunotherapy strategies, the Company aims to develop cutting-edge solutions for cancer patients. Liquidity and Financial ConditionThe Company follows the provisions of Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 205-40, Presentation of Financial Statementsâ€”Going Concern, which requires management to assess the Companyâ€™s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.The Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $243.5 million as of September 30, 2024. The Companyâ€™s cash balance of $2.2 million as of September 30, 2024 is not sufficient to fund its operations for the one-year period after the date these condensed consolidated financial statements are issued. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of 6 Â clinical trial outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: product development financing, private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful. Nasdaq Continued Listing RulesOn April 5, 2024, the Company received a letter (â€œLetterâ€) from the Listing Qualifications Staff (the â€œStaffâ€) of The Nasdaq Capital Market (â€œNasdaqâ€) notifying the Company that the Companyâ€™s shareholdersâ€™ equity as reported in its Form 10-K is no longer in compliance with the minimum shareholdersâ€™ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain shareholdersâ€™ equity of at least $2.5 million (the â€œShareholdersâ€™ Equity Requirementâ€). As reported on the Form 10-K, the Companyâ€™s shareholdersâ€™ deficit as of December 31, 2023 was approximately $0.2 million. As of September 30, 2024, the Company had a shareholders' deficit of $6.7 million and was not in compliance with the Shareholders' Equity Requirement. In accordance with the Nasdaq Listing Rules, on May 20, 2024, the Company submitted a plan to regain compliance with the Stockholdersâ€™ Equity Requirement (the â€œCompliance Planâ€) for the Staffâ€™s consideration. On August 5, 2024, the Company was notified by the Staff that it has been granted an extension until September 30, 2024 to comply with the Compliance Plan and evidence compliance with the Shareholdersâ€™ Equity Requirement. On October 1, 2024, the Company received a delisting determination letter (â€œDelisting Determination Letterâ€) from the Staff notifying the Company that it did not meet the terms of an extension granted by Nasdaq to regain compliance with the Shareholdersâ€™ Equity Requirement. On October 8, 2024, the Company requested a hearing (the â€œHearingâ€) before the Nasdaq Listing Qualifications Panel (â€œPanelâ€) to appeal the Staffâ€™s delisting determination.Â On November 18, 2024, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the Company has regained compliance with the Shareholdersâ€™ Equity Requirement, and that the Hearing, originally scheduled for November 21, 2024, has been canceled. Note 2. Summary of Significant Accounting PoliciesBasis of presentation â€“ The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of expected results for the fiscal year ended December 31, 2024 or any other future period. These interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements as of December 31, 2023 and notes thereto included in its Form 10-K, as filed with the SEC on March 29, 2024. 7 Â Principles of consolidation â€“ The condensed consolidated financial statements include the accounts of the Company, Celsus Therapeutics, Inc., a Delaware corporation, Volution Immuno Pharmaceuticals SA, a private Swiss company, and Akari Malta Limited, a private Maltese company, each wholly-owned subsidiaries. All intercompany transactions have been eliminated.Foreign currency â€“ The functional currency of the Company is U.S. dollars, as that is the currency of the primary economic environment in which the Company operates as well as the currency in which it has been financed.The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company's foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S. operationsâ€™ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses).Use of estimates â€“ The preparation of the Companyâ€™s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.Concentration of credit risk â€“ Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.Fair value measurements â€“ Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, Fair Value Measurements and Disclosures (â€œASC 820â€) establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:â€¢Level 1 â€“ quoted prices in active markets for identical assets and liabilities.â€¢Level 2 â€“ inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢Level 3 â€“ unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. 8 Â The carrying values of the Companyâ€™s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Companyâ€™s liability-classified warrants are recorded at their estimated fair value. See Note 4.Cash â€“ The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of September 30, 2024 or December 31, 2023.Prepaid expenses â€“ Payments made prior to the receipt of goods or services are capitalized until the goods or services are received.Other current assets â€“ Other current assets as of September 30, 2024 and December 31, 2023 were principally comprised of Value Added Tax (â€œVATâ€) receivables.Patent acquisition costs â€“ Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 years. The Company expenses costs associated with maintaining and defending patents after their issuance in the period incurred. Amortization expense for each of the three and nine months ended September 30, 2024 and 2023 was less than $0.1 million.Accrued expenses â€“ As part of the process of preparing the condensed consolidated financial statements, the Company estimates accrued expenses. This process involves identifying services that third parties have performed on the Companyâ€™s behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Companyâ€™s condensed consolidated financial statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials, professional service fees and contingent liabilities. In connection with these service fees, the Companyâ€™s estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. If the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, the Companyâ€™s reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to the Companyâ€™s estimation and judgment. The Company makes these judgments based upon the facts and circumstances known to it in accordance with U.S. GAAP. See Note 5.Convertible Notes â€“ On May 10, 2024, the Company entered into unsecured convertible promissory notes (the â€œMay 2024 Notesâ€) with existing investors: the Companyâ€™s Chairman, Dr. Ray Prudo, and Interim President and Chief Executive Officer and director of the Company, Dr. Samir Patel, for an aggregate of $1.0 million in gross proceeds. The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Companyâ€™s receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Companyâ€™s ADSs on the issuance date, subject to certain restrictions. In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash.The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options (â€œASC 470-20â€) and has not elected the fair value option as provided for within ASC Topics 815 and 825. Accordingly, the Company evaluated the embedded conversion and other features within the May 2024 Notes to determine whether any of the embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value. Based on managementâ€™s evaluation, the Company determined that the May 2024 Notes were not issued at a substantial premium and none of the embedded features were required to be bifurcated and accounted for separately. Accordingly, the May 2024 Notes are accounted for as a single liability measured at its amortized cost. Issuance costs incurred in connection with the issuance of the May 2024 Notes were 9 Â immaterial. Interest expense incurred on the May 2024 Notes was less than $0.1 million for the three and nine months ended September 30, 2024. As of September 30, 2024, accrued interest on the May 2024 Notes of less than $0.1 million is included within â€œAccrued expensesâ€ in the Companyâ€™s balance sheets.Warrant Liability â€“ The Company accounts for ordinary share or ADS warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and/or ASC Topic 815, Derivatives and Hedging (â€œASC 815â€), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at issuance and are remeasured each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are recorded in "change in fair value of warrant liability" in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss. Equity-classified warrants are recorded within "additional paid-in capital" in the Company's condensed consolidated statements of shareholders' (deficit) equity at the time of issuance and not subject to remeasurement.Â In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants (â€œSeries A Warrantsâ€) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants (â€œSeries B Warrantsâ€) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the â€œSeptember 2022 Warrantsâ€).The Company determined that the September 2022 Warrants are not indexed to the Companyâ€™s own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entityâ€™s Own Stock. Accordingly, the Company classifies the September 2022 Warrants as derivative liabilities in its consolidated balance sheets. In September 2024, all outstanding Series A Warrants expired unexercised.Other Current Liabilities â€“ In February 2024, the Company entered into a short-term financing arrangement with a third-party vendor to finance insurance premiums. The aggregate amount financed under this agreement was $1.1 million, bearing interest at an annual rate of 7.49%. As of September 30, 2024, the balance of $0.2 million, which is included in â€œOther current liabilitiesâ€ in the Companyâ€™s balance sheets, is scheduled to be paid in monthly installments through November 2024.Research and development expenses â€“ Costs associated with research and development are expensed as incurred unless there is an alternative future use in other research and development projects. Research and development expenses include, among other costs, salaries and personnelâ€”related expenses, fees paid for contract research services, fees paid to clinical research organizations, costs incurred by outside laboratories, manufacturers and other accredited facilities in connection with clinical trials and preclinical studies.Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Companyâ€™s vendors will exceed the level of services provided

and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Companyâ€™s estimate, the Company will adjust the accrued or prepaid expense balance accordingly.The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024 and 2023, the Company recognized research and development tax credits of approximately $1.3 million and $2.6 million, respectively. 10 Â Merger-Related Costs â€“ Merger-related costs include direct expenses incurred in connection with the proposed Merger, as more fully described in Note 3, and are comprised primarily of legal and professional fees and other incremental costs directly associated to the Merger. For the three and nine months ended September 30, 2024 merger-related costs totaled $1.0 million and $2.3 million, respectively.Â Restructuring and Other Costs â€“ In May 2024, the Company began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced program prioritization under which the Companyâ€™s HSCT-TMA program was suspended. The reduction-in-force was part of an operational restructuring plan (the â€œMay 2024 Planâ€) which included the elimination of certain senior management positions and was completed in the third quarter of 2024. The purpose of the restructuring plan, including the reduction-in-force, was to reduce HSCT-TMA related operating costs, while supporting the execution of the Companyâ€™s long-term strategic plan. During the three and nine months ended September 30, 2024, the Company has incurred restructuring-related charges of less than $0.1 million and $1.7 million related to the May 2024 Plan, respectively. Of the $1.7 million incurred during the nine months ended September 30, 2024, $1.4 million related to severance and other settlement payments to terminated executives and employees, and $0.3 million was non-cash expenses related to accelerated vesting of equity awards. The Company does not expect to incur additional restructuring-related expenses related to the May 2024 Plan.Â As of September 30, 2024, of the $1.7 million total restructuring-related charges incurred, approximately $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be paid in the fourth quarter of 2024.Share-based compensation expense â€“ The Company measures all share-based awards granted to employees, directors and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective awards. Forfeitures are accounted for as they occur. The Company classifies share-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified.The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Companyâ€™s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Companyâ€™s historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Companyâ€™s options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.Leases â€“ The Company accounts for its leases in accordance with ASC 842, Leases. In accordance with ASC 842, the Company records a right-of-use (â€œROUâ€) asset and corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and are recognized on a straight-line basis over the lease term. As of September 30, 2024 and December 31, 2023, the Company did not have any leases with a term longer than twelve months. Accordingly, no ROU assets and corresponding lease liabilities are included in the Companyâ€™s condensed consolidated balance sheets as of September 30, 2024 or December 31, 2023.Income taxes â€“ In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and nine months ended September 30, 2024 and 2023, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. The Company has not recorded its net deferred tax asset as of either September 30, 2024 or December 31, 2023 because it maintained a full valuation allowance against all deferred tax assets as of these dates as management has determined that it is not more likely than not that the Company will 11 Â realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions.Net loss per share â€“ Basic net loss per ordinary share is computed by dividing net loss available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, which includes ordinary shares underlying pre-funded warrants, as such warrant is exercisable, in whole or in part, for nominal cash consideration with no expiration date. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, unvested restricted stock units, and warrants, which would result in the issuance of incremental ordinary shares, unless their effect would be anti-dilutive. For each of the three and nine months ended September 30, 2024 and 2023, diluted net loss per ordinary share is the same as basic net loss per ordinary share as the effects of the Companyâ€™s potentially dilutive securities were anti-dilutive.The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 507,014,688 Â Â Â 680,112,400 Â Restricted stock units Â Â 251,823,915 Â Â Â 418,580,700 Â Warrants Â Â 11,562,653,300 Â Â Â 4,155,347,500 Â Convertible notes Â Â 1,257,860,000 Â Â Â â€“ Â Total Â Â 13,579,351,903 Â Â Â 5,254,040,600 Â Â New Accounting Pronouncements â€“ From time to time, new accounting pronouncements are issued by the FASB and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any other recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Companyâ€™s present or future consolidated financial statements.Â Recently Issued (Not Yet Adopted) Accounting PronouncementsÂ In November 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures. This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and clarified that single reportable segment entities must apply Topic 280 in its entirety. This guidance is effective for the Company for the year beginning January 1, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statement. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures.Â In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. 12 Â Note 3. Agreement and Plan of MergerÂ Agreement and Plan of MergerOn March 4, 2024, the Company entered into an Agreement and Plan of Merger with Peak Bio and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (â€œPegasus Merger Subâ€), as amended by that certain side letter dated August 15, 2024 (the â€œMerger Agreementâ€), pursuant to which, on November 14, 2024, Pegasus Merger Sub merged with and into Peak Bio (the â€œMergerâ€), with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari.Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the â€œEffective Timeâ€), each issued and outstanding share of Peak Bio common stock, par value $0.0001 per share (the â€œPeak Common Stockâ€) (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Pegasus Merger Sub or any direct or indirect wholly owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement)), was converted into the right to receive the Companyâ€™s ADSs representing a number of Akari ordinary shares, par value $0.0001 per share (the â€œAkari Ordinary Sharesâ€) equal to 0.2935 (the â€œExchange Ratioâ€), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The Exchange Ratio was calculated in accordance with the terms of the Merger Agreement, such that the total number of shares of Akari ADSs issued in connection with the merger was approximately 48.4% of the outstanding shares of Akari ADSs on a fully diluted basis. The board of directors of each of Akari and Peak has unanimously approved the Merger Agreement and the transactions contemplated thereby. On November 14, 2024, the Company closed the business combination contemplated by the Merger Agreement, as more fully described in Note 10. Note 4. Fair Value MeasurementsAssets and Liabilities Measured at Fair Value on a Recurring BasisThe following table presents information about the Companyâ€™s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values:Â Â Â September 30, 2024 Â (In thousands) Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Warrant liability - Series B Â $ 725 Â Â $ â€“ Â Â $ â€“ Â Â $ 725 Â Total liabilities Â $ 725 Â Â $ â€“ Â Â $ â€“ Â Â $ 725 Â Â Â Â December 31, 2023 Â (In thousands) Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Warrant liability - Series A Â $ 15 Â Â $ â€“ Â Â $ â€“ Â Â $ 15 Â Warrant liability - Series B Â Â 1,238 Â Â Â â€“ Â Â Â â€“ Â Â 1,238 Â Total liabilities Â $ 1,253 Â Â $ â€“ Â Â $ â€“ Â Â $ 1,253 Â Â The Companyâ€™s Level 3 liabilities consist of the Series B Warrants as of September 30, 2024 and the Series A and Series B Warrants as of December 31, 2023, which were determined to be liability-classified instruments. There were no transfers between Level 1, Level 2, and Level 3 during the nine months ended September 30, 2024 and 2023. 13 Â Changes in Level 3 Liabilities Measured at Fair Value on a Recurring BasisThe following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the nine months ended September 30, 2024:Â Â Â Warrant Liability Â (In thousands) Â Series A Â Â Series B Â Â Total Â Balance, December 31, 2023 Â $ 15 Â Â $ 1,238 Â Â $ 1,253 Â Change in the fair value of liability Â Â (15) Â Â (513) Â Â (528) Balance, September 30, 2024 Â $ â€“ Â Â $ 725 Â Â $ 725 Â Â Assumptions Used in Determining Fair Value of Liability-Classified WarrantsThe fair value of the warrant liability is based on significant inputs, which represents a Level 3 measurement within the fair value hierarchy. The fair value of both the Series A Warrants and the Series B Warrants was determined using the Black-Scholes Option Pricing Model, which uses various assumptions, including (i) fair value of the Companyâ€™s ADSs, (ii) exercise price of the warrant, (iii) expected term of the warrant, (iv) expected volatility and (v) expected risk-free interest rate.Below are the assumptions used for the fair value calculations of the Series B Warrants as of September 30, 2024, and Series A Warrants and Series B Warrants as of December 31, 2023:Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Series B Â Â Series A Â Â Series B Â Â Stock (ADS) price Â $ 2.95 Â Â $ 3.12 Â Â $ 3.12 Â Â Exercise price Â $ 17.00 Â Â $ 17.00 Â Â $ 17.00 Â Â Expected term (in years) Â Â 5.0 Â Â 0.7 Â Â Â 5.7 Â Â Expected volatility Â Â 80.0 % Â Â 85.0 % Â Â 95.0 % Â Â Risk-free interest rate Â Â 3.6 % Â Â 5.1 % Â Â 3.9 % Â Â Expected dividend yield Â Â â€“ Â Â Â â€“ Â Â Â â€“ Â Â Note 5. Accrued ExpensesAccrued expenses consisted of the following as of September 30, 2024 and December 31, 2023: Â Â Â September 30, Â Â December 31, Â ($ in thousands) Â 2024 Â Â 2023 Â Employee compensation and benefits Â $ 624 Â Â $ 187 Â External research and development expenses Â Â 589 Â Â Â 635 Â Professional and consulting fees Â Â 861 Â Â Â 669 Â Restructuring Â Â 450 Â Â Â â€“ Â Other Â Â 81 Â Â Â 75 Â Total accrued expenses Â $ 2,605 Â Â $ 1,566 Â Â Accrued restructuring expenses of approximately $0.5 million as of September 30, 2024 relate to one-time termination benefits payable to former employees, including an executive, which are payable in the fourth quarter of 2024. See Note 2. 14 Â Note 6. Shareholdersâ€™ (Deficit) EquityOrdinary SharesOn September 30, 2023, the Companyâ€™s shareholders approved an increase to the number of authorized ordinary shares, par value $0.0001 (the â€œOrdinary Sharesâ€), the Company can issue by 35,000,000,000 ordinary shares in addition to the number of shares outstanding on June 30, 2023. Accordingly, as of September 30, 2024 and December 31, 2023, the Company was authorized to issue up to 45,122,321,523 ordinary shares. Currently, each ADS represents 2,000 Ordinary Shares (the â€œADS Ratioâ€). All ADS and per ADS amounts in the accompanying condensed consolidated financial statements reflect the ADS Ratio.May 2024 Private PlacementÂ In May 2024, the Company entered into a definitive purchase agreement with certain investors, Dr. Prudo and Dr. Patel, pursuant to which the Company sold and issued in a private placement an aggregate of 4,029,754 ADSs, and Series C Warrants (the â€œSeries C Warrantsâ€) to purchase up to 4,029,754 ADS, at a per unit price of $1.885 per ADS and Series C Warrant for aggregate gross proceeds of approximately $7.6 million (the â€œMay 2024 Private Placementâ€). The Series C Warrants have 3-year terms ranging from May 31, 2027 to June 21, 2027 and have cashless exercise provisions in limited circumstances. The Series C Warrants (other than those issued to Dr. Prudo and Dr. Patel) have an exercise price of $1.76 per ADS. The Series C Warrants issued to Dr. Prudo and Dr. Patel have an exercise price of $1.79 per ADS. Net proceeds from the May 2024 Private Placement were approximately $7.0 million after deducting placement agent fees and other expenses.At close of the May 2024 Private Placement, the Company issued to Paulson Investment Company, LLC (â€œPaulsonâ€), as placement agent for the May 2024 Private Placement, warrants to purchase 332,380 ADSs at an exercise price of $1.885 per ADS and a term expiring on May 31, 2029 (the â€œMay 2024 Placement Agent Warrantsâ€). The estimated fair value of the May 2024 Placement Agent Warrants on the issuance date was approximately $0.4 million.The Company determined that the Series C Warrants and May 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the May 2024 Private Placement, each of the Series C Warrants and May 2024 Placement Agent Warrants were recorded as a component of additional paid-in capital.March 2024 Private PlacementÂ In March 2024, the Company entered into a definitive purchase agreement with certain existing investors, pursuant to which the Company sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million (the â€œMarch 2024 Private Placementâ€). Net proceeds from the March 2024 Private Placement were approximately $1.7 million after deducting placement agent fees and other expenses.At close of the March 2024 Private Placement, the Company issued to Paulson, as placement agent for the March 2024 Private Placement, warrants to purchase 132,061 ADSs at an exercise price of $1.85 per ADS (representing 125% of the purchase price per ADS sold in the March 2024 Private Placement) and a term expiring on March 27, 2029 (the â€œMarch 2024 Placement Agent Warrantsâ€). The estimated fair value of the March 2024 Placement Agent Warrants on the issuance date was approximately $0.2 million.The Company determined that the March 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the March 2024 Private Placement, each of the March 2024 Placement Agent Warrants were recorded as a component of additional paid-in capital. 15 Â December 2023 Private PlacementIn December 2023, the Company entered into purchase agreements to sell, in a private placement, to existing investors, Dr. Ray Prudo and Dr. Patel, (the â€œDecember 2023 Private Placementâ€) an aggregate of 947,868 ADSs at $2.11 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the December 2023 Private Placement were approximately $1.8 million after deducting placement agent fees and other expenses.September 2023 Private PlacementIn September 2023, the Company entered into purchase agreements to sell in a private placement to existing investors and directors, including Dr. Prudo and Ms. Rachelle Jacques, the Companyâ€™s then President and Chief Executive Officer (the â€œSeptember 2023 Private Placementâ€) an aggregate of 551,816 ADSs at $3.30 per ADS, and pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 48,387 ADSs at a purchase price per Pre-Funded Warrant of $3.10, for aggregate gross proceeds of approximately $2.0 million. The Pre-Funded Warrants are exercisable at an exercise price of $0.20 per ADS and will not expire until exercised in full. The September 2023 Private Placement closed in October 2023 resulting in net proceeds of approximately $1.7 million after deducting placement agent fees and other expenses. At close of the September 2023 Private Placement, the Company issued to Paulson, as placement agent for the September 2023 Private Placement, warrants to purchase 42,550 ADSs at an exercise price of $4.13 per ADS (representing 125% of the purchase price per ADS sold in the September 2023 Private Placement) and a term expiring on October 6, 2028 (the â€œOctober 2023 Placement Agent Warrantsâ€). The estimated fair value of the October 2023 Placement Agent Warrants on the issuance date was approximately $0.1 million.The Company determined that the Pre-Funded Warrants and October 2023 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the September 2023 Private Placement, each of the Pre-Funded Warrants and October 2023 Placement Agent Warrants were recorded as a component of additional paid-in capital.March 2023 Registered Direct OfferingOn March 31, 2023, the Company entered into securities purchase agreements with certain accredited and institutional investors, including Dr. Prudo (the â€œMarch Registered Direct Offeringâ€) providing for the issuance of an aggregate of 1,333,333 ADSs in a registered direct offering at $3.00 per ADS, resulting in gross proceeds of approximately $4.0 million. Net proceeds from the March Registered Direct Offering were approximately $3.5 million after deducting placement agent fees and expenses.WarrantsIn connection with various financing transactions, the Company

has issued warrants to purchase the Companyâ€™s ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement. See Note 2 for further details on accounting policies related to the Companyâ€™s warrants. 16 Â The following table summarizes the Companyâ€™s outstanding warrants as of September 30, 2024 and December 31, 2023:Â Â Â Number of Warrant ADSs Â Â Â

committee of the directors be generally and unconditionally authorized to (i) allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of $14,444,680 in connection with the Merger for a period expiring (unless previously renewed, varied or revoked by resolution of Akari) at the conclusion of Akariâ€™s annual general meeting in 2025, and (ii) allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of $5,546,667 for a period expiring (unless otherwise renewed, varied or revoked by the Company at a general meeting) on November 6, 2029.2023 Equity Incentive PlanOn November 7, 2024, the Companyâ€™s shareholders approved an increase in the number of shares available for the grant of awards under the 2023 Plan by 7,800,000,000 Ordinary Shares to an aggregate of 8,780,000,000 Ordinary Shares, plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Plan, to the extent such awards are forfeited, cancelled, or expire unexercised. 23 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â The following discussion and analysis of our financial condition and results of operations should be read in conjunction with: â€¢our unaudited condensed consolidated financial statements and accompanying notes included in Part I, Item 1 of this Form 10-Q; and â€¢our audited consolidated financial statements and accompanying notes included in the Form 10-K, as well as the information contained under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in our Form 10-K. Â In addition to historical information, this discussion and analysis contains forward-looking statements that are subject to risks and uncertainties, including those discussed in the section titled â€œRisk Factors,â€ set forth in Item 1A of our Form 10-K and this Form 10-Q, that could cause actual results to differ materially from historical results or anticipated results. Â Overview Â We are a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (â€œC5â€) and leukotriene B4 (â€œLTB4â€) pathways. Each of these pathways has scientifically well-supported causative roles in the diseases we are targeting. We believe that blocking early mediators of inflammation will prevent initiation and continual amplification of the processes that cause certain diseases. Our activities since inception have consisted of performing non-clinical and clinical research and development activities and raising capital. Our lead product candidate, nomacopan, is a recombinant small protein (16,769 Da) derived from a protein originally discovered in the saliva of the Ornithodoros moubata tick, which modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. Nomacopan is a second-generation complement inhibitor which has been shown to act on complement C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex (â€œMACâ€)). Nomacopan also specifically sequesters and inhibits LTB4. Complement C5 and LTB4 activation and their proinflammatory actions are typically co-localised during an immune reaction. With its unique bispecific mode of action and biophysical properties, we believe nomacopan may be able to prevent inflammatory and prothrombotic activities of these two important pathways and also and has the potential to be formulated for administration by a variety of routes including subcutaneous, intravenous, topical to eye, inhaled and intravitreous. We are investigating PAS-nomacopan, a long-acting form of nomacopan that is a bispecific inhibitor of C5 and LTB4, for the intravitreal treatment of geographic atrophy (â€œGAâ€) secondary to dry age-related macular degeneration (â€œAMDâ€) in preclinical studies. Following a positive and constructive Pre-Investigational New Drug application meeting with FDA in August 2024, we are completing final non-clinical studies and Good Manufacturing Practices (â€œGMPâ€) manufacturing and expect to file an Investigational New Drug Application (â€œINDâ€) with the FDA in 2025 for PAS-nomacopan in GA. We believe PAS-nomacopan has the potential for longer dose intervals between intravitreous injections than currently approved complement only inhibitors, as well as potential reduction of the choroidal neovascularization (â€œCNVâ€) risk that is associated with approved inhibitors. CNV is a sight-threatening over development of blood vessels within the retina, which is typically treated with anti-vascular endothelial growth factor (â€œVEGFâ€) intravitreal injections. As a bispecific inhibitor of complement C5 and LTB4 we believe PAS-nomacopan may be more efficacious than marketed treatments for GA that only inhibit complement. Until May 2024, we were conducting a clinical trial of subcutaneous nomacopan for the treatment of hematopoietic stem cell transplant-related thrombotic microangiopathy (â€œHSCT-TMAâ€) in pediatrics. Following completion of a portfolio prioritization review, we announced that our HSCT-TMA program will be suspended, as more fully described below. 24 Â Recent Developments Â Pipeline Prioritization of the Merged Companies In May 2024, we announced the completion of a joint portfolio prioritization review pursuant to which the anticipated combined entity, following completion of the proposed Merger (as defined below), will focus on Peak Bioâ€™s antibody drug conjugate (â€œADCâ€) platform technology and our PAS-nomacopan GA program. As a result, our HSCT-TMA program was suspended, with enrollment in our pediatric clinical study discontinued due to cost and timeline. Following the closing of the Merger on November 14, 2024, we have expanded our pipeline of assets spanning early and late development stages with the addition of Peak Bioâ€™s ADC toolkit with novel payload and linker technologies as well as the Peak Bio PHP-303 small molecule selective and reversible neutrophil elastase inhibitor. The ADC program includes a novel pre-clinical ADC candidate targeting TROP-2. By combining chemotherapy with immunotherapy strategies, we aim to develop cutting-edge solutions for cancer patients. Further, related to PHP-303, we expect to emphasize partnering/collaboration and licensing opportunities with broad potential impact on patients. We also plan to work closely with the FDA to define the best path for this platform and will pursue opportunities for external partnering/collaboration and licensing for nomacopan, including as a potential treatment for pediatric HSCT-TMA. Restructuring and Reduction-in-Force In May 2024, we began to implement a reduction-in-force (the â€œRIFâ€) of approximately 67% of our total workforce, as a result of the recently announced program prioritization under which our HSCT-TMA program was suspended. The RIF is part of an operational restructuring plan and includes the elimination of certain senior management positions and was substantially completed by the end of the second quarter. The purpose of the restructuring plan, including the reduction-in-force, is to reduce HSCT-TMA related operating costs, while supporting the execution of our long-term strategic plan. For additional information, refer to the below discussion under the heading â€œRestructuring and Other Costsâ€ and Note 2 to the notes to unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q. Â Merger Agreement On November 14, 2024, we completed the previously announced strategic combination (the â€œClosingâ€) contemplated by that Agreement and Plan of Merger by and among Akari, Peak Bio, Inc. (â€œPeak Bioâ€) and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (â€œMerger Subâ€) as amended by that certain side letter dated August 15, 2024 (the â€œMerger Agreementâ€), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub was merged with and into Peak Bio (the â€œMergerâ€), with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari. Â For additional information on the Merger and the Closing, refer to Note 3 and Note 10 to the notes to unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q. 25 Â Results of Operations Â Three and Nine Months Ended September 30, 2024 and 2023 Â Overview Â During the three months ended September 30, 2024, our loss from operations totaled $2.9 million, a 17% increase, compared to a loss from operations of $2.5 million for the three months ended September 30, 2023. During the nine months ended September 30, 2024, our loss from operations totaled $16.4 million, a 40% increase, compared to a loss from operations of $11.7 million for the nine months ended September 30, 2023. Our total operating expenses are set forth by category in the table below: Â Â Â Three Months Ended Â Â Â Â Â Nine Months Ended Â Â Â Â Â September 30, Â Â Â Â Â September 30, Â Â Â Â ($ in thousands) Â 2024 Â Â 2023 Â Â $ Change Â Â 2024 Â Â 2023 Â Â $ Change Â Operating expenses: Â Research and development Â $ 143 Â Â $ (314) Â $ 457 Â Â $ 5,736 Â Â $ 2,941 Â Â $ 2,795 Â General and administrative Â Â 1,709 Â Â Â 2,821 Â Â Â (1,112) Â Â 6,616 Â Â Â 8,775 Â Â Â (2,159) Merger-related costs Â Â 992 Â Â Â â€” Â Â Â 992 Â Â Â 2,290 Â Â Â â€” Â Â Â 2,290 Â Restructuring and other costs Â Â 83 Â Â Â â€” Â Â Â 83 Â Â Â 1,723 Â Â Â â€” Â Â Â 1,723 Â Total operating expenses Â $ 2,927 Â Â $ 2,507 Â Â $ 420 Â Â Â 16,365 Â Â Â 11,716 Â Â Â 4,649 Â Loss from operations Â $ (2,927) Â $ (2,507) Â $ (420) Â $ (16,365) Â $ (11,716) Â $ (4,649) Â Research and development expenses Â Our research and development expenses are charged to operations as incurred, and we incur both direct and indirect expenses for each of our programs. We track direct research and development expenses by preclinical and clinical programs, which may include third-party costs such as CROs, contract laboratories, consulting, and clinical trial costs. We do not allocate indirect research and development expenses, which may include product development and manufacturing, clinical, medical, regulatory, laboratory (equipment and supplies), personnel, facility and other overhead costs, to specific programs. During the three months ended September 30, 2024, total research and development expenses increased by approximately $0.5 million, or 146%, as compared to the three months ended September 30, 2023. During the nine months ended September 30, 2024, total research and development expenses increased by approximately $2.8 million, or 95%, as compared to the nine months ended September 30, 2023. The following sets forth research and development expenses for the three and nine months ended September 30, 2024 and 2023 by category: Â Â Â Three Months Ended Â Â Â Â Â Nine Months Ended Â Â Â Â Â September 30, Â Â Â Â Â September 30, Â Â Â Â ($ in thousands) Â 2024 Â Â 2023 Â Â $ Change Â Â 2024 Â Â 2023 Â Â $ Change Â Clinical Trials: Â HSCT-TMA clinical development (AK901) Â $ 477 Â Â $ 364 Â Â $ 113 Â Â $ 1,560 Â Â $ 1,088 Â Â $ 472 Â BP clinical development (AK802) Â Â â€” Â Â Â (10) Â Â 10 Â Â Â â€” Â Â Â (1,073) Â Â 1,073 Â Chemistry, manufacturing and control Â Â 459 Â Â Â 795 Â Â Â (336) Â Â 3,401 Â Â Â 1,639 Â Â Â 1,762 Â Other external development expenses Â Â 159 Â Â Â 281 Â Â Â (122) Â Â 754 Â Â Â 1,346 Â Â Â (592) Personnel costs Â Â 330 Â Â Â 827 Â Â Â (497) Â Â 1,303 Â Â Â 2,512 Â Â Â (1,209) Tax credits Â Â (1,282) Â Â (2,571) Â Â 1,289 Â Â Â (1,282) Â Â (2,571) Â Â 1,289 Â Total research and development expenses Â $ 143 Â Â $ (314) Â $ 457 Â Â $ 5,736 Â Â $ 2,941 Â Â $ 2,795 Â Â 26 Â HSCT-TMA clinical development (AK901) Â These expenses include external expenses that we have incurred in connection with the development of nomacopan for the treatment of pediatric HSCT-TMA and primarily consist of payments to CROs and other vendors. The $0.1 million, or 31%, increase in expenses incurred during the three months ended September 30, 2024 and $0.5 million, or 43%, increase in expenses incurred during the nine months ended September 30, 2024, each as compared to the corresponding 2023 period, is primarily due to changes in clinical trial status and related impact on direct service fees incurred with CROs and timing of investigator payments. While the increase for three months ended September 30, 2024 was primarily due to clinical trial close out costs, the increase for the nine months ended September 30, 2024 was also due to increases in patient enrollment and related clinical trial costs incurred during the first quarter of 2024, prior to suspension of the program. In May 2024, following the completion of a pipeline prioritization review, we determined to suspend our HSCT-TMA program. Accordingly, we expect future HSCT-TMA costs to decrease following completion of the wind-down and closeout of the clinical trial. Â BP clinical development (AK802) Â These expenses previously included external expenses that we incurred in connection with the development of nomacopan for the treatment of bullous pemphigoid (â€œBPâ€) and primarily consist of payments to CROs and other vendors. In 2022, we discontinued our BP clinical program and in connection with the final reconciliation of clinical trial close-out costs, we recorded a $1.1 million credit in 2023 and do not expect to incur material additional costs related to this program. Â Chemistry, manufacturing and control Â These expenses include external expenses incurred related to the development and manufacturing of nomacopan for use in clinical trials and preclinical development of PAS-nomacopan. Such expenses primarily consist of payments to CMOs and other vendors for manufacturing of drug substance (including raw materials), drug product, supplies, and validation, quality assurance and manufacturing development activities. The $0.3 million, or 42%, decrease in expenses incurred during the three months ended September 30, 2024 and $1.8 million, or 108%, increase in expenses incurred during the nine months ended September 30, 2024, each as compared to the corresponding periods in 2023, is primarily due to the timing of manufacturing and development activities, including decreases in spending on the development of and preparation for manufacturing of PAS-nomacopan during the three months ended September 30, 2024 as a result of the completion of PAS-nomacopan good manufacturing practice (â€œGMPâ€) drug substance manufacturing during the second quarter of 2024 which was the primary reason for the increase in costs during the nine months ended September 30, 2024, as compared to 2023. Â Other external development expenses Â These expenses include external expenses, such as payments to contract vendors, which may be related to preclinical development activities and other unallocated expenses. The $0.1 million, or 43%, decrease in expenses incurred during the three months ended September 30, 2024 and $0.6 million, or 44%, decrease in expenses incurred during the nine months ended September 30, 2024, each as compared to the corresponding periods in 2023, is primarily related to lower costs incurred related to preclinical studies and other development work investigating PAS-nomacopan for the treatment of GA. Personnel costs Â These expenses include compensation and related costs associated with employees, independent consultants and staffing firms. The $0.5 million, or 60%, decrease in expenses incurred during the three months ended September 30, 2024 and $1.2 million, or 48%, decrease in expenses incurred during the nine months ended September 30, 2024, each as compared to the corresponding periods in 2023, is primarily due to the impact of the RIF which was announced in May 2024, along with lower costs incurred with consultants. Separation benefits paid to impacted employees are classified separately under â€œRestructuring and other costsâ€ as discussed below. 27 Â Tax credits Â We record receipts of U.K. tax credits in the year received as a reduction in research and development expenses. Changes in tax credits received are the result of eligible research and development expenses incurred in the previous tax year, which can fluctuate depending on timing of and location in which expenses are incurred. Â The extent of our future research and development expenditures will be determined based on future funding and closing of the Merger. General and administrative expenses Â During the three months ended September 30, 2024, total general and administrative costs decreased by approximately $1.1 million, or 39%, as compared to the three months ended September 30, 2023. During the nine months ended September 30, 2024, total general and administrative costs decreased by approximately $2.2 million, or approximately 25%, as compared to the nine months ended September 30, 2023. The decreases during both periods were primarily due to decreases in personnel costs resulting from the impact of the RIF which was announced in May 2024, along with lower costs incurred with consultants. Separation benefits paid to impacted employees are classified separately under â€œRestructuring and other costsâ€ as discussed below. Â Merger-related Costs Â Merger-related costs consist of direct expenses incurred in connection with the proposed Merger and are comprised primarily of legal and professional fees. Â Merger-related costs for the three and nine months ended September 30, 2024 were $1.0 million and $2.3 million, respectively. No such costs were incurred during the corresponding 2023 periods. Â Restructuring and Other Costs Â Restructuring costs consist primarily of severance and related benefit costs related to workforce reductions incurred in connection with the RIF, which the Company began to implement in May 2024. Â Restructuring and other costs for the three and nine months ended September 30, 2024 were $0.1 million and $1.7 million, respectively, and includes $0.3 million of non-cash share-based compensation expense for the nine months ended September 30, 2024. No such costs were incurred during the corresponding 2023 periods. Â Interest income Â Interest income consists primarily of interest income received on deposits. Â During the three and nine months ended September 30, 2024 and 2023, interest income was less than $0.1 million. Interest income may fluctuate from period to period due to changes in average cash balances and prevailing interest rates. Â Interest expense Â Interest expense primarily consists of interest incurred on the May 2024 Notes and in connection with the financing of director and officer insurance premiums. Â During the three and nine months ended September 30, 2024, interest expense was less than $0.1 million and approximately $0.1 million, respectively. Interest expense may fluctuate from period to period due to changes in average interest-bearing loans and related interest rates. No interest expense was recognized during the three and nine months ended September 30, 2023. Â 28 Â Change in fair value of warrant liability Â Change in fair value of warrant liability represents non-cash warrant revaluation gains or losses related to the remeasurement of our liability-classified September 2022 Warrants, as more fully described in Note 2 and Note 4 of the notes to the condensed consolidated financial statements appearing elsewhere in this Form 10-Q. Due to the nature of and inputs in the model used to assess the fair value of our outstanding September 2022 Warrants, it is not abnormal to experience significant fluctuations during each remeasurement period. These fluctuations may be due to a variety of factors, including changes in our stock price and changes in estimated stock price volatility over the remaining life of the warrants. Â During the three months ended September 30, 2024, we recorded a change in the fair value of warrant liability, representing a non-cash warrant revaluation gain of less than $0.1 million, as compared to a non-cash warrant revaluation loss of approximately $0.3 million for the three months ended September 30, 2023. Changes in the fair value of the warrant liability and resulting warrant revaluation gain for the three months ended September 30, 2024 was driven primarily by decreases in expected term and expected volatility assumptions during the reporting period. Changes in the fair value of the warrant liability and resulting warrant revaluation loss for the three months ended September 30, 2023 was driven primarily by an increase in our stock price during the reporting period. Â During the nine months ended September 30, 2024 and 2023, we recorded a change in the fair value of warrant liability, representing a non-cash warrant revaluation gain, of approximately $0.5 million and $5.9 million, respectively. Changes in the fair value of the warrant liability and resulting warrant revaluation gains for each of the nine months ended September 30, 2024 and 2023 was driven by a decrease in our stock price and decreases in expected term and expected volatility assumptions during the reporting period. Â Foreign currency exchange gain (loss), net Â During the three months ended September 30, 2024, we recorded a net foreign currency exchange gain of $0.1 million, as compared to a net foreign currency exchange loss for the three months ended September 30, 2023. During each of the nine months ended September 30, 2024 and 2023, we recorded a net foreign currency exchange loss of less than $0.1 million. Exchange gains and losses can fluctuate significantly from period to period due to changes in exchange rates as well as the volume and timing of expenditures and related payments

denominated in foreign currencies. Â Other expense, net During each of the three and nine months ended September 30, 2024 and 2023, net other expense was less than $0.1 million and not material. Such expenses are not expected to be material to our future results of operations. Â Net Loss Applicable to Ordinary Shareholders Â As a result of the factors discussed above, net loss applicable to ordinary shareholders for each of the three months ended September 30, 2024 and 2023 was $2.9 million. Net loss applicable to ordinary shareholders for the nine months ended September 30, 2024 and 2023 was $16.0 million and $5.9 million, respectively. Â 29 Â Financial Condition, Liquidity and Capital Resources Â Sources of Liquidity Since inception, we have incurred substantial losses, and we have primarily funded our operations with proceeds from the sale of equity securities, including ordinary shares, warrants and pre-funded warrants, and convertible notes. At September 30, 2024, we had $2.2 million in cash and an accumulated deficit of $243.5 million. To date, we have not generated any revenue. We have devoted substantially all of our efforts to research and development, including clinical trials, and we have not commercialized any products. Our research and development activities, together with our general and administrative expenses, are expected to continue to result in substantial operating losses for the foreseeable future. These losses, among other things, have had and will continue to have an adverse effect on our shareholdersâ€™ equity, total assets and working capital. Due to the numerous risks and uncertainties associated with developing drug candidates and, if approved, commercial products, we are unable to predict the extent of any future losses, whether or when any of our drug candidates will become commercially available or when we will become profitable, if at all. Our future capital requirements will depend on many factors, including: Â â€¢the progress and costs of our preclinical studies, clinical trials and other research and development activities; â€¢the costs associated with the completion of the Merger and integration activities related thereto; â€¢the scope, prioritization and number of our clinical trials and other research and development programs; â€¢the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect to our product candidates; â€¢the costs of the development and expansion of our operational infrastructure; â€¢the costs and timing of obtaining regulatory approval for our product candidates; â€¢the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; â€¢the costs and timing of securing manufacturing arrangements for clinical or commercial production; â€¢the costs of contracting with third parties to provide sales and marketing capabilities for us; â€¢the magnitude of our general and administrative expenses; and â€¢any cost that we may incur under future in- and out-licensing arrangements relating to our product candidates. Â We currently do not have any firm commitments for future external funding. We will need to raise additional funds, and we may decide to raise additional funds even before we need such funds if the conditions for raising capital are favorable. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through debt or equity financings, credit facilities or by out-licensing applications of our product candidates. The sale of equity or convertible debt securities may result in dilution to our existing shareholders. The incurrence of indebtedness would result in increased fixed obligations and could also subject us to covenants that restrict our operations. We cannot be certain that additional funding, whether through grants, financings, credit facilities or out-licensing arrangements, will be available to us on acceptable terms, if at all. If sufficient funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our product candidates, or obtain funds through arrangements 30 Â with collaborators or others that may require us to relinquish rights to certain potential products that we might otherwise seek to develop or commercialize independently. Â November 2024 Private Placement As discussed in Note 10 to our notes to unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q, in November 2024, we entered into a purchase agreement with certain investors, pursuant to which we agreed to sell and issue in a private placement an aggregate of 1,713,402 ADSs, and warrants to purchase up to 1,713,402 ADS, at a per unit (each unit consists of one ADS and one warrant) purchase price of (i) $1.70 per ADS and warrant for all investors other than Drs. Patel and Prudo, and (ii) $2.385, which is equal to the consolidated closing bid price of the ADSs on The Nasdaq Stock Market on November 12, 2024 plus $0.125 for Drs. Patel and Prudo, for aggregate gross proceeds of $3.2 million. Â May 2024 Private Placement As discussed in Note 6 to our notes to unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q, in May 2024, we entered into a purchase agreement with certain investors, pursuant to which we sold and issued in a private placement an aggregate of 4,029,754 ADSs, and warrants to purchase up to 4,029,754 ADS, at a per unit (each unit consists of one ADS and one warrant) purchase price of $1.885, for aggregate gross proceeds of approximately $7.6 million. Net proceeds from the May 2024 Private Placement were approximately $7.0 million after deducting placement agent fees and other expenses. May 2024 Convertible Notes As discussed in Note 2 to our notes to unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q, in May 2024, we entered into convertible promissory notes with existing investors and directors, Dr. Prudo and Dr. Patel, for an aggregate of $1.0 million (the â€œMay 2024 Notesâ€). March 2024 Private Placement As discussed in Note 6 to our notes to unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q, in March 2024, we entered into a definitive purchase agreement with certain existing investors, pursuant to which we sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the March 2024 Private Placement were approximately $1.7 million after deducting placement agent fees and other expenses. Funding Requirements Â As of the date of this report, we expect our existing cash, plus cash expected to be received from the November 2024 Private Placement to be sufficient to fund our operations into the first quarter of 2025. We do not currently have any products approved for sale and do not generate any revenue from product sales. We are currently seeking and expect to continue to seek additional funding through financings of equity and/or debt securities. We may also engage in strategic research and development collaborations, clinical funding arrangements, the sale or license of technology assets, and/or other strategic alternatives. Â Financing may not be available to us when we need it, or on favorable or acceptable terms, or at all. We could be required to seek funds through means that may require us to relinquish rights to some of our technologies, drug candidates or drugs that we would otherwise pursue on our own. In addition, if we raise additional funds by issuing equity securities, our then existing shareholders may experience dilution. The terms of any financing may adversely affect the holdings or the rights of existing shareholders. An equity financing that involves existing shareholders may cause a concentration of ownership. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and are likely to include rights that are senior to the holders of our ordinary shares. Any additional debt or equity financing may contain terms which are not favorable to us or to our shareholders, such as liquidation and other preferences, or liens or other restrictions on our assets. As discussed in 31 Â Note 9 to the consolidated financial statements included in the 2023 Form 10-K, additional equity financings may also result in cumulative changes in ownership over a three-year period in excess of 50% which would limit the amount of net operating loss and tax credit carryforwards that we may utilize in any one year. Â If we are unable to raise additional capital when required, or on acceptable terms, we may be required to: Â â€¢significantly delay, scale back, or discontinue the development or commercialization of our product candidates; â€¢seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future; â€¢dispose of technology assets, including current product candidates, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves; â€¢pursue the sale of our company to a third party at a price that may result in a loss on investment for our shareholders; or â€¢file for bankruptcy or cease operations altogether. Â Any of these events could have a material adverse effect on our business, operating results, and prospects. Â We believe the key factors which will affect our ability to obtain funding are: Â â€¢the receptivity of the capital markets to financings by biotechnology companies generally and companies with drug candidates and technologies similar to ours specifically; â€¢the receptivity of the capital markets to any in-licensing, product acquisition or other transaction we may enter into or attempt to enter into; â€¢our ability to successfully integrate operations with Peak Bio following the Merger and realizeanticipated benefits of the Merger; â€¢the results of our clinical development activities in our drug candidates we develop on the timelines anticipated; â€¢competitive and potentially competitive products and technologies and investorsâ€™ receptivity to our drug candidates we develop and the technology underlying them in light of competitive products and technologies; â€¢the cost, timing, and outcome of regulatory reviews; and â€¢continued compliance with both Nasdaq continued listing requirements and Exchange Act requirements. Â In addition, increases in expenses or delays in clinical development may adversely impact our cash position and require additional funds or cost reductions. Â Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our unaudited condensed consolidated financial statements, included elsewhere in this Form 10-Q (such unaudited condensed consolidated financial statements, the â€œconsolidated financial statementsâ€) are issued. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As such, the accompanying condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary if we are unable to continue as a going concern. 32 Â Cash Flows Â The following table summarizes our sources and uses of cash for each of the periods presented (in thousands): Â Â Nine Months Ended Â Â Â September 30, Â (In thousands) Â 2024 Â 2023 Â Net cash (used in) provided by: Â Â Â Â Â Â Net cash used in operating activities Â $ (10,428) Â $ (12,023) Net cash provided by financing activities Â Â 8,834 Â Â Â 3,503 Â Effect of exchange rates on cash Â Â (5) Â Â 1 Â Net decrease in cash Â $ (1,599) $ (8,519) Â Operating Activities. The net cash used in operating activities for the periods presented consists primarily of our net loss adjusted for non-cash charges and changes in components of working capital. The decrease in cash used in operating activities during the nine months ended September 30, 2024, as compared to the 2023 period, was primarily due to the net impact of deferrals of payables in order to preserve cash until additional capital is raised for working capital purposes, partially offset by an increase in operating expenses. Â Investment Activities. There were no investing activities during the nine months ended September 30, 2024 and 2023. Financing Activities. Net cash provided by financing activities primarily consisted of the following: â€¢For the nine months ended September 30, 2024, an aggregate of $8.7 million in net proceeds received from debt and equity financings, including (i) $1.7 million in net proceeds from the March 2024 Private Placement, (ii) $1.0 million in net proceeds from the issuance of the May 2024 Notes, and (iii) $7.0 million in net proceeds from the May 2024 Private Placement, partially offset by $0.9 million in payments related to our short-term insurance premium financing arrangement; and â€¢For the nine months ended September 30, 2023, an aggregate of $3.5 million in net proceeds received from the March 2023 Registered Direct Offering. Material Cash Requirements Â During the nine months ended September 30, 2024, there were no material changes outside the ordinary course of our business to our contractual obligations and cash requirements, as disclosed in our Form 10-K. Â 33 Â Critical Accounting Estimates Â This managementâ€™s discussion and analysis of financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and judgments, including, but not limited to, those related to (i) share-based compensation, (ii) fair value of warrants classified as liabilities, (iii) research and development prepayments, accruals and related expenses, and (iv) the valuation allowance for deferred income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Â We regard an accounting estimate or assumption underlying our financial statements as a â€œcritical accounting estimateâ€ if: â€¢the nature of the estimate or assumption is material due to the level of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change; and â€¢the impact of the estimates and assumptions on financial condition or operating performance is material. Â There have been no material changes to our critical accounting policies and estimates since December 31, 2023. See â€œItem 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations â€” Critical Accounting Estimatesâ€ of our Form 10-K, for a discussion of significant estimates and assumptions made by our management as part of the preparation of this management's discussion and analysis of financial condition and results of operations and accompanying condensed consolidated financial statements. Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. Â We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item. 34 Â Item 4. Controls and Procedures. Disclosure Controls and Procedures a)Evaluation of Disclosure Controls and Procedures. Â Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2024. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applied its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of September 30, 2024, our disclosure controls and procedures were (1) designed to ensure that material information relating to us is made known to our principal executive officer and principal financial officer by others, particularly during the period in which this report was prepared, and (2) effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms. b)Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â 35 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business. We are not currently a party to any material legal proceedings, and are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. Item 1A. Risk Factors. There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. During the three months ended September 30, 2024, we did not have any sales of unregistered securities. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. None. Item 5. Other Information. None of our directors or â€œofficers,â€ as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report. Nasdaq Compliance Update On April 5, 2024, we received a letter (â€œLetterâ€) from the Listing Qualifications Staff (the â€œStaffâ€) of The Nasdaq Capital Market (â€œNasdaqâ€) notifying us that our shareholdersâ€™ equity as reported in our Form 10-K was not in compliance with the minimum shareholdersâ€™ equity requirement under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain shareholdersâ€™ equity of at least $2.5 million (the â€œShareholdersâ€™ Equity Requirementâ€). In accordance with the Nasdaq Listing Rules, on May 20, 2024, we submitted a plan to regain compliance with the Stockholdersâ€™ Equity Requirement (the â€œCompliance Planâ€) for the Staffâ€™s consideration. On August 5, 2024, we were notified by the Staff that we had been granted an extension until September 30, 2024 to comply with the Compliance Plan and evidence compliance with the Shareholdersâ€™ Equity Requirement. On October 1, 2024, we received a delisting determination letter (â€œDelisting Determination Letterâ€) from the Staff notifying us that we did not meet the terms of the extension. On October 8, 2024, we requested a hearing before the Nasdaq Listing Qualifications Panel to appeal the Staffâ€™s delisting determination. On November 18, 2024, we received a letter from the Nasdaq Office of General Counsel notifying us that we have regained compliance with the Shareholdersâ€™ Equity Requirement. While we have regained compliance with the Shareholderâ€™s Equity Requirement, we cannot guarantee that we will maintain compliance with this requirement and the other continued listing requirements of Nasdaq. 36 Â Item 6. Exhibits. ExhibitNumber Description 10.1 Â Side Letter Agreement, dated August 15, 2024, by and among Akari Therapeutics, Plc, Pegasus Merger Sub, Inc. and Peak Bio, Inc. (incorporated by reference to Exhibit 10.5 to Registrant's Quarterly Report on Form 10-Q, as filed with the SEC on August 19, 2024). 10.2â€ Â Amendment to Interim Chief Executive Officer Agreement, between Akari Therapeutics, Plc and Samir R. Patel, M.D., dated as of September 16, 2024 (incorporated by reference to Exhibit 10.1 to Registrantâ€™s Current Report on Form 8-K, as filed with the SEC on September 18, 2024). 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act

of 2002. 32.1** Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2** Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Documentâ€“the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. 101.SCH Â Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â * Filed herewith. ** This certification is not deemed â€œfiledâ€ for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Registrant specifically incorporates it by reference. â€ Indicates management contract or compensatory arrangement. Â 37 Â SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Akari Therapeutics, Plc Â Â By: Â Date: November 19, 2024 Â /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President, Chief Executive Officer and Director Â Â Â (Principal Executive Officer) Â Â Â Â Â Â By: /s/ Wendy DiCicco Date: November 19, 2024 Â Â Wendy DiCicco Â Â Â Interim Chief Financial Officer Â Â Â Â (Principal Financial Officer) Â Â Â Â Â Â

Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) Short-term debt, terms Short-Term Debt, Terms Finite-Lived Intangible Assets by Major Class [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Depreciation, Depletion and Amortization, Total Description of business. Description of Business Line Items Description of Business [Line Items] Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: 2020 Purchase Agreement Represents the information about 2020 purchase agreement. Remaining shareholders deficit required to get listed in Nasdaq listing. Remaining Shareholders Deficit Required To Get Listed In Nasdaq Listing Remaining shareholder's deficit required to get listed in Nasdaq listing Related Party Transaction [Line Items] Document Information Document Information [Table] Interest expense Interest Expense, Nonoperating Interest Expense, Nonoperating, Total Equity [Text Block] Shareholders' (Deficit) Equity Title and Position [Axis] Earnings Per Share [Line Items] Earnings Per Share Line Items Exercise price range four Exercise Price Range Four Member Class of Warrant or Right [Axis] May 2024 Placement Agent Warrants. May 2024 Placement Agent Warrants [Member] May 2024 Placement Agent Warrants One-time Termination Benefits [Member] One-time termination benefits Sale of Stock [Domain] Shareholders' Equity Fair Value Measurement Inputs and Valuation Techniques [Line Items] CIK Entity Central Index Key Warrant Liability Warrant Liability, Policy [Policy Text Block] Disclosure of accounting policy for warrant liability. Cash equivalents Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value, Total Warrant ADSs Warrant [Member] Warrant Number of shares, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Operating Capital [Abstract] Change in assets and liabilities: American depository receipts. American Depository Receipts [Member] American Depository Shares Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Ordinary shares, shares issued Common Stock, Shares, Issued Gross proceeds from convertible promissory notes Proceeds from Convertible Debt Proceeds from issuance of convertible notes Fair Value Measurements Fair Value, Option, Quantitative Disclosures [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Table] Percentage of cash fee paid to placement agent Percentage of Cash Fee Paid to Placement Agent Percentage of cash fee paid to placement agent. Percentage of aggregate shares Percentage of Aggregate Shares of The Company's ADSs Traded Represents percentage of aggregate shares of the company's ADSs traded. Business Description and Basis of Presentation [Text Block] Description of Business Income Statement [Abstract] Entity Address, State or Province Net loss before income tax Net loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Deferred shares issued Deferred Shares Issued Deferred shares issued. Class of Warrant or Right [Table] Summary of Significant Accounting Policies Summary of Significant Accounting Policies [Line Items] No definition available. 2020 Investor Warrants It represents the information pertaining to Investor warrants 2020. Threshold Consecutive Trading Day Period To Call For Exercise Of Warrants Threshold period of specified consecutive trading days within which the daily volume weighted average price of the share exceeds the said price, to trigger the call for exercise of warrants. Annual turnover rate This member stands for the measurement input, annual turnover rate. Chardan Chardan Member Chardan. Agreement and Plan of Merger Agreement And Plan Of Merger Disclosure [Text Block] Agreement and plan of merger disclosure. Transfers into (out of) level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total Severance and other settlement payments. Severance and Other Settlement Payments Severance and other settlement payments Loss Contingencies [Table] Short-term finance Short-Term Debt Short-Term Debt, Total Number of additional shares available for grant Ordinary shares issued Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Merger Agreement Expected Ownership In Company Counterparty Stockholders Percentage Merger Agreement Expected Ownership In Company Counterparty Stockholders Percentage Percentage of expected ownership in outstanding shares March 2022 Placement Agent Warrants March 2022 Placement Agent Warrants This member represents information pertaining to March 2022 Placement Agent Warrants. Held in escrow until treatment upon termination. Held In Escrow Until Treatment Upon Termination [Member] Held In Escrow Until Treatment Upon Termination Proceeds from issuance of restricted shares Proceeds From Issuance Of Restricted Shares Proceeds from issuance of restricted shares. Aggregate intrinsic value, Options exercisable at end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Capital Redemption Reserve Capital Units [Member] Cover Cover [Abstract] Permanent differences Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Subsequent Event [Line Items] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Earnings Per Share, Basic Earnings Per Share, Basic, Total Net loss per share - basic Stockholders equity requirement. Stockholders Equity Requirement Stockholders equity requirement Required return on equity This member stands for the measurement input, required rate of return on equity. Other Liabilities, Total Other Liabilities Payable balances Total share-based compensation expense Share-Based Payment Arrangement, Expense Number of Warrants ADSs Outstanding, Ending Balance Number of Warrants ADSs Outstanding Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Accumulated deficit Shareholders deficit Plan Name [Axis] Options outstanding Number of shares, Options Outstanding at beginning of the period Number of shares, Options Outstanding at end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Issuance of share capital for services, exercise price Stock Issued During Period Shares Issued For Services Exercise Price Stock issued during period shares issued for services exercise price. Supplemental Cash Flow Elements [Abstract] SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: Current assets: Assets, Current [Abstract] Number of shares remained available for future issuance Common Stock, Capital Shares Reserved for Future Issuance United States UNITED STATES Expected non cash expense relating to vesting of equity awards Expected Non Cash Expense Relating To Vesting Of Equity Awards Expected non cash expense relating to vesting of equity awards. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (per share) Period risk-free rate This member stands for the measurement input, period risk free interest rate. Accumulated other comprehensive loss Beginning Balance Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Operating loss carryforwards Operating Loss Carryforwards Share-Based Payment Arrangement, Employee [Member] Employees Property and equipment, net Total Property, Plant and Equipment, Net Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Non-cash seller-financed purchases Non-cash Seller-financed Purchases Non-cash seller-financed purchases. Type of Restructuring [Domain] Fair Value, Recurring [Member] Recurring Vesting [Axis] Nominal value of ADS (in per warrant ADS) Ordinary shares, par value Share capital, par value Stock options Sale of Stock, Description of Transaction Sale of Stock, Description of Transaction Measurement Input Type [Domain] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Statement of Cash Flows [Abstract] Counterparty Name [Axis] Short-term finance, interest rate Short-Term Debt, Percentage Bearing Fixed Interest Rate Changes in values of liabilities related to options and warrants Change in fair value of liabilities related to warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Change in fair value of liability Warrants issued to purchase ADS (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants to purchase shares Intangibles Deferred Tax Assets, Goodwill and Intangible Assets Restructuring Costs, Total Restructuring Costs Restructuring and other costs July 2021 Placement Agent Warrants July 2021 Placement Agent Warrants This member represents information pertaining to July 2021 Placement Agent Warrants. Equity Components [Axis] Entity Address, Address Line One Related Party Transaction [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Warrants, Issued Computer Equipment [Member] Subsequent Event Type [Axis] Change of tax rate due to U.S. tax reform Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Total other income (expense), net Nonoperating Income (Expense) Schedule of Anti-Dilutive Share Equivalents Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Risk-free interest Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Peak Bio. Peak Bio [Member] Peak Bio 2023 Equity Incentive Plan 2023 Plan Equity Incentive Plan 2023 [Member] Represents the member information pertaining to 2023 Equity Incentive Plan. Unvested at beginning of the period (in shares) Unvested at end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number RSUs outstanding Amendment Amendment Flag Operating Loss Carryforwards [Table] Domestic (UK) Current Federal Tax Expense (Benefit) Domestic Tax Authority Domestic Tax Jurisdiction [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Restructuring Plan [Domain] Share issue price (in dollars per ADS) Sale of Stock, Price Per Share Net loss Net loss Exercise of warrants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period StockIssuedDuringPeriodSharesStockOptionsExercised Number of shares, Exercisable options at end of the period Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and Development Expense [Member] Research and development expenses Convertible notes. Convertible Notes [Policy Text Block] Convertible Notes Ordinary share subscription deposit Ordinary Share Subscriptions Deposit Received Represents the amount of ordinary share subscriptions deposit received in December 2021. Equity Component [Domain] Investor warrants Investor warrants [Member] This member stands for Investor Warrants. Statistical Measurement [Domain] Deferred income taxes Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract] Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other expense, net Options expiration Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Term of awards (in years) Schedule of assumptions used for the fair value calculations of the warrants Disclosure Of Fair Value Assumptions Of Warrants [Table Text Block] The tabular disclosure for fair value assumption of warrants. Class of warrant or right purchase price. Class Of Warrant Or Right Purchase Price Purchase price of share Payables and Accruals [Abstract] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Operating Lease, Expense Weighted average exercise price, Forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Increase Decrease In Accounts Receivables And Prepaid Expense Changes in the value of accounts receivables and prepaid expenses during the period. Class of Stock [Domain] 8880 American Depositary Receipts [Member] American Depositary Shares Stock price Measurement Input, Share Price [Member] Financial Support to Nonconsolidated Legal Entity [Domain] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Ordinary shares, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Finite-Lived Intangible Assets, Major Class Name [Domain] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Percentage of the price per ADS for exercise price Percentage of Exercise Price of ADS for Exercise Price of Warrant Represents the percentage of the price per ADS for exercise price of warrants. Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of components of income tax expense Impact on income tax expense/recovery from Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Summary of activity of the Company's unvested RSUs Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Liability-classified Warrants Class of Warrant or Right, Outstanding, Liability Number of liability classified warrants or rights outstanding. Proceeds from sale of ADS Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity, Total Proceeds from issuance of shares Deferred tax adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred tax adjustments Agreement and Plan of Merger [Abstract] Agreement And Plan Of Merger [Abstract] Agreement and plan of merger. Foreign Deferred Foreign Income Tax Expense (Benefit) Share based compensation arrangement by share based payment award equity instruments other than options underlying unvested in period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Underlying Unvested In Period Shares underlying unvested Entity Interactive Data Current Finite-Lived intangible assets, remaining amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Expected percentage of reduction of workforce Restructuring And Related Cost Expected Number Of Positions Eliminated Period Percent Restructuring and related cost expected number of positions eliminated period percent. Document Quarterly Report Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (per share) Related Party Transaction [Domain] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Cash at beginning of period Cash at end of period Related Party Transactions Related Party Transactions Disclosure [Text Block] Statistical Measurement [Axis] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Foreign currency translation Aggregate nominal value cancelled Aggregate Nominal Value Cancelled Aggregate nominal value cancelled. Lease costs Operating Lease, Cost Payment terms Debt Instrument, Payment Terms May 2024 Convertible Notes Convertible Debt [Member] Convertible notes May 2024 Investor Warrants. May 2024 Investor Warrants [Member] May 2024 Investor Warrants Related and Nonrelated Parties [Domain] 2019 Investor Warrants It represents the information pertaining to Investor warrants 2019. Percentage of fair market value of shares Percentage of Fair Market Value of Shares Represents the percentage of fair market value of shares. Schedule of estimated useful lives of the assets Schedule Of Rate Of Depreciation Of Property, Plant and Equipment [Table Text Block] Tabular disclosure of rate of depreciation of property, plant and equipment. Financial Support to Nonconsolidated Legal Entity [Axis] Number of shares available to grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares remained available for future issuance Granted (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-Average Exercise Price, Issued Weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Foreign Tax Authority Foreign Tax Jurisdiction [Member] Proceeds from Issuance of Private Placement Gross proceeds from private placement Aggregate gross proceeds Loss Contingency, Nature [Domain] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Net deferred tax assets Deferred Tax Assets, Net Accrued Employee Benefits, Current Employee compensation and benefits Amendment Interim CEO Agreement Amendment Interim C E O Agreement [Member] Amendment interim CEO agreement. Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Statement of Income Location, Balance [Axis] Total assets Assets Expected life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Restructuring Type [Axis] Estimated fair value of placement agent warrants. Estimated Fair Value Of Placement Agent Warrants Estimated fair value of the placement agent warrants Payment terms to CEO upon aggrement Related Party Transaction, Terms and Manner of Settlement Foreign Current Foreign Tax Expense (Benefit) Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Ordinary shares vested Restructuring Reserve, Current Restructuring Accrued restructuring expenses New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Entity Address, City or Town Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Stock issuance costs Payments of Stock Issuance Costs Amount paid for placement agent fees and expenses Tax rate difference in foreign jurisdictions Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Grant date fair value of warrants Total Grant Date Fair Value Of Warrants The amount of total grant date fair value of warrants issued by the company. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Weighted average exerciseÂ price issued warrants. Weighted Average Exercise Price Issued Warrants Weighted-Average Exercise Price, Issued Number of shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Prior To Acquisition Gross Gross number of share options (or share units) granted during the period prior to acquisition. Laboratory testing services charges Laboratory Testing Services Charges The amount of laboratory testing services incurred during the period. Prepaid Expenses Prepaid Expenses [Policy Text Block] Disclosure of accounting policy for prepaid expenses. Restructuring Cost and Reserve [Line Items] Per share price Share Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Fair value of time-based RSUs that vested March 2024 Placement Agent Warrants March Two Thousand Twenty Four Placement Agent Warrants [Member] March two thousand twenty four placement agent warrants. Conversion description Debt Instrument, Convertible, Terms of Conversion Feature Private Placement [Member] Private Placement Long-Term Purchase Commitment, Period Equity Incentive Plan Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment

Award, Number of Shares Authorized Number of shares authorized to issue Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Vesting of restricted shares (in shares) Arithmetic average number of lowest closing prices for purchase of ADSs Threshold Number of Arithmetic Average Lowest Closing Sale Prices For Considering The Purchase Price Of ADS Number of arithmetic average of the lowest closing sale prices for the purchase price of ADSs. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Number of shares, Expired Fair Value Disclosures [Abstract] Research and development tax credits Research and Development Tax Credits Research and development tax credits. Stock Issued During Period, Value, New Issues Issuance of share capital related to financing, net of issuance costs Laboratory Testing Services It stands for Laboratory Testing Services . Current liabilities: Liabilities, Current [Abstract] Change in fair value of warrant liability Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss) Change in fair value of warrant liability Patent Acquisition Costs Intangible Assets, Finite-Lived, Policy [Policy Text Block] Issuance of Stock and Warrants for Services or Claims Issuance of share capital for vendor services Exercise Price Range Three Exercise Price Range Three Member Document Type Document Type Earnings Per Share [Table] Earnings Per Share Table Title of 12(b) Security Cash Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Cash balance Statement of Stockholders' Equity [Abstract] Fair value at beginning Fair value at ending Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Fiscal Period Focus Research and Development expenses Research and Development Expense Research and Development Expense, Total Research and development Property and equipment, gross Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Principles of Consolidation Consolidation, Policy [Policy Text Block] Subsequent Event Type [Domain] Leases Lessee, Leases [Policy Text Block] Expected term (in years) Measurement Input, Expected Term [Member] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of assumptions used to determine the fair value of stock granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustment Dr. Prudo and Dr. Patel Dr. Prudo and Dr. Patel [Member] Dr. Prudo and Dr. Patel Switzerland SWITZERLAND Payroll taxes on share-based compensation in accrued expenses Payroll taxes on share-based compensation in accrued expenses Payroll taxes on share-based compensation in accrued expenses. Class of Warrant or Right, Exercise Price of Warrants or Rights Weighted-Average Exercise Price Weighted-AverageExercise Price, Beginning Balance Weighted-AverageExercise Price, Ending Balance Exercise price of warrants Financial Instruments [Domain] United Kingdom UNITED KINGDOM APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Vesting of restricted shares Class of Warrant or Right [Line Items] Sale of Stock [Axis] Patents [Member] Income Taxes Income Tax Disclosure [Text Block] Schedule of income taxes at the UK statutory rate compared to the company's income tax expenses Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Fair value of share capital issued for services Stock Issued During Period Shares Issued For Services Grant Date Fair Value Stock issued during period shares issued for services grant date fair value. The number of equity-based payment instruments, excluding stock (or unit) options, that shares underlying vested during the reporting period. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, underlying vested in Period Shares underlying vested Selling, General and Administrative Expense Selling, General and Administrative Expense, Total General and administrative Short-Term Debt, Type [Axis] ADS American Depositary Shares ADR [Member] Short-Term Debt, Type [Domain] Other Accrued Liabilities, Current Other Entity Address, Address Line Two Liabilities and Equity [Abstract] Liabilities and Shareholders' (Deficit) Equity Paulson Paulson [Member] Paulson. Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Series A warrants Series A warrants Represents the information pertaining to Series A warrants. Stockholders' Equity Note [Abstract] Total Anti-Dilutive Share Equivalents Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Conversion amount Debt Conversion, Converted Instrument, Amount Accrued expenses Accrued Liabilities, Current Total accrued expenses Income tax expense Income Tax Expense (Benefit) Maximum number of Adss traded each working day Maximum Number Of Adss Traded Each Working Day Represents maximum number of ADSs traded each working day. Trading Symbol Convertible debt related party. Convertible Debt Related Party Convertible notes, related party Total shareholders' deficit Total shareholders' (deficit) equity Balance at beginning of the year Balance at the end of the year Equity, Attributable to Parent Pre-Funded Warrants Pre-Funded Warrants [Member] Represents the member information pertaining to Pre-Funded Warrants. Shares/ Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Deferred Tax Assets, Gross Total deferred tax assets Merger-related costs. Merger-Related Costs [Policy Text Block] Merger-Related Costs Long-Lived Tangible Asset [Axis] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Conversion price Debt Instrument, Convertible, Conversion Price Restricted Stock Units (RSUs) [Member] Restricted stock units Related Party Transactions [Abstract] Related Party Transactions Option Indexed to Issuer's Equity, Type [Domain] Issuance of 2020 Warrants Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Issuance of warrants Unrecognized compensation Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Exercise Price Range Two Exercise Price Range Two Member Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss Measurement Input Type [Axis] U.S. state taxes (net of FBOS) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other Permanent Differences, Amount The amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by other permanent differences. Number of Warrants ADSs, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Geographical [Axis] Fair Value Option, Disclosures [Table] Amount available under the share purchase commitment facility Share Purchase Commitment Amount Available Under Facility Amount available under the share purchase commitment facility. October two thousand twenty three placement agent warrants. October Two Thousand Twenty Three Placement Agent Warrants [member] October 2023 Placement Agent Warrants Use of Estimates Use of Estimates, Policy [Policy Text Block] Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Maximum annual eligible compensation contributed by each employee Cash Cash and Cash Equivalents, Policy [Policy Text Block] PP&E and other accrued liabilities Deferred Tax Assets, Property, Plant and Equipment And Other Accrued Liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant and equipment and other accrued liabilities. Related Party [Member] Related party Exercise Price Range [Domain] Shareholders' Equity Class of Stock [Line Items] Volatility Measurement Input, Price Volatility [Member] Akari Akari [Member] Akari. Exercise price (upper range) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Agreement and Plan of Merger [Line Items] Agreement And Plan Of Merger [Line Items] Agreement and plan of merger. Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Exercise Price Range One Exercise Price Range One Member Security Exchange Name Change of tax rate from prior year Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Counterparty Name [Domain] Operating Loss Carryforwards [Line Items] Standard deviation This member stands for the measurement input, standard deviation rate. Operating Expenses, Total Operating Expenses Risk-free rate Measurement Input, Risk Free Interest Rate [Member] Long-Lived Tangible Asset [Domain] Stock Issued During Period, Value, Issued for Services Issuance of share capital for services Loss Contingency Nature [Axis] Class of Stock [Axis] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Transfers between level 1 and level 2 Fair Value Measurement, Recurring Basis, Liability, Transfers Between Level 1 And Level 2, Net Amount of transfers of financial instrument classified as a liability between level1 and level 2 of the fair value hierarchy. Fair Value Measurements Fair Value Disclosures [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value per share of options granted Subsequent Event [Member] Subsequent Event Maximum [Member] Maximum Total liabilities and shareholders' deficit Liabilities and Equity Prepaid expenses Prepaid Expense, Current Prepaid Expense, Current, Total Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFO: Financial liabilities measured at fair value Financial Liabilities Fair Value Disclosure Financial Liabilities Fair Value Disclosure, Total Retirement Plan Sponsor Location [Domain] Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net loss per share - diluted Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Aggregate ADSs issued (in shares) Stock Issued During Period, Shares, New Issues Issuance of share capital related to financing, net of issuance costs (in shares) Unrecognized tax benefits Unrecognized Tax Benefits Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period (in years) Entity Filer Category Aggregate nominal value cancelled per share Aggregate Nominal Value Cancelled Per Share Aggregate nominal value cancelled per share. Number of shares issued upon conversion Debt Conversion, Converted Instrument, Shares Issued September 2022 Investor Warrants September 2022 Investor Warrants [Member] This member represents information pertaining to September 2022 Investor warrants. Unvested restricted stock units. Unvested Restricted Stock Units [Member] Unvested RSUs Capital redemption reserve Capital Redemption Reserve The amount of Capital redemption reserve. Other income (expense): Nonoperating Income (Expense) [Abstract] Accrued external research and development expenses. Accrued External Research and Development Expenses External research and development expenses Current Fiscal Year End Date Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Fully Vested Ordinary Shares Fully Vested Ordinary Shares [Member] Fully vested ordinary shares. Payments on short-term financing arrangement Repayments of Short-Term Debt Repayments of Short-Term Debt, Total Share-based compensation Share-Based Payment Arrangement, Noncash Expense Share-Based Payment Arrangement, Noncash Expense, Total Grantee Status [Domain] Related Party Transaction [Axis] Aggregate intrinsic value, Options outstanding at beginning of the period Aggregate intrinsic value, Options outstanding at end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Related and Nonrelated Parties [Axis] Restructuring charges unpaid Restructuring charges unpaid Restructuring-related charges unpaid Registrant Name Entity Registrant Name Closing bid price (in dollars per ADS) Closing Bid Price (in dollars per ADS) Closing bid price (in dollars per ADS). Operating loss unlimited carryforward amount. Operating Loss Unlimited Carryforward Amount Operating loss unlimited carryforward amount Share-Based Compensation Arrangement by Share-Based Payment Award, Outstanding, Number Number of outstanding stock options and restricted stock units. Number of ordinary shares underlying outstanding equity awards consisting of stock options and restricted stock units Registered offering. Registered Offering [Member] Registered Offering Consulting charges Consulting Charges The amount of consulting charges incurred during the period. Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity Emerging Growth Company July 2021 warrants It represents July 2021 Warrants member. Other current liabilities Other Liabilities, Current Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average number of ordinary shares used in computing net loss per share- basic Vesting [Domain] Loss Contingencies [Line Items] Repayments of convertible notes Repayments of Convertible Debt Ordinary shares, shares authorized Common Stock, Shares Authorized Number of shares authorized Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares withheld for payroll taxes (in shares) Shares withheld for payroll taxes (in shares) Interest Payable, Current Accrued interest Property, pant and equipment, useful life Property, Plant and Equipment, Useful Life Grantee Status [Axis] Proceeds from issuance of shares, net of issuance costs Proceeds from Issuance of Common Stock Net proceeds from sale of shares Schedule of changes in accumulated other comprehensive loss Comprehensive Income (Loss) [Table Text Block] Warrants Issued Class of Warrant Or Right issued Number of warrants or rights issued. Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Proceeds from employee vesting of restricted shares Number of Shares to be Issued Number Of Shares To Be Issued Number of shares to be issued. Weighted average exercise price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortization of intangible assets Amortization of Intangible Assets Exercise Price Range [Axis] Financial Instrument [Axis] Uncertain Tax Positions Income Tax Uncertainties, Policy [Policy Text Block] December 2021 Investor Warrants December 2021 Investor Warrants This member represents information pertaining to December 2021 Investor Warrants. Weighted average remaining contractual life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual life, Options outstanding during the period (in years) Warrants Equity Classified Warrants Equity Classified Member Warrants Earnings Per Share, Policy [Policy Text Block] Net loss per share General and Administrative Expense [Member] General and administrative expenses Stock Issued During Period Issue Price Per Share New Issues Per share price of new stock issued during the period. Price per share Price per share Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Rental expense Operating Lease Rent Expense The amount of operating lease rent expense. Proceeds from Issuance of Warrants Aggregate gross proceeds Restructuring Plan [Axis] Accounting Policies [Abstract] Schedule of share option activity and related information for employees and directors Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-Term Line of Credit, Total Long-Term Line of Credit Equity line of credit Income Tax Disclosure [Abstract] Shareholders' deficit: Equity, Attributable to Parent [Abstract] Warrants exercised Class of Warrant Or Right Exercised Number of warrants or right Exercised. Consulting Services [Member] This member stands for Consulting Services. Number of ordinary shares representing one ADS Number Of Ordinary Shares Representing One American Depositary Share Number of ordinary shares representing one ADS. Exercise price Measurement Input, Exercise Price [Member] Statement [Table] Segment Reporting, Policy [Policy Text Block] Segments Schedule of components of property and equipment Property, Plant and Equipment [Table Text Block] March 2022 Investor Warrants March 2022 Investor Warrants This member represents information pertaining to March 2022 Investor Warrants. Subsequent Event [Table] Significant Accounting Policies [Table] Significant Accounting Policies Table England Great Britain Represents the information pertaining to Great Britain. Excess fair value of warrant liability over cash proceeds Fair Value Adjustment of Warrants Excess in fair value of warrant liability over cash proceeds Entity File Number Series D Warrants Series D Warrants [Member] Series D Warrants [Member] Net decrease in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Percentage of volume weighted average price indicating purchase price Percentage Of Volume Weighted Average Price Indicating Purchase Price It represents the percentage of Volume-weighted average price indicating purchase price. Expiration term of warrants Term of the warrants Warrants and Rights Outstanding, Term Default, interest rate percentage Debt default, interest rate percentage. Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Statement of Financial Position [Abstract] Interest Expense, Total Interest Expense, Operating and Nonoperating Interest expense Interest expense Loss from operations Operating Income (Loss) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Equity Incentive Plan 2014 [Member] Represents the member information pertaining to 2014 Equity Incentive Plan. Equity Incentive Plan 2014 Entity Shell Company Registered direct offering Registered Direct Offering [Member] Represents information pertaining to Registered Direct Offering. Accrued Professional Fees, Current Professional and consulting fees Series B warrants Series B warrants Represents the information pertaining to Series B warrants. Entity Tax Identification Number Assets Assets [Abstract] Class of Warrant or Right [Domain] Payment to CEO upon aggrement Related Party Transaction, Amounts of Transaction Entity Current Reporting Status Aspire Capital Fund LLC Aspire Capital Fund, LLC Series C Warrants. Series C Warrants [Member] Series C Warrants Weighted average remaining contractual term, Options exercisable at end of the period (in years) Remaining contractual life (years for exercisable options) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Effective income tax rate reconciliation, non-deductible transaction costs. Effective Income Tax Rate Reconciliation, Non-deductible transaction costs Non-deductible transaction costs Non-deductible transaction costs Subsequent Events Defined Contribution Plan, Description Description of employee benefit plans Weighted average grant date fair value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Prior To Acquisition Weighted Average Grant Date Fair Value Weighted average per share amount at which grantees can forfeited shares of common stock by exercise of options prior to acquisition. Geographical [Domain] Document Fiscal Year

Focus Financing costs in accrued expenses. Financing costs in accrued expenses The Doctors Laboratory Doctors Laboratory Member Accrued Expenses Accrued Expenses [Policy Text Block] Disclosure of accounting policy for accrued expenses. City Area Code Warrants outstanding, measurement input Warrants outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Total current liabilities Liabilities, Current Weighted average exercise price expired warrants. Weighted Average Exercise Price Expired Warrants Weighted-Average Exercise Price, Expired 2021 Private Placement Represents the member information pertaining to 2021 Private Placement. Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Description of Business Description of Business Local Phone Number Change in operating losses Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Change in Operating Losses, Amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in operating losses. Retirement Plan Sponsor Location [Axis] 2021 Warrants Represents the member information pertaining to 2021 Warrants. Income Tax Jurisdiction [Axis] Proceeds from exercise of warrants to purchase shares Proceeds from Warrant Exercises Restructuring and other costs. Restructuring and Other Costs [Policy Text Block] Restructuring and Other Costs Income Taxes Income Tax, Policy [Policy Text Block] Schedule of components of income/(loss) before income taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Ordinary shares. Ordinary Shares [Member] Ordinary Shares Akari Ordinary Shares Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] October two thousand twenty three investor prefunded warrants. October Two Thousand Twenty Three Investor Prefunded Warrants [Member] October 2023 Investor Prefunded Warrants Equity-classified Warrants Class of Warrant or Right, Outstanding, Equity Number of equity classified warrants or rights outstanding. Unvested stock option. Unvested Stock Option [Member] Unvested Stock Option Document Information [Line Items] Document Information: Income Tax Jurisdiction [Domain] Interest rate per annum Debt Instrument, Interest Rate, Stated Percentage Accumulated Deficit Retained Earnings [Member] Proceeds from issuance of private placement after deducting agent fees and other expenses. Proceeds From Issuance Of Private Placement After Deducting Agent Fees And Other Expenses Net proceeds Accrued Liabilities, Current [Abstract] Schedule of financial liabilities measured at fair value on a recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Transition Report Akari and Peak Bio. Akari And Peak Bio [Member] Akari and Peak Bio Fair Value Measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Minimum [Member] Minimum Number of Warrants ADSs, Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Ordinary shares Common Stock [Member] Share Capital Weighted average grant date fair value per share, Beginning of the period (per share) Weighted average grant date fair value per share, End of the period (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Additional Paid-in Capital Additional Paid-in Capital [Member] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Warrant revaluation Deferred Tax Assets Warrant Revaluation Amount of deferred tax assets warrant revaluation. Statement of Income Location, Balance [Domain] Restructuring and Other Costs [Member] Restructuring and other costs [Member] Restructuring and other costs Other current assets Other Assets, Current Realized Gain (Loss), Foreign Currency Transaction, before Tax Foreign currency exchange gain (loss), net Entity Common Stock, Shares Outstanding Received from issuance of offering Received From Issuance of Offering Amount received from issuance of offering. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Title and Position [Domain] Fair value of warrants Warrants and Rights Outstanding Domestic (UK) Income (Loss) from Continuing Operations before Income Taxes, Domestic Share capital of $0.0001 par value Authorized: 45,122,321,523 ordinary shares at September 30, 2024 and December 31, 2023, respectively; issued and outstanding: 24,289,231,523 and 13,234,315,298 at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Asset Acquisition [Table] Peak common stock. Peak Common Stock [Member] Peak Common Stock Initial valuation of warrant liability Initial Valuation of Warrant Liability, Non-cash Financing Activities The amount of initial valuation of warrant liability non-cash financing activities. Investment Income, Interest Interest income November 6, 2029 Security Expiring on November Six Two Thousand [Member] Security expiring on november six two thousand. Placement agent Placement agent warrants [Member] This member stands for Placement Agent Warrants. Registered Direct Offering 2021 Registered Direct Offering 2021 [Member] This member stands for Registered Direct Offering 2021. Measurement Frequency [Axis] Foreign Plan [Member] U.K. Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Expenses Tax loss carry forward Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Total Commitments and contingencies (Note 9) Commitments and Contingencies Share-Based Payment Arrangement, Nonemployee [Member] Directors Dilutive weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted-average number of ordinary shares used in computing net loss per share - diluted Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Weighted average grant date fair value, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Prior To Acquisition Weighted Average Grant Date Fair Value Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options prior to acquisition. 2020 Placement Warrants It represents the information pertaining to placement warrants 2020. Warrants and Rights Outstanding, Maturity Date Warrant expiration date Operating expenses: Operating Costs and Expenses [Abstract] Entity Small Business Fair value of commitment shares Fair value of Commitment Shares It represents the information pertaining to fair value of commitment shares. Other Current Liabilities Other Current Liabilities Policy [Policy Text Block] Other current liabilities. Stock Issued During Period, Shares, Issued for Services Issuance of share capital for services (in shares) Gain (Loss), Foreign Currency Transaction, before Tax Gain (Loss), Foreign Currency Transaction, before Tax, Total Foreign currency exchange losses (gains) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted average exercise price, Expired Deferred shares issued price per share Deferred Shares Issued Price Per Share Deferred shares issued price per share. Additional share based compensation expense. Additional Share Based Compensation Expense Additional stock-based compensation expense Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Weighted average exercise Price Weighted average exercise price, Outstanding at beginning of the period Weighted average exercise price, Outstanding at end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses Additional restructuring charges. Additional Restructuring Charges Additional restructuring-related expenses Patent acquisition costs, net Intangible Assets, Net (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill), Total Deferred tax assets Deferred Tax Assets, Gross [Abstract] State and Local Jurisdiction [Member] US State Interim CEO Agreement. Interim CEO Agreement [Member] Interim Ceo Agreement Measurement Frequency [Domain] Valuation allowance Deferred Tax Assets, Valuation Allowance Total other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Inputs, Level 3 [Member] Level 3 Subsequent Events Subsequent Events [Text Block] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Weighted average grant date fair value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Change in equity compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Fair value of warrants Stock Options And Warrants Fair Value Disclosure Fair value of stock options and warrants as of reporting date. Held by an executive upon termination. Held By an Executive Upon Termination [Member] Held By an Executive Upon Termination XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 15, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Registrant Name Akari Therapeutics, Plc Â Entity Central Index Key 0001541157 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Common Stock, Shares Outstanding Â 49,517,115,523 Entity Shell Company false Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity File Number 001-36288 Â Entity Incorporation, State or Country Code X0 Â Entity Tax Identification Number 98-1034922 Â Entity Address, Address Line One 22 Boston Wharf Road Â Entity Address, Address Line Two FL 7 Â Entity Address, City or Town Boston Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02210 Â City Area Code 929 Â Local Phone Number 274-7510 Â Document Quarterly Report true Â Document Transition Report false Â American Depositary Shares Â Â Document Information [Line Items] Â Â Title of 12(b) Security American Depositary Shares, each representing 2,000 Ordinary Shares, par value $0.0001 per share Â Trading Symbol AKTX Â Security Exchange Name NASDAQ Â Ordinary shares Â Â Document Information [Line Items] Â Â Title of 12(b) Security Ordinary Shares, $0.0001 par value per share* Â Trading Symbol AKTX Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange

Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=sic_Z8880 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash $ 2,246 $ 3,845 Prepaid expenses 396 299 Other current assets 92 197 Total current assets 2,734 4,341 Patent acquisition costs, net Â 14 Total assets 2,734 4,355 Current liabilities: Â Â Accounts payable 4,782 1,671 Accrued expenses 2,605 1,566 Convertible notes, related party 1,000 Â Warrant liability 725 1,253 Other current liabilities 316 94 Total current liabilities 9,428 4,584 Commitments and contingencies (Note 9) Shareholders' deficit: Â Â Share capital of $0.0001 par value Authorized: 45,122,321,523 ordinary shares at September 30, 2024 and December 31, 2023, respectively; issued and outstanding: 24,289,231,523 and 13,234,315,298 at September 30, 2024 and December 31, 2023, respectively 2,430 1,324 Additional paid-in capital 183,088 174,754 Capital redemption reserve 52,194 52,194 Accumulated other comprehensive loss (926) (1,040) Accumulated deficit (243,480) (227,461) Total shareholders' deficit (6,694) (229) Total liabilities and shareholders' deficit $ 2,734 $ 4,355 X - DefinitionThe amount of Capital redemption reserve. + ReferencesNo definition available. + Details Name: aktx_CapitalRedemptionReserve Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionConvertible debt related party. + ReferencesNo definition available. + Details Name: aktx_ConvertibleDebtRelatedParty Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of liability towards warrants, current. + ReferencesNo definition available. + Details Name: aktx_WarrantLiabilitiesCurrent Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions.

Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) Sep. 30, 2024 $ / shares shares Dec. 31, 2023 $ / shares shares Statement of Financial Position [Abstract] Â Â Ordinary shares, par value | (per share) $ 0.0001 $ 0.0001 Ordinary shares, shares authorized 45,122,321,523 45,122,321,523 Ordinary shares, shares issued 24,289,231,523 13,234,315,298 Ordinary shares, shares outstanding 24,289,231,523 13,234,315,298 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses: Â Â Â Â Research and development $ 143 $ (314) $ 5,736 $ 2,941 General and administrative 1,709 2,821 6,616 8,775 Merger-related costs 992 Â 2,290 Â Restructuring and other costs 83 Â 1,723 Â Loss from operations (2,927) (2,507) (16,365) (11,716) Other income (expense): Â Â Â Â Interest income 3 16 7 75 Interest expense (69) Â (120) Â Change in fair value of warrant liability 30 (258) 528 5,889 Foreign currency exchange gain (loss), net 68 (100) (67) (72) Other expense, net Â (22) (2) (46) Total other income (expense), net 32 (364) 346 5,846 Net loss $ (2,895) $ (2,871) $ (16,019) $ (5,870) Net loss per share - basic $ 0 $ 0 $ 0 $ 0 Net loss per share - diluted $ 0 $ 0 $ 0 $ 0 Weighted-average number of ordinary shares used in computing net loss per share- basic 24,386,005,523 10,116,903,598 18,911,928,794 10,119,421,200 Weighted-average number of ordinary shares used in computing net loss per share - diluted 24,386,005,523 10,116,903,598 18,911,928,794 10,119,421,200 Comprehensive loss: Â Â Â Â Net loss $ (2,895) $ (2,871) $ (16,019) $ (5,870) Other comprehensive income, net of tax: Â Â Â Â Foreign currency translation adjustment (177) (3) 114 (58) Total other comprehensive income, net of tax (177) (3) 114 (58) Total comprehensive loss $ (3,072) $ (2,874) $ (15,905) $ (5,928) X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section

45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling

expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands Total Share Capital Additional Paid-in Capital Capital Redemption Reserve Accumulated Other Comprehensive Loss Accumulated Deficit Balance at beginning of the year at Dec. 31, 2022 $ 1,791 $ 745 $ 167,076 $ 52,194 $ (771) $ (217,453) Balance at the beginning of the year (in shares) at Dec. 31, 2022 Â 7,444,917,123 Â Â Â Â Issuance of share capital related to financing, net of issuance costs 3,502 $ 267 3,235 Â Â Â Issuance of share capital related to financing, net of issuance costs (in shares) Â 2,666,666,700 Â Â Â Â Share-based compensation 265 Â 265 Â Â Â Foreign currency translation 2 Â Â Â 2 Â Net Income (Loss) 1,001 Â Â Â Â 1,001 Balance at the end of the year at Mar. 31, 2023 6,561 $ 1,012 170,576 52,194 (769) (216,452) Balance at the end of the year (in shares) at Mar. 31, 2023 Â 10,111,583,823 Â Â Â Â Balance at beginning of the year at Dec. 31, 2022 1,791 $ 745 167,076 52,194 (771) (217,453) Balance at the beginning of the year (in shares) at Dec. 31, 2022 Â 7,444,917,123 Â Â Â Â Net Income (Loss) (5,870) Â Â Â Â Â Balance at the end of the year at Sep. 30, 2023 213 $ 1,013 171,157 52,194 (828) (223,323) Balance at the end of the year (in shares) at Sep. 30, 2023 Â 10,125,005,923 Â Â Â Â Balance at beginning of the year at Mar. 31, 2023 6,561 $ 1,012 170,576 52,194 (769) (216,452) Balance at the beginning of the year (in shares) at Mar. 31, 2023 Â 10,111,583,823 Â Â Â Â Vesting of restricted shares 1 $ 1 Â Â Â Â Vesting of restricted shares (in shares) Â 10,737,700 Â Â Â Â Share-based compensation 276 Â 276 Â Â Â Foreign currency translation (57) Â Â Â (57) Â Net Income (Loss) (4,000) Â Â Â Â (4,000) Balance at the end of the year at Jun. 30, 2023 2,781 $ 1,013 170,852 52,194 (826) (220,452) Balance at the end of the year (in shares) at Jun. 30, 2023 Â 10,122,321,523 Â Â Â Â Vesting of restricted shares (in shares) Â 2,684,400 Â Â Â Â Share-based compensation 305 Â 305 Â Â Â Foreign currency translation (2) Â Â Â (2) Â Net Income (Loss) (2,871) Â Â Â Â (2,871) Balance at the end of the year at Sep. 30, 2023 213 $ 1,013 171,157 52,194 (828) (223,323) Balance at the end of the year (in shares) at Sep. 30, 2023 Â 10,125,005,923 Â Â Â Â Balance at beginning of the year at Dec. 31, 2023 (229) $ 1,324 174,754 52,194 (1,040) (227,461) Balance at the beginning of the year (in shares) at Dec. 31, 2023 Â 13,234,315,298 Â Â Â Â Issuance of share capital related to financing, net of issuance costs 1,664 $ 264 1,400 Â Â Â Issuance of share capital related to financing, net of issuance costs (in shares) Â 2,641,228,000 Â Â Â Â Vesting of restricted shares 3 $ 10 (7) Â Â Â Vesting of restricted shares (in shares) Â 97,578,000 Â Â Â Â Share-based compensation 296 Â 296 Â Â Â Foreign currency translation 279 Â Â Â 279 Â Net Income (Loss) (5,566) Â Â Â Â (5,566) Balance at the end of the year at Mar. 31, 2024 (3,553) $ 1,598 176,443 52,194 (761) (233,027) Balance at the end of the year (in shares) at Mar. 31, 2024 Â 15,973,121,298 Â Â Â Â Balance at beginning of the year at Dec. 31, 2023 (229) $ 1,324 174,754 52,194 (1,040) (227,461) Balance at the beginning of the year (in shares) at Dec. 31, 2023 Â 13,234,315,298 Â Â Â Â Net Income (Loss) (16,019) Â Â Â Â Â Balance at the end of the year at Sep. 30, 2024 (6,694) $ 2,430 183,088 52,194 (926) (243,480) Balance at the end of the year (in shares) at Sep. 30, 2024 Â 24,289,231,523 Â Â Â Â Balance at beginning of the year at Mar. 31, 2024 (3,553) $ 1,598 176,443 52,194 (761) (233,027) Balance at the beginning of the year (in shares) at Mar. 31, 2024 Â 15,973,121,298 Â Â Â Â Issuance of share capital related to financing, net of issuance costs 6,951 $ 806 6,145 Â Â Â Issuance of share capital related to financing, net of issuance costs (in shares) Â 8,059,508,000 Â Â Â Â Issuance of share capital for services Â $ 9 (9) Â Â Â Issuance of share capital for services (in shares) Â 91,396,000 Â Â Â Â Vesting of restricted shares Â $ 29 (29) Â Â Â Vesting of restricted shares (in shares) Â 285,697,400 Â Â Â Â Shares withheld for payroll taxes Â $ (12) 12 Â Â Â Shares withheld for payroll taxes (in shares) Â (120,490,000) Â Â Â Â Share-based compensation 445 Â 445 Â Â Â Foreign currency translation 12 Â Â Â 12 Â Net Income (Loss) (7,558) Â Â Â Â (7,558) Balance at the end of the year at Jun. 30, 2024 (3,703) $ 2,430 183,007 52,194 (749) (240,585) Balance at the end of the year (in shares) at Jun. 30, 2024 Â 24,289,232,698 Â Â Â Â Proceeds from issuance of restricted shares 26 Â 26 Â Â Â Shares withheld for payroll taxes (193) Â (193) Â Â Â Shares withheld for payroll taxes (in shares) Â (1,175) Â Â Â Â Share-based compensation 248 Â 248 Â Â Â Foreign currency translation (177) Â Â Â (177) Â Net Income (Loss) (2,895) Â Â Â Â (2,895) Balance at the end of the year at Sep. 30, 2024 $ (6,694) $ 2,430 $ 183,088 $ 52,194 $ (926) $ (243,480) Balance at the end of the year (in shares) at Sep. 30, 2024 Â 24,289,231,523 Â Â Â Â X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification

-Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Parenthetical) Sep. 30, 2024 $ / shares Jun. 30, 2024 $ / shares Mar. 31, 2024 $ / shares Dec. 31, 2023 $ / shares Sep. 30, 2023 $ / shares Jun. 30, 2023 $ / shares Mar. 31, 2023 $ / shares Dec. 31, 2020 $ / shares Dec. 31, 2020 Â£ / shares Statement of Stockholders' Equity [Abstract] Â Â Â Â Â Â Â Â Â Â Share capital, par value | (per share) $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 Â£ 0.01 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Net loss $ (2,895) $ (2,871) $ (16,019) $ (5,870) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Depreciation and amortization Â Â 13 3 Share-based compensation Â Â 989 846 Change in fair value of warrant liability (30) 258 (528) (5,889) Foreign currency exchange losses (gains) Â Â 121 (54) Change in assets and liabilities: Â Â Â Â Prepaid expenses and other current assets Â Â 1,114 (223) Accounts payable and accrued expenses Â Â 3,882 (836) Net cash used in operating activities Â Â (10,428) (12,023) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Proceeds from issuance of shares, net of issuance costs Â Â 8,687 3,502 Proceeds from issuance of convertible notes Â Â 1,000 Â Proceeds from issuance of restricted shares Â Â 29 1 Payments on short-term financing arrangement Â Â (882) Â Net cash provided by financing activities Â Â 8,834 3,503 Effect of exchange rates on cash Â Â (5) 1 Net decrease in cash Â Â (1,599) (8,519) Cash at beginning of period Â Â 3,845 13,250 Cash at end of period $ 2,246 $ 4,731 2,246 $ 4,731 SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: Â Â Â Â Financing costs in accrued expenses Â Â 72 Â Non-cash seller-financed purchases Â Â 1,105 Â Payroll taxes on share-based compensation in accrued expenses Â Â 193 Â SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFO: Â Â Â Â Cash paid during the period for interest Â Â $ 120 Â X - DefinitionFinancing costs in accrued expenses. + ReferencesNo definition available. + Details Name: aktx_FinancingCostsInAccruedExpenses Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChanges in the value of accounts receivables and prepaid expenses during the period. + ReferencesNo definition available. + Details Name: aktx_IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash seller-financed purchases. + ReferencesNo definition available. + Details Name: aktx_NonCashSellerFinancedPurchases Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayroll taxes on share-based compensation in accrued expenses. + ReferencesNo definition available. + Details Name: aktx_PayrollTaxesOnShareBasedCompensationInAccruedExpenses Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of restricted shares. + ReferencesNo definition available. + Details Name: aktx_ProceedsFromIssuanceOfRestrictedShares Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3) and still held. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (2,895) $ (7,558) $ (5,566) $ (2,871) $ (4,000) $ 1,001 $ (16,019) $ (5,870) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-

1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 9 Months Ended Sep. 30, 2024 Description of Business Â Description of Business Note 1. Description of BusinessBusiness OverviewAkari Therapeutics, Plc, (the â€œCompanyâ€ or â€œAkariâ€) is incorporated in the United Kingdom. The Company is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (â€œC5â€) and leukotriene B4 (â€œLTB4â€) pathways. The Companyâ€™s activities since inception have consisted of performing research and development activities and raising capital.The Company is subject to a number of risks similar to those of preclinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with preclinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies.To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities.Merger with Peak BioAs further described in Note 10, on November 14, 2024, the Company closed the previously announced merger with Peak Bio, Inc. (â€œPeak Bioâ€). As a result, the Company expanded its pipeline of assets spanning early and late development stages with the addition of Peak Bioâ€™s antibody drug conjugate (â€œADCâ€) toolkit with novel payload and linker technologies as well as the Peak Bio PHP-303 small molecule selective and reversible neutrophil elastase inhibitor. By combining chemotherapy with immunotherapy strategies, the Company aims to develop cutting-edge solutions for cancer patients. Liquidity and Financial ConditionThe Company follows the provisions of Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 205-40, Presentation of Financial Statementsâ€”Going Concern, which requires management to assess the Companyâ€™s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.The Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $243.5 million as of September 30, 2024. The Companyâ€™s cash balance of $2.2 million as of September 30, 2024 is not sufficient to fund its operations for the one-year period after the date these condensed consolidated financial statements are issued. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of clinical trial outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: product development financing, private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful. Nasdaq Continued Listing RulesOn April 5, 2024, the Company received a letter (â€œLetterâ€) from the Listing Qualifications Staff (the â€œStaffâ€) of The Nasdaq Capital Market (â€œNasdaqâ€) notifying the Company that the Companyâ€™s shareholdersâ€™ equity as reported in its Form 10-K is no longer in compliance with the minimum shareholdersâ€™ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain shareholdersâ€™ equity of at least $2.5 million (the â€œShareholdersâ€™ Equity Requirementâ€). As reported on the Form 10-K, the Companyâ€™s shareholdersâ€™ deficit as of December 31, 2023 was approximately $0.2 million. As of September 30, 2024, the Company had a shareholders' deficit of $6.7 million and was not in compliance with the Shareholders' Equity Requirement. In accordance with the Nasdaq Listing Rules, on May 20, 2024, the Company submitted a plan to regain compliance with the Stockholdersâ€™ Equity Requirement (the â€œCompliance Planâ€) for the Staffâ€™s consideration. On August 5, 2024, the Company was notified by the Staff that it has been granted an extension until September 30, 2024 to comply with the Compliance Plan and evidence compliance with the Shareholdersâ€™ Equity Requirement. On October 1, 2024, the Company received a delisting determination letter (â€œDelisting Determination Letterâ€) from the Staff notifying the Company that it did not meet the terms of an extension granted by Nasdaq to regain compliance with the Shareholdersâ€™ Equity Requirement. On October 8, 2024, the Company requested a hearing (the â€œHearingâ€) before the Nasdaq Listing Qualifications Panel (â€œPanelâ€) to appeal the Staffâ€™s delisting determination.Â On November 18, 2024, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the Company has regained compliance with the Shareholdersâ€™ Equity Requirement, and that the Hearing, originally scheduled for November 21, 2024, has been canceled. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Note 2. Summary of Significant Accounting PoliciesBasis of presentation â€“ The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of expected results for the fiscal year ended December 31, 2024 or any other future period. These interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements as of December 31, 2023 and notes thereto included in its Form 10-K, as filed with the SEC on March 29, 2024.Principles of consolidation â€“ The condensed consolidated financial statements include the accounts of the Company, Celsus Therapeutics, Inc., a Delaware corporation, Volution Immuno Pharmaceuticals SA, a private Swiss company, and Akari Malta Limited, a private Maltese company, each wholly-owned subsidiaries. All intercompany transactions have been eliminated.Foreign currency â€“ The functional currency of the Company is U.S. dollars, as that is the currency of the primary economic environment in which the Company operates as well as the currency in which it has been financed.The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company's foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S. operationsâ€™ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses).Use of estimates â€“ The preparation of the Companyâ€™s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.Concentration of credit risk â€“ Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.Fair value measurements â€“ Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, Fair Value Measurements and Disclosures (â€œASC 820â€) establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:â€¢Level 1 â€“ quoted prices in active markets for identical assets and liabilities.â€¢Level 2 â€“ inputs other than Level 1

that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢Level 3 â€“ unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.The carrying values of the Companyâ€™s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Companyâ€™s liability-classified warrants are recorded at their estimated fair value. See Note 4.Cash â€“ The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of September 30, 2024 or December 31, 2023.Prepaid expenses â€“ Payments made prior to the receipt of goods or services are capitalized until the goods or services are received.Other current assets â€“ Other current assets as of September 30, 2024 and December 31, 2023 were principally comprised of Value Added Tax (â€œVATâ€) receivables.Patent acquisition costs â€“ Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 years. The Company expenses costs associated with maintaining and defending patents after their issuance in the period incurred. Amortization expense for each of the three and nine months ended September 30, 2024 and 2023 was less than $0.1 million.Accrued expenses â€“ As part of the process of preparing the condensed consolidated financial statements, the Company estimates accrued expenses. This process involves identifying services that third parties have performed on the Companyâ€™s behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Companyâ€™s condensed consolidated financial statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials, professional service fees and contingent liabilities. In connection with these service fees, the Companyâ€™s estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. If the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, the Companyâ€™s reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to the Companyâ€™s estimation and judgment. The Company makes these judgments based upon the facts and circumstances known to it in accordance with U.S. GAAP. See Note 5.Convertible Notes â€“ On May 10, 2024, the Company entered into unsecured convertible promissory notes (the â€œMay 2024 Notesâ€) with existing investors: the Companyâ€™s Chairman, Dr. Ray Prudo, and Interim President and Chief Executive Officer and director of the Company, Dr. Samir Patel, for an aggregate of $1.0 million in gross proceeds. The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Companyâ€™s receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Companyâ€™s ADSs on the issuance date, subject to certain restrictions. In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash.The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options (â€œASC 470-20â€) and has not elected the fair value option as provided for within ASC Topics 815 and 825. Accordingly, the Company evaluated the embedded conversion and other features within the May 2024 Notes to determine whether any of the embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value. Based on managementâ€™s evaluation, the Company determined that the May 2024 Notes were not issued at a substantial premium and none of the embedded features were required to be bifurcated and accounted for separately. Accordingly, the May 2024 Notes are accounted for as a single liability measured at its amortized cost. Issuance costs incurred in connection with the issuance of the May 2024 Notes were immaterial. Interest expense incurred on the May 2024 Notes was less than $0.1 million for the three and nine months ended September 30, 2024. As of September 30, 2024, accrued interest on the May 2024 Notes of less than $0.1 million is included within â€œAccrued expensesâ€ in the Companyâ€™s balance sheets.Warrant Liability â€“ The Company accounts for ordinary share or ADS warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and/or ASC Topic 815, Derivatives and Hedging (â€œASC 815â€), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at issuance and are remeasured each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are recorded in "change in fair value of warrant liability" in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss. Equity-classified warrants are recorded within "additional paid-in capital" in the Company's condensed consolidated statements of shareholders' (deficit) equity at the time of issuance and not subject to remeasurement.Â In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants (â€œSeries A Warrantsâ€) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants (â€œSeries B Warrantsâ€) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the â€œSeptember 2022 Warrantsâ€).The Company determined that the September 2022 Warrants are not indexed to the Companyâ€™s own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entityâ€™s Own Stock. Accordingly, the Company classifies the September 2022 Warrants as derivative liabilities in its consolidated balance sheets. In September 2024, all outstanding Series A Warrants expired unexercised.Other Current Liabilities â€“ In February 2024, the Company entered into a short-term financing arrangement with a third-party vendor to finance insurance premiums. The aggregate amount financed under this agreement was $1.1 million, bearing interest at an annual rate of 7.49%. As of September 30, 2024, the balance of $0.2 million, which is included in â€œOther current liabilitiesâ€ in the Companyâ€™s balance sheets, is scheduled to be paid in monthly installments through November 2024.Research and development expenses â€“ Costs associated with research and development are expensed as incurred unless there is an alternative future use in other research and development projects. Research and development expenses include, among other costs, salaries and personnelâ€“related expenses, fees paid for contract research services, fees paid to clinical research organizations, costs incurred by outside laboratories, manufacturers and other accredited facilities in connection with clinical trials and preclinical studies.Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Companyâ€™s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Companyâ€™s estimate, the Company will adjust the accrued or prepaid expense balance accordingly.The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024 and 2023, the Company recognized research and development tax credits of approximately $1.3 million and $2.6 million, respectively.Merger-Related Costs â€“ Merger-related costs include direct expenses incurred in connection with the proposed Merger, as more fully described in Note 3, and are comprised primarily of legal and professional fees and other incremental costs directly associated to the Merger. For the three and nine months ended September 30, 2024 merger-related costs totaled $1.0 million and $2.3 million, respectively.Â Restructuring and Other Costs â€“ In May 2024, the Company began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced program prioritization under which the Companyâ€™s HSCT-TMA program was suspended. The reduction-in-force was part of an operational restructuring plan (the â€œMay 2024 Planâ€) which included the elimination of certain senior management positions and was completed in the third quarter of 2024. The purpose of the restructuring plan, including the reduction-in-force, was to reduce HSCT-TMA related operating costs, while supporting the execution of the Companyâ€™s long-term strategic plan. During the three and nine months ended September 30, 2024, the Company has incurred restructuring-related charges of less than $0.1 million and $1.7 million related to the May 2024 Plan, respectively. Of the $1.7 million incurred during the nine months ended September 30, 2024, $1.4 million related to severance and other settlement payments to terminated executives and employees, and $0.3 million was non-cash expenses related to accelerated vesting of equity awards. The Company does not expect to incur additional restructuring-related expenses related to the May 2024 Plan.Â As of September 30, 2024, of the $1.7 million total restructuring-related charges incurred, approximately $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be paid in the fourth quarter of 2024.Share-based compensation expense â€“ The Company measures all share-based awards granted to employees, directors and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective awards. Forfeitures are accounted for as they occur. The Company classifies share-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified.The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Companyâ€™s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Companyâ€™s historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Companyâ€™s options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.Leases â€“ The Company accounts for its leases in accordance with ASC 842, Leases. In accordance with ASC 842, the Company records a right-of-use (â€œROUâ€) asset and corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and are recognized on a straight-line basis over the lease term. As of September 30, 2024 and December 31, 2023, the Company did not have any leases with a term longer than twelve months. Accordingly, no ROU assets and corresponding lease liabilities are included in the Companyâ€™s condensed consolidated balance sheets as of September 30, 2024 or December 31, 2023.Income taxes â€“ In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and nine months ended September 30, 2024 and 2023, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. The Company has not recorded its net deferred tax asset as of either September 30, 2024 or December 31, 2023 because it maintained a full valuation allowance against all deferred tax assets as of these dates as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions.Net loss per share â€“ Basic net loss per ordinary share is computed by dividing net loss available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, which includes ordinary shares underlying pre-funded warrants, as such warrant is exercisable, in whole or in part, for nominal cash consideration with no expiration date. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, unvested restricted stock units, and warrants, which would result in the issuance of incremental ordinary shares, unless their effect would be anti-dilutive. For each of the three and nine months ended September 30, 2024 and 2023, diluted net loss per ordinary share is the same as basic net loss per ordinary share as the effects of the Companyâ€™s potentially dilutive securities were anti-dilutive.The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:Â Â Â As of September 30, Â Â Â Â 2024 Â Â 2023 Â Stock options Â Â 507,014,688 Â Â Â 680,112,400 Â Restricted stock units Â Â 251,823,915 Â Â Â 418,580,700 Â Warrants Â Â 11,562,653,300 Â Â Â Â 4,155,347,500 Â Convertible notes Â Â 1,257,860,000 Â Â Â Â€“ Â Total Â Â 13,579,351,903 Â Â Â 5,254,040,600 Â Â New Accounting Pronouncements â€“ From time to time, new accounting pronouncements are issued by the FASB and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any other recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Companyâ€™s present or future consolidated financial statements.Â Recently Issued (Not Yet Adopted) Accounting PronouncementsÂ In November 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures. This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and clarified that single reportable segment entities must apply Topic 280 in its entirety. This guidance is effective for the Company for the year beginning January 1, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statement. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures.Â In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Agreement and Plan of Merger 9 Months Ended Sep. 30, 2024 Agreement And Plan Of Merger [Abstract] Â Agreement and Plan of Merger Note 3. Agreement and Plan of MergerÂ Agreement and Plan of MergerOn March 4, 2024, the Company entered into an Agreement and Plan of Merger with Peak Bio and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (â€œPegasus Merger Subâ€), as amended by that certain side letter dated August 15, 2024 (the â€œMerger Agreementâ€), pursuant to which, on November 14, 2024, Pegasus Merger Sub merged with and into Peak Bio (the â€œMergerâ€), with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari.Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the â€œEffective Timeâ€), each issued and outstanding share of Peak Bio common stock, par value $0.0001 per share (the â€œPeak Common Stockâ€) (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Pegasus Merger Sub or any direct or indirect wholly owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement)), was converted into the right to receive the Companyâ€™s ADSs representing a number of Akari ordinary shares, par value $0.0001 per share (the â€œAkari Ordinary Sharesâ€) equal to 0.2935 (the â€œExchange Ratioâ€), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The

Exchange Ratio was calculated in accordance with the terms of the Merger Agreement, such that the total number of shares of Akari ADSs issued in connection with the merger was approximately 48.4% of the outstanding shares of Akari ADSs on a fully diluted basis. The board of directors of each of Akari and Peak has unanimously approved the Merger Agreement and the transactions contemplated thereby. On November 14, 2024, the Company closed the business combination contemplated by the Merger Agreement, as more fully described in Note 10. X - DefinitionAgreement and plan of merger. + ReferencesNo definition available. + Details Name: aktx_AgreementAndPlanOfMergerAbstract Namespace Prefix: aktx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAgreement and plan of merger disclosure. + ReferencesNo definition available. + Details Name: aktx_AgreementAndPlanOfMergerDisclosureTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Note 4. Fair Value MeasurementsAssets and Liabilities Measured at Fair Value on a Recurring BasisThe following table presents information about the Companyâ€™s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values:Â Â Â September 30, 2024 Â (In thousands) Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Warrant liability - Series B Â $ 725 Â Â $ â€” Â Â $ â€” Â Â $ 725 Â Total liabilities Â $ 725 Â Â $ â€” Â Â $ â€” Â Â $ 725 Â Â Â Â Â December 31, 2023 Â (In thousands) Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Warrant liability - Series A Â $ 15 Â Â $ â€” Â Â $ â€” Â Â $ 15 Â Warrant liability - Series B Â Â 1,238 Â Â Â â€” Â Â Â 1,238 Â Total liabilities Â $ 1,253 Â Â $ â€” Â Â $ â€” Â Â $ 1,253 Â Â The Companyâ€™s Level 3 liabilities consist of the Series B Warrants as of September 30, 2024 and the Series A and Series B Warrants as of December 31, 2023, which were determined to be liability-classified instruments. There were no transfers between Level 1, Level 2, and Level 3 during the nine months ended September 30, 2024 and 2023.Changes in Level 3 Liabilities Measured at Fair Value on a Recurring BasisThe following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the nine months ended September 30, 2024:Â Â Â Warrant Liability Â (In thousands) Â Series A Â Â Series B Â Â Total Â Balance, December 31, 2023 Â $ 15 Â Â $ 1,238 Â Â $ 1,253 Â Change in the fair value of liability Â Â (15) Â Â (513) Â Â (528) Balance, September 30, 2024 Â $ â€” Â Â $ 725 Â Â $ 725 Â Â Assumptions Used in Determining Fair Value of Liability-Classified WarrantsThe fair value of the warrant liability is based on significant inputs, which represents a Level 3 measurement within the fair value hierarchy. The fair value of both the Series A Warrants and the Series B Warrants was determined using the Black-Scholes Option Pricing Model, which uses various assumptions, including (i) fair value of the Companyâ€™s ADSs, (ii) exercise price of the warrant, (iii) expected term of the warrant, (iv) expected volatility and (v) expected risk-free interest rate.Below are the assumptions used for the fair value calculations of the Series B Warrants as of September 30, 2024, and Series A Warrants and Series B Warrants as of December 31, 2023:Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Series B Â Â Series A Â Â Series B Â Stock (ADS) price Â $ 2.95 Â Â $ 3.12 Â Â $ 3.12 Â Exercise price Â $ 17.00 Â Â $ 17.00 Â Â $ 17.00 Â Expected term (in years) Â Â 5.0 Â Â 0.7 Â Â Â 5.7 Â Expected volatility Â Â 80.0 % Â Â 85.0 % Â Â 95.0 % Risk-free interest rate Â Â 3.6 % Â Â 5.1 % Â Â 3.9 % Expected dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses Note 5. Accrued ExpensesAccrued expenses consisted of the following as of September 30, 2024 and December 31, 2023: Â Â Â September 30, Â Â December 31, Â ($ in thousands) Â 2024 Â Â 2023 Â Employee compensation and benefits Â $ 624 Â Â $ 187 Â External research and development expenses Â Â 589 Â Â Â 635 Â Professional and consulting fees Â Â 861 Â Â Â 669 Â Restructuring Â Â 450 Â Â Â â€” Â Other Â Â 81 Â Â Â 75 Â Total accrued expenses Â $ 2,605 Â Â $ 1,566 Â Â Accrued restructuring expenses of approximately $0.5 million as of September 30, 2024 relate to one-time termination benefits payable to former employees, including an executive, which are payable in the fourth quarter of 2024. See Note 2. X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' (Deficit) Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â Shareholders' (Deficit) Equity Note 6. Shareholdersâ€™ (Deficit) EquityOrdinary SharesOn September 30, 2023, the Companyâ€™s shareholders approved an increase to the number of authorized ordinary shares, par value $0.0001 (the â€œOrdinary Sharesâ€), the Company can issue by 35,000,000,000 ordinary shares in addition to the number of shares outstanding on June 30, 2023. Accordingly, as of September 30, 2024 and December 31, 2023, the Company was authorized to issue up to 45,122,321,523 ordinary shares. Currently, each ADS represents 2,000 Ordinary Shares (the â€œADS Ratioâ€). All ADS and per ADS amounts in the accompanying condensed consolidated financial statements reflect the ADS Ratio.May 2024 Private PlacementÂ In May 2024, the Company entered into a definitive purchase agreement with certain investors, Dr. Prudo and Dr. Patel, pursuant to which the Company sold and issued in a private placement an aggregate of 4,029,754 ADSs, and Series C Warrants (the â€œSeries C Warrantsâ€) to purchase up to 4,029,754 ADS, at a per unit price of $1.885 per ADS and Series C Warrant for aggregate gross proceeds of approximately $7.6 million (the â€œMay 2024 Private Placementâ€). The Series C Warrants have 3-year terms ranging from May 31, 2027 to June 21, 2027 and have cashless exercise provisions in limited circumstances. The Series C Warrants (other than those issued to Dr. Prudo and Dr. Patel) have an exercise price of $1.76 per ADS. The Series C Warrants issued to Dr. Prudo and Dr. Patel have an exercise price of $1.79 per ADS. Net proceeds from the May 2024 Private Placement were approximately $7.0 million after deducting placement agent fees and other expenses.At close of the May 2024 Private Placement, the Company issued to Paulson Investment Company, LLC (â€œPaulsonâ€), as placement agent for the May 2024 Private Placement, warrants to purchase 332,380 ADSs at an exercise price of $1.885 per ADS and a term expiring on May 31, 2029 (the â€œMay 2024 Placement Agent Warrantsâ€). The estimated fair value of the May 2024 Placement Agent Warrants on the issuance date was approximately $0.4 million.The Company determined that the Series C Warrants and May 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the May 2024 Private Placement, each of the Series C Warrants and May 2024 Placement Agent Warrants were recorded as a component of additional paid-in capital.March 2024 Private PlacementÂ In March 2024, the Company entered into a definitive purchase agreement with certain existing investors, pursuant to which the Company sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million (the â€œMarch 2024 Private Placementâ€). Net proceeds from the March 2024 Private Placement were approximately $1.7 million after deducting placement agent fees and other expenses.At close of the March 2024 Private Placement, the Company issued to Paulson, as placement agent for the March 2024 Private Placement, warrants to purchase 132,061 ADSs at an exercise price of $1.85 per ADS (representing 125% of the purchase price per ADS sold in the March 2024 Private Placement) and a term expiring on March 27, 2029 (the â€œMarch 2024 Placement Agent Warrantsâ€). The estimated fair value of the March 2024 Placement Agent Warrants on the issuance date was approximately $0.2 million.The Company determined that the March 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the March 2024 Private Placement, each of the March 2024 Placement Agent Warrants were recorded as a component of additional paid-in capital.December 2023 Private PlacementIn December 2023, the Company entered into purchase agreements to sell, in a private placement, to existing investors, Dr. Ray Prudo and Dr. Patel, (the â€œDecember 2023 Private Placementâ€) an aggregate of 947,868 ADSs at $2.11 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the December 2023 Private Placement were approximately $1.8 million after deducting placement agent fees and other expenses.September 2023 Private PlacementIn September 2023, the Company entered into purchase agreements to sell in a private placement to existing investors and directors, including Dr. Prudo and Ms. Rachelle Jacques, the Companyâ€™s then President and Chief Executive Officer (the â€œSeptember 2023 Private Placementâ€) an aggregate of 551,816 ADSs at $3.30 per ADS, and pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to 48,387 ADSs at a purchase price per Pre-Funded Warrant of $3.10, for aggregate gross proceeds of approximately $2.0 million. The Pre-Funded Warrants are exercisable at an exercise price of $0.20 per ADS and will not expire until exercised in full. The September 2023 Private Placement closed in October 2023 resulting in net proceeds of approximately $1.7 million after deducting placement agent fees and other expenses. At close of the September 2023 Private Placement, the Company issued to Paulson, as placement agent for the September 2023 Private Placement, warrants to purchase 42,550 ADSs at an exercise price of $4.13 per ADS (representing 125% of the purchase price per ADS sold in the September 2023 Private Placement) and a term expiring on October 6, 2028 (the â€œOctober 2023 Placement Agent Warrantsâ€). The estimated fair value of the October 2023 Placement Agent Warrants on the issuance date was approximately $0.1 million.The Company determined that the Pre-Funded Warrants and October 2023 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the September 2023 Private Placement, each of the Pre-Funded Warrants and October 2023 Placement Agent Warrants were recorded as a component of additional paid-in capital.March 2023 Registered Direct OfferingOn March 31, 2023, the Company entered into securities purchase agreements with certain accredited and institutional investors, including Dr. Prudo (the â€œMarch Registered Direct Offeringâ€) providing for the issuance of an aggregate of 1,333,333 ADSs in a registered direct offering at $3.00 per ADS, resulting in gross proceeds of approximately $4.0 million. Net proceeds from the March Registered Direct Offering were approximately $3.5 million after deducting placement agent fees and expenses.WarrantsIn connection with various financing transactions, the Company has issued warrants to purchase the Companyâ€™s ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement. See Note 2 for further details on accounting policies related to the Companyâ€™s warrants.The following table summarizes the Companyâ€™s outstanding warrants as of September 30, 2024 and December 31, 2023:Â Â Â Number of Warrant ADSs Â Â Â Â Â Â Â Â Â September 30, Â Â December 31, Â Â Weighted-Average Â Â Â Â Â 2024 Â Â 2023 Â Â Exercise Price Â Â Expiration Date Equity-classified Warrants Â Â Â Â Â Â Â Â Â Â Â Â 2019 Investor Warrants Â Â - Â Â Â 59,211 Â Â $ 60.00 Â Â 7/1/2024 2019 Placement Warrants Â Â - Â Â Â 8,881 Â Â $ 57.00 Â Â 6/28/2024 2020 Investor Warrants Â Â 139,882 Â Â Â 139,882 Â Â $ 44.00 Â Â Feb-Mar 2025 2020 Placement Warrants Â Â 22,481 Â Â Â 22,481 Â Â $ 51.00 Â Â Feb-Mar 2025 July 2021 Placement Agent Warrants Â Â 19,919 Â Â Â 19,919 Â Â $ 46.40 Â Â 7/7/2026 December 2021 Investor Warrants Â Â 107,775 Â Â Â 107,775 Â Â $ 33.00 Â Â 1/4/2027 December 2021 Placement AgentÂ Â Â Warrants Â Â 8,622 Â Â Â 8,622 Â Â $ 35.00 Â Â 12/29/2026 March 2022 Investor Warrants Â Â 186,020 Â Â Â 186,020 Â Â $ 28.00 Â Â 3/10/2027 March 2022 Placement Agent Warrants Â Â 14,882 Â Â Â 14,882 Â Â $ 30.00 Â Â 3/10/2027 October 2023 Investor PrefundedÂ Â Â Warrants Â Â 48,387 Â Â Â 48,387 Â Â $ 0.20 Â Â None October 2023 Placement Agent Warrants Â Â 42,550 Â Â Â 42,550 Â Â $ 4.13 Â Â 10/6/2028 March 2024 Placement Agent Warrants Â Â 132,061 Â Â Â â€” Â Â $ 1.85 Â Â 3/27/2029 May 2024 Investor Warrants Â Â 4,029,754 Â Â Â â€” Â Â $ 1.77 Â Â May-Jun 2027 May 2024 Placement Agent Warrants Â Â 322,380 Â Â Â â€” Â Â $ 1.89 Â Â 5/31/2029 Â Â 5,074,713 Â Â Â 658,610 Â Â Â Â Â Â Â Liability-classified Warrants Â Â Â Â Â Â Â Â Â Â Â Â September 2022 Series A InvestorÂ Â Â Warrants Â Â - Â Â Â 755,000 Â Â $ 17.00 Â Â 9/14/2024 September 2022 Series B InvestorÂ Â Â Warrants Â Â 755,000 Â Â Â 755,000 Â Â $ 17.00 Â Â 9/14/2029 Â Â 755,000 Â Â Â 1,510,000 Â Â Â Â Â Â Total outstanding Â Â 5,829,713 Â Â Â 2,168,610 Â Â Â Â Â Â Â The following table summarizes the Companyâ€™s warrants activity for the nine months ended September 30, 2024:Â Â Â Number of Â Â Weighted-Average Â Â Â Warrant ADSs Â Â Exercise Price Â Outstanding at December 31, 2023 Â Â 2,168,610 Â Â $ 21.97 Â Issued Â Â 4,484,195 Â Â Â 1.78 Â Exercised Â Â â€” Â Â Â â€” Â Expired Â Â (823,092) Â Â 20.52 Â Outstanding at September 30, 2024 Â Â 5,829,713 Â Â $ 6.65 Â Â Capital Redemption ReserveÂ In December 2020, for the purpose of changing the nominal value of the Company's ordinary shares from Â£0.01 to $0.0001 the Company issued 3,847,331,913 deferred shares (the "Deferred Shares") of $0.01315. The Deferred Shares were created for technical reasons of company law and did not increase the aggregate value of share capital. Also in December 2020, the Deferred Shares were purchased by the Company in accordance with their terms of issue for aggregate consideration of $0.01 and immediately cancelled. The aggregate nominal value at cancellation was $50.6 million.Â Amounts transferred from share capital on the redemption of the Deferred Shares of $50.6 million, along with the resulting foreign currency effect of the redenomination of Company ordinary shares of $1.6 million, are classified as "capital redemption reserve" within the Company's condensed consolidated balance sheets and condensed statements of shareholders' (deficit) equity. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Note 7. Share-Based Compensation2023 Equity Incentive PlanOn June 30, 2023, the Companyâ€™s shareholders approved the 2023 Equity Incentive Plan (the â€œ2023 Planâ€), which provides for the grant of stock options, both incentive stock options and nonqualified stock options, stock, with and without vesting restrictions, restricted stock units (â€œRSUsâ€) and stock appreciation rights, to be granted to employees, directors and consultants. The Company is permitted to issue up to 980,000,000 ordinary shares under the 2023 Plan, plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Equity Incentive Plan (the â€œ2014 Planâ€), to the extent such awards are forfeited, cancelled, or expire unexercised.As of September 30, 2024, the Company had 498,903,915 ordinary shares underlying outstanding equity awards under the 2023 Plan, consisting of stock options and RSUs, and 569,501,522 ordinary shares remained available for future grants under the 2023 Plan.The 2023 and 2014 Plans provide that they be administered by the compensation committee of the board of directors. The exercise price for stock option awards may not be less than 100% of the fair market value of the Companyâ€™s ordinary shares on the date of grant and the term of awards may not be greater than ten years. The Company determines the fair value of its ordinary shares based on the quoted market price of its ADSs. Vesting periods are determined at the discretion of the compensation committee. Awards granted to employees typically vest over two to four years and directors over one year.2014 Equity Incentive PlanUnder the 2014 Plan the Company was authorized to grant stock options, RSUs and other awards, to employees, members of the board of directors and consultants. Upon effectiveness of the 2023 Plan no further awards were available to be issued under the 2014 Plan. As of September 30, 2024, the Company had 259,934,688 ordinary shares underlying outstanding equity awards under the 2014 Plan, consisting of stock options.Stock OptionsThe following is a summary of the Companyâ€™s stock option activity under the 2014 Plan and the 2023 Plan for the nine months ended September 30, 2024:Â ($ in thousands, except share and per share data) Â StockOptions Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractual Life(in years) Â Â AggregateIntrinsic Value Â Outstanding at December 31, 2023 Â Â 651,237,400 Â Â $ 0.01 Â Â Â 8.5 Â Â $ â€” Â Granted Â Â 205,080,000 Â Â Â 0.00 Â Â Â Â Â Â Â Exercised Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Forfeited Â Â (304,302,712) Â Â 0.01 Â Â Â Â Â Â Â Expired Â Â (45,000,000) Â Â 0.02 Â Â Â Â Â Â Â Outstanding at September 30, 2024 (1) Â Â 507,014,688 Â Â $ 0.01 Â Â Â 6.4 Â Â $ 2 Â Exercisable at September 30, 2024 Â Â 425,181,355 Â Â $ 0.01 Â Â Â 6.0 Â Â $ â€” Â _____(1)Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition. Â The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Companyâ€™s ordinary shares for those options that had exercise prices lower than the fair value of the Companyâ€™s ordinary shares.The weighted-average grant-date fair value per ordinary share of options granted during each of the nine months ended September 30, 2024 and 2023 was less than $0.01.Option ValuationThe weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:Â Â Â 2024 Â Â 2023 Â Expected volatility Â Â 82.6 % Â Â 99.2 % Risk-free interest rate Â Â 3.7 % Â Â 3.8 % Expected dividend yield Â Â Â â€” Â Â Â â€” Â Expected term (in years) Â Â 5.1 Â Â Â 6.0 Â Â Restricted Stock UnitsThe 2014 Plan provided, and the 2023 Plan provides, for the award of RSUs. RSUs are granted to employees that are subject to time-based vesting conditions that lapse between one year and four years from date of grant, assuming continued employment. Compensation cost for time-based RSUs, which vest only on continued service, is recognized on a straight-line basis over the requisite service period based on the grant date fair of the RSUs, which is derived from the closing price of the Companyâ€™s ADSs on the date of grant. The following table summarizes the Companyâ€™s RSU activity for the nine months ended September 30, 2024:Â Â Â Time-based Awards Â ($ in thousands, except per share data) Â Number of Shares Â Â Weighted-AverageGrant Date Fair Value Â Nonvested shares at December 31, 2023 Â Â 385,954,925 Â Â $ 0.00 Â Granted Â Â 731,393,807 Â Â Â 0.00 Â Forfeited Â Â (482,249,417) Â Â 0.00 Â Vested Â Â (383,275,400) Â Â 0.00 Â Nonvested shares at September 30, 2024 Â Â 251,823,915 Â Â $ 0.00 Â Â The fair value of time-based RSUs that vested during the nine months ended September 30, 2024 and 2023 was approximately $0.5 million and $0.2 million, respectively. Share-Based Compensation ExpenseThe Company classifies share-based compensation expense in the statement of operations in the same manner in which the award recipientsâ€™ payroll costs are classified or in which the award recipientsâ€™ service payments are classified. Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, was as follows:Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â ($ in thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 27 Â Â $ 42 Â Â $ 83 Â Â $ 105 Â General and administrative Â Â 221 Â Â Â 263 Â Â Â 621 Â Â Â 741 Â Restructuring and other costs Â Â - Â Â Â â€” Â Â Â 285 Â Â Â â€” Â Total share-based compensation expense Â $ 248 Â Â $ 305 Â Â $ 989 Â Â $ 846 Â Â During the nine months ended September 30, 2024, 276,000,000 ordinary shares underlying unvested time-based RSUs held by a former executive upon termination of employment were accelerated, resulting in additional stock-based compensation expense of $0.3 million.Â As of September 30, 2024, total unrecognized compensation cost related to unvested stock options and time-based RSUs was $0.2 million and $0.2 million, respectively. The Company expects total unrecognized compensation costs related to unvested stock options and RSUs to be recognized over a weighted average period of 1.7 and 1.8 years, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party Transactions Note 8. Related Party TransactionsThe Doctors LaboratoryThe Company leases office space for its U.K. headquarters in London from The Doctors Laboratory (â€œTDLâ€) and has incurred expenses of less than $0.1 million plus Value Added Tax (â€œVATâ€) during each of the three months ended September 30, 2024 and 2023, and approximately $0.1 million plus VAT during each of the nine months ended September 30, 2024 and 2024. David Byrne, a former non-employee director of the Company, is the Chief Executive Officer of TDL and Dr. Prudo is the non-Executive Chairman of the Board of Directors of TDL.The Company received certain laboratory testing services for its clinical trials and other administrative services provided by TDL and incurred expenses of less than $0.1 million during each of the three months ended September 30, 2024 and 2023 and less than $0.1 million and approximately $0.1 million during each of the nine months ended September 30, 2024 and 2023, respectively. The Company recorded payable balances owed to TDL of less than $0.1 million as of September 30, 2024 and December 31, 2023.Interim CEO AgreementÂ On May 31, 2024, the Company and Dr. Patel entered into an Interim Chief Executive Officer Agreement, effective as of May 1, 2024 (the â€œInterim CEO Agreementâ€). Pursuant to the Interim CEO Agreement, Dr. Patel serves as the Companyâ€™s Interim President and Chief Executive Officer as an independent contractor on an at-will basis. The Interim CEO Agreement can be terminated by the Company immediately for any reason. As the sole compensation for services provided under the Interim CEO Agreement, Dr. Patel was to be paid $50,000 per month in the form of fully vested ordinary shares. On September 16, 2024, the Company entered into an amendment to the Interim CEO Agreement (the â€œAmendmentâ€), effective July 1, 2024, to revise Dr. Patelâ€™s compensation in connection with the services as Interim President and Chief Executive Officer. Pursuant to the Amendment, in lieu of receiving the stated monthly compensation of $50,000 in the form of fully vested ordinary shares, Dr. Patel shall be paid in the form of fully vested non-qualified stock options to purchase ordinary shares (â€œNQSOâ€), with the number of ADSs underlying each such monthly NQSOs grant to be equal to two times the number determined by dividing (i) $50,000 by (ii) the closing price of the Company's ADSs on the Nasdaq Capital Market on the last day of each month (or partial month) Dr. Patel serves as the Companyâ€™s Interim President and Chief Executive Officer. During the three and nine months ended September 30, 2024, the Company recognized approximately $0.1 million and $0.3 million, respectively, in non-cash share-based compensation costs pursuant to the Interim CEO Agreement, as amended, pertaining to (i) NQSOs granted to Dr. Patel to purchase 87,540,000 ordinary shares at an exercise price of less than $0.01 per ordinary share with a grant date fair value of approximately $0.2 million, and (ii) 91,396,000 fully vested ordinary shares granted to Dr. Patel. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 9. Commitments and ContingenciesLeasesThe Company is currently party to a short-term lease for its U.S headquarters, which currently expires in May 2025, and a short-term lease with TDL for its London offices, which currently expires in July 2025. The Company is not party to any material lease agreements.For each of the three months ended September 30, 2024 and 2023, the Company incurred lease costs of less than $0.1 million. For each of the nine months ended September 30, 2024 and 2023, the Company incurred leases costs of approximately $0.2 million.Â Employee Benefit Plans The Company adopted an employee benefit plan under Section 401(k) of the Internal Revenue Code for its U.S.-based employees. The plan allows employees to make contributions up to a specified percentage of their compensation. Under the plan, the Company matches 100% of employeesâ€™ contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations. Â The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law.Â During each of the three months ended September 30, 2024 and 2023, the Company charged less than $0.1 million to operating expenses related to the

Company's contributions to employee benefit plans. During the nine months ended September 30, 2024 and 2023, the Company charged $0.1 million and $0.2 million, respectively, to operating expenses related to the Company's contributions to employee benefit plans. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events Â Subsequent Events Note 10. Subsequent EventsÂ Conversion of May 2024 NotesIn October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash.Â November Private PlacementÂ On November 13, 2024, the Company entered into a securities purchase agreement with certain investors, including Akariâ€™s Chairman, Dr. Ray Prudo, and a director and Interim President and Chief Executive Officer of the Company, Dr. Samir R. Patel, pursuant to which the Company agreed to sell and issue in a private placement (the â€œNovember Private Placementâ€) an aggregate of 1,713,402 unregistered Akari ADSs, each representing 2,000 of Akari Ordinary Shares, and Series D Warrants (the â€œSeries D Warrantsâ€) to purchase up to 1,713,402 ADSs, at a per unit price of (i) $1.70 per ADS and Series D Warrant for all investors other than Drs. Patel and Prudo, and (ii) $2.385, which is equal to the consolidated closing bid price of the ADSs on The Nasdaq Stock Market on November 12, 2024 plus $0.125 for Drs. Patel and Prudo, for aggregate gross proceeds of $3.2 million. The November Private Placement is expected to close shortly following the closing of the Merger, subject to the satisfaction of customary closing conditions. The Series D Warrants have a term of three years from the closing date of the November Private Placement and have cashless exercise provisions. The Series D Warrants have an exercise price of $2.26 per ADS, which is equal to the Nasdaq official closing price of Akariâ€™s ADSs on the Nasdaq Capital Market on November 12, 2024. The Series D Warrants issued to Dr. Patel and Dr. Prudo are immediately exercisable and the warrants issued to each of the other investors will be exercisable six months after issuance. Akari paid Paulson and Chardan Capital Markets, LLC (â€œChardanâ€) (i) with respect to Paulson, a cash fee equal to 7.0% (or 3.5% for any investor that is a director or affiliate of Akari), and (ii) with respect to Chardan, a cash fee equal to 3.5%, in each case of the aggregate purchase price for the ADSs and Warrants sold in the November Private Placement.Â Merger with Peak BioÂ On November 14, 2024, the Company completed the previously announced strategic combination contemplated by the Merger Agreement, pursuant to which, Merger Sub merged with and into Peak Bio, with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the Effective Time, each issued and outstanding share of Peak Common Stock (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Merger Sub or any direct or indirect wholly-owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement), was converted into the right to receive Akari ADSs representing a number of Akari Ordinary Shares equal to 0.2935 (the â€œExchange Ratioâ€), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The Exchange Ratio was calculated in accordance with the terms of the Merger Agreement and is such that the total number of shares of Akari ADSs issued in connection with the Merger is approximately 48.4% of the outstanding shares of Akari on a fully diluted basis. At the Effective Time, each warrant to purchase capital stock of Peak Bio (â€œPeak Warrantâ€) that was outstanding immediately prior to the Effective Time was converted into and exchangeable for warrants to purchase a number of Akari Ordinary Shares or Akari ADSs, as determined by Akari (each, an â€œAdjusted Warrantâ€), on substantially similar terms and subject to substantially similar conditions as were applicable to such Peak Warrant immediately prior to the Effective Time, except (i) for terms rendered inoperative by reason of the transactions contemplated by the Merger Agreement, (ii) as provided in the following sentence and (iii) such amendments to the terms of the Adjusted Warrants as are necessary to comply with applicable Law (as defined in the Merger Agreement). The number of Akari Ordinary Shares (or the number of Akari Ordinary Shares underlying Akari ADSs, as applicable) subject to each Adjusted Warrant is equal to the number of shares of Peak Common Stock issuable upon exercise of such Peak Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio, with any fractional Akari Ordinary Shares or Akari ADSs rounded down to the nearest whole Akari Ordinary Share or Akari ADS, as applicable, and the exercise price with respect to each Akari Ordinary Share (or each Akari Ordinary Share underlying Akari ADSs, as applicable) underlying such Adjusted Warrant equal to the exercise price of such Peak Warrant immediately prior to the Effective Time divided by the Exchange Ratio.Â At the Effective Time, each option to acquire shares of Peak Common Stock (â€œPeak Optionâ€) that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, was assumed and converted into an option to purchase a number of Akari ordinary shares or Akari ADSs, as determined by Akari (each, an â€œAdjusted Optionâ€). The number of Akari Ordinary Shares (or the number of Akari Ordinary Shares underlying Akari ADSs, as applicable) subject to the Adjusted Option is equal to the product of (i) the total number of shares of Peak Common Stock subject to such Peak Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional Akari Ordinary Shares or Akari ADSs rounded down to the nearest whole Akari Ordinary Share or Akari ADS, as applicable, and the exercise price per share of each Adjusted Option equal to the exercise price of such Peak Option immediately prior to the Effective Time divided by the Exchange Ratio.Â The issuance of Akari Ordinary Shares, which are represented by Akari ADSs, in connection with the Merger were registered under the Securities Act, pursuant to a registration statement on Form S-4 (File No. 333-282127) filed by Akari with the SEC and declared effective on October 11, 2024.Â The parties to the Merger Agreement have agreed that the November Private Placement satisfies the conditions set forth in Sections 7.2(e) and 7.3(e) of the Merger Agreement.Â Authorized SharesÂ On November 7, 2024, the Companyâ€™s shareholders approved certain proposals such that the Companyâ€™s directors or any duly authorized committee of the directors be generally and unconditionally authorized to (i) allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of $14,444,680 in connection with the Merger for a period expiring (unless previously renewed, varied or revoked by resolution of Akari) at the conclusion of Akariâ€™s annual general meeting in 2025, and (ii) allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of $5,546,667 for a period expiring (unless otherwise renewed, varied or revoked by the Company at a general meeting) on November 6, 2029.2023 Equity Incentive PlanOn November 7, 2024, the Companyâ€™s shareholders approved an increase in the number of shares available for the grant of awards under the 2023 Plan by 7,800,000,000 Ordinary Shares to an aggregate of 8,780,000,000 Ordinary Shares, plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Plan, to the extent such awards are forfeited, cancelled, or expire unexercised. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of presentation â€“ The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Companyâ€™s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of expected results for the fiscal year ended December 31, 2024 or any other future period. These interim condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements as of December 31, 2023 and notes thereto included in its Form 10-K, as filed with the SEC on March 29, 2024. Principles of Consolidation Principles of consolidation â€“ The condensed consolidated financial statements include the accounts of the Company, Celsus Therapeutics, Inc., a Delaware corporation, Volution Immuno Pharmaceuticals SA, a private Swiss company, and Akari Malta Limited, a private Maltese company, each wholly-owned subsidiaries. All intercompany transactions have been eliminated. Foreign Currency Foreign currency â€“ The functional currency of the Company is U.S. dollars, as that is the currency of the primary economic environment in which the Company operates as well as the currency in which it has been financed.The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company's foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S. operationsâ€™ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses). Use of Estimates Use of estimates â€“ The preparation of the Companyâ€™s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Concentration of Credit Risk Concentration of credit risk â€“ Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Fair Value Measurements Fair value measurements â€“ Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, Fair Value Measurements and Disclosures (â€œASC 820â€) establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:â€¢Level 1 â€“ quoted prices in active markets for identical assets and liabilities.â€¢Level 2 â€“ inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢Level 3 â€“ unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.The carrying values of the Companyâ€™s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Companyâ€™s liability-classified warrants are recorded at their estimated fair value. Cash Cash â€“ The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of September 30, 2024 or December 31, 2023. Prepaid Expenses Prepaid expenses â€“ Payments made prior to the receipt of goods or services are capitalized until the goods or services are received. Other Current Assets Other current assets â€“ Other current assets as of September 30, 2024 and December 31, 2023 were principally comprised of Value Added Tax (â€œVATâ€) receivables. Patent Acquisition Costs Patent acquisition costs â€“ Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 years. The Company expenses costs associated with maintaining and defending patents after their issuance in the period incurred. Amortization expense for each of the three and nine months ended September 30, 2024 and 2023 was less than $0.1 million. Accrued Expenses Accrued expenses â€“ As part of the process of preparing the condensed consolidated financial statements, the Company estimates accrued expenses. This process involves identifying services that third parties have performed on the Companyâ€™s behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Companyâ€™s condensed consolidated financial statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials, professional service fees and contingent liabilities. In connection with these service fees, the Companyâ€™s estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. If the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, the Companyâ€™s reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to the Companyâ€™s estimation and judgment. The Company makes these judgments based upon the facts and circumstances known to it in accordance with U.S. GAAP. See Note 5. Convertible Notes Convertible Notes â€“ On May 10, 2024, the Company entered into unsecured convertible promissory notes (the â€œMay 2024 Notesâ€) with existing investors: the Companyâ€™s Chairman, Dr. Ray Prudo, and Interim President and Chief Executive Officer and director of the Company, Dr. Samir Patel, for an aggregate of $1.0 million in gross proceeds. The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Companyâ€™s receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Companyâ€™s ADSs on the issuance date, subject to certain restrictions. In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash.The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options (â€œASC 470-20â€) and has not elected the fair value option as provided for within ASC Topics 815 and 825. Accordingly, the Company evaluated the embedded conversion and other features within the May 2024 Notes to determine whether any of the embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value. Based on managementâ€™s evaluation, the Company determined

that the May 2024 Notes were not issued at a substantial premium and none of the embedded features were required to be bifurcated and accounted for separately. Accordingly, the May 2024 Notes are accounted for as a single liability measured at its amortized cost. Issuance costs incurred in connection with the issuance of the May 2024 Notes were immaterial. Interest expense incurred on the May 2024 Notes was less than $0.1 million for the three and nine months ended September 30, 2024. As of September 30, 2024, accrued interest on the May 2024 Notes of less than $0.1 million is included within â€œAccrued expensesâ€ in the Companyâ€™s balance sheets. Warrant Liability Warrant Liability â€“ The Company accounts for ordinary share or ADS warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and/or ASC Topic 815, Derivatives and Hedging (â€œASC 815â€), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at issuance and are remeasured each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are recorded in "change in fair value of warrant liability" in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss. Equity-classified warrants are recorded within "additional paid-in capital" in the Company's condensed consolidated statements of shareholders' (deficit) equity at the time of issuance and not subject to remeasurement.Â In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants (â€œSeries A Warrantsâ€) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants (â€œSeries B Warrantsâ€) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the â€œSeptember 2022 Warrantsâ€).The Company determined that the September 2022 Warrants are not indexed to the Companyâ€™s own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entityâ€™s Own Stock. Accordingly, the Company classifies the September 2022 Warrants as derivative liabilities in its consolidated balance sheets. In September 2024, all outstanding Series A Warrants expired unexercised. Other Current Liabilities Other Current Liabilities â€“ In February 2024, the Company entered into a short-term financing arrangement with a third-party vendor to finance insurance premiums. The aggregate amount financed under this agreement was $1.1 million, bearing interest at an annual rate of 7.49%. As of September 30, 2024, the balance of $0.2 million, which is included in â€œOther current liabilitiesâ€ in the Companyâ€™s balance sheets, is scheduled to be paid in monthly installments through November 2024. Research and Development Expenses Research and development expenses â€“ Costs associated with research and development are expensed as incurred unless there is an alternative future use in other research and development projects. Research and development expenses include, among other costs, salaries and personnelâ€“related expenses, fees paid for contract research services, fees paid to clinical research organizations, costs incurred by outside laboratories, manufacturers and other accredited facilities in connection with clinical trials and preclinical studies.Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Companyâ€™s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Companyâ€™s estimate, the Company will adjust the accrued or prepaid expense balance accordingly.The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024 and 2023, the Company recognized research and development tax credits of approximately $1.3 million and $2.6 million, respectively. Merger-Related Costs Merger-Related Costs â€“ Merger-related costs include direct expenses incurred in connection with the proposed Merger, as more fully described in Note 3, and are comprised primarily of legal and professional fees and other incremental costs directly associated to the Merger. For the three and nine months ended September 30, 2024 merger-related costs totaled $1.0 million and $2.3 million, respectively. Restructuring and Other Costs Restructuring and Other Costs â€“ In May 2024, the Company began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced program prioritization under which the Companyâ€™s HSCT-TMA program was suspended. The reduction-in-force was part of an operational restructuring plan (the â€œMay 2024 Planâ€) which included the elimination of certain senior management positions and was completed in the third quarter of 2024. The purpose of the restructuring plan, including the reduction-in-force, was to reduce HSCT-TMA related operating costs, while supporting the execution of the Companyâ€™s long-term strategic plan. During the three and nine months ended September 30, 2024, the Company has incurred restructuring-related charges of less than $0.1 million and $1.7 million related to the May 2024 Plan, respectively. Of the $1.7 million incurred during the nine months ended September 30, 2024, $1.4 million related to severance and other settlement payments to terminated executives and employees, and $0.3 million was non-cash expenses related to accelerated vesting of equity awards. The Company does not expect to incur additional restructuring-related expenses related to the May 2024 Plan.Â As of September 30, 2024, of the $1.7 million total restructuring-related charges incurred, approximately $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be paid in the fourth quarter of 2024. Share-Based Compensation Share-based compensation expense â€“ The Company measures all share-based awards granted to employees, directors and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective awards. Forfeitures are accounted for as they occur. The Company classifies share-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified.The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Companyâ€™s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Companyâ€™s historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Companyâ€™s options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future. Leases Leases â€“ The Company accounts for its leases in accordance with ASC 842, Leases. In accordance with ASC 842, the Company records a right-of-use (â€œROUâ€) asset and corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and are recognized on a straight-line basis over the lease term. As of September 30, 2024 and December 31, 2023, the Company did not have any leases with a term longer than twelve months. Accordingly, no ROU assets and corresponding lease liabilities are included in the Companyâ€™s condensed consolidated balance sheets as of September 30, 2024 or December 31, 2023. Income Taxes Income taxes â€“ In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and nine months ended September 30, 2024 and 2023, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. The Company has not recorded its net deferred tax asset as of either September 30, 2024 or December 31, 2023 because it maintained a full valuation allowance against all deferred tax assets as of these dates as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions. Net loss per share Net loss per share â€“ Basic net loss per ordinary share is computed by dividing net loss available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, which includes ordinary shares underlying pre-funded warrants, as such warrant is exercisable, in whole or in part, for nominal cash consideration with no expiration date. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, unvested restricted stock units, and warrants, which would result in the issuance of incremental ordinary shares, unless their effect would be anti-dilutive. For each of the three and nine months ended September 30, 2024 and 2023, diluted net loss per ordinary share is the same as basic net loss per ordinary share as the effects of the Companyâ€™s potentially dilutive securities were anti-dilutive.The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 507,014,688 Â Â Â 680,112,400 Â Restricted stock units Â Â 251,823,915 Â Â Â 418,580,700 Â Warrants Â Â 11,562,653,300 Â Â Â 4,155,347,500 Â Convertible notes Â Â 1,257,860,000 Â Â Â Â â€” Â Total Â Â 13,579,351,903 Â Â Â 5,254,040,600 Â New Accounting Pronouncements New Accounting Pronouncements â€“ From time to time, new accounting pronouncements are issued by the FASB and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any other recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Companyâ€™s present or future consolidated financial statements.Â Recently Issued (Not Yet Adopted) Accounting PronouncementsÂ In November 2023, the FASB issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures. This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and clarified that single reportable segment entities must apply Topic 280 in its entirety. This guidance is effective for the Company for the year beginning January 1, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statement. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures.Â In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. X - DefinitionDisclosure of accounting policy for accrued expenses. + ReferencesNo definition available. + Details Name: aktx_AccruedExpensesPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionConvertible notes. + ReferencesNo definition available. + Details Name: aktx_ConvertibleNotesPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionMerger-related costs. + ReferencesNo definition available. + Details Name: aktx_MergerRelatedCostsPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for other current asset. + ReferencesNo definition available. + Details Name: aktx_OtherCurrentAssetsPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionOther current liabilities. + ReferencesNo definition available. + Details Name: aktx_OtherCurrentLiabilitiesPolicyPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for prepaid expenses. + ReferencesNo definition available. + Details Name: aktx_PrepaidExpensesPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRestructuring and other costs. + ReferencesNo definition available. + Details Name: aktx_RestructuringAndOtherCostsPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for warrant liability. + ReferencesNo definition available. + Details Name: aktx_WarrantLiabilityPolicyPolicyTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial

statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4 + Details Name: us-gaap_IntangibleAssetsFiniteLivedPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Schedule of Anti-Dilutive Share Equivalents The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Stock options Â Â 507,014,688 Â Â Â 680,112,400 Â Restricted stock units Â Â 251,823,915 Â Â Â 418,580,700 Â Warrants Â Â 11,562,653,300 Â Â Â 4,155,347,500 Â Convertible notes Â Â 1,257,860,000 Â Â Â â€” Â Total Â Â 13,579,351,903 Â Â Â 5,254,040,600 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of financial liabilities measured at fair value on a recurring basis The following table presents information about the Companyâ€™s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values:Â Â Â September 30, 2024 Â (In thousands) Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liability - Series B Â $ 725 Â Â $ â€” Â Â $ â€” Â Â $ 725 Â Total liabilities Â $ 725 Â Â $ â€” Â Â $ â€” Â Â $ 725 Â Â Â Â December 31, 2023 Â (In thousands) Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liability - Series A Â $ 15 Â Â $ â€” Â Â $ â€” Â Â $ 15 Â Warrant liability - Series B Â Â 1,238 Â Â Â â€” Â Â Â â€” Â Â Â 1,238 Â Total liabilities Â $ 1,253 Â Â $ â€” Â Â $ â€” Â Â $ 1,253 Â Schedule of activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the nine months ended September 30, 2024:Â Â Â Warrant Liability Â (In thousands) Â Series A Â Â Series B Â Â Total Â Balance, December 31, 2023 Â $ 15 Â Â $ 1,238 Â Â $ 1,253 Â Change in the fair value of liability Â Â (15) Â Â (513) Â Â (528) Balance, September 30, 2024 Â $ â€” Â Â $ 725 Â Â $ 725 Â Schedule of assumptions used for the fair value calculations of the warrants Below are the assumptions used for the fair value calculations of the Series B Warrants as of September 30, 2024, and Series A Warrants and Series B Warrants as of December 31, 2023:Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Series B Â Â Series A Â Â Series B Â Stock (ADS) price Â $ 2.95 Â Â $ 3.12 Â Â $ 3.12 Â Exercise price Â $ 17.00 Â Â $ 17.00 Â Â $ 17.00 Â Expected term (in years) Â Â 5.0 Â Â 0.7 Â Â Â 5.7 Â Expected volatility Â Â 80.0 % Â Â 85.0 % Â Â 95.0 % Risk-free interest rate Â Â 3.6 % Â Â 5.1 % Â Â 3.9 % Expected dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â X - DefinitionThe tabular disclosure for fair value assumption of warrants. + ReferencesNo definition available. + Details Name: aktx_DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock Namespace Prefix: aktx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Summary of Accrued Expenses Accrued expenses consisted of the following as of September 30, 2024 and December 31, 2023: Â Â Â September 30, Â Â December 31, Â ($ in thousands) Â 2024 Â Â 2023 Â Employee compensation and benefits Â $ 624 Â Â $ 187 Â External research and development expenses Â Â 589 Â Â Â 635 Â Professional and consulting fees Â Â 861 Â Â Â 669 Â Restructuring Â Â 450 Â Â Â â€” Â Other Â Â 81 Â Â Â 75 Â Total accrued expenses Â $ 2,605 Â Â $ 1,566 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' (Deficit) Equity (Tables) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â Schedule of summarizes the outstanding warrants The following table summarizes the Companyâ€™s outstanding warrants as of September 30, 2024 and December 31, 2023:Â Â Â Number of Warrant ADSs Â Â Â Â Â Â Â Â September 30, Â Â December 31, Â Â Weighted-Average Â Â Â Â Â 2024 Â Â 2023 Â Â Exercise Price Â Â Expiration Date Equity-classified Warrants Â Â Â Â Â Â Â Â Â Â Â Â Â 2019 Investor Warrants Â Â - Â Â Â 59,211 Â Â $ 60.00 Â Â 7/1/2024 2019 Placement Warrants Â Â - Â Â Â 8,881 Â Â $ 57.00 Â Â 6/28/2024 2020 Investor Warrants Â Â 139,882 Â Â Â 139,882 Â Â $ 44.00 Â Â Feb-Mar 2025 2020 Placement Warrants Â Â 22,481 Â Â Â 22,481 Â Â $ 51.00

Â Â Feb-Mar 2025 July 2021 Placement Agent Warrants Â Â 19,919 Â Â Â 19,919 Â Â $ 46.40 Â Â 7/7/2026 December 2021 Investor Warrants Â Â 107,775 Â Â Â 107,775 Â Â $ 33.00 Â Â 1/4/2027 December 2021 Placement AgentÂ Â Â Warrants Â Â 8,622 Â Â Â 8,622 Â Â $ 35.00 Â Â 12/29/2026 March 2022 Investor Warrants Â Â 186,020 Â Â Â 186,020 Â Â $ 28.00 Â Â 3/10/2027 March 2022 Placement Agent Warrants Â Â 14,882 Â Â Â 14,882 Â Â $ 30.00 Â Â 3/10/2027 October 2023 Investor PrefundedÂ Â Â Warrants Â Â 48,387 Â Â Â 48,387 Â Â $ 0.20 Â Â None October 2023 Placement Agent Warrants Â Â 42,550 Â Â Â 42,550 Â Â $ 4.13 Â Â 10/6/2028 March 2024 Placement Agent Warrants Â Â 132,061 Â Â Â â€” Â Â $ 1.85 Â Â 3/27/2029 May 2024 Investor Warrants Â Â 4,029,754 Â Â Â Â â€” Â Â $ 1.77 Â Â May-Jun 2027 May 2024 Placement Agent Warrants Â Â 322,380 Â Â Â Â â€” Â Â $ 1.89 Â Â 5/31/2029 Â Â 5,074,713 Â Â Â 658,610 Â Â Â Â Â Â Liability-classified Warrants Â Â Â Â Â Â Â Â Â Â September 2022 Series A InvestorÂ Â Â Warrants Â Â - Â Â Â 755,000 Â Â $ 17.00 Â Â 9/14/2024 September 2022 Series B InvestorÂ Â Â Warrants Â Â 755,000 Â Â Â 755,000 Â Â $ 17.00 Â Â 9/14/2029 Â Â 755,000 Â Â Â 1,510,000 Â Â Â Â Â Total outstanding Â Â 5,829,713 Â Â Â 2,168,610 Â Â Â Â Â Â Â The following table summarizes the Companyâ€™s warrants activity for the nine months ended September 30, 2024:Â Â Â Number of Â Â Weighted-Average Â Â Â Warrant ADSs Â Â Exercise Price Â Outstanding at December 31, 2023 Â Â 2,168,610 Â Â $ 21.97 Â Issued Â Â 4,484,195 Â Â Â 1.78 Â Exercised Â Â â€” Â Â Â â€” Â Expired Â Â (823,092) Â Â 20.52 Â Outstanding at September 30, 2024 Â Â 5,829,713 Â Â $ 6.65 Â X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of share option activity and related information for employees and directors The following is a summary of the Companyâ€™s stock option activity under the 2014 Plan and the 2023 Plan for the nine months ended September 30, 2024:Â ($ in thousands, except share and per share data) Â StockOptions Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractual Life(in years) Â Â AggregateIntrinsic Value Â Outstanding at December 31, 2023 Â Â 651,237,400 Â Â $ 0.01 Â Â Â 8.5 Â Â $ â€” Â Granted Â Â 205,080,000 Â Â Â 0.00 Â Â Â Â Â Â Â Exercised Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Forfeited Â Â (304,302,712) Â Â 0.01 Â Â Â Â Â Â Â Expired Â Â (45,000,000) Â Â 0.02 Â Â Â Â Â Â Â Outstanding at September 30, 2024 (1) Â Â 507,014,688 Â Â $ 0.01 Â Â Â 6.4 Â Â $ 2 Â Exercisable at September 30, 2024 Â Â 425,181,355 Â Â $ 0.01 Â Â Â 6.0 Â Â $ â€” Â _____(1)Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition. Schedule of assumptions used to determine the fair value of stock granted The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:Â Â Â 2024 Â Â 2023 Â Expected volatility Â Â 82.6 % Â Â 99.2 % Risk-free interest rate Â Â 3.7 % Â Â 3.8 % Expected dividend yield Â Â Â â€” Â Â Â â€” Â Expected term (in years) Â Â 5.1 Â Â 6.0 Â Summary of activity of the Company's unvested RSUs The following table summarizes the Companyâ€™s RSU activity for the nine months ended September 30, 2024:Â Â Â Time-based Awards Â ($ in thousands, except per share data) Â Number of Shares Â Â Weighted-AverageGrant Date Fair Value Â Nonvested shares at December 31, 2023 Â Â 385,954,925 Â Â $ 0.00 Â Granted Â Â 731,393,807 Â Â Â 0.00 Â Forfeited Â Â (482,249,417) Â Â 0.00 Â Vested Â Â (383,275,400) Â Â 0.00 Â Nonvested shares at September 30, 2024 Â Â 251,823,915 Â Â $ 0.00 Â Â Schedule of stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, was as follows:Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â ($ in thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 27 Â Â $ 42 Â Â $ 83 Â Â $ 105 Â General and administrative Â Â 221 Â Â Â 263 Â Â Â 621 Â Â Â 741 Â Restructuring and other costs Â Â - Â Â Â Â â€” Â Â Â 285 Â Â Â Â â€” Â Total share-based compensation expense Â $ 248 Â Â $ 305 Â Â $ 989 Â Â $ 846 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in restricted stock units (RSUs). + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Description of Business [Line Items] Â Â Accumulated deficit $ 243,480 $ 227,461 Cash balance 2,246 3,845 Stockholders equity requirement 2,500 Â Remaining shareholder's deficit required to get listed in Nasdaq listing $ 6,700 $ 200 X - DefinitionDescription of business. + ReferencesNo definition available. + Details Name: aktx_DescriptionOfBusinessLineItems Namespace Prefix: aktx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRemaining shareholders deficit required to get listed in Nasdaq listing. + ReferencesNo definition available. + Details Name: aktx_RemainingShareholdersDeficitRequiredToGetListedInNasdaqListing Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionStockholders equity requirement. + ReferencesNo definition available. + Details Name: aktx_StockholdersEquityRequirement Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Antidilutive securities excluded from computation of earnings per share (Details) (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share [Line Items] Â Â Total 13,579,351,903 5,254,040,600 Stock options Â Â Earnings Per Share [Line Items] Â Â Total 507,014,688 680,112,400 Warrants Â Â Earnings Per Share [Line Items] Â Â Total 11,562,653,300 4,155,347,500 Restricted stock units Â Â Earnings Per Share [Line Items] Â Â Total 251,823,915 418,580,700 Convertible notes Â Â Earnings Per Share [Line Items] Â Â Total 1,257,860,000 Â X - DefinitionEarnings Per Share Line Items + ReferencesNo definition available. + Details Name: aktx_EarningsPerShareLineItems Namespace Prefix: aktx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=aktx_WarrantsEquityClassifiedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended May 10, 2024 May 01, 2024 Oct. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Feb. 29, 2024 Dec. 31, 2023 Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Cash equivalents Â Â Â $ 0 Â $ 0 Â Â $ 0 Short-term finance Â Â Â 200,000 Â $ 200,000 Â $ 1,100,000 Â Short-term finance, interest rate Â Â Â Â Â Â Â 7.49% Â Short-term debt, terms Â Â Â Â Â monthly installments through November 2024. Â Â Â Gross proceeds from convertible promissory notes Â Â Â Â Â $ 1,000,000 Â Â Â Research and development tax credits Â Â Â 1,300,000 $ 2,600,000 1,300,000 $ 2,600,000 Â Â Merger-related costs Â Â Â 992,000 Â 2,290,000 Â Â Â Expected percentage of reduction of workforce Â 67.00% Â Â Â Â Â Â Â Restructuring-related charges Â Â Â Â Â 1,700,000 Â Â Â Restructuring-related charges unpaid Â Â Â 500,000 Â 500,000 Â Â Â May 2024 Plan Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Restructuring-related charges Â Â Â Â Â 1,700,000 Â Â Â Additional restructuring-related expenses Â Â Â Â Â 0 Â Â Â Severance and other settlement payments Â Â Â Â Â 1,400,000 Â Â Â Expected non cash expense relating to vesting of equity awards Â Â Â Â Â $ 300,000 Â Â Â May 2024 Convertible Notes Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Gross proceeds from convertible promissory notes $ 1,000,000 Â Â Â Â Â Â Â Payment terms Â Â Â Â Â The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Companyâ€™s receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. Â Â Â Interest rate per annum 15.00% Â Â Â Â Â Â Â Default, interest rate percentage 17.00% Â Â Â Â Â Â Â Conversion description Â Â Â Â Â Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Companyâ€™s ADSs on the issuance date, subject to certain restrictions. Â Â Â Conversion price $ 1.59 Â Â Â Â Â Â Â Â May 2024 Convertible Notes | Subsequent Event [Member] Â Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Conversion amount Â Â $ 125,000 Â Â Â Â Â Â Number of shares issued upon conversion Â Â 406,236,000 Â Â Â Â Â Repayments of convertible notes Â Â $ 750,000 Â Â Â Â Â American Depositary Shares | May 2024 Convertible Notes | Subsequent Event [Member] Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Conversion amount Â Â $ 125,000 Â Â Â Â Â Â Number of shares issued upon conversion Â Â 203,118 Â Â Â Â Â Â Â Series A warrants | American Depositary Shares | Registered direct offering Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Aggregate ADSs issued (in shares) Â Â Â Â 755,000 Â Â Â Price per share Â Â Â Â Â $ 17 Â Â Â Series B warrants | American Depositary Shares | Registered direct offering Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Aggregate ADSs issued (in shares) Â Â Â Â Â 755,000 Â Â Â Price per share Â Â Â Â Â $ 17 Â Â Â Maximum | May 2024 Plan Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Restructuring-related charges Â Â Â 100,000 Â Â Â Â Â Maximum | May 2024 Convertible Notes Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Interest expense Â Â Â 100,000 Â $ 100,000 Â Â Â Â Â Accrued interest Â Â Â $ 100,000 Â $ 100,000 Â Â Â Patents [Member] Â Â Â Â Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Â Â Â Â Finite-Lived intangible assets, remaining amortization period Â Â Â 22 years Â 22 years Â Â Â Amortization of intangible assets Â Â Â $ 100,000 $ 100,000 $ 100,000 $ 100,000 Â X - DefinitionAdditional restructuring charges. + ReferencesNo definition available. + Details Name: aktx_AdditionalRestructuringCharges Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type:

duration X - DefinitionDebt default, interest rate percentage. + ReferencesNo definition available. + Details Name: aktx_DebtDefaultInterestRatePercentage Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionExpected non cash expense relating to vesting of equity awards. + ReferencesNo definition available. + Details Name: aktx_ExpectedNonCashExpenseRelatingToVestingOfEquityAwards Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionResearch and development tax credits. + ReferencesNo definition available. + Details Name: aktx_ResearchAndDevelopmentTaxCredits Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRestructuring and related cost expected number of positions eliminated period percent. + ReferencesNo definition available. + Details Name: aktx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRestructuring charges unpaid + ReferencesNo definition available. + Details Name: aktx_RestructuringChargesUnpaid Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSeverance and other settlement payments. + ReferencesNo definition available. + Details Name: aktx_SeveranceAndOtherSettlementPayments Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: aktx_SignificantAccountingPoliciesLineItems Namespace Prefix: aktx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share price of new stock issued during the period. + ReferencesNo definition available. + Details Name: aktx_StockIssuedDuringPeriodIssuePricePerShareNewIssues Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDescription of conversion terms for debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDescription of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPaymentTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtPercentageBearingFixedInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDescription of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermDebtTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=aktx_MayTwoThousandTwentyFourPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=sic_Z8880 Namespace Prefix: Data Type:

na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aktx_RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Agreement and Plan of Merger - Additional Information (Details) Nov. 14, 2024 $ / shares Sep. 30, 2024 $ / shares Jun. 30, 2024 $ / shares Mar. 31, 2024 $ / shares Dec. 31, 2023 $ / shares Sep. 30, 2023 $ / shares Jun. 30, 2023 $ / shares Mar. 31, 2023 $ / shares Dec. 31, 2020 $ / shares Dec. 31, 2020 Â€ / shares Agreement and Plan of Merger [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Share capital, par value | (per share) Â $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 Â€ 0.01 American Depositary Shares | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Â Agreement and Plan of Merger [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of expected ownership in outstanding shares 48.40% Â Â Â Â Â Â Â Â Â Â Akari Ordinary Shares | Subsequent Event Â Â Â Â Â Â Â Â Â Â Agreement and Plan of Merger [Line Items] Â Â Â Â Â Â Â Â Â Â Share capital, par value $ 0.0001 Â Â Â Â Â Â Â Â Â Â Merger agreement exchange ratio per ordinary share 0.2935 Â Â Â Â Â Â Â Â Â Â Peak Common Stock | Subsequent Event Â Â Â Â Â Â Â Â Â Â Agreement and Plan of Merger [Line Items] Â Â Â Â Â Â Â Â Â Â Share capital, par value $ 0.0001 Â Â Â Â Â Â Â Â Â Â X - DefinitionAgreement and plan of merger. + ReferencesNo definition available. + Details Name: aktx_AgreementAndPlanOfMergerLineItems Namespace Prefix: aktx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMerger agreement exchange ratio per ordinary share. + ReferencesNo definition available. + Details Name: aktx_MergerAgreementExchangeRatioPerOrdinaryShare Namespace Prefix: aktx_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionMerger Agreement Expected Ownership In Company Counterparty Stockholders Percentage + ReferencesNo definition available. + Details Name: aktx_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=sic_Z8880 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_OrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_PeakCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value Measurements Â Â Financial liabilities measured at fair value $ 725 $ 1,253 Recurring | Series A warrants Â Â Fair Value Measurements Â Â Financial liabilities measured at fair value Â 15 Recurring | Series B warrants Â Â Fair Value Measurements Â Â Financial liabilities measured at fair value 725 1,238 Level 3 Â Â Fair Value Measurements Â Â Financial liabilities measured at fair value 725 1,253 Level 3 | Recurring | Series A warrants Â Â Fair Value Measurements Â Â Financial liabilities measured at fair value Â 15 Level 3 | Recurring | Series B warrants Â Â Fair Value Measurements Â Â Financial liabilities measured at fair value $ 725 $ 1,238 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FinancialLiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Schedule of the activity in warrant liability (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Fair Value Measurements Â Fair value at beginning $ 1,253 Change in fair value of liability (528) Fair value at ending 725 Series A warrants Â Fair Value Measurements Â Fair value at beginning 15 Change in fair value of liability (15) Fair value at ending 0 Series B warrants Â Fair Value Measurements Â Fair value at beginning 1,238 Change in fair value of liability (513) Fair value at ending $ 725 X - DefinitionAmount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32 + Details Name: us-gaap_FairValueOptionQuantitativeDisclosuresLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Assumptions used for the fair value calculations of warrants (Details) Sep. 30, 2024 USD ($) shares Dec. 31, 2023 shares USD ($) Series A warrants | Exercise price Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input Â 17 Series A warrants | Volatility Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input Â 85 Series A warrants | Stock price Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input | shares Â 3.12 Series A warrants | Risk-free rate Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input Â 5.1 Series A warrants | Expected term (in years) Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input Â 0.7 Series B warrants | Exercise price Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input 17 17 Series B warrants | Volatility Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input 80 95 Series B warrants | Stock price Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input | shares 2.95 3.12 Series B warrants | Risk-free rate Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input 3.6 3.9 Series B warrants | Expected term (in years) Â Â Fair Value Measurements Â Â Warrants outstanding, measurement input 5 5.7 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32 + Details Name: us-gaap_FairValueOptionQuantitativeDisclosuresLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Liabilities, Current [Abstract] Â Â Employee compensation and benefits $ 624 $ 187 External research and development expenses 589 635 Professional and consulting fees 861 669 Restructuring 450 Â Other 81 75 Total accrued expenses $ 2,605 $ 1,566 X - DefinitionAccrued external research and development expenses. + ReferencesNo definition available. + Details Name: aktx_AccruedExternalResearchAndDevelopmentExpenses Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Additional Information (Details) $ in Thousands Sep. 30, 2024 USD ($) Restructuring Cost and Reserve [Line Items] Â Accrued restructuring expenses $ 450 One-time termination benefits Â Restructuring Cost and Reserve [Line Items] Â Accrued restructuring expenses $ 500 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' (Deficit) Equity - Additional Information (Details) $ / shares in Units, $ in Thousands 1 Months Ended 9 Months Ended May 31, 2024 $ / shares shares Mar. 31, 2023 USD ($) $ / shares shares May 31, 2024 USD ($) $ / shares shares Mar. 31, 2024 USD ($) $ / shares shares Dec. 31, 2023 USD ($) $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Jun. 30, 2024 $ / shares Jun. 30, 2023 $ / shares Dec. 31, 2020 USD ($) $ / shares shares Dec. 31, 2020 Â£ / shares Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Number of shares authorized | shares Â Â Â Â 45,122,321,523 35,000,000,000 45,122,321,523 35,000,000,000 Â Â Â Â Net proceeds from sale of shares Â Â Â Â Â Â Â Â $ 8,687 $ 3,502 Â Â Â Â Nominal value of ADS (in per warrant ADS) | (per share) Â $ 0.0001 Â $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 Â£ 0.01 Capital redemption reserve Â Â Â Â $ 52,194 Â $ 52,194 Â Â Â $ 50,600 Â Deferred shares issued | shares Â Â Â Â Â Â Â Â Â Â Â Â 3,847,331,913 Â Deferred shares issued price per share | $ / shares Â Â Â Â Â Â Â Â Â Â Â Â $ 0.01315 Â Aggregate nominal value cancelled per share | $ / shares Â Â Â Â Â Â Â Â Â Â Â Â $ 0.01 Â Aggregate nominal value cancelled Â Â Â Â Â Â Â Â Â Â Â Â $ 50,600 Â Ordinary Shares Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Capital redemption reserve Â Â Â Â Â Â Â Â Â Â Â Â $ 1,600 Â ADS | Ordinary Shares Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Number of ordinary shares representing one ADS | shares Â Â Â Â Â Â Â Â 2,000 Â Â Â Â Â Â Â Â ADS | Series C Warrants Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Purchase price of share | $ / shares Â Â $ 1.885 Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase ADS (in shares) | shares 4,029,754 Â 4,029,754 Â Â Â Â Â Â Â Â Â Â Â Â Term of the warrants 3 years Â 3 years Â Â Â Â Â Â Â Â Â Â Â Â Private Placement | Placement agent Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Estimated fair value of the placement agent warrants Â Â $ 400 $ 200 Â $ 100 Â Â Â Â Â Â Â Â Private Placement | ADS Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate ADSs issued (in shares) | shares 4,029,754 Â Â 1,320,614 947,868 551,816 Â Â Â Â Â Â Â Â Price per share | $ / shares Â Â Â $ 1.48 $ 2.11 $ 3.3 Â Â Â Â Â Â Aggregate gross proceeds Â Â $ 7,600 Â Â Â Â Â Â Â Â Â Â Â Â Percentage of the price per ADS for exercise price Â Â Â 125.00% Â 125.00% Â Â Â Â Â Â Warrant expiration date May 31, 2029 Â May 31, 2029 Â Â Oct. 06, 2028 Â Oct. 06, 2028 Â Â Â Â Net proceeds from sale of shares Â Â $ 7,000 $ 1,700 $ 1,800 Â Â Â Â Â Â Â Â Gross proceeds from private placement Â Â Â $ 2,000 $ 2,000 Â Â Â Â Â Â Â Â Warrants issued to purchase ADS (in shares) | shares 332,380 Â 332,380 132,061 Â 42,550 Â 42,550 Â Â Â Â Exercise price of warrants | $ / shares $ 1.885 Â $ 1.885 $ 1.85 Â $ 4.13 Â $ 4.13 Â Â Â Â Private Placement | ADS | Pre-Funded Warrants Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Purchase price of share | $ / shares Â Â Â Â Â Â $ 3.1 Â Â Â Â Â Â Â Â Aggregate gross proceeds Â Â Â Â Â Â Â Â $ 2,000 Â Â Â Â Â Â Â Â Net proceeds from sale of shares Â Â Â Â Â Â $ 1,700 Â Â Â Â Â Â Â Â Warrants issued to purchase ADS (in shares) | shares Â Â Â Â Â 48,387 Â 48,387 Â Â Â Â Â Â Exercise price of warrants | $ / shares Â Â Â Â Â Â $ 0.2 Â $ 0.2 Â Â Â Â Â Private Placement | ADS | Series C Warrants Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Exercise price of warrants | $ / shares 1.76 Â 1.76 Â Â Â Â Â Â Â Â Â Â Â Â Private Placement | Dr. Prudo and Dr. Patel | ADS | Series C Warrants Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Exercise price of warrants | $ / shares $ 1.79 Â $ 1.79 Â Â Â Â Â Â Â Â Â Â Â Â Registered direct offering | ADS Â Â Â Â Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate ADSs issued (in shares) | shares Â 1,333,333 Â Â Â Â Â Â Â Â Â Â Price per share | $ / shares Â $ 3 Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of shares Â $ 4,000 Â Â Â Â Â Â Â Â Â Â Net proceeds from sale of shares Â $ 3,500 Â Â Â Â Â Â Â Â Â Â X - DefinitionAggregate nominal value cancelled. + ReferencesNo definition available. + Details Name: aktx_AggregateNominalValueCancelled Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate nominal value cancelled per share. + ReferencesNo definition available. + Details Name: aktx_AggregateNominalValueCancelledPerShare Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe amount of Capital redemption reserve. + ReferencesNo definition available. + Details Name: aktx_CapitalRedemptionReserve Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionClass of warrant or right purchase price. + ReferencesNo definition available. + Details Name: aktx_ClassOfWarrantOrRightPurchasePrice Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDeferred shares issued. + ReferencesNo definition available. + Details Name: aktx_DeferredSharesIssued Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDeferred shares issued price per share. + ReferencesNo definition available. + Details Name: aktx_DeferredSharesIssuedPricePerShare Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionEstimated fair value of placement agent warrants. + ReferencesNo definition available. + Details Name: aktx_EstimatedFairValueOfPlacementAgentWarrants Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of ordinary shares representing one ADS. + ReferencesNo definition available. + Details Name: aktx_NumberOfOrdinarySharesRepresentingOneAmericanDepositaryShare Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the percentage of the price per ADS for exercise price of warrants. + ReferencesNo definition available. + Details Name: aktx_PercentageOfExercisePriceOfAdsForExercisePriceOfWarrant Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPer share price of new stock issued during the period. + ReferencesNo definition available. + Details Name: aktx_StockIssuedDuringPeriodIssuePricePerShareNewIssues Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-

gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_OrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=dei_AdrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesCWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=aktx_DrPrudoAndDrPatelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=aktx_RegisteredDirectOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' (Deficit) Equity - outstanding warrants (Details) - American Depositary Shares - $ / shares 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 5,074,713 658,610 Liability-classified Warrants 755,000 1,510,000 Warrants exercised 5,829,713 2,168,610 2019 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 0 59,211 Weighted-Average Exercise Price $ 60 Â May 2024 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 4,029,754 Â Weighted-Average Exercise Price $ 1.77 Â May 2024 Placement Agent Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 322,380 Â Weighted-Average Exercise Price $ 1.89 Â 2019 Placement Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 0 8,881 Weighted-Average Exercise Price $ 57 Â 2020 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 139,882 139,882 Weighted-Average Exercise Price $ 44 Â 2020 Placement Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 22,481 22,481 Weighted-Average Exercise Price $ 51 Â July 2021 Placement Agent Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 19,919 19,919 Weighted-Average Exercise Price $ 46.4 Â December 2021 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 107,775 107,775 Weighted-Average Exercise Price $ 33 Â December 2021 Placement Agent Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 8,622 8,622 Weighted-Average Exercise Price $ 35 Â March 2022 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 186,020 186,020 Weighted-Average Exercise Price $ 28 Â March 2022 Placement Agent Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 14,882 14,882 Weighted-Average Exercise Price $ 30 Â October 2023 Investor Prefunded Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 48,387 48,387 Weighted-Average Exercise Price $ 0.2 Â October 2023 Placement Agent Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 42,550 42,550 Weighted-Average Exercise Price $ 4.13 Â March 2024 Placement Agent Warrants Â Â Class of Warrant or Right [Line Items] Â Â Equity-classified Warrants 132,061 Â Weighted-Average Exercise Price $ 1.85 Â Series A warrants | September 2022 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Liability-classified Warrants 0 755,000 Weighted-Average Exercise Price $ 17 Â Series B warrants | September 2022 Investor Warrants Â Â Class of Warrant or Right [Line Items] Â Â Liability-classified Warrants 755,000 755,000 Weighted-Average Exercise Price $ 17 Â X - DefinitionNumber of warrants or right Exercised. + ReferencesNo definition available. + Details Name: aktx_ClassOfWarrantOrRightExercised Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity classified warrants or rights outstanding. + ReferencesNo definition available. + Details Name: aktx_ClassOfWarrantOrRightOutstandingEquity Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of liability classified warrants or rights outstanding. + ReferencesNo definition available. + Details Name: aktx_ClassOfWarrantOrRightOutstandingLiability Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=sic_Z8880 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_InvestorWarrants2019Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_May2024InvestorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_May2024PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_PlacementWarrants2019Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_InvestorWarrants2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_PlacementWarrants2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_July2021PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_December2021InvestorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_December2021PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_March2022InvestorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_March2022PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_OctoberTwoThousandTwentyThreeInvestorPrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_OctoberTwoThousandTwentyThreePlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_MarchTwoThousandTwentyFourPlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_September2022InvestorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesBWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' (Deficit) Equity - Summary of Company"s Warrants Activity (Details) - Warrant [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Number of Warrants ADSs Outstanding Beginning Balance | shares 2,168,610 Number of Warrants ADSs, Issued | shares 4,484,195 Number of Warrants ADSs, Expired | shares (823,092) Number of Warrants ADSs Outstanding, Ending Balance | shares 5,829,713 Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares $ 21.97 Weighted-Average Exercise Price, Issued | $ / shares 1.78 Weighted-Average Exercise Price, Expired | $ / shares 20.52 Weighted Average Exercise Price Outstanding, Ending Blance | $ / shares $ 6.65 X - DefinitionWeighted average exercise price expired warrants. + ReferencesNo definition available. + Details Name: aktx_WeightedAverageExercisePriceExpiredWarrants Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exerciseÂ price issued warrants. + ReferencesNo definition available. + Details Name: aktx_WeightedAverageExercisePriceIssuedWarrants Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted Average Exercise Price Outstanding Warrants + ReferencesNo definition available. + Details Name: aktx_WeightedAverageExercisePriceOutstandingWarrants Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference

27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of non-option equity instruments granted to participants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - shares 9 Months Ended Sep. 30, 2024 Jun. 30, 2023 2023 Plan Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of ordinary shares underlying outstanding equity awards consisting of stock options and restricted stock units 498,903,915 Â Number of shares remained available for future issuance 569,501,522 Â 2023 Plan | Maximum Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of shares authorized to issue Â 980,000,000 2023 and 2014 Plans Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Percentage of fair market value of shares 100.00% Â 2023 and 2014 Plans | Directors Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Vesting period (in years) 1 year Â 2023 and 2014 Plans | Minimum | Employees Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Vesting period (in years) 2 years Â 2023 and 2014 Plans | Maximum Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Term of awards (in years) 10 years Â 2023 and 2014 Plans | Maximum | Employees Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Vesting period (in years) 4 years Â Equity Incentive Plan 2014 Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of ordinary shares underlying outstanding equity awards consisting of stock options and restricted stock units 259,934,688 Â Equity Incentive Plan 2014 | Maximum Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Number of shares available to grant Â 855,637,300 X - DefinitionRepresents the percentage of fair market value of shares. + ReferencesNo definition available. + Details Name: aktx_PercentageOfFairMarketValueOfShares Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of outstanding stock options and restricted stock units. + ReferencesNo definition available. + Details Name: aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2023And2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Stock Option Activity (Details) - 2023 and 2014 Plans - USD ($) 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Number of shares, Options Outstanding at beginning of the period 651,237,400 Â Â Number of shares, Granted 205,080,000 Â Â Number of shares, Forfeited (304,302,712) Â Â Number of shares, Expired (45,000,000) Â Â Number of shares, Options Outstanding at end of the period 507,014,688 Â 651,237,400 Number of shares, Exercisable options at end of the period 425,181,355 Â Â Weighted average exercise price, Outstanding at beginning of the period $ 0.01 Â Â Weighted average exercise price, Granted 0 Â Â Weighted average exercise price, Forfeited 0.01 Â Â Weighted average exercise price, Expired 0.02 Â Â Weighted average exercise price, Outstanding at end of the period 0.01 Â $ 0.01 Options exercisable at end of the period, Weighted average exercise price $ 0.01 Â Â Weighted average remaining contractual life, Options outstanding during the period (in years) 6 years 4 months 24 days Â 8 years 6 months Weighted average remaining contractual term, Options exercisable at end of the period (in years) 6 years Â Â Aggregate intrinsic value, Options outstanding at end of the period $ 2 Â Â Maximum Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Weighted-average grant-date fair value per share of options granted $ 0.01 $ 0.01 Â X - DefinitionGross number of share options (or share units) granted during the period prior to acquisition. + ReferencesNo definition available. + Details Name: aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodPriorToAcquisitionGross Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-

2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2023And2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Assumptions used for the fair value of stock awards (Details) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Expected volatility 82.60% 99.20% Risk-free interest rate 3.70% 3.80% Expected term (in years) 5 years 1 month 6 days 6 years Restricted stock units | Equity Incentive Plan 2014 | Minimum [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Vesting period (in years) 1 year Â Restricted stock units | Equity Incentive Plan 2014 | Maximum [Member] Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Vesting period (in years) 4 years Â X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-

2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summarize the activity of the company unvested RSUs (Details) - Restricted stock units - USD ($) $ / shares in Units, $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Shares/ Units Â Â Unvested at beginning of the period (in shares) 385,954,925 Â Granted (in shares) 731,393,807 Â Forfeited (in shares) (482,249,417) Â Vested (in shares) (383,275,400) Â Unvested at end of the period (in shares) 251,823,915 Â Weighted average grant date fair value per share Â Â Weighted average grant date fair value per share, Beginning of the period (per share) $ 0 Â Granted (per share) 0 Â Forfeited (per share) 0 Â Vested (per share) 0 Â Weighted average grant date fair value per share, End of the period (per share) $ 0 Â Equity Incentive Plan 2014 Â Â Weighted average grant date fair value per share Â Â Fair value of time-based RSUs that vested $ 0.5 $ 0.2 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total share-based compensation expense $ 248 $ 305 $ 989 $ 846 Unvested Stock Option Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Unrecognized compensation 200 Â $ 200 Â Weighted average period Â Â 1 year 8 months 12 days Â Restricted stock units Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Shares underlying unvested Â Â 276,000,000 Â Additional stock-based compensation expense Â Â $ 300 Â Unrecognized compensation 200 Â $ 200 Â Weighted average period Â Â 1 year 9 months 18 days Â Research and development expenses Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total share-based compensation expense 27 42 $ 83 105 General and administrative expenses Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total share-based compensation expense $ 221 $ 263 621 $ 741 Restructuring and other costs Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Total share-based compensation expense Â Â $ 285 Â X - DefinitionAdditional share based compensation expense. + ReferencesNo definition available. + Details Name: aktx_AdditionalShareBasedCompensationExpense Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award equity instruments other than options underlying unvested in period. + ReferencesNo definition available. + Details Name: aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingUnvestedInPeriod Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=aktx_UnvestedStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=aktx_RestructuringAndOtherCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 16, 2024 May 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Interim Ceo Agreement Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Payment to CEO upon aggrement $ 50,000 Â Â Â Â Â Â Amendment Interim CEO Agreement Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Payment to CEO upon aggrement $ 50,000 Â Â Â Â Â Â Payment terms to CEO upon aggrement Â Â Â Â Dr. Patel shall be paid in the form of fully vested non-qualified stock options to purchase ordinary shares (â€œNQSOâ€), with the number of ADSs underlying each such monthly NQSOs grant to be equal to two times the number determined by dividing (i) $50,000 by (ii) the closing price of the Company's ADSs on the Nasdaq Capital Market on the last day of each month (or partial month) Â Â Issuance of share capital for services Â Â $ 100,000 Â $ 300,000 Â Â Issuance of share capital for services (in shares) Â Â 87,540,000 Â 87,540,000 Â Â Fair value of share capital issued for services Â Â $ 200,000 Â $ 200,000 Â Â Amendment Interim CEO Agreement | Fully Vested Ordinary Shares Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Issuance of share capital for services (in shares) Â Â 91,396,000 Â 91,396,000 Â Â Amendment Interim CEO Agreement | Maximum Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Issuance of share capital for services, exercise price Â Â $ 0.01 Â $ 0.01 Â Â The Doctors Laboratory Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating Lease, Expense Â Â Â Â $ 100,000 Â Â The Doctors Laboratory | Maximum Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating Lease, Expense Â Â $ 100,000 $ 100,000 Â Â Related party Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Laboratory testing services charges Â Â Â Â Â $ 100,000 Â Related party | Maximum Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Laboratory testing services charges Â Â 100,000 $ 100,000 100,000 Â Â Payable balances Â Â $ 100,000 Â $ 100,000 Â $ 100,000 X - DefinitionThe amount of laboratory testing services incurred during the period. + ReferencesNo definition available. + Details Name: aktx_LaboratoryTestingServicesCharges Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock issued during period shares issued for services exercise price. + ReferencesNo definition available. + Details Name: aktx_StockIssuedDuringPeriodSharesIssuedForServicesExercisePrice Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares issued for services grant date fair value. + ReferencesNo definition available. + Details Name: aktx_StockIssuedDuringPeriodSharesIssuedForServicesGrantDateFairValue Namespace Prefix: aktx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(12)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of the terms and manner of settlement of the related party transaction. + ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionAxis=aktx_InterimCeoAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=aktx_AmendmentInterimCEOAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_FullyVestedOrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aktx_DoctorsLaboratoryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Loss Contingencies [Line Items] Â Â Â Â Lease costs Â Â $ 200,000 $ 200,000 Maximum Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Lease costs $ 100,000 $ 100,000 Â Â Employee Benefit Plans Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Description of employee benefit plans Â Â Under the plan, the Company matches 100% of employeesâ€™ contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations. Â Maximum annual eligible compensation contributed by each employee Â Â 5.00% Â Operating Expenses Â Â $ 100,000 $ 200,000 Employee Benefit Plans | Maximum Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Operating Expenses $ 100,000 $ 100,000 Â Â Employee Benefit Plans | U.K. Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Description of employee benefit plans Â Â The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law. Â Maximum annual eligible compensation contributed by each employee Â Â 10.00% Â X - DefinitionMaximum percentage of employee gross pay the employee may contribute to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDescription of defined contribution pension and other postretirement plans. + ReferencesNo definition available. + Details Name: us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_WithdrawalFromMultiemployerDefinedBenefitPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events - Additional Information (Details) 1 Months Ended Nov. 13, 2024 $ / shares shares Nov. 12, 2024 USD ($) $ / shares Nov. 07, 2024 shares Oct. 31, 2024 USD ($) shares Nov. 14, 2024 Jun. 30, 2023 shares November 6, 2029 Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Additional shares authorized Â Â 5,546,667 Â Â Â Â Equity Incentive Plan 2014 | Maximum Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Number of shares available to grant Â Â Â Â Â 855,637,300 Subsequent Event Â Â Â Â Â Â Subsequent Event

[Line Items] Â Â Â Â Â Â Additional shares authorized Â Â 14,444,680 Â Â Â Subsequent Event | Dr. Prudo and Dr. Patel Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Purchase price of share | $ / shares $ 0.125 Â Â Â Â Â Gross proceeds from private placement | $ Â $ 3,200,000 Â Â Â Â Subsequent Event | Paulson Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Percentage of cash fee paid to placement agent Â 7.00% Â Â Â Â Subsequent Event | Director or Affiliate Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Percentage of cash fee paid to placement agent Â 3.50% Â Â Â Â Subsequent Event | Chardan Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Percentage of cash fee paid to placement agent Â 3.50% Â Â Â Â Subsequent Event | Series D Warrants Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Term of the warrants Â 3 years Â Â Â Â Subsequent Event | 2023 Equity Incentive Plan Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Number of additional shares available for grant Â Â 7,800,000,000 Â Â Â Subsequent Event | 2023 Equity Incentive Plan | Maximum Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Number of shares available to grant Â Â 8,780,000,000 Â Â Â Subsequent Event | Equity Incentive Plan 2014 | Maximum Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Number of shares available to grant Â Â 855,637,300 Â Â Â Subsequent Event | American Depository Shares Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Closing bid price (in dollars per ADS) | $ / shares Â $ 2.385 Â Â Â Â Percentage of expected ownership in outstanding shares Â Â Â Â 48.40% Â Subsequent Event | American Depository Shares | Series D Warrants Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrants issued to purchase ADS (in shares) 1,713,402 Â Â Â Â Â Purchase price of share | $ / shares $ 1.7 Â Â Â Â Â Exercise price of warrants | $ / shares Â $ 2.26 Â Â Â Â Private Placement | Subsequent Event | American Depository Shares Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Aggregate ADSs issued (in shares) 1,713,402 Â Â Â Â Â Akari Ordinary Shares | Subsequent Event Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Merger agreement exchange ratio per ordinary share Â Â Â Â 0.2935 Â Number of ordinary shares representing one ADS 2,000 Â Â Â Â Â May 2024 Convertible Notes | Subsequent Event Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Conversion amount | $ Â Â Â $ 125,000 Â Â Number of shares issued upon conversion Â Â Â 406,236,000 Â Â Repayments of convertible notes | $ Â Â Â $ 750,000 Â Â May 2024 Convertible Notes | Subsequent Event | American Depository Shares Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Number of shares issued upon conversion Â Â Â 203,118 Â Â X - DefinitionClass of warrant or right purchase price. + ReferencesNo definition available. + Details Name: aktx_ClassOfWarrantOrRightPurchasePrice Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionClosing bid price (in dollars per ADS). + ReferencesNo definition available. + Details Name: aktx_ClosingBidPriceInDollarsPerAds Namespace Prefix: aktx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionCommon stock additional shares authorized. + ReferencesNo definition available. + Details Name: aktx_CommonStockAdditionalSharesAuthorized Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMerger agreement exchange ratio per ordinary share. + ReferencesNo definition available. + Details Name: aktx_MergerAgreementExchangeRatioPerOrdinaryShare Namespace Prefix: aktx_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionMerger Agreement Expected Ownership In Company Counterparty Stockholders Percentage + ReferencesNo definition available. + Details Name: aktx_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of ordinary shares representing one ADS. + ReferencesNo definition available. + Details Name: aktx_NumberOfOrdinarySharesRepresentingOneAmericanDepositaryShare Namespace Prefix: aktx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage of cash fee paid to placement agent. + ReferencesNo definition available. + Details Name: aktx_PercentageOfCashFeePaidToPlacementAgent Namespace Prefix: aktx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=aktx_SecurityExpiringOnNovemberSixTwoThousandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=aktx_DrPrudoAndDrPatelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=aktx_PaulsonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=aktx_DirectorOrAffiliateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=aktx_ChardanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=aktx_SeriesDWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=aktx_EquityIncentivePlan2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=aktx_AmericanDepositoryReceiptsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=aktx_OrdinarySharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

;3PH$>BHYQFE*>'TTA'8@0SC/ACA4% ME:JM4/E %:2*94I)RP=2)@HM>/>[BFX0O[?"GC5L#U5@+5C_NZ%#YP>2A>%L M\K_-,"<9RU/"Q4^Z=Z$)E=;T#]^47]_*VJ'; Q?#>3)NW 8)KJB.4G8/SIP+ ME8J@3EY@C_:;@*M:9HS3OTBZ!IZ_A @M7027/G(!XRDM5<,*A#:CHD8"U9-(M4MRID_G2F#2QI'J-[FW7;^@T*2K2-)[Y\P= A=!Y7LNJ!EE(}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~H81C6+K>G(\3'S< M$Q^_BC@^(-JP&C=70^S'+V#_T'<_>W^G,]I7Z3-3*UYK(F")T<'H"&%4V^E; MP\C&-\AQ>DH=DKA^X^+O8,R;18Y;FQ(=/[!< _;+E(J-2 M/8K=K#@(1N.R4);.B./XLXPF^61Q7; [[)!;7_"C3)&>?!"J.64;%TRU+^7WQ.=GNI7\P6UP>Z8W=,?CU\$NIIUD2)DXSE1<)S)-CV9O(>7ZV)KPN4 MB#\3]E":RCWG?^N'#_'-Q-$M8BG;2!V"JH\36[(TU9%4._ZI@TZ:.G7! M\^_/T7\NR2LR] [1@2YY^2V*YOYF$$Q2S+3VF\C- ^)75A#P=;\/3HOR+'FJL M,T&;8R%Y5A=6+ M7:"D/JNXE*MJ*2+:\$?D-!H%4U_*=4O2RN]DEPGRIT4ZM=$E9.+)<]CU>TL M1NI;P=,DIE()W$GUH?)!%HAOT1\')JCNUP+17",SE91[G2TGAG[C18&FZ.O= M"KU^]0:]0DF.ONSYL5#0XGHF52-U5;--W:#;JD%DH$$N^LASN2_06C4L!LJO M[.4C2_F9$J=1B#PK=$NL >_8X1URG;>(.&0.M&?Y\N(O4]*R,'_;'[5'WQ"; M="+>.Y O#H3\AUOCP+\45U,55D#D<1,]]5\6!;MC-1.51P<2)318__H!] MYR=(WS&#K<8,MAK55MYLP$:QL?V&Y2KRT M)$MC-0\FA=2)>& (0WRJ6=\XW<"*#IK2"T-N+)%8ZYL8P9;C1EL/5*P3F]@I_6DCC4!/^22J;BR[A+0 M1#]]3# '+0 QI^X5@#$RS_?F$%0E M)N;L/E:=7>U(JQVQ:K?:!"T%RB-*'W29K()U!4 MTL\;Q]2TCU%35FBF3A_ED="4"@"%8320/JT+QU9KN5![9+4#SM4&40B6;YY4 M&FTJ5794Z?(Z53/XF[:F5P9 7CA(O77+V&Z7?V=JW*ND!QGZ_:T-"2// M) G" G-' ,%4ON#() K@O#!P!IBV[A;; [>TS4Z2L&2KV5# TU4=ER0;D'O1: MT9OM+D)6ER%K*Z1+M;6AV.Y#0:IQDAXE>#!T6X>SDKT(65V6&K*V0+MG6@F*K MIUI*X\T63RE)<Y6YU4R>'[-[Q5LM;%S$24[%4Z5!@8[ZN$Y-\VJ$'X[E84S> M4\J6$U%_"S=W0]]Q/,_D@B PPCC2(VC:&Z*'$>.YD0Y MC@$Y26LAB=U"CBRG/?%(WR(.*PJ AQ6%P(.*#D2V*]I:5H*MFZ3NJ:^6!]P@ MD3$-Z7+4:*M1HZW'BM;MC]8&$[L-MBUY==%+2QX,ZRUY$ Q:\B#<\))'6K=+ M+APZU^@Q+>DCG(VCGD2/&FTU:K3U6-&Z?=3:<6*WX[T=B51[ML2*EU6U@_->QD$.GTP0PPS@PCY$@E&LF:A^#S3/L-13H;'/7Y=]Z;_)R[WTI M4T$1 (L-B 9<5,$X/2[+P(0:%"$UH43NPNO1-CT%@J0,.";/72,QDQH@/I]R[E\?M 5-/]SL/@74$L#!!0 (R&&PO=V]R:W-H965T&ULO9UA<]LV$H;_"D??N4MG MJIH$ 9++V9YI)1+MS? 4N$[>]SXQ$6YQ(HDO2%_>K=O^!Q??E_?Y77%3M+_=OZN[5Q='E56Y+79-6>\\ MNKB]FOP0O)71K&^PM_B]+!Z;9]][_5OY4%4?^Q<_KZXF?M^C8E,LVUXB[!Y\ M*N;%9M,K=?WXXR Z.? KL&S[__HMZMG_SW9OYD#?%O-K\KURUZZM),O%6Q6W^ ML&G?5X_%8NO9Y7NU67 M6,7*Z[YKJDVYRMONQ4W;?>DRKFV\ZM:;K_/=7=%XY=UL:XVJZ)N_N&E M?SR4[6? OS:*X+9=E^ZTW]7Z[67AOOOG6^Z:W_G5=/33Y;M5<7K1=9WN7%\M# MQWY\ZA@[T;%?JS>,WF[F;[_GGS_+ZDFR_KJ;=>SBM ME;JU#@V]]\6JV-[O)] [[HBGJ3P6AE9WIUW+YL'W8[&/SWW9=U%VXMMW:L^X7 MA4^%]^^JH<98#E<]A% 7N>BRZ9A2[)A2;* *3ZC^F&_RW;+P\M;[4-R5NUVY MN^NSJ.NV] [G(Z_X7BV+YO1<&WWG,9XQ*CB<7T=Y%OYQ^N@[B67!Y\>EY*MA& M,1>ZS8(0BF(_CG2SU#83+)AQW2JSK:9Q;/1*$D8LZ#H6'NVT80V/PQH.'=9^ M).FA?=,E;-- /@>;,0!\%L0!"XVH(/VF2+$,*29!8EJ^\&.^<&>^_-PFMR:!*2?)CGQ+>\K @U<73 ME&\K[[;<=39=%GWG[;I]3V=:?FFVK)Z67+>Y%>90^,R8FMR:!"R*C20@A%AH MS-_4^2;'!AP:?)^AT*E041$SIBEWD0.S M&. P13K,D&(2)*:%-3Z&-7:&M3N=<6>O77=PJ.MBM_SLM76^:S8G0QO;(VT$ MUNEO;&"18BE2+#L[$!+D3@MK<@QKX@SK?[K5^^==-T\+ [TV_TR=7Z\1Z"X'O MFSMFIY^QX42*I4BQ#"DFSPRL%M'9,.*S,9OY8K/1V3%V>QN[!3JHZ9D4!(%(PL0Z(4%=IU"U#*HF46IZRCP#8,'KXXJ##WT. M6;SB8.4&%I0412P(.VH^$F8$LZ"L7- B4# H&$R#<-C"[7/TO&3#P0748>$.@NH6@I5RZ!]$]6FIX "6(&; M8)W?)-T4]]U"X3L^P&W&Q(+03 \;5G6?R]),MZ6Z!2(0L;DNVW;DNFR;31.6 MF.LR86+58&+)3Z[("(2(&; ((W;*9T?:"@L"FQ:U.];A>^+F;TD0WD15"V#JDF4 MFIXRBAD%;F@T9*=T?DMMTQWBW'*P.G-P(;3(DPMA1TY)VXPXNU!6SL.+@C>! MF]Y\S5;I_'@C.N(H/!2X^=#O1=,>\J23;^MR MV5\!>,H2,B<(I&%.P,2>@&9XH?P'JI9!U21*30^O8D6!&Q:YPGON&HY;>O3T M)U"1'X>Q?0T'ZC>%JF50-8E2TVLM%/%B;N(UYDH.LP$4,S\LYVY_8P]+0URF M4)<95$VBU/3P*CK%W'1J[!4=1H <\X@R=_L<'6*D6@I5RX8,AT2YU$/\K%S* M3<@&D0YF,ZHI]\UE=^YV-3JR4-@%5[E AF+LBV'5D.1^"WA$7F]"*L&/-/'IB8 D3L18#(M."J="VED>="<$;RH.!*RD 7".BI!7:=0M0RJ)E%]>LHH[,7VFW].C\ MH"JB$LZMK334;0I5RZ!J$J6FYX;B6PQ7%,5L"A3Z9E64V]_H3^,!+E.HRPRJ M)E%J>G0S7F/8XBAFLZZI61[E=CDZPE!@!E7+!HR&1'G4 ZPP& .423&;?7 4U9 M8EX0G[M=C0XL%)5!U3*HFCP[O'IL%0-C+RV8.GN)BMGPRKX6R,B**6N[1I5, M$=<""3MR'TW40]G7 BDKU[7 4#&D$%DU=7:@W=Y&WU5"5DV=N!8(=9U"U3*H MFD2IZ2FCN%2(K9JB$X6J.F+&!;=Y:%=-!2'C9N2I"BP>"\,N)>RH*4EU+?"Y ML3>7]#P"U

M,BID1C5!.7R>@^D)285CU(;^";=SYP)_6@;9^5;_6V)"6MFNH\]U)MB[X%VV MBBP7@S+_SLEG)Q/+2'E?\^;RBTHEXB;PDW0YA#\XL%09V\A85K.&\@ M/Z5NBQYLRK1'C;40S &+OZ_A3]17YI-#/9?LHO U9*R$B#J[7+'UDKWB'@ M!-$G1];42P3#DBB+7K("3_ HDT51-
$0.TWH1B7&0A"/5<1!TE.+A!AW[#:)P M.WQN2*[I=A8L$EDT4RMT5[4CC!<,LR&@QPV+<"'LC$M1B;3?3^&T*H#DFZ+>N6$-[^_Y)B3Y9U!6FB/"N) U& M(JC^\L)8@HAUH&'@Z[?9+8G8OP4#=!)F[.\$V IF#-\E/!N[KHQP V)K.QJXL9/'H@@,SD,/X'1%;Q^-VNJ6\96=F0 M/=!'8;0DHSE9NR'V3EB@*:Q&9D\ (->J@[?DTL@PO'Y.\I'&T^?#T@OF'(6MK M*7+0K^CQ[DJIA(L5)P0!@4OB$' _.XNT[T:O-^7=I-2T]3#8!*EM5,U8@TS[
M6B,IL<4"Q:+0(I_-2,_O1".4\0$]T:0D.J;9C&:3+_B<41+$BRCU6?,(<2&K MN/>2S3",)&WINWNY2:01!Y+@EO_!QD.TBD*)QW)
[R.ACQS']NJX+7A*DE4VM M *&=;K.2A)H\-UDS*2.,O^N@S#1Y/R)_GIS1AP?7RHY[+Q%[HGKEZC5L8#G_ MH!F-K*S_OR@@,Y^R6^_L?[WXY!V]$
LUH-WXD+5,2[1Q>6W:F(4'7H@#RYA7 MI5J3V*R490U!OZ;E!P!+"-J(* E/4&NS(*>^MG$;ZQ7]VZJ]S$2\]MG#4J^L MI0AZ0-:&_ L_ II;+#@O/Q
T+QF6]@&R=E&(P+*"P]^*RR [7CZ-6+5")"F= M)OS%D?(PK..=)2&XD#4+]'$9,+A&MLYV=5];KJ 710!(8%CW&*E\F\RF&$8D8:\;
(VJARU4TA.'U+\BZY'VW44^0YHP[0QKA/DJFI M2P3P@F56;.^]-MEJH&X*0=#*9K*)Q\@ZA8+9T)@NU28K5Q*;"REN226C">1< MY"/17"X-
$LD#!,1OI?T8[5Y0=\F%8B-'LI]ZG+BOX.HT>7V;;5U))(CYGK=R M=0Y42E&9]\MCU1NK#-%.DZT1Y*.[LTGM3>.Z%0_ M(S5-
WO*W*M4O0@6F\0SI*&/Z^9(M>"]I0(%SP#D<>@)0LCY:^06_.J&J175C W*>TOB]JU+I2U3P#=UNAGDEWQ+_I]7@I0]1(B$\"*O.T7#GRP[Z375P?
$LK#\ MAMI+$*0&&0$)HX&\R>1-PN+'Q)2]C$R*7R*J<$_&>>F3IEY$5AQ9#M$@36KC M6+1'(F0T:WB',H](N3J^N/0&3EH8Z72O6%L$-
_MK$D)V;U>VL_E+FO.Z1SH MKY"LB,=AIYR*(WZV&G#SYSK.R[]'(?0NF5O3/K"CJ.A)/PAR1@:U=[$;?C:2 MSBWY((0;4I)]A FLI\?,[##XF][I,Z7J5AL6!(%
[=6.>C[+T#?7E)(L2+31>2RPKU?42B#M V*T3"D:-XIYHU/NAGVM2EQ$!D M7V#!VU+VW2H84\7V,A3,:HI#T63*26/TY,T7V.Q%*V@8
M71DG7A[+BCF.;*T3=I!.L]D" _GZ]Z3+V&"Q7:_@)-D*)9D04>*5M1BYA+ M"UFV(Z3V=-T%9:CW'7C9UT;V\MT MR7=@3SBBS?L+L+U5BE,PO?
3:P!V0$/G4/5)0/(Z;35;]#_BY0LY_J5==DPM< M=^9I(S&"JYTY;<>NV85SJR)R]M>"/WO5E"FZ1 46A4IYP#,^:]]G251\\"V3
M@W5R;H#!*>F$9(VR.!V+"&"KNZWMYJK480;P5+XS4G(Y$2OV5VRDST"5=R/[M.J"3\P+[_(+E(C$/:5/?1L/U-!/E$@ 7R1@YU1>8[,&V'@U(>I;B$/?
T%H@< MX=!4D [,D&]BZ8>%>Q,L,DTF&.$J&&E=V@4AR"=!7KGLM M(0DW+WB]&Q1$[K&6YS"5 H\
[;38P^S]%@UGW7\NW>Z;RO&W6X^:F;)27R=S;YY'J#77<$#(!/BKOFD(S\D9*(YZ>_**', ML,1K"^LZC_7Z.%IE" #M3M#5+8K5!KA/+%?
&'8]$0B#.%:%N-*<+4+PI>@T5 M;2_7UZ_0?$7^G&8ZLNU3Z*WJ33/LLKD[^LHT3K];\(L-RU,K1U^FVBKE4584 MVO8(C9,
PQG5(ZC\>2"1KF87"_T@>41A#^+%][+1KD-;OB0+\2P03O52(M"([G@A*3E=[L,ORT9 ?#1B9K09'%FE20X]]7'#0BCN3*=]\76O]F,P(^FL5Q M S?
^2G$WYD5@K5,X_\2:J1 DTWP[\G"$==0>E#P[%>#*U&<,9<^F]#."2I@J M>]IA\/F7!S__\J_]_*.< C[%I5WG=/WW>BP>?G7ZZ0L8X\!X7T_6)&ZW83.&
M.H/4"6U._MEM.4&>BMLFR6]M=Z4K*%LS.#F93<1JAA+KOSQB(_'RH.L1V8[7 M#K>\$=SRF"
!O>,)HA&O$>,%)@@+G(^IG$*,SUYEOS]/@#51@W,G&>:31?A M*[;'/()(1[UZWC1QG\53DJY02S?J*(K/<9V82$#0^E7(S-?NA:]IN[6FY!C
M$8SX\5#N9J*=#E:_3J8^Q$OOA-ODD4 NZLLIF3(S/U?.+W05*(*]KB+[7=R M#9T'VU9K^!+SD'7X/EN2'>
CV0Y/22+9GX%^MFG56VV$=O#T(1M,J01E-$G)09]_4#??VD!GL MD' F1C5QZP)@O9+3.O0X,BA#MSHHWLBR :[LKTW;%5I*O'^L""X"Z?JY[A62
M/U8KCSV/8!X3MCKJMAPN23I.//]@"WH$2;\/7O1=>H,VY55<[3&A$Y&KARL2 MB-92 KTGGPSXT]I$%LN)[9+8(A6U*]6(_/3$8H1BL9BV8
3,UN6M>PUG(VP[M25B+7874.8<'5N+(,.<_32V1J2BZ_)(#+ M$99%[>\^JR&R%&F N!A3;Z..G;"E$GB!T:[IW/7RL;1T.>K7Z#5055.+39;2
M''/71+4L/C;L:K7C;V#@P%8K6SAU*8T.-H3Y^B>OA^Y3I#=OPB]LH MA.>>6\S/953R3@\0GR95QRX%O]-2QF_Y8%JHDOO-$!6Q!L+K"0HCB
M=SYFM MG-J::RC3VI8)/O)I?6]<\AS[TK58=I^ .U1&[K.*%R^'>2PEDM5 >W&_8\A[MYBQ PGN2L@\HEO1;HS0?5H*!S&R;,GK^69B7TH^&_)%^[QE='
MI*\ZWP'R!_M2^JR'.5]7[\>Q"SD[D/W'>$>8+YCGZG"T&^3Q?1IP&?$0!J7-^+U0>^IOTMO*9R[XH+8D[M4GV'514/3U^
OZ2O370U(96TY9^>"#U%)1?9"T<[7X4B+[.^6>]A31) 0,7< MK"I2]9QWJ5XWV3:TNHOVBA?9.[KJK=&/5Y>?)I_>7?CQ"&),9\1.NN+2W@+P
MENO1PO$&I[4"-B,64M!Q*,8'&$F/CHD.?LD/JX:-J.:]?VY>E&S^?3,_R8"R+VT_P?F;U\%W\OB^Q-XJHJPTH>M#_.9MR7@ZC' M-
D:,U0%9@:@DD9]*]QSG;'K:8Y=K5Y"#V3Z7,=)0Z%!2N)_F +[H)3+Z;4\Q M9X6?
KN_*>9$XS<%EY+IKR+D.+$E"TT9G9$$3$=)OJ1VK*MELM#2Y[Y^R3=9(MI,E.18+F6I2,*XU._,,01!ZN142M.@BEI2XC-Z<(##+C"^#MAZ6TQ/E.:*Z\
M H?'3:N$JJ.\5#A#B0%.U%TLX"VOM0)>\@D1K)26(N]H'9;K-]SWU-_,*"EJ MOK0Q(?_Y%Z!3)R=\18[-'O>NCN"E@==ZI^-*.ID;A#JNYQL K%=Y>M
DGO_. M=O7GV3M:XYJ#7=L,?ZI7VY0OH/N'D_8R[8,&%QZ(\XO@&V8^ M2*NMN4H/AWS[>3YNRV2EV66?YY(X5&)&F/F+;YQF8 M1A&7<%= M_
MA/8+/GD*B($=RYXOK#@V#-& M:F$ T[IUB5C>_AM57GLH[8_+V9JIK_#7]Z9Q^B2&/@R?6_GRD2I9/*@Z#$/' M3YH-NL^T5/[Y: -?
BA"O7Y8=.#OA%WC&3SSCL*LA=-Q9 |#Y M:.NEW7UQUB/TFAI9H+E5S;HEE_BP55&Q>7P2)KL5*VJSNA6L&H/(S)G7RB;9
M^80NXZ2("2QRKO2)DW:3MIXP,'C4)_"QB.(?SD$=3BRRYB!@HZ5X)(WS)95: MZ38^J.NM;DRP@$H.A]J>)Y9[/L;O! F=1+B#"|>]W
TYH,*;'CFR)7UJ#Q0Q MI((S+I2V_A0BME_.S(]=SY/Q_4]R=^,^$4[")>0JW$UJ46IGDYF]/@^YK 3K MY%1FJ3\K$8F*?
SE^1:=3;$25=!J&=V+E]/,]IQ_).VOO59-6QYKC^(DY$ M<[W*];-IXUKPY-X*#G=JN1T!.D[AMIRXD>OA2D$%[I1X%M+>M O<=R*_DDCB
ME2Z9>?]&W=;%DY!V4LQ7$VNAW%3 MX@Y"8)=CTU&@T)%KMKFDP"SAM=S+$JJ(H"2N$HYS[H/M2*,F"+11"JCTE]N@ MX7I2@$ED=,4&_@6'?
Y&H> #?38B7,|:77]"&+-ZB@[0Q_NXZ[_RT^@K/O&H>MJ&E_>6MQ0U>XLC6Y_968C[# M-<9288PWSG$@NK6[S)^
E>+FHVC9J%00C'_^S8CY^X;W$WOYS54LP,GI["R= MS4_2I^?GR=/S63]?+]*3V>R;CZ/BG"Q.Y^DY"<2S^6ER,C]/3VG(&;WN.\7F
M_3TZ2)]>GJ<'L]FR4DZ/SU-CT_.TE-Z*SZ;*$=)YNGB]"P]?RJ'5'C/%R^^ M^<29R/EQ>GKV+#VF3SZ;'2>G].I).B,P|Y1>_5G=]"[";FJIGO0OGGK#O.<
MMN;_$PJD@;TKJ'L#18ZYR]/:V3<75R\EJ2:W2^^]@#MF1R,G/HC"I6!BMO6/ MF>NJ1DC&%NT74>?
0C@S&%&GL.L=O^@K7_/H2DCM_<7!Y(TLC*M>=%DRYOS^2 M,SY(I$T4:M8L@RG?8"6'%JSH'4H[6 W#1-9?/^ |^D>WJK="U:.?B0/_3UVO7&
(V]@H9SRN"7G2!*WR(?HCS,,B%=(;7B4[P! M:3]/WFX!7)6O,<@C]N+N[?@F+'LQ Y_#NNJ2KV15&^A*]?';14F^/8P](-\D72*SS](] M
0W!X"'!U#+"=OO@ICM<&V]O- Z!62RS2W>IE"W@X$)&2(Z]H\HUT*T)O[=\ MCYEQ/;G6(<97Y5ON+_4P['_H[&D^C/GW_!_[("SY"UE;^ M$HK_K?\[,A?
RYU/"Z_)':-YES1I7=)9J14-GT[/3(TG'N1_:>L=_3&59MVV] MY7]N5$91!%Z@Y_AC"^X'?,#_=9T?_@]02P,$% @ #(9S6=>:>*DB!0 MY@P !D
!X;"]W;W)K&ULE5?;ZRT?>CT 217(FH28 !0LOZ^NP!)2;:L-B\20.Z> MW3U[7BYTN;)YH@.GLM"V:LH=ZXZ[_=MFF,I;$]7J.C-7)M2.-J:1=]6!D7F
MEZ.)/F;G\ M*CJ+(,.Y] OWJ%>_81//*>.ENK#^%U9!=AQ'D-;6Z;)1)@]*J<*_>&YXV%(X M>TMAV"@,O=_!D/?RC@QN31Z!8:E"8T7/E2O3FYR71A$(ED
M!T)E\% (!7H.=V@6:"[[CBRP7#]MT*X#VO -M$]PIY7++7Q6&6:[^GWRK'-O MV+IW/3P(,,J!Z/X!(;Q<'P ;]2%._)XH_\=]J&>]^&"W]-$^L,U 0
MZN&7]PKNA$ES&(?,G(#+$6YT60FU!E)"@QE(Y31'X9:29?# XHGN)8Z".!" MV-JV K,Z.8$O*NV=@(!;+,1*&(14FTH;$3];E 2LC]N[/A,+YXC>]?
#"Z.R8(%09Y2\4*RIJ"$@Q2-H^$&A(=0H*/8 M(!..)*;U@AH4!J>!!#AB$AHC+UG",H_8,=^2]MK^QNDNSK/&SYOZ7= M17KB/:LK"HI?$UVE]8\
((1^;Q:U>JE4F.7^6MP;UG#2=?X7S.?II#8X. +:] M96@[RL^=X#<2W$2+@FI36EM3$&R:3B/K:,$1VYSKAS [-E)=EN0MS=KTB?(C
M#"Q%42/\!'$OCN,!5&0VJ&T;]_HW07?&NJU].-(<$9>/@J/GXZ!K.YO;.I!C MX6MMTP+$!QVOE*)UZY(V!R%"L@C#9VAOX1 "=V8F#6>
=E(UZ_T)E\%6:!QF M\&A]#+?$*"6829P%=X[(63H"I?+=OK<9R\/'"PO1V9DG #}5@6X"J?:MT#FI#F>4J#2S]0 Z#_GVK'\+J\HC?
M:U&P@W%O^&ETNEMZSRFE=X'PR$/H1>G9FG^\M:PF=IE!\D=FM&[+V(U4UHF](.0?J,-RR1/2H2 /=1XM4\%T8H*](P!BE2AV45
MF/8S,5GW^*S=Q],HS(AVXW3E;[*)=G0O]LN[39O(O4$L# M!!0 (R&&PO=V]R:W-H965T';^[^^Y(7FVD>M()@"'/*1?ZVDN,65UV MNSI,(*7:ERL0.!-
+E5*#GVK9U2L%-')**>|&O=Y9-Z5,>),K]^]:3:YD9C@3 M<*^(SM*4JNT,N-Q<>WVO_/' EHFQ/[J3JQ5=PAS,M]6]PJ]N925B*0C-I" *
MXFMOVK^<#:V\$_C.8*-K[\1ZLI#RR7Y\B:Z]G@4$'$)C+5 B2"F&3 M9)/+#H8>"3-M9%HH(X*4B7RDST4<:@KCWA&%H% ('.Y\(8?REAHZN5)R0Y25
M1FOVQ;GJM!$<$S8IF7RF3)'OE&= [H#J3 %&W.BKKD'C5J0;%H9F MN:'@B*$+%233Y)"*(7NIW$52%+"B1S8)7#M
M(C\GL+^+LG7[M^4*$^Y[X%H^V53W!8=0? MY&,P)B>[Q1J2N]JG#;]8D[_!.* M#OXYCN<[H5J>QCT4^(6,1VZX<$/KH3E7B.@,A49^'Y\#_P(E*Y,1]M|
(NQ_9 M,N#1P19=CDU'WV[MAI*"6KI[F-UQ,V'RRTKUM[KJ3;,;SDX\OR?>4;7$[0^/ M<3&JHM\C#XGG[E[YAY$K=]_!.L;;DWM-|+H*R@K@?"SQZ%M|V
6J"_#D'U!+ M P04 " ,AG-90CB3'3P# !!P &0 'AL+W=OP<A^'/2@V M'1N3)4^2F_3?CY1=+QW:X%X2B2(_?23%S\N]-
MJMB>C@4$ME5T'I7',9AC8K ML19VHAM4=%)H4PM'6[,+;6-
0Y#ZHEF$<16E8BTH%ZZ6W;KE'J_2J8!H^&VVI7.C:$ZV4C=GB'[N]F8V@7#BAY5:.RE59@L%@%5]/+
MZSG[>X=_*MS;HS5P)ENMO_/FKWP51$P()6:.$03]W>,[E)*!B,:/'C,8KN3 MX_4C^@>?.^6R%1;?:?
EOE;MR%2P"R+$0K72W>O\1^WP2QLNTM/X7]IWO;!9 MUEJGZSZ8&-25ZO[%H:_#4< B>B$@[@-BS[N[R+-\+YQ8+XW>@V%O0N.%3]5' M$[E*
<5/NG*'3BN+<^BK+3(LYW!RHS1;M,G2$RF=AUB-<=PCQ"P@7\$DK5UJX M43GF3^-#8C-0BA\I7<^PF< L&D,+,AQ9G'F[V MQ$/8BO1@E Y
M^'R%M/#?U=8Z0X_BVW,I=XCSYQ%Y4"YM(S)NM4V^=78Z>>AX[C-Z<0:4(7K>6@NT?'0Z'C6[J1NH'1&)2,R?1
MS2I=L46%1>4LG$%*WFU*4AK7"_4DL6%Y#. MDM'&Z (MBPB%L3?G3#/+.19(CHMT"FEZ,;I%>A!MYEK#1_,D@M>O%O$T?COZ
M0I4QL)C">3+ZJAWC_%[(,XC':90PS7&2ID.ES1/0P9TJ*YK&Z$-%PH+R@>*B M24(#+J7/_Z7:&Y3D#TZ#5OBG(WD$*@CI0E>WH69-]^;9D86;(+
OM!U3+S+9 MYK[']BBAAUK(RCF%?5EQ0@T.X]QH_BM:X$GZTPM!M3(W)3(@@@G]K\>2Y=Q6\> MR1)1V'GQY3?7*M!V&Z<; M+W);
[4@R_;*D;Q0:=]#$O0A//?L,7#%^]]4]02P,$% @ #(9S6=ML!7Q& M# A2H !D !X;"]W;W)K&ULM5I9<]LX$G[7 MKT!ILC-)%2WQE*@K ED>A&GU\WCN>
[3/V=KX4HV-TF2?,7XW51;)].IWFT%AN>3[*M2.'-,E,; M7L!/M9KF6R5X3$2;9.K:]FRZX3(=GS^G9]?J_'E6%HE,Q;5B>;G9<'7_4B39
M[L78&5^,]3D)LO^QA]OXA=C&P42B8@*Y,#AXU9O,QB\J\R#:&&"38R%1_\CMCAQ9!: \0N(;);GU1"3E%2_X^7.5[9C"T< - MOY"J1
W"R12=\KE0\%8"77'^>ZGYN0/\%NQ]EA;KG+U*8Q%WZ:<@6RV@6PGXTCW*\+/83IAG6\RU M7?|(/Z]6V"-^WA"_(HO^KA76:K(/62'8?
R]N\D)!F/RO3VW-U>_GBJGS--_R M2+P80V[D0MV*\?GOOSDS^]D1F?U:9O\8]^]PTG%^L.YLPMI\?_\M=)WYLP/N M[*.*90KYJD?G[&/*P">%V-
P(53G&LUBQ%NPRVVQY>F]8Y2QO\6=\NU79K8@9 M3YE,(T'07+ B(*T)&[9DO&R6&=*_@/CLFIB8I-;;,L5N^5)*=@C9D]LVW;8
M8Z3&^5S[V9Z@]-1YIJ0C&HMP]CP''C?WS LLX%+]['4\(4C(>QY+0XT!0,P9P M+B]X"H0K!L/>EJFHC3)A%U%$3%?)O<5XCG0'MO/!(#&[$I%YZO18E.V
N&4: MD$8K46[QNQ]8CNM:GNM8@>OMZS%AEZ52(BU0",&C-;NX^@R 2H&:%CES2?M] M/[=-BP2?.!BB,BJHEB3$!X7?@MST?9.5R!
,A\0)HH[9[#MY6;D*Y:CU-K+2Y M _,"90+_E6 6%"XB&1XQ9Q*&0>/9'AD8M 0MR56\|D,2EB28#ZUQ1_V:Q-N?\'P0R.L.3C28V?W J !'+V!V.'T"N-MJ;(-
MQ81)]#DJ^GI5@]O*>(0\7R=")!>W D52; 5OI7$QH.".9$;B<$:2165&\SW M"-.J7Z;'&:@&TJPY9D$&S(S[8?Z\0'JBQ0""E@ M3|QGE2.&)CTYQ:D9%LT,
M'T31N)',B+XZDGP[R+ >9]NUL_D2? .Y%Y?0@X%O6K&_PO]+ =J@N-ITXFZ+ M2 $6OBA8E*)0.&W+"?#&11+?8%B;T/ M"CJ&P!KD+(!@+JNZ>F#F
58H" Y$.V,R, 1S7:3VPL"> ^%48Z'DK%\4"58/& M),94T5A_&-=HA-/2;"!B.=0C(WZD(%N5Y.0PH;N8*.%Y+J&SP5*2[E7F<@OZ
M8*"1C4^'&A51, ^Y[9::D40*EP)X(R!A6RRS%40B>IO. RKCE,CX#&(KX5A8\ MP4((@76T%%;O?U8Q%',0!O7 ($/LKX'!8C!. > +@CO'MA3@'(,Z>.0^ N
;A'M<] M*%K!<0/VKTZJSFJ^FK2@HJ$QW>4S()\H243S7OQL/T$!#W)[%LPU'TXACYD MYE^#E\=BIHV8#Y'P1]"Q7DKA,JH?
(#M#CF#D(2Q2U.:_']$L'- 'E]B* M?8*RT+N0: ?B"?GKWGX?.A?^W IG80LXW8GC_!3@',+!4Z8>@,+PQZ&P648/ M>[D[YOOIU,DL82XE:
[7*914M+60+MJ&;/+M11+]NI.1"65[H]+R%+0L;L@/&Z=P1@* L<*G5DKAKR) M9S_9:OW_(>C2$UGC>U(T^Z#_DJ*N)-W%L]H.! MC7C:
(S'C$+FF@O$;<--P30-XMCM=^PYXLS0K=.4!1:')34I%;!EF2356NY$ M(%/%)Z*/$%;U0(B),C'AQ]V=O9H_$NZCU.2_T@'K?06O ML][C401TM.E%:
[@4XJLHC:RMIJ:OPATVU<,*U(6!-MR(404!=22BH0Y7B9Z' M?SK5J4:K9A)=@F&@L9(I9':KD'7@\W3)\$_W0J=4[6^&O$GP[X&UKS?9/RZI@128W-R3
M9[H @>':!#>VBT(?\KDT^;)45-P LKA,"/R,<&3W+)&1)(T2PE1S^+-O M@$IZK>4R2Y)L1V:FAD$?<\M_1-YOO=;!4=L,WW!$]'3TH3Z.JOHBM/JHRZ!#
M]X6.J45\=G$K%(35B-@3S+RJ2N4UE;M76*T(5=D56&&DCP//*L!M(2+PFSJVGKM%/JR_KSW@&P=X=I=' MIU360D!A-6L(LP P'Z:=_@ U4G.ZS
M:I_*F[KDQ,6HWLX]-&)SGM:FGL]Q"_CL;9DR8\A3^\&>J\|(.C(L6##U'"U# M8-ESWYJ#,<'JTC5 M1*30CK*-OI$B*-P.P;4#H_OPV,;5/80B-KK$^
M((YO.8L 0R4>(0!B>/V8A]';VPF5/@/4DS M@%WJWA)ZE%ALMH3LG_1=E?T],=NJ+0@MP-8L^J 5T&>K9-D,6GU@UEEJ&,?|

M<=@<4)N$%V*|9WAWP|&:6M_BZ%DG>E;HSZ'#MQW/"9@NRWN#=!>&MT]HL81*BFB=POHA87@E!4]\454C3<)W9E,G MIA5]
(O8*&+#>:>;8LAN:I^BQJHCE5T@Z)BZHBIO8/7 M4C6-C[X/TMT*P9L6,A:FBM?&T2W]9@,-OFY#(^2:)"+6)FL8=)T,869&:H:X
M.H2J:3?'^J"QN0)"K:,1D'S?L4S5OZDFDT{9N%A&Y/8<&*,,.>R=B@UM,ZH)Y,*U1-6%EW/UC-445[3I2] 5E0?%RITM*ANOE% MPID=@B8E!F[
W/"GIW^'1_WXQL78JIHJNY!Q97-[5TZSSINVDV;5T-W BU MH@N0* MX2=|2K)_6=RPO]-7"9KB^H F5%+(_9XE8 JD]F0=CIO2E1_VCR+9T MT?
F*XIL0U_7@H.P. #>+S/HP,T/G*"^>7K^?U!+ P04 " ,AG-9U ;T MCH|* !N'0 &0 'AL+W=O%]7 (HCBQ;?K1)@/2Q>WO MD73=G|X' ZT1-N\2J(K4G%\?
_U]0U(/ M.XXWW2M01PJR.#.<^>8;ZFJKRJ]Z+81A#WE6Z.O^VIC-B|\M+G:Q%SO5 ;42! M-TM5YMS@MEQ=ZDTI>&HGY=EE%
(:3RYS+HG]S99]]*& ^N5&4R68@/)=-5GO-R M]TID:GO='_;K!Q_E:FWHP>7-U8:OQ)TPGSN&5FR4.HKW?
R67O=#4DAD(C$D@>//O7@MLHP$08UO7F:_ M69(F=J]KZ;]8VV'+@FOQ6F5_R-2LK_NS/DO%DE>9^:BV?Q?>GICD)2K3]I=M
MW=CQJ, ^22AN5^\G0()>%^\L?O!\Z$V;A$Q,B/R&R>KN%K)9ON.$W5Z7:LI)& M0QI=6%/M;"@G"]J4.U/BK<0_J*L-
7M;I"+=GW\)K1K5HEJU5]%)@7=B,V"C,&!1&(U/R!LU MIHZLO-%3|M:|%-[4#WR'R#+LMBQYL1+V^I^W"VU*A,F_CAGO9(^/RZ;4>:$W M/!'7?
>2&%N6]Z-_|_-P$KX\H?FXT7Q\2OIW=;)=2*62KT?L M[;=*FAW[K4C@%R0-^Y#Q@KTOV# ^J0M1;,@J860L[FQ>
[GW^81R:6$:@>3[2V6E)!!8^D" M8,;NA3:R6 &($"0R\:/KNT9.54BCV9FWY>/=9UV;8:6Y0>06D4CG\9)P Z*, M8@MO$SE,,9%O,K43 N]2B?
%&E4[]!$L#=#!0#]BG=@^8U&PCREP:+T%J70E6 M;>AZ/@N#,+3_F2I360""W69I*(W=:O>(G!^P359A-RLXGJ>I)%5YQHHJ7V H
M?'XHX|PM,XOC8#*:!J/'RYQ#VN(_L(/&\2TO4]V8V]5@.'Y6E?I1 *@T0 M#X:RV6GN5L'J%#1+(;%6P!(.N5E&EX@D\;"!=Z&!>!!E(I$1 W:KR40 D!'6
MWAJ%]D*>K7G*QO-9,]*P7P8'W=KMJ.H001I;%A*U\(9YW4[ZGO:8>GB[3"| M;0107 7V*I[,@S@KM0,)UNFKAV2]8[M@'5DXI3MVEZ[+.<[I+"AM3.A-
6E3L"$"[J=Z@267)8:57\%J[GE6-2L?HM6A MR[(#4NYL5,I6^5HD3Q1CD'^7FW;^[@P"|>H(4OF@;Y9$##!AGF=1)*:PW
MO4N.;Q5R8#]#NX#$S&XC$YYE.PN+#! /V[>*!BU557KSR6\M$SP>A*)X' M\]$XF,QF_S\(^?5/@A (A+U][S&)PGRI,C!\&HTRQ&N6_U3B[>Y(IR#2>
<19+WIG/X(+,"KB&J*PX^(AP3#G'RL=&>/OD/?\ MW-OVAR7T(KUHKVX1PNA4V.T*';]"QO?>=UR*#'LC$K_\T'$D-HF'081Z. 8\ M_P$T@/]M/'FE)X,Q+J-
:*QO" MQP6,HS@8SH;!*([;R6%K,?MW^|^NAN3/*N)UEK<1H!RR,L8I?;*,_E;%T1$4 M$XXF4F24%-X:+F)$Q0DJ'2HB6[3';$$])84;%:W*N))&,0
^(!*/>!;=&ACF M5J*>]+92EL? IJ85A) M.S :3#%H-)AA3",EE<3XX+*=%-EC+&K&67)T:CWU 88,7-Y_;#LDAZN?;8?T M:0_C/:],

*M$%*HR;XGY2Y"1J-%!IE_0A'BC) MH-!L.F<7(_$3HT:(,W'&%9L"!(ID_-Y#)@LU4.N@]^ZE],=@X#RH=<^_D#(7 MZ7UKI&^0\P^;P@FPW84/)FPF9F9*'+45709=.TX_K:LJ8\Y"2=G#"/[;Y4U2 MD"X38"$C+D7 X6LNE=&=2]9D0:Y\I!INA; <6;PRX.[MS]!IKZ)SJVIE" [_LXCAKES,>7!D$=IE!:S\E=PYN_7;YR4$MX1L,T6A,,?<- M _/1"O^K#TG#/ O4X:K2!]CWH*E"S4HQ52!ZL8D/MC0TK^-'Y"92 I="::#(5\9U>,-((HI< !W\% M>+]8<+VQ9PFZ&@#9L%IV> M_'6C$OC*$=-U<.FV#-5EYHC)5_CJ5!4-GT@]V-(1^1O8Pl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|=,1B@&*QY*;0"&S;IHU]#.?S3'N<7XM9A=3'^XK;="!Z+=4 E0PVAXZLKW)+"UMBKX'M,JHLJ[$5TA)E[FK@QHHW^9@ M3[R$TGL/QP=07YJ"NTE!<50LRM\&?13[%?>H6VSF2,;$J=P%)#QWW&)^+H-6 MB?@ \7%4MNSJ\%DN[1\-']#VW15N,T1%C(%P>H)"%N)GVT-K*NZF5N_+^Z;C MAV]B,)@@+)4/O>E&++M+F!YJ/^BRBAZK9>7/>%8F\^C(_L<^LJV MJB[K8<[7)?N#!S$+M1;?34QX#%CTV&46,?3;;#$]\B1IWM9N'-4FOF31O/Q MHBT2VIM\C=M*2X%-=^G:T&DOU7O /SJY)\ZW81[/? 5I8]L9K6<+LU/<%5&U-3G\GB6)1IV9 M/U6S&#\2<\W74$C[,BBQ1R\TNI!4TG$G093.8P]5"LU-18Y\K1_)T:T1GI8 M!">0>]L J&WCP<1]Z4/^PQ6VH!$.B0^I-LKU$$F<<>LM]6&1IGA=/NG*LYC>]6 MF/I[$?S)^BYF<7<:2I%,&@AO*O3QHQ8==Q_]"8&Q^5[7#LQ60%=N")$[=K-MW> L1T:HA+XX4WO>,[4N:S),3G?W^GL5W&D3#N\D,6[XSH5 H1'WFPL.FG1C M\C6#"Y8Y*W.'BYS.&GIN3X1V]LH[82N8&5DA9H P>X\?Y3 MS: [@/KK/59&AZ/#EDG)K5"]RKW(="@PTA'ETV&ZY_A=\^NXW/78;T7+4)7K MOJG3;W4WKRSW-@+JB1]Q.9D5 Y1=`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|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|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{@/92E(4(9OSK.86_2_'? G&_8/UG?T9<85O!2E?9'KY=4P&9(< MYKPI]7>Q_@B=/Z'ART2I{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¥RVUAS[,QVVNW?8SMI:-EC##"@U1%K&0\OI=$<:X.Y\R_[)>M=>[K"$&:<_2*Z*B7/FH!R6N*;J MAF\^0^MG;/@R3J7]19LF- @X"UQ*S7":NTN<;%C=KSYHV M9_DOG/4>77&F"HD^LASR?;RK=7?B_:WXJ3{N(#J% 7>6^1[?MBC9S8,GT.F MX2,+#P;D!%TN \L7_&4N?*

W[1(I44,I??5EK6,-^5O,,SV6%,Y@X^IU$&MP MTM>O1I'WH<_R?R+;2T#8)2 <8D\OLJPN:XH5Y.8ID8RH/K\-261)3)59IWX8 MA&=>XJYWG?*
2^{7}8C;JP/8WC3N-X4,,,RT(_?(I9!GWB&O1X[]0P>B;M,"@X M"\?]PJ).6#0H;%X=E]PFH.0"!YJHIYTF=2C %TU>Q,9'6H=>_3.'CJ/UZ(MN/,4#WJZ =-*
("%LA66 !C;LW9KUCF^,%N:'B? M^?C@>D3Q@?G#('\GIO'D[E3/$L3-A6),EXSU132;K?K6Q>V7+M_PINF=X7% MBC")*"PUU#N-*
*]7\CFD;2+!2O;"V^XTI7=CLM=.\%80+T]R7G:KLP!W3=//T-M4$L#!!0 (R&&PO=V]R:W-H965T+&>V@<3ML (K8,3;^J'8!T8^*
MVT0D4B,I._OW(RE%MF)9: I]L?AR]^B>XV/ZSK.CD$]J#Z#1W MOJ^R/114W8@2N-G9"EE0;;9RYZM2 MTXIR+W XP3OZ",>XN96UO)Q4Q4.F<<
*M5A*IJBBH_.|>\1[67A@N[VV"_YB5M(=K$'_5:ZDF?DMRH85P!43'$G8 MSKT[/? M!M1KWVD=S\#T^\0-_[!:X?HBD/8.(2.:!V9H_61-M:KJ827%$TEH;-*
*#MPN7'>A@WC]AC76IH=9OST8ET?'Q));M&8[SK8LHURCNRP3 M%=>,[]!*Y"QCH-_'=&=6-BRO;.:1@JR23-L=>,[R:@,;M)6B0)DHRDI3=TH&*
M%JCD!D>A$HQ\]E0">O<1-&6Y>G\V^E#OJ9FO#2T;G)\U%.YK"L$5"E/T17"] M5^@3-S%T_7V3CC8GP4M.[H-!P#64-RC$OZ !U%#,OO=P\!P@G;
(PH=7G@% M[]-+ E^^@KD ;S%SS^1 M!/_:QW8DL [WJ.4>#:$O_A2:YGT,:[?8N=FKZK @83R9AC&98I/TPSF!2]LX
*MB",T*BM%KO5>Z@^UL/8B2P#M.D99J,+<)D3.XC M@76X3UKNDQ\3X>126'B"292DZ2L)7EHF*28DB*XI,&UC2P=C^TJE-!=VK_@& M/=]Z*
",!=4A.6Y+3L<4W'9/2& =[@2?J'QC\FO\>M<@B1.@B0.PS-=U1QZ MC",2QV$TB:]ID)P5>$@ PQ0 =06K),FQ) N2NQXJQ?D\- ,$V8L="ZM(,3[6!L M73:
(8_$?":W+_U28D,'?_@%EAA=B"V*2!N&4Q*]U>6D:D31.S45Z39:GXH$, M5P]+P0\@-7O, 7&AKQ27@QAO/I&1T+J,3_4(B4=7Y@UREAH7?ZG*H4,%@(#*
*MBDPN[\H@GJ2F!+R*D]LNN MZ3O!U,WV%RIWC"N4P]9 XIN)H2GK_K6>:%&Z%O!1:--0NN'>}/P@K8'9WPKS M[6@F]@7MOPB+_P%02P,$% @ #*
*(9S68Z\N;'N#@ XZH !D !X;"]W M;W)K&ULM9UK<]NX%8;_"L;=W4EF'%LD1=O*VIYQ MS'OKU!-WVP^=?H I2&*7%X6$?.GLCR]*
TJ(H09"T>9T/L401#T#J'/ EK-2T;' M=:,L/34'@[/3C";YT?5EO>V^O+XL%CQ-$WDHCT7QNWP3CJ^.!G)$++&4QEP@J_CRQ6Y:FDB3&\;V%'BW[E U77[_1
MO?K@Q<$\THK=%NF_DC&?71U=')$QF]!%RK\5SP%K#Z@>8%RD5?T_>6[W'1R1 M>%'Q(FL;BQ%D2=[\I2_MB5AI8%A;&IAM
W/?!E;;P%IO8&]I,&P;#/=M8+<-_M[/4&PRT-SMH&9VL-MIZE\[,!^;X]7+0-+O9M,&H;C/9M8 S>OKE!;4'-5U[;
*MBT,YO;XLBV=2ROT%3[ZHC:YN+\PDR:5_//12?)](=OSZH?$+4DS(0S+-DTD2 MTYR3FS@N%CE\BFY+](D3EA%/I&;\3B15DU3$N:-;TH;_^*
P3I.T^BAV^>W! M(1]^^GAYRL7@9!>G<3L0IQF(N64@!KDK_!CO8?ZYAY[/"'F:&OOD;ZYP^+EF;=8/^Z=BK%\;]E#-EI?>S]6/JT:-[(!?V=W ,[$*
F+=&/OF:&]-$-;X8/LZ+DGS@K M,S))4R27+QC%2]-2L'#:!G_^=+^S_?U_[']$?$_E2&25H.8<;/1+F M(&$N%N8A8;[^B\QD?IZ^BLFKXC1-
*,QGL$3XKB\5T1KX63RQ[9&6=MIVHG Y MTA)BT"PGG=<++WC0GM2_;*H*C(OBYBQ<44F99&1N,B?6,F3QY3)3[*DJ@J1*
M@N8%5V>9VAX.]1LDS$"'"7"3,0\+\B\TP9*'*?9"=ADA8!(+U7&"T=(&1U@6^_M"2(MXQFA^5A<(IY86LSEY$(X?2%QR<:),JG44@\U>R3,0<+_)"Y,%&
(%C/#HU!=R]^H+7$.U9.6?FI9*D(R\=B'J[4EJ?' M'&IZ4)H#I;DM;=5:1B-ST_B@O?J*7DUSI+!1:+"IM?E$D^[>;V&15SO7IVU_(_M-GPDS8'27"C-
*@]+\EM:+4\Y5<0JTVQ!*BU'"TONEWVJ6A%7[TID\6^9PF*J7^ MBQY[L_= A4LHS6UIJU9FJX)K:*_^GKT&T%Y#*'"U"T?JFW8F.AEYUE/49\E83*
*MN4]IKK1AJ.8(I3E0F@NE>5":#Z4%4%H(I44H6M\?.O73L-^Q3L6 Z}0OF@.E MN5":!Z7Y4%H I8506H2B]9VE4V0-O21[>$H U6.A- =**0%4*
M<(72(A2M;_J=&&OH1;R5$N)2Z07L9<[R:HL;0!5:,V!TEPHS8/2_):VZ@8; M#@ 56Z&T"$7K.T"GMQIZP?6!/,%25N'4,\9;7F-*>OV;8J1CWY*
*M8/.'*JU0F@NE>5":W}]Z5X&A\BH E5NAM A%ZSM!I[@:>LEU'*0[D14[BNH"W MF?9)?*
1F0Z0(OR).X0,B7(J>0],W\E=!G6H[5O@%58Z$T!TISH30/2O.-3=%6 MJ>U">PVAM A%ZS\TU&G Y@X-^.W&TNU'%<[7;;4W>MBA9@^E.5":"Z5Y4)H/*
MI0506@BE12A:WSDZ4=DTWO$NDPE5E*$T!TISH30/2O.AM !'"Z&T"$7K.TLG M/)MZX1E1VMEVL;.T\%8_EH.]
2HS0VD>E.9#:0&4%D)!$8K6]X9.BS;U6O1]MDUAOK_[7MS_XZ@ 5G;$T%TKSH#1_Q[?XCQDCRPBYCHK)(Z-E]T 3Y<2P?Y9%
*M9X3F^2(]L^S))Z13#1Z9&*_N&2T$IFGR"^-\Y_)8BXR4"ZH11PORI+)&S,B MNHC%)$F3G+"G^BD#L:5=TWBXWB -+$W$@HO_5B*?CEDRYY)!*
MR6\G?SV1MUUWE3LWUXK@CGR3Q[]H;E7=ULM15,VQ?GC\V#UR\;;@?*Q"ZAY*
MA%!:A+UIZ2NAL#4UQ"$JT_A=2:KG)P:TEKYHF&O7X6A90)0F@NE>5":#Z4% M4%H(I44H6M_DNS(!4_^4M-/,HFM/H*[4""N-WU8:__FZ\4-E?RC-A=*
(,V' MT@(H+832(A2M;_R=[&_J9?_FCEZ]LE@30LRE$JJT>*C>#Z4Y4)H+I7E0FK_C MZ[POBZ=DS,;'9%8\2U7O6$:?(O@B/,E$5%?*
6?]O$>QG@B4!,OI89=QU)R?M6 M:,U)Q'=\U@ON9#@I,06)TZ)JI1"Y:_.@T'%'FA7I6)@6H:4(&P61ITV(V^;[M]:CF1?
GVX$4=|"YXQ<4()+892!V2I,3=)PNZ@_78MHVGGV;P.NIO'B+ M.\F-\U#5IX%,DI?Z&::ES0N.'*[9]X4@B18_&2?VZ%B$H_57T=R]D^/Z2JLQ
M_2Y&.4GB1.SZ=NA-|W;PZV%NW6T;1R=5M:@%5GF^CTFU>/POBWE]-MJHOJX\ M2.K'4"IUT HMX(#2(A2M/XEU!1RFOH#C=NT+54Y?#<(P5F\;B6]
[_8(-+<" MTEPHS8/2?"@M@-)""U"T?JVWM5JF/I:C>U:'/F#/"P>*S&9R6 TAPH MS872/"C-A](":*V$TB(4K;_ 9U?*
Q8>DK/E8BJB;X5OF$GC&H3T!I3DOKB82F MO:$1NM!>/2C-A](":*V$TB(4K6_M70F!I5\7X.NBU@S$E:&;B6RUJM,UD2C6 M0DR7+2I] %[_
*:4Y+6VU*C0X.#.M,X4;0(LSH#0?2@N@M!!*BU"TOAMTQ1G6 MKE4!WBJ]:[EQ);_86HNA)QYL_M""#6NS3N3E":#Z4%4%H(I44H M6M_V5Y8TUXOX-*
QDK94) '#8OJH3+3.&AN1C\07 YMWX4!_L+=OES[/KGV 70 ML2N@8Y= QZZ!CET$_3VJ":RNFL ;OF/,;2%5YELHS8'27"C-@])"V TD(H*
*M+4+1^L[2U2%8^C]$_7)NZ*H$4)IC*98>5^;&5B) ;8ZU^3R^,; ,XV+=!Z U!E":#Z4%4%H(I44H6M\',MW: MVK$,O,@YA.7?*
*D&=:EE3FW7\0;2+RC4V32M8XC,DX*64%03&9,+E6@=)/H$L3 M0&D.E.9":1Z4YD-I 9060FD1BM;WIDX9MR[>,]F JN%0F@.EN5":!Z7Y4%H*
MI8506H2BJ9VE4\,M_6H'-]-IR::R^*\N4VN+RP}WH9CJE_+,>G'NPC4!$< M2G.A-_]*\XV-U>K/IZN7M^[IN4$[=4EN!RM;U MA$-M'4ISH#072O.@-
'^HD/'/UW_0#RIL0VD1BM:W\T[8'NJ%[3;!^/). "8:^ M]X-]!"I^0VDNE.9!:3Z4%D!I(906H6AJ;^KT\;YC@G&$"J50VD.E.9":1Z4 MYD-I
9060FD1BM9WEDY0'^X0U/],@J%G'NPC4'D<2G.A-_]\X>;2_KPQH MKR&4%J%H?>M?^?UOK5;X5X(!5;>A-*
*=*5":;#Z4%4%H(I44H6M]9.B%\J!?"OQWZXQ-ZWL'^ M 96VH31WN+FRO:'Z-2YHKSZ4%D!I(906H6A]R^]$Z^&NQ[DW JB]%EG68P]V M*
A<#:6Y4)H'I?E06@"EA5!:A+UW:23JX?O^?#V$*I;0VD.E.9":1Z4YD-I M 9060FD1BM9S%KM3MVV]NKUN;<2=>VWKQ^F9M52^E&4,5:"C-@=+*
MO0;07D,H+4+1^F;\KK1ZIUCX7J$0>,,50;AM)<,V#TGPH+8#2 M0B@M0M'Z+M%IP[;UCM&\#16)H30'2G.A-_]*\Z&T*
$H+H;0(1>L[2RFEB(YM/ZUA"M*L8KN5AI1L4NH30'2G-WG%G3)*^,EJ)QH,.Q/_S PF@ PFAM A%ZWM&)S[;>O'Y9M7> MQ;5DPSF4U@^5H:$T!TIS;
<7CV,J,8;_]_#WW"_;<+X0>;82B-;9X6LT8XP[E MJ/HRDPM;W\[TK4@=G\BX9F6KF(G\M=%/]^81Z<;VUWCLV?MKA MKR_G=,KN:#E-
*\HJD;'*Z&IR&PO=V]R:W-H965TN,% U"3.<0ST2/OPLY,T)1--3??T#23@YY<+_N- M/#M2]ECL".'H*4VR8J[M.,_^O=;V(=B3%Q17-*
22;>V5"68BY6V58OHV?#B8!YP098T M^2M>\JU=KNHE91>S,,>+&:-'Q&1[X3*ZI? 2Z;O M3O?2J%78N,3DY>UA85P9AF'.],-IB-2:V6K-*
*'+5FKEHS3ZV9K]8L4&L65LTF M[68OC5I=8M!TB4%GE[A)*8LC\;5KD9P6HE^P[ZCL)H7H%*O]0T&^[>77LWT0 MC^=Z5I=*
Q"Q(S(;$'$C,A<0\2,R'Q)(+ 3"6HD;-HD;?MPESQ R;9"8 M!8G9D)@#B;F0F >)^9!8 (F%0%@K;:,F;:/.\>V>L$AD#6^)3!EYRDG$R1K1 M8T98L8MS%
(OX[7G!11CC;/OZ#Z7;:CO3UN@[F S:8_2R).9#8@$D%@)AK4R-FTR-NZ\9'S&+T>],!.;BR\5. ^=(!#!*S(#$;$G,@ M,1<2\R Q'Q(+
(+$0"&N%;=*$;?)QEXL3R+1!8A8D9D-B#B3F0F(>).9#8@$D M%@)AK;1-F[1-W_4/V;EP397^M5EV;O#2V$!B-B3F0&(N).9!8CXD%D!B(1#6 MBHUIO-
PR-3J#4P](N!FMR%.TPYGXV<7D[5$D_UZFSU>,Y8^LL[=]XV8O5:H M>M/^\'^AZMZ;2U,%]MF@F@.JN:"\!ZKYH%H JH506CM=)Q,2S#?^Q<"/:$G3
ME&9HQ6GTJ/AKJYN]] (05+--1M4S6>6T[CO,MG%6H(1L!&]$V8;"#>WU#*GU?DG-EFOOKB/U!+ P04 M" ,AG-98N2")E$# #"$@ &0
*'AL+W=O:%QO!HR\637-(H])RQ7(Z]I5*K<]^7Z1(R(D_Y"G+] M9,Y%1I0>BH4O5P+(K !ES_^#H.]GA.9>,BKN\W8EDQ->*T1SN!)+K+"/B[R4P*
*MOAU[V'NY<4\72V5N^,EH118P ?6PNA-ZY-(YNC7DJ\ER6=RY"L]OV'QTVJNRW*N\,!<$UB=HBCX@L(@[+7 K^SP M:T@U'!?PJ*
*GWM>I;>EA+#PN^J)OT-ETE4:^=R'S3SN6*I##V]%=)@MB EWS^ MA/O!MS:5CL@:FJ-:B)(OW[1RW MFWE0RQMT-?.EUO MW-*
9RIOZ#=HY&MB9.^^A(!;F.NQR$>XY M\Z[33.2*K:E[EXJP-8"\W[M.PU+%]I.0@'+\L"D"'X+LU4LLM59M3]LP$/XL5H8FD
.)W3:TK(U$86C[@(3H8)_=YMI8.'9G.RW\ M^]E)FA211 .5+XW?[KGGSH^O-]Y*]:03 (.>4R[TQ$N,65_XOEXDD%)])M<@
M[,Y2J!0:.U4K7Z\5T#@W2KE/@B#T4\]$%XWSM3L5C65F.!-PIY#.TI2JEREP MN9UXV-LMW+-58MR"'XW7= 4S,__K.V5G?H42LQ2$9E(@!>
(%C!!P6QD%0^]G %7#ND"R/OR6H5_ETAOOC'?I- M'KP-9DXU7$G^A\4FF7A##\6PI!DW]W+[$\J !@YO(;G.?]&V/!MX:)%I(]/2 MV#)(F2B^]+E,Q)X!
*(2T&I#0@.>_"4<[RFAH:C97<(N5.6S0WR$/-K2TY)MRM MS(RRN\S:F>B&,H4>*<\ W0+5F0*;7X.AC.L3=.0._$YDIJF(]=@WEJ7SY2]*1M."$6EA-*
*$*W4IA$ MHQ\BAOBUO6^CJT(DNQ"G!-P!NLSU N^(1*0/GJ87:/CHY,.W%Z5NEZ.VWM? MZIHB+H#ZS4#NX5WH-5W*
Q+,O2X/:@!=]_8+#X'L'S7Y%L]^%7M#5^T&G^ZN$BA4X32QK(E92E72:B!20 M@STBIP,R;"825D3"=^0!1-R2A/"-[W,R:'9]7KD^[W0]\5 H\O=NVG42"?
*$ M!S4RK @.#R7EX2?0'%4T1X>2\NC-+>*62\1!72]#PTNYQ'REY58J>U4;'T3, M)9ET5;5QXON])8J>S$:<5A:T^#LW :NBH:OF!BYSINLN32V9'P &0 'AL*
*M+W=OLS07LV C97$=AB+9D R+'BM(KIZL&,_^P5$V^#D7!"5Z605D:HB@:AAFF M>3"?EO<>^'S*MC*E.7G@0&RS#/.W6Y*R_2R P?'&*
(UUOI+X1SJ<%7I,%D=^+ M!ZY:88VRI!G)!64YX&0U"V[@]5U"I1/]:DE=DGK$@=RS]09=R,PO& 5B2 M%=ZF\I'M_R85H8'&2U@JRE^PK_I&
*4BV0K*L"E8CR&A^^,>O52). M"D)0!5 M>AW ^(J("Z)'D96TKK'$L^GG.T!U[T5FKXHJ#[XM[MG#]7I0R5\WO6PG"K &\/]*
M/_#7^$)%004G":D*0%.3/WA7HL")V06J"]3$+XCP?S//^ P^M+$WQ.813^N MZ<MQ-/4V<8Y^0&?J YL56-N7 M"=PU!P>P00FF%^O='(ZFX:Z!V:!F-*
*N@LYB>F/^^4RK2)3\Z>P"S.,#(N)O*A9:6#5B-QZWY%UWQ4:# ^T77<@ZA9 MV?#$K\'.VGZDXN7SBA,'.):-*
\G:#=N;I"2X2N5=K5J%9(H]Z+18;&M,%W:ZK M$OEMMXK1#=J9FBQIE!IPFZ2-H35[57L7/VL;@&[+R[X0G-IF_<%H^I(J\6BQ?:#;ODVTM]*
*[[6!5*MD*UZ M+CJ3:D.?2$O-AXP]0FY[U"357U1];L3.<_8>VU+(V"24]ZW5KB]0%YK-VS@E MY-*
ZV\E'[5:^PJC74.]%DQ;2A6WM1AXSI06[3TR3=7Q=U;M#.L_@>>U'(^"(T MJ]9>KV;(%YK-VY@AY-ZKNF2E'?_L4./>\%RSC;TF+9(U9@:YS4RSC_W]8LT-
*MWWD2WV/[*38N*8Z\G8-XM4>^T&S>QA[%[LVH"\1;(9]:@//5MNIRMLUP;FG# MD\-/??+\#?,US05(R4I%J8I-O8(?#G,/#&ULK99=;YLP%*
*(;_BL6JJ96Z\I% :)<@M4FG M3=]TJ&FWBVD7#AR"5;"0;9+TW\\V%*6!LFG;36+C\[X\Y_B+Z8[Q1Y$!2+0O M67;(LZ@P,*"E4#52,IX@:7]\HTM2@XX,:*
*(BMSW"">P"$VI%4_-L MR:,]JV1.*"PY$E518/YT SG;S2S7>GYP1S:9U_L:%KB#:Q /I1+KGIVZY*0 M J@@C"(.ZH54] MH8BEJ#-ZN@")22[.5-S#:H%.3|*
*{0"2(4W6>L$I@F8FI+A:7-[;A!N*D1O%<0 M5E!>H)%SCCS'&_?(Y\/R!<1*[AKYZ*7<5L5H*^^U%?&,W^@/%?E,)\KD1!(0 MYVA>*
*<0Y4HA_7:R&Y6GL_^_*LC::X]_^.I3X]M%.@) MW1YFU8UQPTD;\P)VW,*.AV'W$CC%.=)UP#S.#&@"6W5$E86>-6B6;Q]Tf>T? M /GAY1%T-R88^?W0?*
*@OM#T(O.4M!Z+-0@6O>F%&ACAY"_RB%?E2_@Q$&[A%J M-R8(+OM1@Q8U&$2] [7DJUA67,'U<06=+XY]YXAK\!7_N)HG;0*3P02^R@QX*
*M'_BD6]#C>G9#)]_,?-C2A(,T]TSJ*6].F:&E&7;VBA62E>,;*A7H:DULL(752*,HR@)*\9ED*5^[E9GJ6I(M<(FW&DQ354S_ND*A-I/@+-A.W/%526XBS-*
*-K7".=%_?:AN%/4K!*Y2&*PD: MEY/@\NSB*G'Y/N$KQXW9&8-3LE#JP04WQ22('"$4F)-#8/:UQBD*X8 LC9\=*
M9M!OZ0IWQUOT#UZ[U;@\J=?,,%E9/@;0 %+EDCZ$YMKK'3,W9XN1+&/V'3 MYB;G ->2-(55UQ99!Q67[9H_=.>P4Q/$S!7%7$'O>[4:>Y8P1RU^*M-*
*J!=MD5S M R_55UMR7#I3YJ3M*K=UE%WFN6ZP@/>/UF:#!D[ALBBX.SFX:VMKOS.YXA M,2[,"1P!E_"E5(UALC!I2):'0POS;L ^K=L_XF3WG6*
*]@&+V!.(I'<#^?P?'1 MR5.8T,KHM<2]EMCC#I_!O4-#NLFIT5RN8*H,@24(=AKU&N'[1YL/-X25^;&/ M=*
L^V@_N+L>%]5F.D\]^_1XQR%Z_.DNB=P>H#WOJPT/HO0WZB03L3-G'ML5+ M/)Z[>>ML-([2<+V'Q@G,3I(XK/$4[(W#@BU_=1:VQ# M[/@ES1Z_*
/6DIY[\9[.3O\P>1W^;'>XT ==//S&]XM P*6MB@;G5K)N>\U0; MD*]J7U@HLEW&#TO;UE&LU_8\B^PU02P,$% @ #(9S6<5* M)#3N#@*
*^-4 !D !X;"JW;W)K&ULM=U;<^+(M'8?AKZ)R4LE.56*C S:>>%PU8YT/B6N=32Y2N=!"VZ86$)'DF9U4/GPD$(@& MN2W-O#L78QNWGFX,_Y9*
/S4W7[+\E^)9B%+[=;E8%1_.GLMR_?[BHI@^BV5: MG&=KL:I^\YCER[2L?LR?+HIU+M+99J/EXL(8C2XOENE\=79[L[GM/K^]R5[
MQ7PE[G.M>%DNT_SK)['(OGPXT\]V-_PX?WHNZQLN;F_6Z9-X$.5/Z_N\^NEB
MK\SF2[$]YME*R\7CA[./^OMD/*XWV+3XQUQ*0Z^U^J[\G.6_5+_$,P^G(WJ M$8F%F)8UD59?/HL[L5C44C6._S3HV;[/>L/#
[W>ZN[GSU9WY.2W$7;;XYWQ6 M/G\XFYQI_&8OBS[,OOFCNT&: TVQ1,/7OC1M1V?:I*&7IV6&6

*M/^!AL*N&;3'}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l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|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{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{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{&IO'5L^CRH?1Y8?7X1QXFZ7521 MKR5\MR+?3N\T2M4-I9"=U7JZ0M/[LRRKHTE5'8U/5D=0XS+C40MGWZZ<98$D M1[I8(9S'*"9;DM*UWF[+/_+^H]41H/20E!:!$4SHU_+:?^MM;0/*J9!:2$H M+8*BF:&L!;5O5]0__FS.;]'7H^9&S?G'LGG<:^X.QQS_X"&?.?=: M#OMVL?@;R66R3W6.P7&6Y(E495C]CF1/,Z#B&)06@M(B*)H9GUHD^Y.W3C.@M\J4%H+2(BB:^9-6K; #J^Q[19HIP4;U&/B-/-/6:-A((F'9Z#*)#)NDJ(4T MZOOMF2:H56E@5Z7Z><]F(39,*5*5;ZA8$2:=P-L?^]AY71-+,6J'IV M#[NRA;ZM=JN/3F)A?%3_?5U>K5G0O]PDKC^J5_?N6W7__]\ZAX,:?&%^\) M?<%LF>01!=N6=C62V9L6K-\6)H&O}LD]%8)F^G!%<$R8:B"_?Z!4/)^H M#JH7H.;_ U!+ P04 " ,AG-9Z_%[[/$' 63@ &0 'AL+W=O4J33%SVEE(6Y_V^6^Q92L5)7K!,[;G+>4JE6N7W?5%P1J,R*$WZ]F P M[JY"N9Q!F[X42LTI3R]4>6Y(^7/:OWO.%K?+^4>D-_>E'0 M>W;+Y!_%#5=K_2TEBE.6B3C/"&=WE[TKZSQTRH#RB#]C]BAVEHD^E7F>?],K

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||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~; ??*.G7@[O4+_6?3>=69 M"1$P9LF?-):+@7?NH1AF9)G(.[;^!8H.=31ORA)A?J/UIFRWZZ'I4DB6%L&J M!2G--G_)4R'$3H#BU E%4U?&/5-M-*+9GJ@W$NN/J4J3@['+$V15)F7 I$L1F.6 M29K-(9M2$-.W3)+01'Q&/Z&'^Q!]^N%SWY>]6AWL3XJ1ILJF@>]:*$;!5T(M%&4QQ#7QH3W^PA+OJ^Z6?6Z^]'G4M +O(6^@5G"&FD&S7=.>\|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}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{XBF8'P_C;T.UO;YM-/6X/ M-O7X:77G[K-S9*!V%TJC4!J#TCB*9B?+". 0O.5#"!6^4%H,I5$HC4%I'$6S M4V.$;^A>%WRS7"]YK$8D/97=3W%?F]*>[@! {9DH+];E0&H72&)3&430[%,;G MAFZ?>__-J(3\JN9))BS3\H;]>=WHSJ,*=,4OE$:A-_:E<13-?@L)HWHC\,8. M$=3H0FDQE$:A-_:E<13-3HT1OY%;_'Z1:BD5$;HB[:,&\DF?66=+253U'EKU M"TGYRZ!4EZ?6*$%-+Y060VD42F,-S?.M5P?\R^/KASFJ6SLE1N)&[NT=S H8 M.PL%4;+N,"NK5X_RK){2M";$/YF^^"=+(:?NP^C\S$-M+93&H#2.HMGQ,+8V M-Z=S6K!O MFP95P='1;L*>'YU46P;ME:-H=@Z,Y(TZ+M)MM,IVHY,QVX>D-1E0E0NEQ5 : MC4Z7_8:#H1\,6\(!J;0HFAT.XVDC]T+=KW(CGM?UFP57NP8=S%*R9I,2/F1 M;2V4%D-IM*$=#AFCZ/1:)0;ME:-H=BJ,AXW<'K;3M+7S"T3NSCN'!VIUH30* MI3$HC:-H=L2,U8W FS=$4)4+I<50&H72&)3&433[76"-RAV^=?.&SG,9-[EK M? J"T&$JCP],M(/Q!X'GCHY(%[96C:+MD](N5E&4L2C&Y6EY5$G?_4Z+DHMH>_,,-W^OKEN;NDZN-6,HO0BV3K""I7.BF@XN1_L.H9+G: MWRCS384D]WE9YNOZVY44/N?I6']|D?U!+ P04 M" ,AG-9)J7[[W\# "[& #0 'AL+W-T>6QEUNVC 4?94H M7:=6FAI"UD!60-J0*DW:IDKMC_VK#'' DO,QQW30U]F;[,GF:XKHU)N.+U>4BJ==%XY7]*4E&=Y03.%)+E(MB51=L?#*0E 2E^"42ECF3D;9*KU,9>G,\U4FQZ[OUS;'W#[']RAJ^_M=QW#-\UC.G9O3]|^6.7RXHUC[D?OCHYZMZ<7N_83#9RZGI7T_ #2LYZZ4&:_ M8O2AG?[WKQW^%GN-U?08^> A^?;Q8T56^QYCSD.+<^.)ND6'Y6M? MA#J0<|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|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}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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v.2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{*

font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2722641false750false5 falsefalseR1.htm100000 - Document - Document and Entity InformationSheethttp://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm100010 - Statement - Condensed Consolidated Balance SheetsSheethttp://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive LossSheethttp://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCondensed Consolidated Statements of Operations and Comprehensive LossStatements4 falsefalseR5.htm100040 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)Sheethttp://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitCondensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)Statements5 falsefalseR6.htm100050 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Parenthetical)Sheethttp://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitParentheticalCondensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Parenthetical)Statements6 falsefalseR7.htm100060 - Statement - Condensed Consolidated Statements of Cash FlowsSheethttp://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsCondensed Consolidated Statements of Cash FlowsStatements7 falsefalseR8.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes8 falsefalseR9.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes9 falsefalseR10.htm995455 - Disclosure - Description of BusinessSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDescription of BusinessNotes10 falsefalseR11.htm995465 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes11 falsefalseR12.htm995475 - Disclosure - Agreement and Plan of MergerSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAgreement and Plan of MergerNotes12 falsefalseR13.htm995485 - Disclosure - Fair Value MeasurementsSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes13 falsefalseR14.htm995495 - Disclosure - Accrued ExpensesSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAccrued ExpensesNotes14 falsefalseR15.htm995505 - Disclosure - Shareholders' (Deficit) EquitySheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquity1Shareholders' (Deficit) EquityNotes15 falsefalseR16.htm995515 - Disclosure - Stock-Based CompensationSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStock-Based CompensationNotes16 falsefalseR17.htm995525 - Disclosure - Related Party TransactionsSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsRelated Party TransactionsNotes17 falsefalseR18.htm995535 - Disclosure - Commitments and ContingenciesSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes18 falsefalseR19.htm995555 - Disclosure - Subsequent EventsSheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsSubsequent EventsNotes19 falsefalseR20.htm995565 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies20 falsefalseR21.htm995575 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies21 falsefalseR22.htm995585 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurements22 falsefalseR23.htm995595 - Disclosure - Accrued Expenses (Tables)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesTablesAccrued Expenses (Tables)Tableshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpenses23 falsefalseR24.htm995605 - Disclosure - Shareholders' (Deficit) Equity (Tables)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityTablesShareholders' (Deficit) Equity (Tables)Tableshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquity124 falsefalseR25.htm995615 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTablesStock-Based Compensation (Tables)Tableshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensation25 falsefalseR26.htm995635 - Disclosure - Description of Business (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetailsDescription of Business (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusiness26 falsefalseR27.htm995655 - Disclosure - Summary of Significant Accounting Policies - Antidilutive securities excluded from computation of earnings per share (Details) (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsSummary of Significant Accounting Policies - Antidilutive securities excluded from computation of earnings per share (Details) (Details)Details27 falsefalseR28.htm995665 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetailsSummary of Significant Accounting Policies - Additional Information (Details)Details28 falsefalseR29.htm995675 - Disclosure - Agreement and Plan of Merger - Additional Information (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetailsAgreement and Plan of Merger - Additional Information (Details)Details29 falsefalseR30.htm995685 - Disclosure - Fair Value Measurements (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetailsFair Value Measurements (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables30 falsefalseR31.htm995695 - Disclosure - Fair Value Measurements - Schedule of the activity in warrant liability (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetailsFair Value Measurements - Schedule of the activity in warrant liability (Details)Details31 falsefalseR32.htm995705 - Disclosure - Fair Value Measurements - Assumptions used for the fair value calculations of warrants (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailsFair Value Measurements - Assumptions used for the fair value calculations of warrants (Details)Details32 falsefalseR33.htm995725 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetailsAccrued Expenses - Summary of Accrued Expenses (Details)Details33 falsefalseR34.htm995735 - Disclosure - Accrued Expenses - Additional Information (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetailsAccrued Expenses - Additional Information (Details)Details34 falsefalseR35.htm995745 - Disclosure - Shareholders' (Deficit) Equity - Additional Information (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetailsShareholders' (Deficit) Equity - Additional Information (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityTables35 falsefalseR36.htm995755 -

Disclosure - Shareholders' (Deficit) Equity - outstanding warrants (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetailsShareholders' (Deficit) Equity - outstanding warrants (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityTables36 falsefalseR37.htm995765 - Disclosure - Shareholders' (Deficit) Equity - Summary of Company"s Warrants Activity (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetailsSh (Deficit) Equity - Summary of Company"s Warrants Activity (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityTables37 falsefalseR38.htm995775 - Disclosure - Stock-Based Compensation (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetailsStock-Based Compensation (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables38 falsefalseR39.htm995785 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetailsStock-Based Compensation - Stock Option Activity (Details)Details39 falsefalseR40.htm995805 - Disclosure - Stock-Based Compensation - Assumptions used for the fair value of stock awards (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAward Based Compensation - Assumptions used for the fair value of stock awards (Details)Details40 falsefalseR41.htm995815 - Disclosure - Stock-Based Compensation - Summarize the activity of the company unvested RSUs (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedR Based Compensation - Summarize the activity of the company unvested RSUs (Details)Details41 falsefalseR42.htm995835 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetailsStock-Based Compensation - Stock-Based Compensation Expense (Details)Details42 falsefalseR43.htm995845 - Disclosure - Related Party Transactions (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetailsRelated Party Transactions (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactions43 falsefalseR44.htm995855 - Disclosure - Commitments and Contingencies (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsCommitments and Contingencies (Details)Detailshttp://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies44 falsefalseR45.htm995915 - Disclosure - Subsequent Events - Additional Information (Details)Sheethttp://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetailsSubsequent Events - Additional Information (Details)Details45 falsefalseAll ReportsBookAll Reports aktx-20240930.htmaktx-20240930.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aktx-20240930.htm": { "nsprefix": "aktx", "nsuri": "http://www.akaritx.com/20240930", "dts": { "inline": { "local": ["aktx-20240930.htm"] }, "schema": { "local": ["aktx-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 208, "keyCustom": 56, "axisStandard": 24, "axisCustom": 0, "memberStandard": 31, "memberCustom": 41, "hidden": { "total": 7, "http://www.xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 3 }, "contextCount": 272, "entityCount": 1, "segmentCount": 75, "elementCount": 695, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 551, "http://xbrl.sec.gov/dei/2024": 33, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R3": { "role": "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R4": { "role": "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "longName": "100040 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_7b5a30ae-0ac6-40d2-abf3-22eddbaca1d2", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_82ff9a8b-8579-466e-9d35-e9bc09a2e5ea", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R6": { "role": "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitParenthetical", "longName": "100050 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm",

```
"unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusiness", "longName": "995455 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMerger", "longName": "995475 - Disclosure - Agreement and Plan of Merger", "shortName": "Agreement and Plan of Merger", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "aktx:AgreementAndPlanOfMergerDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "aktx:AgreementAndPlanOfMergerDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpenses", "longName": "995495 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquity1", "longName": "995505 - Disclosure - Shareholders' (Deficit) Equity", "shortName": "Shareholders' (Deficit) Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensation", "longName": "995515 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactions", "longName": "995525 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies", "longName": "995535 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEvents", "longName": "995555 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995565 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995575 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978",
```

```
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables", "longName": "995585 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesTables", "longName": "995595 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityTables", "longName": "995605 - Disclosure - Shareholders' (Deficit) Equity (Tables)", "shortName": "Shareholders' (Deficit) Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables", "longName": "995615 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails", "longName": "995635 - Disclosure - Description of Business (Details)", "shortName": "Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "aktx:StockholdersEquityRequirement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R27": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat "longName": "995655 - Disclosure - Summary of Significant Accounting Policies - Antidilutive securities excluded from computation of earnings per share (Details) (Details)", "shortName": "Summary of Significant Accounting Policies - Antidilutive securities excluded from computation of earnings per share (Details) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995665 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CashEquivalentsAtCarryingValue", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_99b1e393-3a29-46be-ba94-075b76984627", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R29": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails", "longName": "995675 - Disclosure - Agreement and Plan of Merger - Additional Information (Details)", "shortName": "Agreement and Plan of Merger - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_17daa180-f555-41b8-86b4-6fc85a3c9884", "name": "aktx:MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "aktx:AgreementAndPlanOfMergerDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R30": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails", "longName": "995685 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails", "longName": "995695 - Disclosure - Fair Value Measurements - Schedule of the activity in warrant liability (Details)", "shortName": "Fair Value Measurements - Schedule of the activity in warrant liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_99b1e393-3a29-46be-ba94-075b76984627", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_99b1e393-3a29-46be-ba94-075b76984627", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef":
```

"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails", "longName": "995705 - Disclosure - Fair Value Measurements - Assumptions used for the fair value calculations of warrants (Details)", "shortName": "Fair Value Measurements - Assumptions used for the fair value calculations of warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_7be627d1-8142-4215-b626-55749d4c200d", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "aktx:DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7be627d1-8142-4215-b626-55749d4c200d", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "aktx:DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails", "longName": "995725 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "longName": "995735 - Disclosure - Accrued Expenses - Additional Information (Details)", "shortName": "Accrued Expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_05d102b2-9cfc-4082-b15c-b1dc2d3cf618", "name": "us-gaap:RestructuringReserveCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_29292b82-53c2-424a-8ea6-baead9cf1ab7", "name": "us-gaap:RestructuringReserveCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R35": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "longName": "995745 - Disclosure - Shareholders' (Deficit) Equity - Additional Information (Details)", "shortName": "Shareholders' (Deficit) Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_99b1e393-3a29-46be-ba94-075b76984627", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockSharesAuthorized", "span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bc49b956-989b-4a8a-a1ae-b54a2ea5787b", "name": "aktx:CapitalRedemptionReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R36": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails", "longName": "995755 - Disclosure - Shareholders' (Deficit) Equity - outstanding warrants (Details)", "shortName": "Shareholders' (Deficit) Equity - outstanding warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_881ecfb8-eeaf-4d03-ace8-73028ed1d99e", "name": "aktx:ClassOfWarrantOrRightOutstandingEquity", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_881ecfb8-eeaf-4d03-ace8-73028ed1d99e", "name": "aktx:ClassOfWarrantOrRightOutstandingEquity", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails", "longName": "995765 - Disclosure - Shareholders' (Deficit) Equity - Summary of Company\"s Warrants Activity (Details)", "shortName": "Shareholders' (Deficit) Equity - Summary of Company\"s Warrants Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_a8f3df07-4666-4c7b-a498-4e4c6515557d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a8f3df07-4666-4c7b-a498-4e4c6515557d", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails", "longName": "995775 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_46549783-6e55-4f85-bad9-be8af45ad92d", "name": "aktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_46549783-6e55-4f85-bad9-be8af45ad92d", "name": "aktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails", "longName": "995785 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_85ec4a7d-4c1f-49bb-8efe-b42414a3c080", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1597e69c-39f6-4c72-979d-ca08704334e2", "name": "aktx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodPriorToAcquisitionGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "unique": true } }, "R40": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "longName": "995805 - Disclosure - Stock-Based Compensation - Assumptions used for the fair value of stock awards (Details)", "shortName": "Stock-Based Compensation - Assumptions used for the fair value of stock awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure",

```
"xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails", "longName": "995815 - Disclosure - Stock-Based Compensation - Summarize the activity of the company unvested RSUs (Details)", "shortName": "Stock-Based Compensation - Summarize the activity of the company unvested RSUs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_e7054793-fb12-44fe-a758-2c8f5180cc71", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e7054793-fb12-44fe-a758-2c8f5180cc71", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails", "longName": "995835 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16617d89-5255-41ad-b89d-c441a7702ec7", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails", "longName": "995845 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_5bfefc6b-29fe-4ddb-a15b-65727ffe3c0b", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5bfefc6b-29fe-4ddb-a15b-65727ffe3c0b", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "995855 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a2ab29c3-061d-4054-a803-aa35018be978", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "995915 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_a73994bc-cf12-4a82-9a75-24a4e9965c1b", "name": "aktx:CommonStockAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a73994bc-cf12-4a82-9a75-24a4e9965c1b", "name": "aktx:CommonStockAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aktx-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r436" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r59", "r831" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits, Current", "terseLabel": "Employee compensation and benefits", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r61" ] }, "aktx_AccruedExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AccruedExpensesPolicyTextBlock", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accrued Expenses [Policy Text Block]", "documentation": "Disclosure of accounting policy for accrued expenses." } } }, "auth_ref": [] }, "aktx_AccruedExternalResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AccruedExternalResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued external research and development expenses.", "label": "Accrued External Research and Development Expenses", "terseLabel": "External research and development expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails", "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and consulting fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r61" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated
```

depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r34", "r134", "r641"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r20", "r21", "r75", "r139", "r636", "r659", "r660"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r4", "r11", "r21", "r488", "r491", "r544", "r655", "r656", "r954", "r955", "r956", "r964", "r965", "r966", "r967"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r891"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r69"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r675", "r964", "r965", "r966", "r967", "r1044", "r1108"] }, "aktx_AdditionalRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AdditionalRestructuringCharges", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Additional restructuring charges.", "label": "Additional Restructuring Charges", "terseLabel": "Additional restructuring-related expenses" } } }, "auth_ref": [] }, "aktx_AdditionalShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AdditionalShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Additional share based compensation expense.", "label": "Additional Share Based Compensation Expense", "terseLabel": "Additional stock-based compensation expense" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r904"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r904"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r904"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r904"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Shares withheld for payroll taxes", "terseLabel": "Shares withheld for payroll taxes", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Vesting of restricted shares", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r47", "r48", "r393"] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "ADS", "terseLabel": "American Depositary Shares", "label": "ADR [Member]", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": ["r857"] }, "aktx_AggregateNominalValueCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AggregateNominalValueCancelled", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate nominal value cancelled", "label": "Aggregate Nominal Value Cancelled", "documentation": "Aggregate nominal value cancelled." } } }, "auth_ref": [] }, "aktx_AggregateNominalValueCancelledPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AggregateNominalValueCancelledPerShare", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate nominal value cancelled per share", "label": "Aggregate Nominal Value Cancelled Per Share", "documentation": "Aggregate nominal value cancelled per share." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r937"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r863", "r873", "r883", "r915"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r866", "r876", "r886", "r918"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri":

```
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r938" ] }, "aktx_AgreementAndPlanOfMergerAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AgreementAndPlanOfMergerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Agreement and Plan of Merger [Abstract]", "label": "Agreement And Plan Of Merger [Abstract]", "documentation": "Agreement and plan of merger." } } }, "auth_ref": [] }, "aktx_AgreementAndPlanOfMergerDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AgreementAndPlanOfMergerDisclosureTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMerger" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement and Plan of Merger", "label": "Agreement And Plan Of Merger Disclosure [Text Block]", "documentation": "Agreement and plan of merger disclosure." } } }, "auth_ref": [] }, "aktx_AgreementAndPlanOfMergerLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AgreementAndPlanOfMergerLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement and Plan of Merger [Line Items]", "label": "Agreement And Plan Of Merger [Line Items]", "documentation": "Agreement and plan of merger." } } }, "auth_ref": [] }, "aktx_AkariAndPeakBioMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AkariAndPeakBioMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Akari and Peak Bio.", "label": "Akari And Peak Bio [Member]", "terseLabel": "Akari and Peak Bio" } } }, "auth_ref": [] },
"aktx_AkariMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "AkariMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Akari", "label": "Akari [Member]", "documentation": "Akari." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r904" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r911" ] },
"ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r867", "r877", "r887", "r911", "r919", "r923", "r931" ] },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r929" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r425", "r434" ] },
"dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "aktx_AmendmentInterimCEOAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AmendmentInterimCEOAgreementMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Interim CEO Agreement", "label": "Amendment Interim C E O Agreement [Member]", "documentation": "Amendment interim CEO agreement." } } }, "auth_ref": [] }, "aktx_AmericanDepositoryReceiptsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AmericanDepositoryReceiptsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "American depository receipts.", "label": "American Depository Receipts [Member]", "terseLabel": "American Depository Shares" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r261", "r267", "r798" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "terseLabel": "Total Anti-Dilutive Share Equivalents", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r191" ] }, "aktx_AspireCapitalFundLLCMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "AspireCapitalFundLLCMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Aspire Capital Fund LLC", "documentation": "Aspire Capital Fund, LLC" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r1043" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r108", "r117", "r135", "r162", "r194", "r198", "r211", "r212", "r247", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r483", "r485", "r521", "r631", "r711", "r793", "r794", "r831", "r853", "r1001", "r1002", "r1063" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r130", "r142", "r162", "r247", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r483", "r485", "r521", "r831", "r1001", "r1002", "r1063" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": {
"en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r926" ] }, "ecd_AwardGrantDateFairValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r927" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r922" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]",
"terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r922" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel":
"Award Timing Method" } } }, "auth_ref": [ "r922" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri":
```

```
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r922" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r922" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r922" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r925" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r924" ] },
"ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r923" ] },
"ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r923" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Merger-related costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r49" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r58", "r85", "r86" ] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CH", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Switzerland", "label": "SWITZERLAND" } } }, "auth_ref": [] }, "aktx_CapitalRedemptionReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "CapitalRedemptionReserve", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Capital redemption reserve", "label": "Capital Redemption Reserve", "documentation": "The amount of Capital redemption reserve." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Redemption Reserve", "label": "Capital Units [Member]", "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r25", "r132", "r782" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r26" ] },
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total", "periodStartLabel": "Cash at beginning of period", "periodEndLabel": "Cash at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r25", "r82", "r159" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their
```

maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r82"] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "totalLabel": "Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r951", "r1075"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r902"] }, "aktx_ChardanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ChardanMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Chardan", "label": "Chardan Member", "documentation": "Chardan." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r899"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r897"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r127", "r136", "r137", "r138", "r162", "r185", "r186", "r188", "r190", "r196", "r197", "r247", "r289", "r291", "r292", "r293", "r296", "r297", "r312", "r313", "r316", "r319", "r326", "r521", "r664", "r665", "r666", "r667", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r699", "r721", "r744", "r761", "r762", "r763", "r764", "r765", "r941", "r960", "r968"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r136", "r137", "r138", "r196", "r312", "r313", "r314", "r316", "r319", "r324", "r326", "r664", "r665", "r666", "r667", "r809", "r941", "r960"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r42"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Weighted-Average Exercise Price", "periodStartLabel": "Weighted-AverageExercise Price, Beginning Balance", "periodEndLabel": "Weighted-AverageExercise Price, Ending Balance", "terseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r327"] }, "aktx_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Warrants exercised", "label": "Class of Warrant Or Right Exercised", "documentation": "Number of warrants or right Exercised." } } }, "auth_ref": [] }, "aktx_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ClassOfWarrantOrRightIssued", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Warrants Issued", "label": "Class of Warrant Or Right issued", "documentation": "Number of warrants or rights issued." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued to purchase ADS (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of warrants to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r327"] }, "aktx_ClassOfWarrantOrRightOutstandingEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ClassOfWarrantOrRightOutstandingEquity", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": {

```
"terseLabel": "Equity-classified Warrants", "label": "Class of Warrant or Right, Outstanding, Equity", "documentation": "Number of equity classified warrants or rights outstanding." } } }, "auth_ref": [] }, "aktx_ClassOfWarrantOrRightOutstandingLiability": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ClassOfWarrantOrRightOutstandingLiability", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability-classified Warrants", "label": "Class of Warrant or Right, Outstanding, Liability", "documentation": "Number of liability classified warrants or rights outstanding." } } }, "auth_ref": [] }, "aktx_ClassOfWarrantOrRightPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ClassOfWarrantOrRightPurchasePrice", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right purchase price.", "label": "Class Of Warrant Or Right Purchase Price", "terseLabel": "Purchase price of share" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r42" ] }, "aktx_ClosingBidPriceInDollarsPerAds": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ClosingBidPriceInDollarsPerAds", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Closing bid price (in dollars per ADS)", "label": "Closing Bid Price (in dollars per ADS)", "documentation": "Closing bid price (in dollars per ADS)." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r903" ] },
"ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r903" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r66", "r112", "r634", "r698" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r90", "r281", "r282", "r768", "r990", "r998" ] },
"aktx_CommonStockAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "CommonStockAdditionalSharesAuthorized", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares authorized", "label": "Common Stock Additional Shares Authorized", "documentation": "Common stock additional shares authorized." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares remained available for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "label": "Common Stock [Member]", "verboseLabel": "Share Capital", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r843", "r844", "r845", "r847", "r848", "r849", "r850", "r964", "r965", "r967", "r1044", "r1105", "r1108" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Nominal value of ADS (in per warrant ADS)", "terseLabel": "Ordinary shares, par value", "label": "Share capital, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares authorized", "label": "Common Stock, Shares Authorized", "verboseLabel": "Number of shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r68", "r699" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r68" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, shares outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r68", "r699", "r717", "r1108", "r1109" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital of $0.0001 par value Authorized: 45,122,321,523 ordinary shares at September 30, 2024 and December 31, 2023, respectively; issued and outstanding: 24,289,231,523 and 13,234,315,298 at September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r68", "r635", "r831" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r908" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r907" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r909" ] },
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
```

```
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r906" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r22", "r145", "r147", "r152", "r626", "r647", "r648" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Comprehensive Income (Loss)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r57", "r121" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } },
"auth_ref": [ "r50", "r787" ] }, "aktx_ConsultingCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ConsultingCharges", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting charges", "label": "Consulting Charges", "documentation": "The amount of consulting charges incurred during the period." } } },
"auth_ref": [] }, "aktx_ConsultingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ConsultingServicesMember", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Consulting Services [Member]", "documentation": "This member stands for Consulting Services." } } },
"auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "terseLabel": "May 2024 Convertible Notes", "label": "Convertible Debt [Member]", "verboseLabel": "Convertible notes", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r91", "r298", "r299", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r804", "r805", "r806", "r807", "r808" ] }, "aktx_ConvertibleDebtRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ConvertibleDebtRelatedParty", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"documentation": "Convertible debt related party.", "label": "Convertible Debt Related Party", "terseLabel": "Convertible notes, related party" } } },
"auth_ref": [] }, "aktx_ConvertibleNotesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ConvertibleNotesPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"documentation": "Convertible notes.", "label": "Convertible Notes [Policy Text Block]", "terseLabel": "Convertible Notes" } } }, "auth_ref": [] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r167", "r168", "r301", "r314", "r551", "r572", "r630", "r784", "r786" ] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Cover", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current income taxes", "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] },
"us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic (UK)", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r943", "r962", "r1042" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r943", "r962" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Conversion amount", "label": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Number of shares issued upon conversion", "label": "Debt Conversion, Converted Instrument, Shares Issued",
"documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r27", "r28" ]
}, "aktx_DebtDefaultInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DebtDefaultInterestRatePercentage", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Default, interest rate percentage", "documentation": "Debt default, interest rate percentage." } } }, "auth_ref": [] },
"us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [
```

"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion price", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r92", "r300"] }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion description", "label": "Debt Instrument, Convertible, Terms of Conversion Feature", "documentation": "Description of conversion terms for debt instrument." } } }, "auth_ref": ["r38", "r65", "r95", "r96"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate per annum", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r63", "r299"] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPaymentTerms", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payment terms", "label": "Debt Instrument, Payment Terms", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": ["r56", "r64"] }, "aktx_December2021InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "December2021InvestorWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "December 2021 Investor Warrants", "label": "December 2021 Investor Warrants", "documentation": "This member represents information pertaining to December 2021 Investor Warrants." } } }, "auth_ref": [] }, "aktx_December2021PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "December2021PlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "December 2021 Placement Agent Warrants", "label": "December 2021 Placement Agent Warrants", "documentation": "This member represents information pertaining to December 2021 Placement Agent Warrants." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Domestic (UK)", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": ["r962", "r1041", "r1042"] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r962", "r1041"] }, "aktx_DeferredSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DeferredSharesIssued", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred shares issued", "label": "Deferred Shares Issued", "documentation": "Deferred shares issued." } } }, "auth_ref": [] }, "aktx_DeferredSharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DeferredSharesIssuedPricePerShare", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred shares issued price per share", "label": "Deferred Shares Issued Price Per Share", "documentation": "Deferred shares issued price per share." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangibles", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": ["r1039"] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": ["r461"] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": ["r1037"] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax loss carry forward", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": ["r1039"] }, "aktx_DeferredTaxAssetsPropertyPlantAndEquipmentAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentAndOtherAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "PP&E and other accrued liabilities", "label": "Deferred Tax Assets, Property, Plant and Equipment And Other Accrued Liabilities", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant and equipment and other accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": ["r1039"] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r462"] }, "aktx_DeferredTaxAssetsWarrantRevaluation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DeferredTaxAssetsWarrantRevaluation", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Warrant revaluation", "label": "Deferred Tax Assets Warrant Revaluation", "documentation": "Amount of deferred tax assets warrant revaluation." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum annual eligible compensation contributed by each employee", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined

contribution plan." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r9", "r194", "r201", "r212", "r793", "r794"] }, "aktx_DescriptionOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DescriptionOfBusinessLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails"], "lang": { "en-us": { "role": { "documentation": "Description of business.", "label": "Description of Business Line Items", "terseLabel": "Description of Business [Line Items]" } } }, "auth_ref": [] }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Description", "terseLabel": "Description of employee benefit plans", "documentation": "Description of defined contribution pension and other postretirement plans." } } }, "auth_ref": [] }, "aktx_DirectorOrAffiliateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DirectorOrAffiliateMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Director or Affiliate", "label": "Director or affiliate [Member]", "documentation": "Director or affiliate." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r391", "r395", "r426", "r427", "r429", "r815"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Stock-Based Compensation" } } }, "auth_ref": [] }, "aktx_DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of assumptions used for the fair value calculations of the warrants", "label": "Disclosure Of Fair Value Assumptions Of Warrants [Table Text Block]", "documentation": "The tabular disclosure for fair value assumption of warrants." } } }, "auth_ref": [] }, "aktx_DoctorsLaboratoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DoctorsLaboratoryMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "The Doctors Laboratory", "documentation": "Doctors Laboratory Member" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Information", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r858"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r890"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Domestic Tax Authority", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r446"] }, "aktx_DrPrudoAndDrPatelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "DrPrudoAndDrPatelMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Dr. Prudo and Dr. Patel", "label": "Dr. Prudo and Dr. Patel [Member]", "terseLabel": "Dr. Prudo and Dr. Patel" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfletdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfletdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r901"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Net loss per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r153", "r174", "r175", "r176", "r177", "r178", "r179", "r183", "r185", "r188", "r189", "r190", "r193", "r479", "r482", "r496", "r497", "r627", "r649", "r789"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "terseLabel": "Net loss per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r153", "r174", "r175", "r176", "r177", "r178", "r179", "r185", "r188", "r189", "r190", "r193", "r479", "r482", "r496", "r497", "r627", "r649", "r789"] }, "aktx_EarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EarningsPerShareLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Line Items]", "documentation": "Earnings Per Share Line Items" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": {

```
"label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r29", "r30", "r192" ] }, "aktx_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EarningsPerShareTable", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Table]", "documentation": "Earnings Per Share Table" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r530" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense
], "lang": { "en-us": { "role": { "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r164", "r446", "r470", "r819" ] },
"aktx_EffectiveIncomeTaxRateReconciliationNonDeductibleTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleTransactionCosts", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense
], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation, non-deductible transaction costs.", "label": "Effective Income Tax Rate Reconciliation, Non-deductible transaction costs", "negatedLabel": "Non-deductible transaction costs", "verboseLabel": "Non-deductible transaction costs" } } }, "auth_ref": [] },
"aktx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherPermanentDifferencesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherPermanentDifferencesAmount", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense
], "lang": { "en-us": { "role": { "terseLabel": "U.S. state taxes (net of FBOS)", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other Permanent Differences, Amount", "documentation": "The amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by other permanent differences." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense
], "lang": { "en-us": { "role": { "terseLabel": "Change in equity compensation", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r942", "r1034", "r1035" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r451", "r453", "r963", "r1034" ] },
"aktx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitChangeInOperatingLossesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitChangeInOperatingLossesAmount", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense
], "lang": { "en-us": { "role": { "terseLabel": "Change in operating losses", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Change in Operating Losses, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in operating losses." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r428" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r428" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ],
```

```
"lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCentralIndexKey", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "terseLabel": "CIK", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify
entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r855" ] },
"dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity
Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of
capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist
define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest
[Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity
Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file
such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's
current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity
Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r855" ] },
"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits,
the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } },
"auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityFilerCategory", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated
Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information
should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r855" ] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity
Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInteractiveDataCurrent", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12
months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r940" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityRegistrantName", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "terseLabel": "Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the
report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r855" ] }, "dei_EntityShellCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell
Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } },
"auth_ref": [ "r855" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntitySmallBusiness", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } },
"auth_ref": [ "r855" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax
Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a
unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r855" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } }
}, "auth_ref": [ "r895" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the
Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [
"r936" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards
Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r936" ] },
"ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel":
"Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r936" ] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance
including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r128", "r149", "r150",
"r151", "r169", "r170", "r171", "r173", "r178", "r180", "r182", "r195", "r248", "r249", "r270", "r328", "r468", "r469", "r476", "r477", "r478", "r480",
"r481", "r482", "r487", "r488", "r489", "r490", "r491", "r492", "r495", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r540", "r544", "r645",
"r655", "r656", "r657", "r675", "r744" ] }, "aktx_EquityIncentivePlan2014Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "EquityIncentivePlan2014Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Equity Incentive Plan 2014 [Member]", "documentation": "Represents the member information pertaining to 2014 Equity Incentive Plan.",
"terseLabel": "Equity Incentive Plan 2014" } } }, "auth_ref": [] }, "aktx_EquityIncentivePlan2023And2014Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EquityIncentivePlan2023And2014Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "2023 and 2014 Plans", "label": "Equity Incentive Plan 2023 and 2014 [Member]", "documentation": "Represents the
member information pertaining to 2023 and 2014 Equity Incentive Plan." } } }, "auth_ref": [] }, "aktx_EquityIncentivePlan2023Member": {
"xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EquityIncentivePlan2023Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "2023 Equity Incentive Plan", "terseLabel": "2023 Plan", "label": "Equity Incentive Plan 2023 [Member]", "documentation":
"Represents the member information pertaining to 2023 Equity Incentive Plan." } } }, "auth_ref": [] },
```

"ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r905"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r863", "r873", "r883", "r915"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r860", "r870", "r880", "r912"] }, "aktx_EstimatedFairValueOfPlacementAgentWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "EstimatedFairValueOfPlacementAgentWarrants", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Estimated fair value of placement agent warrants.", "label": "Estimated Fair Value Of Placement Agent Warrants", "terseLabel": "Estimated fair value of the placement agent warrants" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r911"] }, "aktx_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ExercisePriceRangeFourMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "label": "Exercise price range four", "documentation": "Exercise Price Range Four Member" } } }, "auth_ref": [] }, "aktx_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ExercisePriceRangeOneMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range One", "documentation": "Exercise Price Range One Member" } } }, "auth_ref": [] }, "aktx_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ExercisePriceRangeThreeMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range Three", "documentation": "Exercise Price Range Three Member" } } }, "auth_ref": [] }, "aktx_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ExercisePriceRangeTwoMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range Two", "documentation": "Exercise Price Range Two Member" } } }, "auth_ref": [] }, "aktx_ExpectedNonCashExpenseRelatingToVestingOfEquityAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ExpectedNonCashExpenseRelatingToVestingOfEquityAwards", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected non cash expense relating to vesting of equity awards", "label": "Expected Non Cash Expense Relating To Vesting Of Equity Awards", "documentation": "Expected non cash expense relating to vesting of equity awards." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Excess fair value of warrant liability over cash proceeds", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Excess in fair value of warrant liability over cash proceeds", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r2", "r9"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of financial liabilities measured at fair value on a recurring basis", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": ["r820", "r1046", "r1047", "r1054"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r501", "r502", "r503", "r823"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r501", "r502", "r503", "r823"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r304", "r352", "r353", "r354", "r355", "r356", "r357", "r498", "r500", "r501", "r502", "r503", "r512", "r513", "r515", "r559", "r560", "r561", "r805", "r806", "r811", "r812", "r813", "r820", "r823"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r499", "r500", "r501", "r503", "r820", "r1049", "r1056"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r508", "r510", "r511", "r512", "r515", "r516", "r517", "r518", "r519", "r625", "r820", "r824"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r304", "r352", "r353", "r354", "r355", "r356", "r357", "r500", "r501", "r502", "r503", "r513", "r561", "r805", "r806", "r811", "r812", "r813", "r820", "r823"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "crdr": "credit", "presentation": [

```
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "terseLabel": "Change in fair value of warrant liability", "label": "Fair Value, Liability, Recurring Basis, Still Held, Unrealized
Gain (Loss)", "negatedLabel": "Change in fair value of warrant liability", "documentation": "Amount of unrealized gain (loss) recognized in income
from liability measured at fair value on recurring basis using unobservable input (level 3) and still held." } } }, "auth_ref": [ "r509", "r514" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Measurements", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line
Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504", "r505", "r506", "r507", "r508", "r509" ] },
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of
information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r504",
"r505", "r506", "r507", "r508", "r509", "r514" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of
activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3)", "documentation": "Tabular
disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending
balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating
those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a
description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities);
(2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example,
transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r504", "r509", "r514" ] }, "us-
gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement
Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r499", "r500", "r501", "r503", "r820", "r1049", "r1056" ] },
"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementPolicyPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity.
Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure
measures the fair value of those assets and liabilities." } } }, "auth_ref": [] },
"aktx_FairValueMeasurementRecurringBasisLiabilityTransfersBetweenLevel1AndLevel2Net": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "FairValueMeasurementRecurringBasisLiabilityTransfersBetweenLevel1AndLevel2Net", "crdr":
"credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Transfers between level 1 and level 2", "label": "Fair Value Measurement, Recurring Basis, Liability, Transfers Between
Level 1 And Level 2, Net", "documentation": "Amount of transfers of financial instrument classified as a liability between level1 and level 2 of the
fair value hierarchy." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails" ], "lang": { "en-
us": { "role": { "verboseLabel": "Issuance of 2020 Warrants", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation,
Recurring Basis, Liability, Issuances", "terseLabel": "Issuance of warrants", "documentation": "Amount of issuances of financial instrument
classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants
would use in pricing." } } }, "auth_ref": [ "r507", "r514" ] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails" ], "lang": { "en-
us": { "role": { "negatedLabel": "Changes in values of liabilities related to options and warrants", "verboseLabel": "Change in fair value of liabilities
related to warrants", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase
(Decrease)", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase
(Decrease), Total", "terseLabel": "Change in fair value of liability", "documentation": "Amount of increase (decrease) of financial instrument
classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants
would use in pricing." } } }, "auth_ref": [ "r1051", "r1055" ] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Transfers into (out of) level 3", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers,
Net", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net, Total",
"documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy." } } },
"auth_ref": [ "r1052", "r1055" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails" ], "lang": { "en-
us": { "role": { "periodStartLabel": "Fair value at beginning", "periodEndLabel": "Fair value at ending", "label": "Fair Value, Measurement with
Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability
measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } }
}, "auth_ref": [ "r504", "r514" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value
Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } },
"auth_ref": [ "r304", "r352", "r353", "r354", "r355", "r356", "r357", "r498", "r500", "r501", "r502", "r503", "r512", "r513", "r515", "r559", "r560",
"r561", "r805", "r806", "r811", "r812", "r813", "r820", "r823" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value,
Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value
adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r820", "r1046", "r1047", "r1048",
"r1049", "r1050", "r1056" ] }, "aktx_FairValueOfCommitmentShares": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "FairValueOfCommitmentShares", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Fair value of commitment shares", "label": "Fair value of Commitment Shares", "documentation": "It represents the information
pertaining to fair value of commitment shares." } } }, "auth_ref": [] }, "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionQuantitativeDisclosuresLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value, Option, Quantitative Disclosures [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r522", "r523", "r524" ] }, "us-
gaap_FairValueOptionQuantitativeDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueOptionQuantitativeDisclosuresTable", "presentation": [
```

"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Option, Disclosures [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option." } } }, "auth_ref": ["r522", "r523", "r524"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r310", "r324", "r493", "r520", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r646", "r797", "r820", "r821", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r832", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r975", "r976", "r977", "r978", "r1045", "r1048", "r1049", "r1050", "r1053", "r1056"] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities measured at fair value", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": ["r1046", "r1047", "r1053"] }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Support to Nonconsolidated Legal Entity [Axis]", "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds." } } }, "auth_ref": ["r1", "r670", "r671"] }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Support to Nonconsolidated Legal Entity [Domain]", "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds." } } }, "auth_ref": ["r1", "r670", "r671"] }, "aktx_FinancingCostsInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "FinancingCostsInAccruedExpenses", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Financing costs in accrued expenses.", "label": "Financing costs in accrued expenses" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r260", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r593", "r594", "r780"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r260", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r780"] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived intangible assets, remaining amortization period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r593"] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": ["r446", "r447"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total", "negatedLabel": "Foreign currency exchange losses (gains)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r526", "r527", "r528", "r529", "r741"] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "terseLabel": "Foreign currency exchange gain (loss), net", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r719", "r851", "r1058", "r1059", "r1107"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r525"] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Foreign Plan [Member]", "terseLabel": "U.K.", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r1005", "r1006", "r1007"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r867", "r877", "r887", "r919"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r867", "r877", "r887", "r919"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r867", "r877", "r887", "r919"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r867", "r877", "r887", "r919"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r867", "r877", "r887", "r919"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r900"] }, "aktx_FullyVestedOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "FullyVestedOrdinarySharesMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fully Vested Ordinary Shares", "label": "Fully Vested Ordinary Shares [Member]", "documentation": "Fully vested ordinary shares." } } }, "auth_ref": [] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "United Kingdom", "label": "UNITED KINGDOM" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expenses", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r78"] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": ["r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424"] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": ["r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424"] }, "aktx_GreatBritainMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "GreatBritainMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "England", "label": "Great Britain", "documentation": "Represents the information pertaining to Great Britain." } } }, "auth_ref": [] }, "aktx_HeldByAnExecutiveUponTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "HeldByAnExecutiveUponTerminationMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti], "lang": { "en-us": { "role": { "documentation": "Held by an executive upon termination.", "label": "Held By an Executive Upon Termination [Member]", "terseLabel": "Held By an Executive Upon Termination" } } }, "auth_ref": [] }, "aktx_HeldInEscrowUntilTreatmentUponTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "HeldInEscrowUntilTreatmentUponTerminationMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti], "lang": { "en-us": { "role": { "documentation": "Held in escrow until treatment upon termination.", "label": "Held In Escrow Until Treatment Upon Termination [Member]", "terseLabel": "Held In Escrow Until Treatment Upon Termination" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r89"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Domestic (UK)", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": ["r163", "r445"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense], "lang": { "en-us": { "role": { "verboseLabel": "Net loss before income tax", "totalLabel": "Net loss before income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r76", "r114", "r116", "r628", "r643", "r790", "r793", "r969", "r970", "r971", "r972", "r973"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": ["r163", "r445"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r271", "r272", "r275", "r505", "r509", "r514", "r652", "r654", "r728", "r780", "r822", "r1077"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r272", "r275", "r505", "r509", "r514", "r652", "r654", "r728", "r780", "r822", "r1077"] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": ["r158", "r446", "r447", "r457", "r465", "r819", "r1038"] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": ["r158", "r446", "r447", "r457", "r465", "r819", "r1038"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r164", "r439", "r446", "r454", "r455", "r456", "r459", "r464", "r471", "r473", "r474", "r475", "r669", "r819"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpense "http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r118", "r126", "r181", "r182", "r194", "r202", "r212", "r444", "r446", "r472", "r650", "r819"] }, "us-

```
gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "terseLabel": "Impact on income tax expense/recovery from", "label": "Income Tax Expense (Benefit), Effective
Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income
taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances,
recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining
its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r148", "r442",
"r443", "r459", "r460", "r463", "r467", "r663" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in
Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit)
and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from
continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r452", "r819",
"r1034" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "verboseLabel": "Change of tax rate due to U.S. tax reform", "label": "Effective Income Tax Rate Reconciliation,
Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected
income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing
operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r441", "r446", "r450", "r819" ] }, "us-
gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "terseLabel": "Tax rate difference in foreign jurisdictions", "label": "Effective Income Tax Rate Reconciliation,
Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and
expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from
continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r447", "r449", "r819", "r1034" ] }, "us-
gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr":
"debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation":
"The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from
continuing operations." } } }, "auth_ref": [ "r446", "r819" ] }, "us-
gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit",
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "verboseLabel": "Permanent differences", "label": "Effective Income Tax Rate Reconciliation, Nondeductible
Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less
than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from
continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to,
expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r819",
"r1034", "r1036" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "negatedLabel": "Deferred tax adjustments", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments,
Amount", "terseLabel": "Deferred tax adjustments", "documentation": "Amount of the difference between reported income tax expense (benefit)
and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from
continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r819", "r1034", "r1035" ] }, "us-
gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesIncomeTaxesAtUkStatutoryRateComparedToCompanySIncomeTaxExpenses
], "lang": { "en-us": { "role": { "terseLabel": "Change of tax rate from prior year", "label": "Effective Income Tax Rate Reconciliation, Prior Year
Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax
expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations
attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r1034", "r1035" ] }, "us-
gaap_IncomeTaxUncertainties Policy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxUncertainties Policy", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Uncertain Tax Positions", "label": "Income Tax Uncertainties, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be
sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"verboseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "totalLabel":
"Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in
the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } },
"auth_ref": [ "r8" ] }, "aktx_IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"negatedLabel": "Prepaid expenses and other current assets", "label": "Increase Decrease In Accounts Receivables And Prepaid Expense",
"documentation": "Changes in the value of accounts receivables and prepaid expenses during the period." } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Change in assets and liabilities:" } } }, "auth_ref": [] },
"ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r867", "r877", "r887", "r911", "r919", "r923", "r931" ] },
"aktx_InitialValuationOfWarrantLiabilityNonCashFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "InitialValuationOfWarrantLiabilityNonCashFinancingActivities", "crdr": "debit", "presentation":
[ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Initial valuation of warrant liability", "label": "Initial Valuation of Warrant Liability, Non-cash Financing Activities",
"documentation": "The amount of initial valuation of warrant liability non-cash financing activities." } } }, "auth_ref": [] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading
Arrangements:" } } }, "auth_ref": [ "r929" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies
and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r859", "r935" ] },
"ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
```

"InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r859", "r935"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r859", "r935"] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Patent Acquisition Costs", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": ["r589", "r590", "r591", "r593", "r788", "r980"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Patent acquisition costs, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r260", "r986", "r987"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Total", "label": "Interest Expense, Operating and Nonoperating", "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r194", "r198", "r200", "r203", "r212", "r538", "r793", "r794"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "totalLabel": "Interest Expense, Nonoperating, Total", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r200", "r958"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r154", "r156", "r157"] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r61"] }, "aktx_InterimCeoAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "InterimCeoAgreementMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Interim CEO Agreement.", "label": "Interim CEO Agreement [Member]", "terseLabel": "Interim Ceo Agreement" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r194", "r199", "r212", "r793", "r957"] }, "aktx_InvestorWarrants2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "InvestorWarrants2019Member", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "label": "2019 Investor Warrants", "documentation": "It represents the information pertaining to Investor warrants 2019." } } }, "auth_ref": [] }, "aktx_InvestorWarrants2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "InvestorWarrants2020Member", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "label": "2020 Investor Warrants", "documentation": "It represents the information pertaining to Investor warrants 2020." } } }, "auth_ref": [] }, "aktx_InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "InvestorWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investor warrants", "label": "Investor warrants [Member]", "documentation": "This member stands for Investor Warrants." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Issuance of share capital for vendor services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": ["r9"] }, "aktx_July2021PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "July2021PlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "July 2021 Placement Agent Warrants", "label": "July 2021 Placement Agent Warrants", "documentation": "This member represents information pertaining to July 2021 Placement Agent Warrants." } } }, "auth_ref": [] }, "aktx_JulyTwoThousandAndTwentyTwentyOneWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "JulyTwoThousandAndTwentyTwentyOneWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValeMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"], "lang": { "en-us": { "role": { "label": "July 2021 warrants", "documentation": "It represents July 2021 Warrants member." } } }, "auth_ref": [] }, "aktx_LaboratoryTestingServicesCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "LaboratoryTestingServicesCharges", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Laboratory testing services charges", "label": "Laboratory Testing Services Charges", "documentation": "The amount of laboratory testing services incurred during the period." } } }, "auth_ref": [] }, "aktx_LaboratoryTestingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "LaboratoryTestingServicesMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Laboratory Testing Services", "documentation": "It stands for Laboratory Testing Services ." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r541"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r73", "r113", "r638", "r831", "r961", "r979", "r1057"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' (Deficit) Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r62", "r131", "r162", "r247", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r484", "r485", "r486", "r521", "r831", "r1001", "r1063", "r1064"] }, "us-

gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails"], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Line of Credit, Total", "label": "Long-Term Line of Credit", "terseLabel": "Equity line of credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r19", "r111", "r1073"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r283", "r284", "r285", "r288", "r435", "r661", "r803", "r999", "r1000"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r283", "r284", "r285", "r288", "r435", "r803", "r999", "r1000"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r283", "r284", "r285", "r288", "r435", "r803", "r999", "r1000"] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": ["r283", "r284", "r285", "r288", "r435", "r661", "r803", "r999", "r1000"] }, "aktx_March2022InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "March2022InvestorWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "March 2022 Investor Warrants", "label": "March 2022 Investor Warrants", "documentation": "This member represents information pertaining to March 2022 Investor Warrants." } } }, "auth_ref": [] }, "aktx_March2022PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "March2022PlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "March 2022 Placement Agent Warrants", "label": "March 2022 Placement Agent Warrants", "documentation": "This member represents information pertaining to March 2022 Placement Agent Warrants." } } }, "auth_ref": [] }, "aktx_MarchTwoThousandTwentyFourPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MarchTwoThousandTwentyFourPlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Placement Agent Warrants", "label": "March Two Thousand Twenty Four Placement Agent Warrants [Member]", "documentation": "March two thousand twenty four placement agent warrants." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r284", "r285", "r286", "r287", "r390", "r435", "r503", "r588", "r651", "r653", "r661", "r690", "r691", "r752", "r754", "r756", "r757", "r759", "r778", "r779", "r796", "r809", "r814", "r823", "r824", "r828", "r829", "r841", "r1003", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070"] }, "aktx_MaximumNumberOfAdssTradedEachWorkingDay": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MaximumNumberOfAdssTradedEachWorkingDay", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of Adss traded each working day", "label": "Maximum Number Of Adss Traded Each Working Day", "documentation": "Represents maximum number of ADSs traded each working day." } } }, "auth_ref": [] }, "aktx_May2024InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "May2024InvestorWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "May 2024 Investor Warrants.", "label": "May 2024 Investor Warrants [Member]", "terseLabel": "May 2024 Investor Warrants" } } }, "auth_ref": [] }, "aktx_May2024PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "May2024PlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "May 2024 Placement Agent Warrants.", "label": "May 2024 Placement Agent Warrants [Member]", "terseLabel": "May 2024 Placement Agent Warrants" } } }, "auth_ref": [] }, "aktx_MayTwoThousandTwentyFourPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MayTwoThousandTwentyFourPlanMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "May 2024 plan.", "label": "May Two thousand twenty-four plan [Member]", "terseLabel": "May 2024 Plan" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r903"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r903"] }, "aktx_MeasurementInputAnnualTurnoverRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MeasurementInputAnnualTurnoverRateMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"], "lang": { "en-us": { "role": { "label": "Annual turnover rate", "documentation": "This member stands for the measurement input, annual turnover rate." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExercisePriceMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "label": "Measurement Input, Exercise Price [Member]", "documentation":

```
"Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] }, "aktx_MeasurementInputPeriodRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MeasurementInputPeriodRiskFreeInterestRateMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "label": "Period risk-free rate", "documentation": "This member stands for the measurement input, period risk free interest rate." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r823", "r1048", "r1049", "r1050" ] }, "aktx_MeasurementInputRequiredRateOfReturnOnEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MeasurementInputRequiredRateOfReturnOnEquityMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "label": "Required return on equity", "documentation": "This member stands for the measurement input, required rate of return on equity." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Stock price", "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] },
"aktx_MeasurementInputStandardDeviationRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MeasurementInputStandardDeviationRateMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "label": "Standard deviation", "documentation": "This member stands for the measurement input, standard deviation rate." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r501", "r502", "r503", "r823" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetailss"
], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r501", "r502", "r503", "r823" ] }, "aktx_MergerAgreementExchangeRatioPerOrdinaryShare": { "xbrltype": "pureItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MergerAgreementExchangeRatioPerOrdinaryShare", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Merger agreement exchange ratio per ordinary share", "label": "Merger Agreement Exchange Ratio Per Ordinary Share",
"documentation": "Merger agreement exchange ratio per ordinary share." } } }, "auth_ref": [] },
"aktx_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Merger Agreement Expected Ownership In Company Counterparty Stockholders Percentage", "label": "Merger Agreement Expected Ownership In Company Counterparty Stockholders Percentage", "terseLabel": "Percentage of expected ownership in outstanding shares"
} } }, "auth_ref": [] }, "aktx_MergerRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "MergerRelatedCostsPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"documentation": "Merger-related costs.", "label": "Merger-Related Costs [Policy Text Block]", "terseLabel": "Merger-Related Costs" } } },
"auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r390", "r435", "r503", "r588", "r651", "r653",
"r661", "r690", "r691", "r752", "r754", "r756", "r757", "r759", "r778", "r779", "r796", "r809", "r814", "r823", "r824", "r828", "r841", "r1003",
"r1065", "r1066", "r1067", "r1068", "r1069", "r1070" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r922" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r930" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel":
"Named Executive Officers, Footnote" } } }, "auth_ref": [ "r904" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities",
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } },
"auth_ref": [ "r155" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } },
"auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r82", "r83", "r84" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } },
```

"auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r77", "r84", "r115", "r129", "r143", "r146", "r151", "r162", "r172", "r174", "r175", "r176", "r177", "r178", "r181", "r182", "r187", "r247", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r479", "r482", "r497", "r521", "r644", "r720", "r742", "r743", "r851", "r1001"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "aktx_NewEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "NewEquityIncentivePlanMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "2014 Equity Incentive Plan", "documentation": "New Equity Incentive Plan Member" } } }, "auth_ref": [] }, "aktx_NonCashSellerFinancedPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "NonCashSellerFinancedPurchases", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash seller-financed purchases", "label": "Non-cash Seller-financed Purchases", "documentation": "Non-cash seller-financed purchases." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r903"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r867", "r877", "r887", "r911", "r919"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r894"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r893"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r911"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r930"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r930"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r79"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "aktx_NumberOfOrdinarySharesRepresentingOneAmericanDepositaryShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "NumberOfOrdinarySharesRepresentingOneAmericanDepositaryShare", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of ordinary shares representing one ADS", "label": "Number Of Ordinary Shares Representing One American Depositary Share", "documentation": "Number of ordinary shares representing one ADS." } } }, "auth_ref": [] }, "aktx_NumberOfSharesToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "NumberOfSharesToBeIssued", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares to be Issued", "label": "Number Of Shares To Be Issued", "documentation": "Number of shares to be issued." } } }, "auth_ref": [] }, "aktx_OctoberTwoThousandTwentyThreeInvestorPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OctoberTwoThousandTwentyThreeInvestorPrefundedWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "October two thousand twenty three investor prefunded warrants.", "label": "October Two Thousand Twenty Three Investor Prefunded Warrants [Member]", "terseLabel": "October 2023 Investor Prefunded Warrants" } } }, "auth_ref": [] }, "aktx_OctoberTwoThousandTwentyThreePlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OctoberTwoThousandTwentyThreePlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "October two thousand twenty three placement agent warrants.", "label": "October Two Thousand Twenty Three Placement Agent Warrants [member]", "terseLabel": "October 2023 Placement Agent Warrants" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OneTimeTerminationBenefitsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "One-time Termination Benefits [Member]", "terseLabel": "One-time termination benefits", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": ["r799", "r800", "r801", "r802"] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses:", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Operating Expenses, Total", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r116", "r790", "r969", "r970", "r971", "r972", "r973"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r542", "r830"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us":

{ "role": { "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r1060"] }, "aktx_OperatingLeaseRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OperatingLeaseRentExpense", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Rental expense", "label": "Operating Lease Rent Expense", "documentation": "The amount of operating lease rent expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r466"] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r466"] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": ["r466"] }, "aktx_OperatingLossUnlimitedCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OperatingLossUnlimitedCarryforwardAmount", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Operating loss unlimited carryforward amount.", "label": "Operating Loss Unlimited Carryforward Amount", "terseLabel": "Operating loss unlimited carryforward amount" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Axis]", "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock." } } }, "auth_ref": ["r35", "r52", "r53", "r107"] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "aktx_OrdinaryShareSubscriptionsDepositReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OrdinaryShareSubscriptionsDepositReceived", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Ordinary share subscription deposit", "label": "Ordinary Share Subscriptions Deposit Received", "documentation": "Represents the amount of ordinary share subscriptions deposit received in December 2021." } } }, "auth_ref": [] }, "aktx_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OrdinarySharesMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Ordinary shares.", "label": "Ordinary Shares [Member]", "terseLabel": "Ordinary Shares", "verboseLabel": "Akari Ordinary Shares" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Description of Business", "label": "Description of Business" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r61"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r141", "r831"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r7", "r11", "r105"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r5", "r75", "r645"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r7", "r11", "r105", "r144", "r147", "r178"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "aktx_OtherCurrentAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OtherCurrentAssetsPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Current Assets [Policy Text Block]", "documentation": "Disclosure of accounting policy for other current asset." } } }, "auth_ref": [] }, "aktx_OtherCurrentLiabilitiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "OtherCurrentLiabilitiesPolicyPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities Policy [Policy Text Block]", "documentation": "Other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [

"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Other Liabilities, Total", "label": "Other Liabilities", "terseLabel": "Payable balances", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": ["r110", "r632", "r694", "r695", "r853", "r1074", "r1106"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r61", "r831"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r80"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r903"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r865", "r875", "r885", "r917"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r868", "r878", "r888", "r920"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r868", "r878", "r888", "r920"] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r104", "r981", "r982", "r983", "r984", "r985", "r986", "r988", "r989"] }, "aktx_PaulsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PaulsonMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Paulson", "label": "Paulson [Member]", "documentation": "Paulson." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r892"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Stock issuance costs", "label": "Payments of Stock Issuance Costs", "terseLabel": "Amount paid for placement agent fees and expenses", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r24"] }, "aktx_PayrollTaxesOnShareBasedCompensationInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PayrollTaxesOnShareBasedCompensationInAccruedExpenses", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Payroll taxes on share-based compensation in accrued expenses", "label": "Payroll taxes on share-based compensation in accrued expenses", "documentation": "Payroll taxes on share-based compensation in accrued expenses." } } }, "auth_ref": [] }, "aktx_PeakBioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PeakBioMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Peak Bio.", "label": "Peak Bio [Member]", "terseLabel": "Peak Bio" } } }, "auth_ref": [] }, "aktx_PeakCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PeakCommonStockMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Peak common stock.", "label": "Peak Common Stock [Member]", "terseLabel": "Peak Common Stock" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r902"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r902"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r894"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r911"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r904"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r893"] }, "aktx_PercentageOfAggregateSharesOfCompanySAdssTraded": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PercentageOfAggregateSharesOfCompanySAdssTraded", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate shares", "label": "Percentage of Aggregate Shares of The Company's ADSs Traded", "documentation": "Represents percentage of aggregate shares of the company's ADSs traded." } } }, "auth_ref": [] }, "aktx_PercentageOfCashFeePaidToPlacementAgent": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PercentageOfCashFeePaidToPlacementAgent", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of cash fee paid to placement agent", "label": "Percentage of Cash Fee Paid to Placement Agent", "documentation": "Percentage of cash fee paid to placement agent." } } }, "auth_ref": [] }, "aktx_PercentageOfExercisePriceOfAdsForExercisePriceOfWarrant": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PercentageOfExercisePriceOfAdsForExercisePriceOfWarrant", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of the price per ADS for exercise price", "label": "Percentage of Exercise Price of ADS for Exercise Price of Warrant", "documentation": "Represents the percentage of the price per ADS for exercise price of warrants." } } }, "auth_ref": [] }, "aktx_PercentageOfFairMarketValueOfShares": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PercentageOfFairMarketValueOfShares", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair market value of shares", "label": "Percentage of Fair Market Value of Shares", "documentation": "Represents the percentage of fair market value of shares." } } }, "auth_ref": [] }, "aktx_PercentageOfVolumeWeightedAveragePriceIndicatingPurchasePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PercentageOfVolumeWeightedAveragePriceIndicatingPurchasePrice", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of volume weighted average price indicating purchase price", "label": "Percentage Of Volume Weighted Average Price Indicating Purchase Price", "documentation": "It represents the percentage of Volume-weighted average price indicating purchase price." } } }, "auth_ref": [] }, "aktx_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PlacementAgentWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Placement agent", "label": "Placement agent warrants [Member]", "documentation": "This member stands for Placement Agent Warrants." } } }, "auth_ref": [] }, "aktx_PlacementWarrants2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "PlacementWarrants2019Member", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": {

```
"label": "2019 Placement Warrants", "documentation": "It represents the information pertaining to placement warrants July." } } }, "auth_ref": [] },
"aktx_PlacementWarrants2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"PlacementWarrants2020Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": {
"label": "2020 Placement Warrants", "documentation": "It represents the information pertaining to placement warrants 2020." } } }, "auth_ref": []
}, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1008", "r1009",
"r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025",
"r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1008", "r1009", "r1010",
"r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026",
"r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } },
"auth_ref": [ "r895" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension
Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r939" ] },
"ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits
Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r894" ] },
"aktx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"PreFundedWarrantsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Pre-Funded Warrants", "label": "Pre-Funded Warrants [Member]", "documentation": "Represents the member information
pertaining to Pre-Funded Warrants." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel":
"Prepaid expenses", "label": "Prepaid Expense, Current", "totalLabel": "Prepaid Expense, Current, Total", "documentation": "Amount of asset
related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle,
if longer." } } }, "auth_ref": [ "r140", "r258", "r259", "r783" ] }, "aktx_PrepaidExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "PrepaidExpensesPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Prepaid Expenses", "label": "Prepaid Expenses [Policy Text Block]", "documentation": "Disclosure of accounting policy for prepaid
expenses." } } }, "auth_ref": [] }, "aktx_PrivatePlacement2021Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "PrivatePlacement2021Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "2021 Private Placement", "documentation": "Represents the member information pertaining to 2021 Private Placement." } } }, "auth_ref":
[] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrivatePlacementMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Private Placement [Member]", "terseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a
limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref":
[] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Gross proceeds from convertible promissory notes", "label": "Proceeds from Convertible Debt", "verboseLabel": "Proceeds from
issuance of convertible notes", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a
specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r23" ] },
"us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Proceeds from issuance of shares, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Net
proceeds from sale of shares", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] },
"us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Proceeds from Issuance of Private Placement", "terseLabel": "Gross proceeds from private placement", "verboseLabel": "Aggregate gross
proceeds", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public
placement." } } }, "auth_ref": [ "r6" ] }, "aktx_ProceedsFromIssuanceOfPrivatePlacementAfterDeductingAgentFeesAndOtherExpenses": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"ProceedsFromIssuanceOfPrivatePlacementAfterDeductingAgentFeesAndOtherExpenses", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "Proceeds from issuance of private placement after deducting agent fees and other expenses.", "label": "Proceeds From Issuance
Of Private Placement After Deducting Agent Fees And Other Expenses", "terseLabel": "Net proceeds" } } }, "auth_ref": [] },
"aktx_ProceedsFromIssuanceOfRestrictedShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"ProceedsFromIssuanceOfRestrictedShares", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Proceeds from issuance of restricted shares", "label": "Proceeds From Issuance Of Restricted Shares", "documentation": "Proceeds
from issuance of restricted shares." } } }, "auth_ref": [] }, "us-
gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from
employee vesting of restricted shares", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement.
Excludes option exercised." } } }, "auth_ref": [ "r6", "r18" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Proceeds from Issuance of Warrants", "terseLabel": "Aggregate gross proceeds", "documentation": "The cash inflow from issuance of
rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r6" ] }, "us-
gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"verboseLabel": "Proceeds from sale of ADS", "label": "Proceeds from Issuance or Sale of Equity", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "terseLabel": "Proceeds from issuance of shares", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r6", "r664"] }, "us-gaap_ProceedsFromWarrantExercises": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit",
"presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants to purchase shares", "label": "Proceeds from Warrant Exercises", "documentation":
"The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r959"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": {
"label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r10", "r543"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r88", "r133", "r642"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": {
"totalLabel": "Property and equipment, net", "terseLabel": "Total", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r543", "r629", "r642", "r831"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": {
"terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r10", "r122", "r125", "r640"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of components of property and equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation":
"Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } },
"auth_ref": ["r10"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": {
"label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } },
"auth_ref": ["r88", "r543"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Property, pant and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [
"r892"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]",
"terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r892"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": {
"en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r284", "r285", "r286", "r287", "r350", "r390", "r421", "r422",
"r423", "r435", "r503", "r562", "r571", "r588", "r651", "r653", "r661", "r690", "r691", "r752", "r754", "r756", "r757", "r759", "r778", "r779", "r796",
"r809", "r814", "r823", "r824", "r828", "r829", "r841", "r845", "r994", "r1003", "r1049", "r1066", "r1067", "r1068", "r1069", "r1070"] },
"srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": {
"en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r284", "r285", "r286", "r287", "r350", "r390", "r421", "r422",
"r423", "r435", "r503", "r562", "r571", "r588", "r651", "r653", "r661", "r690", "r691", "r752", "r754", "r756", "r757", "r759", "r778", "r779", "r796",
"r809", "r814", "r823", "r824", "r828", "r829", "r841", "r845", "r994", "r1003", "r1049", "r1066", "r1067", "r1068", "r1069", "r1070"] },
"aktx_ReceivedFromIssuanceOfOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"ReceivedFromIssuanceOfOffering", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Received from issuance of offering", "label": "Received From Issuance of Offering", "documentation": "Amount received from issuance of offering." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } },
"auth_ref": ["r860", "r870", "r880", "r912"] }, "aktx_RegisteredDirectOffering2021Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "RegisteredDirectOffering2021Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Registered Direct Offering 2021", "label": "Registered Direct Offering 2021 [Member]", "documentation": "This member stands for Registered Direct Offering 2021." } } }, "auth_ref": [] }, "aktx_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "RegisteredDirectOfferingMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": {

```
"en-us": { "role": { "verboseLabel": "Registered direct offering", "label": "Registered Direct Offering [Member]", "documentation": "Represents information pertaining to Registered Direct Offering." } } }, "auth_ref": [] }, "aktx_RegisteredOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "RegisteredOfferingMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Registered offering.", "label": "Registered Offering [Member]", "terseLabel": "Registered Offering" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r216", "r375", "r548", "r549", "r633", "r639", "r693", "r694", "r695", "r696", "r697", "r716", "r718", "r751" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r165", "r166", "r548", "r549", "r550", "r551", "r633", "r639", "r693", "r694", "r695", "r696", "r697", "r716", "r718", "r751" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment to CEO upon aggrement", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r55", "r548" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r548", "r549", "r1062" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r724", "r725", "r728" ] }, "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment terms to CEO upon aggrement", "label": "Related Party Transaction, Terms and Manner of Settlement", "documentation": "Description of the terms and manner of settlement of the related party transaction." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r216", "r375", "r548", "r549", "r633", "r639", "r693", "r694", "r695", "r696", "r697", "r716", "r718", "r751", "r1062" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "verboseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r545", "r546", "r547", "r549", "r552", "r672", "r673", "r674", "r726", "r727", "r728", "r748", "r750" ] }, "aktx_RemainingShareholdersDeficitRequiredToGetListedInNasdaqListing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "RemainingShareholdersDeficitRequiredToGetListedInNasdaqListing", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Remaining shareholders deficit required to get listed in Nasdaq listing.", "label": "Remaining Shareholders Deficit Required To Get Listed In Nasdaq Listing", "terseLabel": "Remaining shareholder's deficit required to get listed in Nasdaq listing" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of convertible notes", "label": "Repayments of Convertible Debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r81" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on short-term financing arrangement", "label": "Repayments of Short-Term Debt", "totalLabel": "Repayments of Short-Term Debt, Total", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r81" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r167", "r168", "r301", "r314", "r551", "r572", "r630", "r785", "r786" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development expenses", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [
"r438", "r780", "r793", "r1071" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r437" ] },
```

```
"aktx_ResearchAndDevelopmentTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ResearchAndDevelopmentTaxCredits", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development tax credits", "label": "Research and Development Tax Credits", "documentation": "Research and development tax credits." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r861", "r871", "r881", "r913" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r862", "r872", "r882", "r914" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r869", "r879", "r889", "r921" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "aktx_RestructuringAndOtherCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "RestructuringAndOtherCostsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and Other Costs [Member]", "label": "Restructuring and other costs [Member]", "terseLabel": "Restructuring and other costs" } } }, "auth_ref": [] }, "aktx_RestructuringAndOtherCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "RestructuringAndOtherCostsPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and other costs.", "label": "Restructuring and Other Costs [Policy Text Block]", "terseLabel": "Restructuring and Other Costs" } } }, "auth_ref": [] }, "aktx_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected percentage of reduction of workforce", "label": "Restructuring And Related Cost Expected Number Of Positions Eliminated Period Percent", "documentation": "Restructuring and related cost expected number of positions eliminated period percent." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Charges, Total", "label": "Restructuring Charges", "terseLabel": "Restructuring-related charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r277", "r278", "r995" ] }, "aktx_RestructuringChargesUnpaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "RestructuringChargesUnpaid", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Restructuring charges unpaid", "label": "Restructuring charges unpaid", "terseLabel": "Restructuring-related charges unpaid" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r273", "r274", "r278", "r279" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r278", "r279", "r280" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Restructuring Costs, Total", "label": "Restructuring Costs", "terseLabel": "Restructuring and other costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve, Current", "terseLabel": "Restructuring", "verboseLabel": "Accrued restructuring expenses", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r953", "r996", "r997" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Shareholders deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r70", "r97", "r637", "r658", "r660", "r668", "r700", "r831" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r128", "r169", "r170", "r171", "r173", "r178", "r180", "r182", "r248", "r249", "r270", "r468", "r469", "r476", "r477", "r478", "r480", "r481", "r482", "r487", "r489", "r490", "r492", "r495", "r539", "r540", "r655", "r657", "r675", "r1108" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r1005", "r1006", "r1007" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [
```

"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r1005", "r1006", "r1007"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r930"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r930"] }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock, Description of Transaction", "label": "Sale of Stock, Description of Transaction", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": ["r12", "r51", "r106"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share issue price (in dollars per ADS)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Anti-Dilutive Share Equivalents", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of components of income tax expense", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": ["r1040"] }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of changes in accumulated other comprehensive loss", "label": "Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans." } } }, "auth_ref": ["r74"] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of deferred tax assets and liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r1037"] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of income taxes at the UK statutory rate compared to the company's income tax expenses", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r448", "r819", "r1034"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r46"] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of components of income/(loss) before income taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": ["r962"] }, "aktx_ScheduleOfRateOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ScheduleOfRateOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of estimated useful lives of the assets", "label": "Schedule Of Rate Of Depreciation Of Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of rate of depreciation of property, plant and equipment." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r54", "r55", "r724", "r725", "r728"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r273", "r274", "r275", "r276", "r278", "r279", "r280"] }, "us-

gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424"] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": ["r43"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of share option activity and related information for employees and directors", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r16", "r17", "r98"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions", "terseLabel": "Schedule of assumptions used to determine the fair value of stock granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r103"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r36", "r37", "r38", "r39", "r40", "r41", "r93", "r95", "r96", "r97", "r136", "r137", "r138", "r196", "r312", "r313", "r314", "r316", "r319", "r324", "r326", "r664", "r665", "r666", "r667", "r809", "r941", "r960"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of summarizes the outstanding warrants", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r42"] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of activity of the Company's unvested RSUs", "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r854"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r856"] }, "aktx_SecurityExpiringOnNovemberSixTwoThousandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "SecurityExpiringOnNovemberSixTwoThousandMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "November 6, 2029", "label": "Security Expiring on November Six Two Thousand [Member]", "documentation": "Security expiring on november six two thousand." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r214", "r215", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r687", "r688", "r689", "r753", "r755", "r758", "r760", "r767", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r781", "r810", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r842", "r845", "r1004", "r1076", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r204", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r214", "r791", "r792", "r795"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "totalLabel": "Selling, General and Administrative Expense, Total", "verboseLabel": "General and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r78"] }, "aktx_September2022InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "September2022InvestorWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "September 2022 Investor Warrants", "label": "September 2022 Investor Warrants [Member]", "documentation": "This member represents information pertaining to September 2022 Investor warrants." } } }, "auth_ref": [] }, "aktx_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "SeriesBWarrantsMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails",

"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Series B warrants", "label": "Series B warrants", "documentation": "Represents the information pertaining to
Series B warrants." } } }, "auth_ref": [] }, "aktx_SeriesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "SeriesCWarrantsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Series C Warrants.", "label": "Series C Warrants [Member]", "terseLabel": "Series C Warrants" } } }, "auth_ref": [] },
"aktx_SeriesDWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"SeriesDWarrantsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"verboseLabel": "Series D Warrants", "label": "Series D Warrants [Member]", "documentation": "Series D Warrants [Member]" } } }, "auth_ref": []
}, "aktx_SeriesWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"SeriesWarrantsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfActivityInWarrantLiabilityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Series A warrants", "label": "Series A warrants", "documentation": "Represents the information pertaining to
Series A warrants." } } }, "auth_ref": [] }, "aktx_SeveranceAndOtherSettlementPayments": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "SeveranceAndOtherSettlementPayments", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": {
"en-us": { "role": { "documentation": "Severance and other settlement payments.", "label": "Severance and Other Settlement Payments",
"terseLabel": "Severance and other settlement payments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": {
"terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "totalLabel": "Share-Based Payment
Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [
"r8"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period (in years)", "documentation":
"Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or
performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen
days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r815"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments,
excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r413"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDa
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFa
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (per share)", "documentation": "Weighted average fair
value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of
the occurrence of a terminating event." } } }, "auth_ref": ["r413"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Number of Warrants, Issued", "documentation": "The number
of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation
rights plan, performance target plan)." } } }, "auth_ref": ["r411"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGra
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDat
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Granted (per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-Average
Exercise Price, Issued", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the
period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance
target plan)." } } }, "auth_ref": ["r411"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested at beginning of the period (in shares)", "periodEndLabel": "Unvested at end of the
period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Nonvested, Number", "terseLabel": "RSUs outstanding", "documentation": "The number of non-vested equity-based payment instruments,
excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r408", "r409"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation":
["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Shares/ Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a
concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value per share, Beginning of the period (per share)",
"periodEndLabel": "Weighted average grant date fair value per share, End of the period (per share)", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and
unit options." } } }, "auth_ref": ["r408", "r409"] }, "us-

```
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value per share", "label": "Share-Based Compensation Arrangement
by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } },
"auth_ref": [] },
"aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingUnvestedInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingUnvestedInPeriod",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ],
"lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other
than options underlying unvested in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity
Instruments Other Than Options Underlying Unvested In Period", "terseLabel": "Shares underlying unvested" } } }, "auth_ref": [] },
"aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingVestedInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingVestedInPeriod",
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that shares
underlying vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, underlying vested in Period", "terseLabel": "Shares underlying vested" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
Options, Vested in Period", "negatedLabel": "Vested (in shares)", "terseLabel": "Ordinary shares vested", "documentation": "The number of equity-
based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r412" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr":
"debit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
Options, Vested in Period, Fair Value", "terseLabel": "Fair value of time-based RSUs that vested", "documentation": "Fair value of share-based
awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other
instruments, or cash." } } }, "auth_ref": [ "r415" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGra
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDat
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails"
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (per share)", "documentation": "The weighted average
fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right
during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in
accordance with the terms of the arrangement." } } }, "auth_ref": [ "r412" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be
paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r422" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is
expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the
mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period.
That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." }
} }, "auth_ref": [ "r421" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Risk-free interest", "label": "Share-Based Compensation Arrangement by Share-Based Payment
Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate
assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r423" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel":
"Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": [ "r392", "r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409",
"r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails" ], "lang": {
"en-us": { "role": { "negatedLabel": "Number of Warrants ADSs, Expired", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Non-Option Equity Instruments, Expirations", "documentation": "Number of shares under non-option equity instrument
agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r101" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails" ], "lang": {
```

"en-us": { "role": { "terseLabel": "Number of Warrants ADSs, Issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": ["r15"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Warrants ADSs Outstanding, Ending Balance", "periodStartLabel": "Number of Warrants ADSs Outstanding Beginning Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r99", "r100"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares available for grant", "verboseLabel": "Ordinary shares issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized to issue", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r817"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares available to grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares remained available for future issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r43"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares, Exercisable options at end of the period", "terseLabel": "Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r402"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price (for exercisable options)", "periodEndLabel": "Options exercisable at end of the period, Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r402"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of shares, Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r407"] }, "aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodPriorToAcquisitionWeightedAverageGrantDateF { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodPriorToAcquisitionWeightedAverageGrantDateFairVa "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value, Forfeited", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Prior To Acquisition Weighted Average Grant Date Fair Value", "documentation": "Weighted average per share amount at which grantees can forfeited shares of common stock by exercise of options prior to acquisition." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r406"] }, "aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodPriorToAcquisitionGross": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodPriorToAcquisitionGross", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares, Granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Prior To Acquisition Gross", "documentation": "Gross number of share options (or share units) granted during the period prior to acquisition." } } }, "auth_ref": [] }, "aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodPriorToAcquisitionWeightedAverageGrantDateFair { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodPriorToAcquisitionWeightedAverageGrantDateFairValue "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value, Granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Prior To Acquisition Weighted Average Grant Date Fair Value", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options prior to acquisition." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value per share of options granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r414"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate intrinsic value, Options outstanding at beginning of the period", "periodEndLabel": "Aggregate intrinsic value, Options outstanding at end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,

Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r43"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding", "periodStartLabel": "Number of shares, Options Outstanding at beginning of the period", "periodEndLabel": "Number of shares, Options Outstanding at end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r400", "r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise Price", "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of the period", "periodEndLabel": "Weighted average exercise price, Outstanding at end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r400", "r401"] }, "aktx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Outstanding, Number", "documentation": "Number of outstanding stock options and restricted stock units.", "terseLabel": "Number of ordinary shares underlying outstanding equity awards consisting of stock options and restricted stock units" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r407"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average exercise price, Forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r406"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r404"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r391", "r399", "r418", "r419", "r420", "r421", "r424", "r430", "r431", "r432", "r433"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": ["r45"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (lower range)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r45"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (upper range)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r45"] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "terseLabel": "Employees", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r394", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424"] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember":

{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Directors", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r392", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r420", "r421", "r422", "r423", "r424"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Per share price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "aktx_SharePurchaseCommitmentAmountAvailableUnderFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "SharePurchaseCommitmentAmountAvailableUnderFacility", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount available under the share purchase commitment facility", "label": "Share Purchase Commitment Amount Available Under Facility", "documentation": "Amount available under the share purchase commitment facility." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Options expiration", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Term of awards (in years)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r816"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Expected life in years", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r420"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate intrinsic value, Options exercisable at end of the period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r43"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average remaining contractual term, Options exercisable at end of the period (in years)", "terseLabel": "Remaining contractual life (years for exercisable options)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r43"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAssumptionsUsedForTheFairValueOfStockAwardsDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average remaining contractual life, Options outstanding during the period (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r102"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning of the year (in shares)", "periodEndLabel": "Balance at the end of the year (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares withheld for payroll taxes (in shares)", "negatedLabel": "Shares withheld for payroll taxes (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term finance", "label": "Short-Term Debt", "totalLabel": "Short-Term Debt, Total", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r59", "r109", "r831", "r1072"] }, "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtPercentageBearingFixedInterestRate", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term finance, interest rate", "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate", "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTerms", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term debt, terms", "label": "Short-Term Debt, Terms", "documentation": "Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements." } } }, "auth_ref": ["r952"] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r60", "r991", "r992", "r993"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r59", "r991", "r992", "r993"] }, "aktx_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "SignificantAccountingPoliciesLineItems", "presentation": ["http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Summary of Significant Accounting Policies [Line Items]", "documentation":

```
"No definition available." } } }, "auth_ref": [] }, "aktx_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "SignificantAccountingPoliciesTable", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": {
"label": "Significant Accounting Policies [Table]", "documentation": "Significant Accounting Policies Table" } } }, "auth_ref": [] }, "us-
gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for
all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r85", "r160" ] }, "us-gaap_StateAndLocalJurisdictionMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"State and Local Jurisdiction [Member]", "terseLabel": "US State", "documentation": "Designated state or local jurisdiction entitled to levy and
collect income tax." } } }, "auth_ref": [ "r446" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock
[Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r127", "r136", "r137", "r138", "r162",
"r185", "r186", "r188", "r190", "r196", "r197", "r247", "r289", "r291", "r292", "r293", "r296", "r297", "r312", "r313", "r316", "r319", "r326", "r521",
"r664", "r665", "r666", "r667", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r699", "r721", "r744",
"r761", "r762", "r763", "r764", "r765", "r941", "r960", "r968" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r68",
"r71", "r72", "r128", "r149", "r150", "r151", "r169", "r170", "r171", "r173", "r178", "r180", "r182", "r195", "r248", "r249", "r270", "r328", "r468",
"r469", "r476", "r477", "r478", "r480", "r481", "r482", "r487", "r488", "r489", "r490", "r491", "r492", "r495", "r531", "r532", "r533", "r534", "r535",
"r536", "r539", "r540", "r544", "r645", "r655", "r656", "r657", "r675", "r744" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" ], "lang": { "en-us":
{ "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r214", "r215", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603",
"r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622",
"r623", "r624", "r687", "r688", "r689", "r753", "r755", "r758", "r760", "r767", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777",
"r781", "r810", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r842", "r845", "r1004", "r1076", "r1078", "r1079", "r1080", "r1081",
"r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097",
"r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "terseLabel": "Statement", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": [ "r169", "r170", "r171", "r195", "r540", "r592", "r662", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r699",
"r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r712", "r713", "r714", "r715", "r716", "r718", "r722", "r723", "r729", "r730",
"r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r744", "r846" ] }, "us-gaap_StatementOfCashFlowsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": {
"label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": {
"label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": {
"label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income,
other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r169", "r170", "r171", "r195", "r216",
"r540", "r592", "r662", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709",
"r710", "r712", "r713", "r714", "r715", "r716", "r718", "r722", "r723", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738",
"r739", "r740", "r744", "r846" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]",
"terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r864", "r874", "r884", "r916" ] }, "us-
gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash
or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] },
"aktx_StockIssuedDuringPeriodIssuePricePerShareNewIssues": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930",
"localname": "StockIssuedDuringPeriodIssuePricePerShareNewIssues", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Stock Issued During Period Issue Price Per Share New Issues", "documentation": "Per share price of new stock issued
during the period.", "verboseLabel": "Price per share", "terseLabel": "Price per share" } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of share capital for services (in
shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not
limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] },
"aktx_StockIssuedDuringPeriodSharesIssuedForServicesExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuedForServicesExercisePrice", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Issuance of share capital for services, exercise price", "label": "Stock Issued During Period Shares Issued For Services Exercise Price",
"documentation": "Stock issued during period shares issued for services exercise price." } } }, "auth_ref": [] },
"aktx_StockIssuedDuringPeriodSharesIssuedForServicesGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuedForServicesGrantDateFairValue", "crdr": "debit",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Fair value of share capital issued for services", "label": "Stock Issued During Period Shares Issued For Services Grant Date Fair
Value", "documentation": "Stock issued during period shares issued for services grant date fair value." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "verboseLabel": "Aggregate ADSs issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel":
"Issuance of share capital related to financing, net of issuance costs (in shares)", "documentation": "Number of new stock issued during the
period." } } }, "auth_ref": [ "r13", "r67", "r68", "r97", "r664", "r744", "r762" ] }, "us-
gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total", "label": "Shares Issued,
Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Vesting of restricted shares (in shares)", "documentation": "Number,
after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock
ownership plan (ESOP)." } } }, "auth_ref": [ "r13", "r67", "r68", "r97" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Exercise of warrants (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Exercises in Period", "terseLabel": "StockIssuedDuringPeriodSharesStockOptionsExercised", "documentation": "Number of share options (or share
units) exercised during the current period." } } }, "auth_ref": [ "r13", "r67", "r68", "r97", "r405" ] }, "us-
gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of share capital for services",
"documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited
to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit",
"presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of share capital related to financing, net of
issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public
offering or a secondary public offering." } } }, "auth_ref": [ "r13", "r67", "r68", "r97", "r675", "r744", "r762", "r852" ] }, "us-
gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "terseLabel": "Proceeds from issuance of restricted shares", "label": "Stock Issued During Period, Value, Restricted Stock
Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r13",
"r67", "r68", "r97" ] }, "aktx_StockOptionsAndWarrantsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "StockOptionsAndWarrantsFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Fair value of warrants", "label": "Stock Options And Warrants Fair Value Disclosure", "documentation": "Fair value of stock
options and warrants as of reporting date." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": {
"en-us": { "role": { "totalLabel": "Total shareholders' deficit", "terseLabel": "Total shareholders' (deficit) equity", "periodStartLabel": "Balance at
beginning of the year", "periodEndLabel": "Balance at the end of the year", "label": "Equity, Attributable to Parent", "documentation": "Amount of
equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r68",
"r71", "r72", "r87", "r701", "r717", "r745", "r746", "r831", "r853", "r961", "r979", "r1057", "r1108" ] }, "us-gaap_StockholdersEquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel":
"Shareholders' deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": {
"label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquity1" ], "lang": { "en-us": { "role": { "label": "Equity [Text
Block]", "verboseLabel": "Shareholders' (Deficit) Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r94", "r161",
"r311", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r328", "r494", "r747", "r749", "r766" ] },
"aktx_StockholdersEquityRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"StockholdersEquityRequirement", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation":
"Stockholders equity requirement.", "label": "Stockholders Equity Requirement", "terseLabel": "Stockholders equity requirement" } } }, "auth_ref":
[] }, "aktx_SubscriptionReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"SubscriptionReceivable", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Subscription receivable", "label": "Subscription Receivable", "documentation": "Subscription receivable." } } }, "auth_ref": [] }, "us-
gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventLineItems", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items
from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements
pertaining to a subsequent event." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred
after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-
gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring
between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-
gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but
before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventTypeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before
financial statements are issued or available to be issued." } } }, "auth_ref": [ "r537", "r554" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label":
"Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
```

```
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "verboseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r553", "r555" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowElementsAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES:" } } },
"auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFO:" } } }, "auth_ref":
[] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r910" ] },
"aktx_ThresholdConsecutiveTradingDayPeriodToCallForExerciseOfWarrants": { "xbrltype": "integerItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "ThresholdConsecutiveTradingDayPeriodToCallForExerciseOfWarrants", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Threshold Consecutive Trading Day Period To Call For Exercise Of Warrants", "documentation": "Threshold period of specified consecutive trading days within which the daily volume weighted average price of the share exceeds the said price, to trigger the call for exercise of warrants." } } }, "auth_ref": [] }, "aktx_ThresholdNumberOfArithmeticAverageLowestClosingSalePricesForConsideringPurchasePriceOfAds": {
"xbrltype": "integerItemType", "nsuri": "http://www.akaritx.com/20240930", "localname":
"ThresholdNumberOfArithmeticAverageLowestClosingSalePricesForConsideringPurchasePriceOfAds", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Arithmetic average number of lowest closing prices for purchase of ADSs", "label": "Threshold Number of Arithmetic Average Lowest Closing Sale Prices For Considering The Purchase Price Of ADS", "documentation": "Number of arithmetic average of the lowest closing sale prices for the purchase price of ADSs." } } }, "auth_ref": [] }, "aktx_ThresholdPeriodForExerciseOfWarrantsOnCashlessBasis": { "xbrltype":
"durationItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "ThresholdPeriodForExerciseOfWarrantsOnCashlessBasis",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Threshold period for exercise of warrants on cashless basis", "label": "Threshold Period For Exercise Of Warrants On Cashless Basis", "documentation": "The threshold period after the issuance during which, if there is no effective registration statement registering the ADSs underlying the warrants, the warrants can be exercised on cashless basis." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Title and Position [Axis]" } } }, "auth_ref": [ "r974", "r1061" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label":
"Title and Position [Domain]" } } }, "auth_ref": [] }, "aktx_TotalGrantDateFairValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.akaritx.com/20240930", "localname": "TotalGrantDateFairValueOfWarrants", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Grant date fair value of warrants", "label": "Total Grant Date Fair Value Of Warrants", "documentation": "The amount of total grant date fair value of warrants issued by the company." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [
"r902" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref":
[ "r909" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]",
"terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r929" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } },
"auth_ref": [ "r931" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"TradingSymbol", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation":
[ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r217",
"r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236",
"r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r310", "r324", "r493", "r520", "r556", "r557", "r558", "r559", "r560",
"r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581",
"r582", "r583", "r584", "r585", "r586", "r587", "r646", "r820", "r821", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r832", "r944", "r945",
"r946", "r947", "r948", "r949", "r950", "r975", "r976", "r977", "r978", "r1045", "r1048", "r1049", "r1050", "r1053", "r1056" ] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r932" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r933" ] },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r933" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r931" ] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title",
"terseLabel": "Title" } } }, "auth_ref": [ "r931" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r934" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date",
"terseLabel": "Termination Date" } } }, "auth_ref": [ "r932" ] }, "aktx_TwoThousandAndTwentyPurchaseAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "TwoThousandAndTwentyPurchaseAgreementMember",
"presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "2020 Purchase Agreement", "documentation": "Represents the information about 2020 purchase agreement." } } },
"auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TypeOfRestructuringDomain", "presentation": [
```

```
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r273", "r274", "r278", "r279" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r928" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r440", "r458", "r818" ] }, "aktx_UnvestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "UnvestedRestrictedStockUnitsMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units.", "label": "Unvested Restricted Stock Units [Member]", "terseLabel": "Unvested RSUs" } } }, "auth_ref": [] }, "aktx_UnvestedStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "UnvestedStockOptionMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Unvested stock option.", "label": "Unvested Stock Option [Member]", "terseLabel": "Unvested Stock Option" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r119", "r120", "r123", "r124" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityParentheticalDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummarizeTheActivityOfTheCompanyUnvestedRsusParentheti
], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033" ] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r898" ] }, "aktx_WarrantLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "WarrantLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Warrant Liabilities Current", "documentation": "The amount of liability towards warrants, current." } } }, "auth_ref": [] }, "aktx_WarrantLiabilityPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "WarrantLiabilityPolicyPolicyTextBlock", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liability", "label": "Warrant Liability, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for warrant liability." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant ADSs", "label": "Warrant [Member]", "terseLabel": "Warrant", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r843", "r844", "r847", "r848", "r849", "r850" ] }, "aktx_Warrants2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "Warrants2021Member", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "2021 Warrants", "documentation": "Represents the member information pertaining to 2021 Warrants." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Warrant expiration date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssumptionsUsedForFairValueCalculationsOfWarrantsDetails2
], "lang": { "en-us": { "role": { "verboseLabel": "Warrants outstanding, measurement input", "terseLabel": "Warrants outstanding, measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expiration term of warrants", "terseLabel": "Term of the warrants", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1048", "r1049", "r1050" ] },
"aktx_WarrantsEquityClassifiedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "WarrantsEquityClassifiedMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedFromComputat
], "lang": { "en-us": { "role": { "label": "Warrants Equity Classified", "documentation": "Warrants Equity Classified Member", "terseLabel": "Warrants" } } }, "auth_ref": [] }, "aktx_WeightedAverageExercisePriceExpiredWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "WeightedAverageExercisePriceExpiredWarrants", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price expired warrants.", "label": "Weighted Average Exercise Price Expired Warrants", "terseLabel": "Weighted-Average Exercise Price, Expired" } } }, "auth_ref": [] }, "aktx_WeightedAverageExercisePriceIssuedWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "WeightedAverageExercisePriceIssuedWarrants", "presentation": [
```

"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise\u00a0price issued warrants.", "label": "Weighted Average Exercise Price Issued Warrants", "terseLabel": "Weighted-Average Exercise Price, Issued" } } }, "auth_ref": [] },
"aktx_WeightedAverageExercisePriceOutstandingWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.akaritx.com/20240930", "localname": "WeightedAverageExercisePriceOutstandingWarrants", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquitySummaryOfCompanysWarrantsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price Outstanding Warrants", "label": "Weighted Average Exercise Price Outstanding Warrants", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending Blance", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning Balance" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "verboseLabel": "Dilutive weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "terseLabel": "Weighted-average number of ordinary shares used in computing net loss per share - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r184", "r190"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "verboseLabel": "Basic weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted-average number of ordinary shares used in computing net loss per share- basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r183", "r190"] }, "us-gaap_WithdrawalFromMultiemployerDefinedBenefitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WithdrawalFromMultiemployerDefinedBenefitPlanMember", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Withdrawal from Multiemployer Defined Benefit Plan [Member]", "terseLabel": "Employee Benefit Plans", "documentation": "Obligation(s) resulting from employer withdrawal from a multiemployer 1) pension plan under circumstances that would give rise to an obligation or (b) other postretirement benefit plan under circumstances that would give rise to an obligation or an increase in the contribution to the fund during the remainder of the contract period to make up a shortfall necessary to fund the vested and negotiated benefits." } } }, "auth_ref": ["r14"] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r896"] },
"sic_Z8880": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/sic/2024", "localname": "Z8880", "presentation": [
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureAgreementAndPlanOfMergerAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureShareholdersDeficitEquityOutstandingWarrantsDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.akaritx.com/20240930/taxonomy/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "8880 American Depositary Receipts [Member]", "terseLabel": "American Depositary Shares" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "12", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "45", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "058", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r128": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r129": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r130": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r131": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r132": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },
"r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },
"r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },
"r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },
"r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r153": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" },
"r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" },
"r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r156": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r157": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r158": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r159": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r160": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r161": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" },
"r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r164": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" },
"r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r167": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
}, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
```

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r467": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-31" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r615": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":

"65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r750": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB",

```
"URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)
(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r848": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)
(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r850": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r856": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-
1" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section":
"15", "Subsection": "d-3" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number":
"240", "Section": "308", "Subsection": "a" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r862": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "A" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r864": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "C" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r866": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r869": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" },
"r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" },
"r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r874": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1",
"Sentence": "iii" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r877": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2"
}, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "3" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "b" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-
CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r884": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph":
"1", "Sentence": "iii" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section":
"18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r887": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph":
"2" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph":
"a", "Subparagraph": "3" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section":
"18", "Paragraph": "b" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240", "Section": "13", "Subsection": "a-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r893": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "ii" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r895": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r896": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r897": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r898": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r899": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r900": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r901": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r902": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "2", "Subparagraph": "iv" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r904": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "3" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number":
"229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r907": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "5", "Subparagraph": "ii" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r909": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":
"v", "Paragraph": "5", "Subparagraph": "iv" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r911": { "role":
```

{"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r941": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r968": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1015": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":

"850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 61 0000950170-24-128727-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-128727-xbrl.zip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|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| <%S'[B+@E#-_M$!%42>(MG#KOA:+,ANR,O5?-U__/]V##'B=HA>Q#(WO8+TG^D.3QO5^>Y5@) M]O.C,X._>"Y9,E6\5Z3(GUR WTR%DDQ,8KLLU/!G9[+\S'LZ.%3F${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{(D"@F$((9)P!^>P9(ST<% M2"\8XAFGGCF1BENZLG0#"Y"YO@6H-R.>#%[ZS(@S&F-|>"%>ET*L5XHQQC-5 MPT5?0\/$_2G[,DI8>D&4QGO;K#WQ'+8F%Q495XR+- 'ST\PU<\F(V&AW^1V>]J M>]VD>HP^7Y&KH#=!^#9W?.P-G*'#=Y@K9IZHX:Q(FJ>[Z$Q0]?3YZ]W/C9Y M2:$;0S#7RU0B8X%8IT'\B(0&PTEBKG N$DAE[*A-'6RZU-?CW-Z[IMQ/?ZX M?'>.:]OL98\V>Z6#9YJ1[.F8C$9D(@I1(?LN W4'?/QP^WA=R=OG>50Y M,JK@/%/]\R66 *)T1F@25 R8!,WCV1+^>E9L;D\QZW#DC-3J$US3QI8@5SZ$!CB[5PL/@:&; 1[DW#EN428()3(,-DE]24"YM400$(+!8JQ3G M19)$\|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{G+-SE-B%F?SJ6W0@.L25VD$#Z<K)U&2:C M+5D3Q1.FR=:>N, B4=K"Q]D V]ET^^OJ]W$-Z!*T6$ M J7<1VLS':RVL+T)72(<- R A$B];G! \X9"3%Z@!:<1N,"+W:P7IT;0QB; M%VUJ6- '"TDP<,@UIF2$^:4ZX-4ZE6(JT@S5Q#]ZZ<$KRU',JP59W03JUD^;W M2?0G'N;'$5Z3)M:HP;)YUAG&*8@2>2^T2"C(E0 M+VR*N.9FL-)]=1QB\VO=&B^$=IABBF+HDV>26)D+M!Z9M4Y*3P>;?>QZF9R/ MWCZZ@.FPWORK/Z9L]XI[4): (]EP1*7(FUDM%6":.A5AMPBLT<52?!>$\IQ1\]"PMW9+W?9/O,3#>A*RY20QT4,E!:#%%@N:: M*&6D2S)R2@; M,PA#3"S- B)34$(^ET*FVf3&:A8O#3W$PO'")6Y'G;%S/M^?]AP,0[,?+OS*M]+\LVH!?CQHX>G+T-[9P06OH'8]\;!LP'UVJF$4T3^,C$:^:;O+Z>.N4OT) M=NAT$Z]F\+J'(WY^-'4[41E'K_???:MX7SU??SP61Y/]NOQ1CLZ+^]&O.V+UG=JSN^H,6_A(-;+^-??GVS6J'C\YF+3=,8?V\$;U4WYR[U0C!T=- A$D#S0/IY. Q>Z@.IE6:S,(H/SGP MP",&'^_M3O;]^.C%,)E.)_OP+AYLXD? UQ_'C42Y3'%1[X,=`P_F\!T>2P"'NCD5S6&W3UN4[3O<>EGI*.CXRQC__U+TS3)S_PJY@%0[.KL$2YH8& MM-R'E8]_\^G?]UY]9? GU=/7O__^M7RUT9'/>R MUX;><&W^[ML]..S3R?A!]>SATX<5ITJZR]9C,2\\OH\E_==C5K&8:)_<8L&= M3EJNVLFH3D?O-=TJX!BN7-DK& (M8,6.YLK\5GRI[P_F_>/WV]^IH^J?'\QUM MPTQ SHTGXTZ8U[$3I"\^6&Y\%@*TC\0PB2_\""E+XIRP"K33;**[5RVPXMM< M$+Y[{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{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

*M^N5&RW9*C6A9&SL4@X!]\&J%@+T"V$$K:1GGD+5V!7R3!DMH-NVLC(F98&SJ-M(Y[9&&!3JQ&QJWS/H_N&#<0[W>?*
N6\#S83IW8PQXJN+/O3!AS.7=-UBQGCDB-M&%!)$HB0(CC!*:CD4HQ4>])/H=0F:(\--1>8Q<,-#P1)!,E-@B27D9!4-@1%-M.2L@J2UXZ0U$K6TV-
*'MF61\!PB9-4@RYH-B2U6UU].3JU^_+OW7SSHD/OR]&-MRZ;Y%T/Z)FF.?(5)L:H9[0"28N?#"E#M*O*L,<6/:H5HUN>>K\N*@M4MN?!*
MN&;@I$@&&63N9O\-O+CM/3E7Z?¥RT_GLY+_:SJ-[8S2OI+^-MNTUJ/!);VWK._]'Y_7?N>K9,ZF,ROSZF9$]8:[¥QNFAG=^S0?JL\W'<763U2*
MVM1)&^DD!>J3!!&I-A=3!JJ3\#JEQ%3N;W?@T6P+5&I=]08XUT2$(^VT75SP8O7KXZ?G[\-8'M4(#M(7UK!]BY-M%ET"M!RTG(J
*QSP<+\!#^.1ZC;,CQ).>3@<[*J)V%-B:"ZH'(PH(6FO^2V6O2O^-2>1HK@>"*,-M"1-P$3-W"IB6&&=M\?U%M*G\X-JL%@RTM2&JF#7)NJ=08*.*
*28=2X=0;W"?8-MDVC@^732+;H]43*9SE,S',S2V,U+@'#F9O//2'9(=DAV?9,=D99$X30XQSB(-MY-4X*0RHX%4PU!CO^$.B_>?^:>GETS[1?+E8SJS?*
MM:=6]<5^2!7(?!_>(E-MXN7>-G_;"Y7![']D=_O+_N-G,7;JR10<9-1\!OW<'V;LDM><.(DWM&-!7G%T;-M5>OQ&J)=HJM=+B^MX-\;LL,2P5IAIES=*
*(X1*Q$K-XN5(5E.0@83.071HJ8C-MF@,QWKE@HS\^LW;.5#I'8\ANC>"9!-M<$?-6!]-4>D]498IJWMTZ9]/3T]'\]/4]B%TD]BYZ47-:1(N9Q9O^J>G"U@J*
MX8^OI_,TL']![.X+NQ]Q&#IX<"?WVH53$[&AY52F'&@YNW&-MI_KD'VD.G96-MNXD@AB!6$<.A1-!<4#G07/JJ5WK4F8X>?,WW)VZ63J;CF&;-
Q:3#F/(HC.8X-MJ-A3M)BBK4-B:"ZH'(?"GGO<3;JGF-MJ%R0Z"T88-RD(Q3T8EC)0'6B,-G(15Z88K%/-V6ZG3"?OY]/PG[=-N]F;V?MXV
*M=/NG&R_2VS3K%G^U:*G\FF+WJN9-/CI-LZ(.+Z;CL9LUYZ_^6LAT_/K5=RJ9-M;NO4$:T+5H#**
*[4*RY^!]^2U1ESB7S%JSTNAZG0*M'2^>/"G*^\%S>7@E>-_)++3OH/=-VR@X\CN"G0?,K=G,3^9-MSLH5QJ>#K;BU,F@7#*%*
LRA>FLP"C.8:.-66L.PIT[EGM[9SS)JO[WBT37=-MDWWXK)FY1'-9CZ=$@TBD7&*$E2DEAD>N-PKTQH?Z+/VOC(AAY2Q(6=T*-E-MG9.VX9@6DQY-*
W.SS8+F"@9O_U<]^.G_R\L_WZ6R>3GV:#3@9#AAAHBL(>Y"'M^:.T>Y2WW>>;LU0N^6,:?WYVRZ>-FJ:=8-5^PG0Q;^;EEV+Y6S(+%YB-ADNP-MVA
*0SC(PG"N@+.L<2}@3W&;,XKA;]89,0DBM-RF&H*4UY0I9,=eC@F1\8-)H-MHJ39R*K>?+V!#UX:$T-F[)#Q7=1$JY5;442N9;DICD.0NHC?*%TB;Y,ABF2#*
*MY5$1V\O$E(W>LENF9S&F.2V:Y5W6K386&W.,@@LA1UY^>N,VLK2>;(SRHH1B-MR*D<,GO3.=FM*&*_8(SG6_%*YYO[1O$J2N&EEP*
G5A!.DI21Y]@30Z,>,>D-M>E"CXQN0KLN9]C8>4'"<-()!-G$2?#H1-4?%85@&8E!-M"9_X2M3U0(^P3¥RD)5#'+@!UMS?*
*&;./E;&-97]NC;CPXNWQ:R/)\^71GV)]OIB-M/,.'Q&"/,(P-$#L1.S>*G58%&0F58+/7(%Q6X+3-H+3.,4=);>ZE1?#V1%.+*
MH988+V!UPM[$"^>V.)BEF$[/.N.PBUQ-1'M(2Q.%^/VG-9@NAR8.#TM[SI)DV;T,0W&TP;GBR#?(=\]P,9^W$JI*>/;$EUH
*MT'O*2K3!-3AI%:.U62DW7VIWXBAC=/*[GE_'B>%+@(_U20.-UFK_)-M']RGNS-K4V1??OO>5!.VV^&*.^_!P736D3*5+$@G-M#91XQX-C*D*
*,1@>9I+ZA$<%:&R&[A6DZ).+@BDX?-2X2Ū)C1'3>K@R9%2#OL3*6E)5RBP)5CYR7,E-O(A65U+/_=4*:P3A#U+LW=:)+B2S>;-ME'O97*
=%TO,Z9N0F>!#879+R57:<971%4ZH?S3ZA3SQ"'DB]D"5"A%H(+E@-MOB90PC-)Q!/EDC&$]M'%+<#GF!Z*-1-7=0.W(ZW&MSUN=TE-*
Q3<[6/WR0_3-MM@"NN;TS-89Z2.%(X8=-X59PW>V2):TX".8$&"8"".R%)X%2E;ZEZP3ZG5%-MY^=@_+WQ6C^N6_*5D.UXZ*3*JT6*
SMD!60%9(5[L8+)EHL,)"3#%-AD'A"-M$NA(!P9I$3]GF'KJ>8K9Z@K/NV/Y8B\T7UOQ.EC4?.C\:C-M^2@M)Q-?
CMK^'XS7:F1F]H2U9AZG"S].]=OYGW9)TC?+:N]I^F9:39RY:"0'
MZVTNM)H,^"@H6$<\9I^GN\J_KEQ\]VL5&'OINUGY[F]^W5U7O8O%W376^GHEZRW5,,J>W?V?@Y#-M_SOX<));6(MITJ0X\&*
*[L)B&5Z#2E^<#-5UMT#TY<,_-I30H/<8O83D!K/ZY+C71%IWDT*9\X:OW'4UJ]R.D27QV-FVZ?DU/9VGLVB;VA08_M8(MG_CT"R-^NB/Q?*
1_6ZU0%>H5&-MRYTX_]G>MI,OV<;SBQ]-QJ-)N8IY48RG;C&?/KOZ1!'K\N'N+B]3CBZ7M3UU-MXS_;W)CN_EU2@6NWLM\[ME72[PV6OMZ=>L'IBHJ
NOOJ+XOZ;Y7].S-'.MS37_MNHSZ=2C&K^_J'RZ¥A;=)B[K$CF^_-^I&%1¥]!68%5W¥M8.=VM.%MQL[5XXF*
M#GZ¥VG&B;FD\;/$__CH¥CP"&Q=\;_/KD_9,2\'?CC_^R+;ET/Q0>+XDN./J7X;/E5E)-GY,\7;PBM+,^:]+1)Q8LN-M(''AA2¥#MOSL'Z[OZ7X<-:,NX?*
3¥Z<7[;JBL77X=UT^(¥7^^[&=+W3I-OUT-MR_OH$['&F]9X"WUBM=G.5SV^);$GVMK'MJB]OT_?J,,PWRS#N-G/UJW-J/D4-M>DUSEO=\^5^&
*<*M>AW!?7/8-HC%5N#5W*M(¥F:4T^$?¥^Z09O"PQ0-S&M.Z=-MB:XFJWIL\D-SN]W,7H\F:&4]]I?LRT=8E=:&27,O!(_K[QG.UJVBWA^-NS+I-M>&,Z5:*
*<<:[*Z]4\F[8^,T#+1,A^;()*CX['K6['1'1MKI-MQ#L#X1K$N6_NTF.3&1KP-PV8HP&C:,!{Z\!(P.C:,!{[$!(P-O.J_QG8Z&*
MAU%\8#SEN<5J\/?!NG365M:VSS%-HW-XV$=YW1K8EB4")H+*@=*!"6"%H3Z-M@H2#YE*?QT-MI=>^3?S5-O'V#:QR[¥[5!T-PLGW:9X3!_3>'K6GI_<*
M;F^E/8>^.\CDT8PTW'+7K3IPK_>.6B)':P@QX#,W(&(RX+AR;5MZR446RCI_-MO:,658K]:"Q()B4(Z@H4&EL@4I3?M28LA1N&RBS-^V@27WPU[I?
*+7%-/[;2H-MX(0H$**\¥SED;_A*-M=T/.J;8%NJ6C-H0+$ISV&AQEQ%'+8[9L0U^A\MY;PG.ZV:6VU-KB1(2!5R0'1-M&=%¥=¥XMR4X*2@EX((@HRZM:I-*
*3R",I)8PI,IV'H=31USGMG-@2@:01-IP!G"-MP3DN"2WOL/J&L;J;]VSE4'-U:#"*OBVB)Z+GCM#32.$S,0FX$PX$TPH,20FH-MU4ZQ;*U)*\-FE>#<4,.!*
*<5/04\L$3D0&)>O0L[,2[$+]&1#*W8[7'8OT'.G-M$¥V,Q&7[¥)OU7FJ2V#V^;"W>QO&K4S&==XU.DO8.CO9K\H$?*=L1QQXD5$"PK*
M;,=C82X6#'!/O4VZG1BT$BNLDP5_G\;C(M%S\RZ<=W3%N'M.AP\UV>TXO@,W
M%D3/"B12DT(\4O3TV=$0M0&G""OH&3@X0ST$F8@B5#NA61]¥ZZVB)QL:AD$#-MHB>B9RT*\4C1TW@I="A^I$G6@M
*I@Q76@TZ,AD1>]MHJ<:*HH)-M:T1/1,];%,*1HB<7*I<(W8!6!3@%)Z%XH2(!8SQEDQUQ=@4]U\E3;Q4]S5#K-MWKM:A+6_TBSW](,NO%'U37C1,&V-*
*NI'DV¥XU5'X?3%:#N)[MS3TYZV=-M]T1ZUC*D/-P8$#\K48B]Q_5"=&H,H@AB"&((0\^-!>$LSH(X):IXH,Y#EX(-M!9R17+RRF%-:.32W3LIVZSX8&S)+T*
*M#!4K40A]AY!T0O#:MO*DY?O4C.?-M+<)\,2N+[&INI_.3-,,L9@WXO^Y\D,K,?7,JL/O)(3=[X8&X+#D/H(WA-M($(N'C6+&9B0GH?*
B7%L3>VI=\14>^O2VS6[,5:!EK2^@[TPG0\!&M3IDP-Z!-MTX]JAVB&:E656CT6-+O9_90QV$R-_)ND-2$T-Q=<<2J)}5HHJ06A/?67V(S[
M28>;H0>ZK\;%F(UJA9B-'F@%B>D>]VKIYC+3=![3T[],FV:09]/3P70YH&!ILL!UTJ-1J]Y0HD@FB\=VB<98J26_.F^(RD^+T>B$\2,L2-M)]13J5?
*0>)V>&MM-8SK4A]>(Z-%HO'Y9^DUZM^Z6P/X(]U[F]J8K*Q]UVC[X-M,2U[QOSE*0¥RO7GY.,@5![GBW&,TER]4-R7R^"6"%H3Z@H2#YE*%<&*
*(#TE*T-9*$$Y:,-1J("0EHPEE2]V,-MSUNG^NMX\K&8*5;*F!2U0H/D-MSH/@7("5T8,*E/+H'(MZ9?C:.L59&\;*P]MF0MM_$0=V3E^:E4<1R,#"*^*
MW\@H-6.]-(8\0XY7@OW2@WC)\'5]1-DVF@KUF!1&I2B$>*E4$Z);F0);(V-M[:DLG<#KUHUDA-3#5>-!J6G#.J5-F\;@RLPQ0:;CR'E?%[RA-R&W(;*
*<5GL9-M<)#!&1T\$&TT",4%E,#-E!]6"A*LTC[WD\->HL/Y#+W7T\GTHC"XKVFD]M#H-M$L]C(!-C$&\6>.LH.;4(3>'"(Q(C%ZI>8?R36+68IO)N]26,S:;O*
_NV;4+'"A-M>/+KI$#LN-@U_I<;3>[73.';1<-'YV_79$D(K15(I":%V'MHW4["@ULG-=<,-MF!4)A&E;/HI-(:DH#7,T6[_2?
*W>=JN)M0_4=NT1**+,%F9B%G1ZAVBG';2UER5;ZR9>'NS69$CK+%4BD)H5X-MI-A*,X^1$-8AM-*
A@RT0*158GH,D(CO/5TJSUBECK@M;A\8<7"$7UCW0<;;^-MU716!#\9M&:2)N'S('T*RP3^,\4T!C^.BW'\93B8I#G2)-(DTF3?-$F"CYRU*
M/8R=+91'RP\OG0.=B562Q>)ZR5=O[3SY^=F_F'F)LWR0BXH\-TY)?95T(Q1-M!D89")^U,3>P>^V:A!93%%G8,22$H%$#DX:#8Y+9FG(VE+52TI^*
*W!\QW;S-MY.#V2JM,NR-"5R-11.B]0V@KN'?!<.!!MYNFW('E2H&AJORN;1!6]Y*SWQE"-MJX-K,X(-C0"--/U(*
*%HX8Q6A$KR+&41({6@F:\#KP)765DFZLJFZ5N)_9P"M-M&0+T!J@7TL,C1=#9?DDZP1;I@=D!V0'9-=D!V2'AVU0RCL-MP-P#F[P'XX,4P2,';.IC@V**
[!"!V.]NG2O/=ZK9%CT<4Z.,V+>@^;EQ\F,[=-M>##MMB^6(T$'/YYO8^#9!"1O).\;R/N6(]8YN9B-A.)++<0I"%BE+(BV]P41-M045-^CC?T-//?KO#*$$9?
^VI@&'2A6B%N[SCH\D)&(WD-PDL4)31/8%W/EN+MKI+AG.F5:=-/K[-AL+=[B2B-C8#X.J0&IX=%2PRW#L!/EC!,/(:GVR'(,8-N)
MKI0;SXSS1,@5%]G=V7C+CVFS/;6PA"X4:T0N.\)W$KD@K.$@)9.@[!!@5/6-M@.&92IFCY-KUL?&Q:>"60X/0O9=3$_8N[_X*
*&WR=YH.V>Q+N3=3$A^P):XTU-M3A=^G.H/E?^T2V]\659[3XY;2GCIH(,O49*C6H+PT8-UY4]N5-16.D7M2HGR-M6AL?Z7Q^^T9Z=_^-W>T<]*
[VVWITFNJ[)"B.FQZECR!#[RA!.2,T1<>-=+^&8-MY-X<5Q$(X3$XYZUWO1QBV31#:(H,@0R!#%&KCB%#["M#""$-9=H!3:F@O"

*(6BK"",FLY<,XH-MB%-PWY)(0-O-C3/*9\M[V=/9)$7($D3LMBOM7EOOG0^PW+Z?'#V:@XE'V:HC[M,W_[@?WP8%'4@?*
*0U*0=*!,T%E0,E@A)!"T)]0<)!Z>-NN:-Z@L8>*@-'9ZE(]L3-TJ!K]DJ?G?\S|*X9A8&;Q$$0\8T$]2OLH%GSI9I-R%YNW-M:?:^Q:-V*G*XFLTMOZ;X?*
*N[FJ7F3CT[3K.C"B^EX[&9-]Y8ON5YR.=?+OI/A-MO679@ALB38),LP*110:CK((8M3:4ILS"RK2U/I;]8@FVVU@X>7+CO#5,=>-F-M*-)HG3J&-+]O-*
&JUD4X0!RQGVK8%5^!L$!\5CXE+J1<&;.\3D5E93!JG7"-MZ@-FDEB\AY3!9FHA$L4,.UP$MM+NMH]E(XWN*\0AC2*-(HTBC=YR3IQ'I1A5-M,31:N$$F
*<8D6F*SF'-@.7'32_OTRFC4:6J=%ARTC&4)TI856V&A4"MC-HJ0-MXDI?X#Z6C32ZKQ"'-(HTBC2*-'H+C29!M30!>&$/$%FU#,ID&Y81ZT.F3N8^*
M2G,KH'H7+8\NQ-4M9VF2ELR(OW0&)BELJ@15@9T-[']I%&]Q7BZI@:?##;-MTO_323%%<&5U[K$/$AJ]%I(:nM,M4Y4,"]D*
MB=1B8;;0[C6V\ZV]EXK(3),@O70#VCVI>1<=%SR#\EF7J,M[\)8:L,IDEC65-M:75H7(\KW12IF:&E=&B9&6I[T_@)+6]11XD-50M)+5U2"U'9HKIG-
*<:N6#!-M*9T@D,!TC%Q*%_K8+=-P]J1%+*.5$0&+=_-"53[Q=G?8QTB\#8RLG/'I<:6;-MC-3L4#-Z9+@INB'DV5TOIVXI%U/)6Z$\?-YV=4*
\II.D.^YF]!G>X$]%P4N-M_Y"7CX:-FH#+1T-3<#EHR&@)CRXI](&&-%6)>@')>3T_+:T[2I!E]3%TQ-MZE-4000C!"-ILMM=R31+#-/)@8"0BE-*
1BL@BJ$]/2-M9&)6ZG=PS/W^6-V66]P@'E<@$<3C_<5C9@T1B7(/KF"K=2-XS&7]0LJ)8O&-M*X=#Y??*
7ZA"/$8\1C_<'CY52@JI(VS;:'H0A#*S0%A11)FI9#:LM-?-$>Y[-M9'8(R-C("-C[-\B;Z.-()T!9@6'AN0:C)0=OO=+>6N=Y+UT9'-G-]&]MKJ=F
M@INHQI]>-#_(//^;^4F:=0T%O]9PC3I#&7;-!:=Y,'>?I(+MRUQVQ*7CX:-MFH#+1T-3<#EHR&@)M1=T=5]PV9*NG;7-N$!L=ZKZ:R(?*
C((B]DL3<+GP7SF-M)LW8=>D8%_^]...GY9680:VI0Q-YTK9):::C4=RO+BG;ZL]TDX-P^7]WW3!F-MHY.)-E,Z@##@(_M;!BE./]]MT[JB*
MMDF5P$&5FW'?D!0V!-PQ_4*Z>81T$T5607--@O!"-S%+\"IH\,1F:MH&Z;27-M-O![33U+,)'-9Q,A^RAL-M+9
MU3F5ZU3F54H.WPY!Z$W]R=%J]\%JD0Q0K9_=AYYQ!(NI-PN&PK"B-2&$P;$-MY.P%LTF[U$>58:7D"&0KA#$I&TE7.HM];EOUS@"X-M$?5(1
#!E0KA/<=-!PS!)F6,R>W-60I"1PX^B@0A>]MJ[+8X';Q6%E:E&N"U4$TE7,SZZRN93!S'!?OE-0+RBD#-M0E$%3A,#+%
:"X$KRU88>YT]HAO(^H*H>T_?#8EF%1'RGMGR3I-XUV2%0=WC-MU#'DBWWE*T$LC39)H-P+$"2S=DM(0:$$I4T.A&?6QY;0%OFB[?]=4]YOSVP9
*M^0+Y-OD"^>*6^")1&8@T4$()-B+D$BMPGH%23BP)-IC<2T?R+?(%E4-+=CO-M9Z^-&0D#"0,)*
PGCEH[IL=U"2@JDY(4PVG(SRP.#;+W1P1L35KLHK+.%M$7"-M'S!;MHAVC-;_N8>4?FWW=GK?MWDY7\UV>]"^+5O_^87WA7M=[.\.QAW#XO]-M<)*
(&+K0[4F[RN2CN8#=ES>Z67FXH$)YV6\S-QZQR6=M3-_[#26Z>_?#3%WVX"7.[^W=)!:[=RG[OV.8]RTW-TM>[*
*M4R\X_;&\97XZCGW(X.B_C[X=#S[_>6[H[\C6[E-M+?])K?72UEJ-%+5>&RY'/U&LUFO#Y3P^93,;^*+U*Y$[G!"XSK#/"_J^P44P-MVW>_JAI8TM?*
ZMS>Y1CU\=,V!CLY\0WDJB2-NQU^WB??U:)(&_RA_GC2#ER7P-M]%5.BO1E4^S-2?#-2-,;$SU[GGF>7<2W^"$'41'1,>]F.N%FH'R."1YH.V@*
*MKB#+U#$IX.K1"E-/-2PKP"&+;ONUC*YN[&WR+KK>3PXCVL'7T:%7/[R]Q_4-M)]5>-H;7:ZV5-GGTS:?LC=]YHW*
*M^>@TS8J*O5@V13Y_]=>)*,>O7WUG$LHM(U\H)S19!93:"$)Q"L91!2EK%TUV-MVK?SA*\NGC+IRA();*88"$8TE%*
<)"""K3X(534:F]6'PL:B0IHV"C[P8P)W"6-MMK>?]J:18=CRMW'DB(R7,L_*B'(JV&-:>RE!^Q,-B#UG1FP:D[7+QY$DQ'7K#
M$)SO/[!JG9N#AB4,G[G9X&,KF3UHXX<,OF<,CB'(BNC>NE&$\AQ&(6A:$H/-M,J5W*:,3LY8YT9@P58CFU?*
*=FZ.6ID:A1:&%H87W7[N"A)W0'T9IZLJ8;QKNA-M53VVK9[O)_2W;^]!*O&/QY/!_&2Z:-PD-L-!^A12N\(NB^],RVV8-S?.B-Y:-MI@[QL^^]I3U#*V*
83Q>C.H#E68(Y''1^@.:(YHCE68(Z;/CR-]HCVB/9XG^VA-M)LTVF+E&>SSHO-E:Z(,M])=I@l$DFB>:9YWF^2+E41AA@%F3A:)#B_:(]KCI-MC2][X\97!+*
{8>T]KALO^]K-:^]N]7;/=G3^MF-W22DX>!%"N>CXVDW.I[?-M5Y7O(L+[8NWF?L=J*!\R+H:O-MXL2=(>%/B+!;._*4E-T)=#!*!#2>W#!"-Y*&(!-*
*U*D7A"V/=]X7N-QM:/[YZ]'&]R]*D%5N4WD+OXRTP+\'M$;/.!.(KXBOB*^)K??C**6-<604\$-G"-M20=><@_)>>-3-H$P>AU?*
*E:4W[Z;K2"""!C4KVG(]SXYAB2-NH,D\&A)@!$?-M#">YB"LY$(@3,"&U)&-%\=H2XN5U$A"AP*VS#%00;?=&P\&TO0EC^1FEB5E8*
MLGT28$P/A;JIYQZ:\]Y!),M.Q<(8CYB_CGF"T%3MD9#IC&-D(]!9*VN$8GH7F&\1[]?&^WM7/UZT_5BS
*M^K%;VF@2RR4]E>4+>JJ&/)=@*ZWN8R]_#;ENE]NKE;SMUAPWS:*MC1Q,\WF3-MCW#>JGN6NKY0@_GTKW[VTSE+7?*
Z01Y/RSB:X6"2YNT'C"X^+$R;^;T/UB#)-M]SDZ[&/^M()]DWN64E+)M-D6O&"%2F/A1D--!B8IE<$152*EE6T20;5BA7EI*
MNZLB6(Q@=,S@,K54\R1UI#=2:8L4;Y8S(]DWZ;9:[]7%99%.MU3S8/K*]E0-M"3IDS-R+?-Z,66NR*832G0ND)G4X""A5E*G,?8E*_*$@M&XW)A*'Y&2(G*
5_-MO-H@E':C(6Y&TO4WH9G""6A$4431*M3A(%"4B,@ES19<;.MVC-M@:8'%X+0,-MF7I-N+F.HDE'0]KT/Y6:@$B&@A,ZMG4[PAKG/6-
*BERA*AP*]4<11Q-$ZU*&*-M/?T'-&?7&)}APAR6PB"DH(8@I*#"(*2@AB"DH,)4L'K$CXK5X2"R15*(1'+T*

*MX'*B()@CX+@T(#Q+649)LUPYY65D8D(F!9FX#*(=VVVI=N6'X$E8*XV)N\T6 M*QC[REOD|$*(#\@.$$X1CA&.*Y"'>]`X[L>|]K2T;)[!KE,).G@(M#("MC3 M(,%;JT$D*E)448>PTDEXG6JC:L'^;L?4](&!_E4]PS/(B/[!B_ZX/X@*4X_" M(*2@AB"DH,(@I*"&(*2@PE2P>L2/BM6ACAS7AK-0@CLON!# J/,@&%7@>0R@ MLU66R2#9ZCRK=;J8JLU"?3/YQ \L^;2%6BCL@[2!6JC.>A!MALFJ3"'S=N!M MTMYDM]4R$4PSU6YQV"6GALJ05]-9D? ED$!:569]SX/YSV:,.5;'(&WN!VVB MVXT*@_A1AT!J4@?$#U28RE>/^%&Q.B!^H,)4OGK$CXK5 ?$#%6;_% 8AY1%H MR%[O)+|@#;&*@HY,@> F@PE>@^3&WTE0Q%J7J <3DP7A@P''=8(8 MN!66*9G22L'JF_E)FK4;!+-TDB;-Z&,ZGH3I:?!EVC3G2='GYSG1#VU*=*F1 M1Y/XX6N"],MNQ,\IE_=| <)_ZVD#0%C<0JC^\3Z5;8BWA!ZYVB%.(M4XA3B%.UJQWB%.(4XA3B5.UJASB%.(4XA34N5N|I5H50(77NM0PA="%T(70A= M>ZA#_4$7SG]J=:<\1TZ- 2A2X] 2$=AX\(0&8S-)$&Y-@_OI..2>1I>05:"4C MB&PE6$> N M/)"RCS%:H$$E$,X8L-8(B)3Q+&QB4JQT:UZG8@IY8+]X8- N]YD'CU^_^@[_43FTF@\|HT-F#=;^X@[C MX>+H59RX,R3\"1%V\PA+N'3920*$M:=FJ93@=?G-*I,((EY3M|*SR MGI3K2|/FY>^+T? QS3RNBN_J64P^*G4=86V240H2(%O*0*2V4WT0"311 MT?/RBY Q*C!*V8@2IMB#EJ%P/J$^+MMBVI% M#PSHUS3C+52"(-4| (MU!"GA\%*!8%#8F!5QQ6KQ\S< 74 =17'4:A2Q>/K]. M ;&\2D?G(#"GRRL+&5AG,[CDA'6:EX];*8K9/ 4PSH>$;:2!"FD 4RT[%PAB M/F+^1>Z\K8BGW$) (@K>MXQS8S#(8:P+/VL:05]S^8 (1H<']DE&TN7,%SGD! M+G.?,/6L((_V.9\/I3RT%']?B(^MX;99*'G;K3ENFD5;&#F8Y0D%7$S4(RV&; M@UD:NWF*@_GTKW[VTSE/7?Z91Y/RSB*:X6"2YNT'C"X^+$R;.7:;.S2:W\?\ M;V7[)OSMA=5E@6Z71/-0^NKS1#(NU0DO(O(0?& MK#79#D+IS@52DSH4W M(^GZF|"&X+!R1%%$T2K4X2!05),<+&EQT&;59N7=08(KKW6"1QV"VB6*JF&Y<,11Q%'$T1K4H8I=_?WJIX4* MLW.%04A!#4%(085!2$$-04A!A:E@]8@?%:O#062+I#-$6Q[_<$5!T,# $\8@ M.6V9I=%;NS)&T@FKM!89A#&DO,X:U/_>K_2DJ/FC2[..H)"SC01Y$'MPH#P:JDA+)02!2@!"@S?E1Y T M9)V)#6ZE.6CO93S+QU]-9^_/I? !!Y3R6#KE56,N+07B:2WJ(S,KY\KZKN7Y-IM2X@R'G$4L32*M2A#BS=Z[;X MQF1",#,0@@L@'',%=46"!D5,BI.VM.\FZT?>@!2W^V@V*%!- HY%0>Q^+-B- M^W.H,/4H#$(*:@A""BH,0@IJ"$(**DP%JT?\J%@=$#\>I<)@YYP:JF?^F9IV M65U;/#,KO\Y&H>V6L|PH1]1'U*\>]?=ZCU?*MDZ&!- N>Q"&9?#<;*!>926- MB%%MLE_#LF:F^_FS:U)\/CTI2Y/&M5?XX,(99N1063T46#F#OC2B:AWJ,<"J4D=ZH#CO2Z^L2EX[A,'*TC;=)^TI?=9+'@G;4PQ M9)=6ND>N4WQ3+=C?L;?_H:$^UN\@_#\6^,?,-BL,/0J#D((:@I"""H.0@AJ" MD((*4\'J$3\J5@?$CT>I,-C]IH;ZG>46_N"/T?SD) (UCU_/FS'V>3A/X|@'|BD1ZH"DWO9.A.@92H-=0?1B(7$';!90@Q1^D")2FXGDN1WBTGGGZ8K@B/>PT4X90CE"-(4Y0ONVZ3T^5 M#:%XR2GQ! ()&#L5%MA"ESR:&XFS2E8YI#RP%VAS8(L;6:DL(K3L72$WJ@.EM M5)C]4QB$%-00A!14&(04U!"$%%28"E:/^%&Q.B!^/$J%P28\U13Q@&^3A8-P M*5N(B(^(CXB/B+\?"H/XL7.!U*0.B!^H,)6O'O&C8G4XB)(%(QGC1#"@Y0-! M9%;"@"(XI,"#]H%)V0Z"WF+W$K_:O>0[G4JZ\4,]U34((;&P 0$8 ;@&=4_' M#A5F_Q0&(04U!"$%%08A!34$(045IH+5(WY4K X'D68*+%#)!&_[XQH06D?P MP0LP+DHF(I4JY>MD\B>LTEID$,80$-0D\-D$(-Y0J31QH4U-89KID5HI MH3+DU7169#X9A,5LEB;A\V ^00:LM<[^3XIJBBUH%)2(PG MX)*4P((DPDH3;)#7=Q*\"HE&ZT"[&$#*$F.!H92#PD%W..L2TLI/P9GZ29NT& MP2R=I$D5^IB.)V%ZFGZ9-LUY4O3Y>4[T0YL275]DT21^^)H@_,H\7/*Y3T?MW"?LOW4X=H9(C:[^SAT]3)6K1_RH6!.T.PI-SUE;"* 5E*&OK.S)X+SS0X+@0 MTL?,=1\U(>C)[;F=88^0&BI!7]?Y8%Q.!HEQ\3HBPZGV9='GA1-&C33\2@. M+N[J/ICTYA3F^_)!Y[Q/I5MB++>$'KG:(4XA3B%. (4[6K'>(4XA3B%.)4[6J' M.(4XA3B%.%6|VE6A5 A=>ZU#'"%T(70A="%U[$/!01?.<+YUHSPDG35U'"+) M%H2U%CQU&3*-D@>A2) (KS1.LB#E0ZL%85=[#.0<3- %)K:=,1Y]ROKY1_CK- MO^Z,]SV560^E-#O=Z]Z3$7!X,_(|@#RP!UX@"D1'"%<*+",)"NX[\$Q1\-GQ M9+,-)L0^"]:0!_:+!];=*:>G>]AJ*IZZ;_MC*3 _'<=;I?^S&[M)2,/|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|Q>W|Q&_,@J#"('(W4(I"9U0+_OP7X? 5RH['U41ADD@ M',M@7/G3.\:$]5;J:/LHT#F*_UXT\]-R*CB,0^UNC^*@ M+XA87H=]A'+T1=$A:E'81!24$,04E!A$%)00Q!24&$]6#WB1\7J@!FK!V>L M!!I"*,U7YFK+ +3#4%0^!;RRBV M^-4TD'V1?;MG7_3>46$0/^H02$WJ@/B!"E/YZA$_*E:'.J+_#;@ M"2^Q=LP4#'.B!-PA,&>@QNWI<7'D^? N;#1WXRX*\=?# M\W?I|\6H*0M]GV8?1R$M#_R\2V'ZVZ3[E.[L3U]'?,1N)U(?ML4A .]<(#6I M SIP]##[IS (*:@A""FH, @I]"$(*:@P%:P>\:-B=3B(- %.TTCG"--BN#(2H M"-8F BX;DA077EO?SZX3[T?9=7ZP/8IJFR^AM!?HZKL M(_2C-XD*@]%H'0*I21W0=7RPZVA4\0&+PU>U+J_3?# N5H1,O%,FID6'T^S+(T^*)@Y:Z7@4!Q=WJ;"Y M^OORP6B@3Z5;8BWA!ZYVB%.(4XA3B%.UJQWB%.(4XA3B5.UJASB%.(4XA34 MN]I5H50(77NM0PA="%T(70A=>ZA#_4$7]IW?NG=.'&$IA0@N&0(B*|^:]PK6 M9T\E22[1E2ZD5BKOJ**0G(\@B$[@K,Z@?++,>&:)B=?WSE^G^=?- \KYWO-G0 M6+G3/>\Z&:!*DDJ.OI$'D =]XX%$"HS[:("F)$"(%,%FZB%230Q-1K*XP@/K MU% A#^P7#VR[%U|/]5#55#QUW_;'4F!^.HZW2O]G- W;3D(:#]^ELGD\[F@TX M&0X880+YN2)^9D]8:]1QNO#CA-Q]9PG5P='W9M$[V^_-M.IY#))Y YFKU)8F M*W"29_ ";^)"L2M;EZ[2J3"",! Y,<5?"*\G)JU 2Y:=D"YZRZ{3:M=9KWFS MF#=S-VEOSQ5J;;IG+W/|\>M7WVV4-V3&##AFG0\EV.U;QF^J%"3=$[?U!{:N(M1UXKDTJ|$PR"'"XY"&,#>,\,"'"5I4HKK\FPO>#Z?AO^TXW/3K'GY M^V(T_]Q7_].AX 31'-$K2;^-H3DU?$C,;CM:(YXCGB.>(YY7 M@.<%LXF..@ EK8M.@V[[-460)F<>68B!ZI61FBXJG9D&8K4&P8P%Y|(21FW MJ3C+E&[/.Y=L2*U .*\$7[=';!M;H(_D%!,L,YHZ:S4-Z (L:4 M]\02]5A%0"5C6P,$[05FD0+@00% M@LD2GD@EP*LL$O-",K+ ",$1&2IAG8$,.((AAX*D,7:]%%GG()>#0/L.HH<)< MV<;YY:(N/SKRKJZ7S=IDU\M_[O, <.W;O_F%=R61W2SO7D<'UE[LAY,T<'%, M3\LW?RZJ/)A,Y^6-;E8>+O!07O;;S(T'9VXV'TSS8'Z2FM0B04R3)L7VMZZ4 MWR M[]V+.E6!7S'U1+H? _YQ8\FX]&D7,6*,93MYA/GUU]HHHAU^7!W MEY?E_BZ7M3UUXS_;4+B[?Y=4X-JM[/>.;=YAW00L?;T[]8+3 MS0[1VC(X^N^C=|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|_5Y- F],E!'Z;HW>&>0LV'1P#["F#8LNMN[93- M-Z:)=!V0!^=Q[>#+.)?+7W[U@S8_6R1]IXW1 FP($80E"CQ+!IC-(IH0F0_^ M^FP1I4STW#-PP;? CGD8SF'S&)B.66J5J=7/9^>GDXGW821MV[V9M9UB8[_M=,.%>IMFG6"N#AN9M!V1NURM#%L$1LS)\6'C/65FR4^TP%E*D9A7QH)TK_VB> M)][L7@C1.!66XC!21#&!?!1YW;RLBU+D\)&N3(H4YA$5,C B#-E\2[!)X*5 MVR_*?SPQ)TEEBR=/BNG0&V;.?/^!5>O<'#0L8?C,S08?6\GL01L_9/]8W , M059$]];-(I3G, I!4T)3>I IO4LQG9ZUS(G&A*E"-*^^-T.GI^5-)VG2C#YN MSCNL06IH86AA.ZG=P4-/Z ZB-?5D33<,>T.K>FQ;/=]/Z&_?P/M4XA^/)X/Y MR731N$ELAH/T*:1VA5T6WYV6VS!O;AS O+5,'>)GWWM+>X:P#2.*T9U! #M$>T1[?$^VT--FFTP-!Y$[30!UOH+],& MHTDT3S3/.LWS1^+T?PSFN/&] [WLC?M>H4@@A[6W MN&Z\[&LWI[SV[D9O]V1+ZV @ O/@&5% !/X"RW"M\LYLW< M35K17SEPT^UG-_<[5:.'0HBAI7I(&;_UZ S:#<+HHX? 1JS!Q9T3X$P+LY@&6 M&5F@E%I0+BH0[?%&3USY4_-D)&4QAGX MCW=>%[MM@P,KAYI?/^BA%CE-I6W M\M "_QI."LDHBNB*Z(KHFMJZ*H(D4QX IFPXKX&Q< D$D &%G*2.7KFKJ.K MH2(;QRQXR]KC\5F#RU:#%R:&5'!6R^VA*U5Z2+1"A$6$181%A*T/82,C/$5Y6,|=^XV>.S]^NP'7EIQH'U2FJ0![M<@R*@(_&@O4Z1<6BB;Y7)[HI M-Z?\]KU2Z[[.]LL3;[L]QTRS:,L3!-)^WTPCG3;%GJ>O -)A/ M_^IG/YW?R,I_\VA2WEE$,QQ,TKS]@-'%AX5I, [_W$18DU8/# *3..ZK/+1DK M1V120@*Q+5-;Q\ 'DAJ"NCQ?0;.0Q<6]= M=#SOJ@BEW1*&FY%T_3B$*8THBBB* M*%J#.AP$BA)BA6'%(16D_1%X .4:1:XR#Q;SMV*0YHE%[9-W9AD='%B63?& MAX',S$F3G;;1{Q)%^9!Q+/U&'$4TL63VU MRG*VSG@P4EL02B6PL;PG61^(=2S)M-. <.Q]*PC!;5%F3,:S]N75N"7C7I+8% MX>E9FC1NG;&AR'P'9\"[9S[TG%%A$#_J$$A-ZH#X@0I3^>H1/RI6AX.(O+.A M23'5'FRDID3>W)8HNCWQR .+WFFK6>BC3N,H_GO1S$_+I30?ID=%UNTUN/%; M-XK'D_/!4%T4T@4ASR_%(._2[XM14Q;Z/LT^CD):ANSO4IC^-ND^I8O>>RN4 MPP(/!& $X"K4 1TX5)C]4QB$%-00A!14&(04U!"$%%28"E:/^%&Q.AQ$FLE+ M':A1!&*T&00+_S]][_<-I+D#_XKB+Z=V^X(E@8H5_$%=]Q%R+(/IH^^Z;9_M M|OUQHIX6IRE239'V-7_]958!(/B0K0[B,E)'IRC_N8Q0XA M0\@#>6.7R=B?FR@9#RH9%7"QG7=._0)>2NK99&R2]KT^AD-]?PSS??I$[7R? M3!>R[M+\B;-=Q*F(4Q&G(DX-G>TB3D6&A/^*"O_",M27KF2%T1SEQ-&14:4 MRBB1.BLT%0+@6GL'Z[+Q^^==RO+CJ#B*\17R.^#A!? ME99.Y- 82K5U%F%;"":"$8S8@5V#Q:<4Z4%85>5$E;DDN4LK M1O-XA7D_+DEYR$AOLRJ@[>:.DDR5*6$%+8F2949<(6QFC"O3:FOL M1D6M=CF5Q$CE"#- .:$5E11BPWE%L+=\S2?4)\#2\'?OH.UI=%]<2 _I;'^)=A M'N,H AX!|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|V0BH<="8]S E MPB S*J/U'>5 E -#DP.95BJKA"-&EREAPN2D$KDDA50Y$Z6T*M/[2*&*CA*:TCR*Y@&) M9GI$\3R;V5)- ,!3.UZ;0,.3SC07HM8_N%6WW.>6IYQ4($W!LF)@+I&<@]%E M"IO17_BZ-=TA98RG1BG"JIP1)A4C2JB1N4Z+ZEXG%V^6B7L@I MOIXU]5K[3_OB|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|^XL> V>%)Y&H:D7(C>$5HCAV.1.1$2?'YG1Z(B_&"SGQ5HC:3)E\;_]:CFO8Z-C_]&6.B19OK=Z[FGJ[_*G"SM MGDH1\I3'Q.H(P!& A| .48&+#//X&"9"2N20""F182*D1 Z)D!(99@"[C_@Q M8'9X$FZFO"@*(:DC2CM'&*TJHFQFB.0]Y\J:U!9VT\U4Y7E65KD@7&8X]D!S M]U7$IG15&95;ERUU0CF?VZF^3!9S.:TG M,3LDBLW'(3:CVAT9)N+', @R)':(^!$99N"[C_@Q8':(M^!$9YO$Q3(24'X!#AC%@X8'F*=PL3L$RG:6.E\28(B4LRW.B-"L(L[(J*"MM M+K<&P"'#-R_6D)\;A^1(=K6.3QU'Q&)1BG5^*

*8;B32S+Q$P!QS+EMDV)]F+EMA0'Z\:+17(RP5J6) 1W$;_XX.*W)Q\4I M"2&Y%>X6](LF"\H'R.WJF&P&V\W.]W6#K>^]QQS/0?B55!%968"13*5$")#G*

*M@BMM79J:G&ZUX;A)U\0^C-QBND_>;R-W^N;56A\Y4EN-O>30JU';Z55;3*4!*

MC;$4)+4%1=2KB&12$%MI7N2BL%INM8>X[1RC>]_B=+:C4=YP.N=M'H"KYPO! MF=HJ=W[H:

*(Z"*9KE#D2AL_"/U'"5]KQG);:&%S$NA]OWM7T75+67C:85)6=O MO.:Z#GOX-+%W3=XNR %C0_2X-^+(CB]\4<.GV:PLMW?;9,K'KX:09C*B@(.*

5SK6.R)Q:DJ:L$(7BK-1W:KKD&?XMFB&A MB&]Q[$V"R/-=7[$=)MH!^;T]<3N7=25T^SR1{1;1.)2AZ6CC8SR^TF?L$W%< MDVYR;-"@^RB_=AD>?*

QQ_[+((PJE &_7!_H83PLFBY14JE3 Y%4!:I!V1%4R MHX(;;5RQ#VQJ=+]0TT\XKSR\-EX)Q>>^WI:M9[5@\C, MNVII:U4=?0$PL9]P_(QM\%Z>H_?^/^U

0)R'@J0CZ)M72[QMG'X>6&;A0^.I-MZ_!F.<>^10?Q+E+:]Y&M(>G!3A828\,\[O3 YFAM

*MI(*W:?,A.=./NK9AML^%/YWU:N+H>.X'A\HP,GN]Y">,WCY*^F^M*[O%1 4? M;VL.WTU[6\$7NW$)DS!J'2@[N.;RKB@+EDI*I%8@[0K.P/HW?*

NLT#M?>\;NW6%9& MI%H+DBLN"+/, #8P3G29BQ+,?I>SK5XT1A>,REP#,10 A .R* '6HAXA8=--LOO7CC5#A -3QX]H7<*PZP\RP MEV33>/8BM(1?*

*W*S?U'IS[U[Y\,;N4649U]TCQ//LPE608<4S-#4NW/U-#U6 MQW,3"DYLT\\)E!%$BE4;TLWHJ+)GO=I:\I[B MA)I4I_,T#\-YD9TO*G0J08UG1V^2|>*

*[%W8"]1\G+K_*\;4FV,E>YP1]MMR|\ MV0ATW?:\";6KWR8R5C=2- P_[\\7K3%&/G/PCD*SF+7[A8ZFO@#*KI?U'R6G M_EE3N]*

*[:HX)Y_5QW{5HPTQUK/4'6&"<-@NI+5YG>QJ7>!AIOB'S$9NOUD-RV[SA,=_MBSA?B+69"(?#[D/Y5TO:15@@+BK\%]P,S]&SMN*_W6>W/%]HZCLD[%*

*[^VI&% MVS=3)63R"=[(U-]!U"6T#B)FOUKVB:W4H(NRR&/CU!/X5+N><*H62MW 2F[,K M$...5B1WQFEGH,J&*_Z.]-Y,8KK.$[I8D6R/ID)X'AB#U M#*

*[>$MV&N4K9SKI+/Q R=Y+'BW<\^#K*QHR @\/D8I/+\LFGFW)]7$R8V41;H MW#G#_6FT7YO),B%C83:OG^V$C9,S.0;+8SI*7LR/DO=PQW?*

*SI9D%1#IM&EZ_ MF]O: [W_Z\G9V#H0S[!<+U3"M))Y<*WX%-K9?",'+=S]]!N[CVBDU$ 94"1 M3Y]P4,G"IT4,SMW!K<:IZPZL>8.^ Y6I*:*

+FF52I5GF;NV[>]2E&,@I&>UF@=TH2]\H!+;0LA#);KAN:FK+(6G]0R<"P#][A 2^]T+0Y]<^K>5_3'332M. MV^\)"W95TT;0!.@"* =CX?*

*VO"D(OQ=&5)=?D$(6L=VY TK@/L\+><^@2B M#@;'(5.]68$)N>RKCL(F9-QB*S^+']D'T!S[.4M_@5O5XREZ, ^^=OR7O<_S)EZ6H-"=-ST ?U:_ M]*

,.I9N#.@83MKL?L0Y26%LN' H'L/>44$32W)!"BS1C(BUXN=55Z>YBO:>B M>='^UH6_H,?HE?6U#0>1]N\:A\\H.9M] 8:9 XL<[I4O?#^PD/(\[_^M5Y,.

M3:/RAVY>33OC5?(;WN)L[7BML$G5.+29 F MC5WE5^5=0:N&JK/EHG.MA85X> CMC?I#EC90I4&4%D9&P91K[;OC%PF'K_KB?TRT17_G;'@FEY)

*<&0%2TE'FX'1B?HT6.1*B4)66ANS M%9N\N_;7.]&KH_P,296M&V"8U&&\?HCS_#P4R1>AE[>?]7E#=?"(5P,2PCLZ M?#4326=HXZ,'OCU\@8VNJ#0[?*

O&A;F5IETX1')T]+V8KV?'DP-TV^I\.1G"= MKJ8!Q?."_2'>R^)!P'OSPB1$-MT(,Z!S>#.EX%KN18@[M(471JJ(L*(DI16 M9GD)AK!26]5?1.:I-*

*1CQSW@!9S(7(&5I25+A!+=.Z3S?*MO \[4Z2LWYPERH M]L@=>W#-MOT;JP.4?N_X4#X"L@SH!(5(XE6:YTK=7!<3'T)3Z*;%_GCCX(3Q*

*MV6N.LJ$Q%9=6R0P4*5T6H%)IPXFLJHI0L. =+04MQ)9WA7&PYEG*L->P)9Q-BBGL4K>4Z&'("J;Z'VK3:\Y"WU7I\&),%XH,/E9)5DA M*2AY#HR^*

KDJJW)J2RH!._:!-N^[;ORM@?<-K_SUI5;)TX$ARLBGG39%51C# MQQ[43V:(42N'NW8'37/6]X-P.Z+?V&_TX^QBK!-6IF1H?5N19<,Z5P#IM9-0

MOO.VZ7-[.]LMVTIW"K"]^L"J4B@KLUX]]HOM,.Z"!D7O60:Y)ZFNU/"%'4B M,N[O)RC?GH&]U=4I/ -]>K[L2:^_M&9$<7

*TK;62V@CU@)+9M3;&=DO^.C_? MS*T_H+O7JB>R&KOE7(?\K-9I>0<+36;?HH M>=YV5U[-EUDEL'3]=-*

=ITFO.W$T>W]BG+R#SV4A>M@?/1Z]M(*9\G8^7Y\U0 MY*F]F@#^5MV \5";WR/%]H[K,)W'3BYWO->-=?]"GFUZH4$-,+-J$=9--?.M

*M]>M>$1#F!QTEIZUI$/*BNNRJ\\WCI278 MHV#!;I6(M61K2DNNEPKV?<_%%%D8762D8%6&9T7"68$CJS48R(XS^&S+*

*MAY=96=BBHNC5R0E3BL'VLIQPY2R\=8.7[U9@:@? M'K*SI\)HV[N\^TS!U0,^4D8Q+8K*D,SB\2A*3:I'%,1D!?IS++/;J36%$AFK*

*M3$4$%Y8P2BT&_P4I+=,E*ZC3?"O3LN6^=2&E8=-1Y'Y6J\ |-_^[*9$OK+;;V M]D8Y36/[7E7 LU;L]U]8X>2OM]Z/I5GJF38JY!F#(#7I$1:.)TLS0H#[&#-*

*M'KK0_&_H)?FZ-<>N,SUKT!K$GC/\&_HD'8$&D.%_I1]O/5:"[NSC%Q]Z[4+K M=OP"FOQ^!%4WY&]M4&WB1ZIV?HV-P0C?\ ,:*H;D"0UW !T!+*

*(U=)R!*0\T;3 M:)2%;GXO.MNZ%L+M^&+Y"9254$[V>D_M=WU^4N>9\GXU?VWG^]K9O7Z5(G89 M\KN^XHS'&E/>@I<0GX+!]-[BVL$D7\:^%A-*

*G(IBUD;^+M88XZX,/;M!M&.[T M4S,Y'L?*K]UF*7%FDW M6J*NL0+Z!:\86#]D7IC]KPSKWL,PB.QNTPZJ>6D[Z#SBWMDZ.5P>C*

*MAG%EI!6"$Y&7CC!A0%EV)B.NR@N%B6.4;^5&?UB /ARR*E[X41ZAE57(MMH#]^8_J.^=;E'QPR5Z>3^4 D_QL#H-M.BDH%6"'&Z(XMX6*

)EP/JI'=&E55NG&)9JK<R#=Y]1%UKH\Z M/\S,&4%#(V&;&#F36%A-LCCY^)_?BBNN[>9 ^QKI2O3;M& ^PA4N,[:\4\ MV,[4S@-

*;G%],VH&0CT*GOX!R GQKX^Y55\R5ZI+_3$$;V!V8U+=*P M/!&9/J3.!>-9ACYQ!/O$72:?[=2$,LEP"=J^]7+N?VJRX)H4\946&?#\D/3N/(-!X\59$J+*

*[']NA&9$;BP$+\M-< GF-=5MV#K4%8X45 MQ$A3@<:AL9EM(4GA0-?C2FFJLRUE$]\$EOH^QI"%6.*JKI:>V2 CAB/?)204*

M(ZT:A:#1,9UBX>A\H,:']+A+"U$2ER$7.&>)TB(E,B]2L&)34V7;_7KNP@^8 M6+WJS/ \$.T5UMSV>S?LKW](><2&5##ZMV_E)2"R]:I+!@<>A7%IFH-

]RCBG MA+%,_[-827!:\LID)MO1!?DVTYWN#SS2(SH@9EB!+CHTL\Z6&4F' M-TH]&.'=:WUFS7+2Y6FWY2OWTVJ"9RF@"L]

*(+DKDF1*L6R4*0B7\7I6\L'(O M@S[6L.5PG:-\0M(D!,1!!0]1G<79?+;]=+9]. '*=9B,/I((K)YU6>4$$=SFH*

*MX(4CHJ2.Y+K2P@C'!=OR/MSF_;QONK8<3\V+5<^6)IOMR8]B>7]53YO-65T' MQ*F3G5,BKNS&$^+,%R'>*7OE%LMIDU"'-2.H+(-^-*

*&I/PVVKUOZ(;=+G^[: M%.U<^9"+^0RCG:";?Y^"#;J,4'''''Y 5-S4",-HTMO'>/6%G=<8:ILT-&_G MS;1W&H6FQAXWFZ*WT$,Y6^:JU>]JF[X%2],QN?*

OB;/Y)3IL^^/#MC<(4=>E- M^+&QR42J&:B/,USD")T_2^PW"X2:]T<18TXC]C_R\7C=\R!LA@XW>C>';6/X MQ_ESO5B:\<94J &?

*QL,,H0OBL7/+E7V^:EZ; M7**1] @65L0^C<#:ZBVL@Q=3*N.TFV?[99[9)"@W0'3+]H5H):?GFF(P M:!IX^+/0S'D]Q^8,%Q.[XXRLL?*

Z.%0>3O.F)C9D32[UHOP9&0SL">[679A>A ME7L@WJ%>C_!R]K#?1 \E[2Q-1^FBW&34'=9W0X^/RN:OV]/8Z:Y5PV72B0

*M"Y93[#@6QG^ZR>Q+\!I@=_*V45_;%WKFGUG?>FC*]>:4A_0D+C:\+E^;B M,K@VX6=LT8]CL>QT/@O*3^@^[JE;]]U8XOZMI/4&O=>HCJ,20?*

3IC=\4\3G MXTV MA.L#K/'WN44A$&]M%"#Z>3BP"I/J0U5KT\#0IV]]7Z/YUM2-&^>^A<#@7>9P MK;,7BJQ/4R_SKD4L[-AS

*=3XZED5C*C!^3Z8M&DJP43BWI@5#$LG;$GRO,S3 MM);EF\7^Q1%5AI1$4XY#OR6ABA18>06?BY+[&U=KL4K=EM*'^77DT"G>QT*

M5>1I5945#BDS.3;\,& 8EIB1P-GIKMPI;AR1>: =9D?YHZAMPC,Q.%:W M5<5SIU.22RMQV%E*1*4I,97.4ET:5YBM-*

+@JS[.RR@7A$NM,I.9$EC@.+.I MS#";H:+#876E4BF]JB-%+PKLOF5(Q75!C*QD8>!8Y]M-4 N6YR(3.:$X\(R5 M'_"*

*&4I2YU2AG:.*LT/LD!X5CX'5?;^VBS;_XAK1YMC#X#'V,,C2V,3@<:7- M[ZV) ;M=$P_^QR8&6V[M@HM"""!!%U@&D,Z4$P3D()).TT)FE)>=;(>X;ZS&A*

MA_+[X(CQ[M&83M+R6 -:8C3.(\'-"?[\/[TAD+=-//6]^OG\@49M>:_F:S M(C"; ,C@\[:O-QB3YS@PS2TGD\M>QW^XWI\8RT==]9BW!3'1"WV?*

P%VPBU#V M_JE!QKHVV\;Z!=[1"Q4T7]VPN*/DU:VJ^9/S711; MS.#1\-OAWN3@=/?2:E.5%DPWE99@=-HWDP M^!76$,(*CO5?*

RW$0]'U<_'',1UP!7AT(N.OC%8G,FMU14J35805(/_%KQ2A-ME0%;CRE3V:WE.5\;39?P;&Y(_KNJ^7[69991)@5E!SA(E:4F4 M*3)B!9.R4E5.TRV?R&W-*

MF<"&38=;P78ZN@]_0S\Q2AGB+@#7&'\&C"3P'T ZIL!!6OACJ%)4Y5S05.9 MPL&F"J=$Y41AIEBF);>P;R'U5NJ>H;8HI:I(*C2 05$QHBI*B:P*IE@J*JN**

*M;X)!3WABL,M#:^1ZR6H!Z3>PQO/E#+'Q7 MO/B?'TX^DH^_'7?78QU#O:Q#)+MMEK_%TO@M+*AHAFIT,<>0\M3#M(L)?+QS M*:*

[^&0UDS=DQ+;IL#YGH7GW;?) -U=\BFD[JP;)2>O7"\8JKJO).PA&<# _ MQW.3_+6$%8? ?N@9AYL#]D%[>D79S=7WQULM=E(CM(?

*W@5SXR*YHVMJO#7G@ M!DT6&FQW@GD4%VWWEI"DX2<&KZ9N;ZKR0P[G5CN FN$&W\":8XXO=-QW0*

MSOK9>VN46)GBASL@9R#2!]^GCYL^2&6W$0+>,AI*.] MD"BDJP)EMLU)I55&"I-R+I-40J M^,<*8_*,:EWE6_TM(E]>;Q9\(YG-2MI?*

*3\8/CDE42;E1CA..[F=&,T>$$)K0 M2E')&/ #VZI#O F3A$X8..$59R22L+85VB#5E2A@#_!$5!;5*IKQP M*:UV#%*

[,5=UMNIL>B+KLZ:NR1NS<"@_SOZPOG_H6Q<;#!Y_D7.S/\ULB,YA M;_W DHC/A=]5MB"UMA,T@>#7SX$ ^/J6Y:73H2;1>![&%F=K?_ZY#\E6I6IJ4K

MX8'2@FA3)?"'72@E7G>695+G6TTL;LQ?QUV?R>M)N*NKHTEM-?+0%RPGL=.? M_M_I;$#<$T+>H<["2[:DUV%SM^VYB[6V]*38_O*@#O**

*[!?/8OG&)1(-P_Z- M*LT+5>6,9.A[909P29@#V!51EI4H>*G,G7]U/UE%^X K"*[?*SOQ2/K#K:V7*

*MFC0:>O5&H4JE*LP$9!:.ADHYD0P4P;S2E10:/G9WZERQ'<]HSL7O4ZREVINV MQP=X.KRV=[AE+#V%O?W1;YXA-*

^9TM(Y_+.3R&F5PON\LGUKKG'$$TL>&Q#F^ MKJ(&=;7N:B5#2E]_KX:?23E;SA=GFZ&& S:L>^ N$RF%XY-6; QSJG!]L;" MYA4I,IZ+S+(T9UO5)+?K*

B+GUH_+Q/<#;]4'BL@5K#W3Z<8(/+%57"^LEW MG?#4([$&7/?HU55]'CZ^WS]]33?[VO3".FHLZ9/-M*

*AJDW8>K\O>K9QF$STS3N>M3F.O@*ZN;XL9Z-^F\9HH1Q&9QOO@X! 1#HEA7 M7M_4_?Z_WRR4S"+,6\7+VA-X[:*N8M(-F[?*

SE)^-9L[.PX#6?2.3/7S'V8: MQ/4ZAO5Z5-;?8XE5.\H]U)RV\%C#(6X[FG9U\1ZH<6M(Z_%V/:FWE[(2RS2

*M;O#6)S&O3:ZXUDTZ^K=NKO7[/)WZYO6A&\T$$5!CQGYV\\8LH$#-<=WOA_*[#X-R7]7M';'LQ MB.XQG$[$A$YM*3?4EJY+PN[EK+^]S7=U-*

*L:Q$$W3AM7E:TT+$.]D'[2P!MZ_ M47BN/FOZ,^S<<+AG>!&-!W#G][98]![G(C@D+RMHGP>6N*__M"'^CR3JI,47+ M' ;VC=]Y\=1N #,_MU\R*&*

*[P/2QI:"^]F,#[)I_E%/1?V5Z]MN0KWM4&;RJL MDW?P,1*M\5S]?O0!;C'WXNXRN1S;B<'6;Y\]^EKGT#^V,0>[2V$BGE?R@4@9;>+O1\GK*

MWAX9Y>$S>.JKNY.Z^_\PNKFK[EH1]<7,PZ#R,XDFB;PASZA9-AV MGU\K^]]HI#^=)?#>PONJQ_O"QHW=T_< [5(3KD-#WY%_.PW@%6V1X'J29K?4

M<#;CC#E#>,,$$80RSI4LM2)5IC"C2O-@>,'4;J?$ZQ7Y#'^77;XN,S?KMZRQO MZ,/@]RQI B6Q=[%0NN/O0DA:#FR&JN_M/3Y/WK?

*3*0]9/X9@@E0JV>"HY)GK MXV&9ZR%HC)KX%86/ZCQN6:LQ,L!$ZTRJ(;K2Z6ENWK:1H MNO$'0PI=4=B$S)MF32._*9I*_S\[[]KW-*

?)#=#L(,FV_#MU0?\KG6ZC[X M?WN?M88CH+LLKI))0<[P_2<)A3N(R]0)I;8?N,W&-;_K\E5X 2=$VD(]I>!DWN MTU)(@N;?

*FZKU]Z[TEBSX67=AUC[\G:))C99C](>X7*OR =W)29OOONHR2*5 M]VSZ*(Q'?Z56)2;-#SM!;FFFN$=G4'LI'6DO)5I[*1U6#=85J^]^Y%UZ^,V3*

*M^B\]M9'2#?<]A@#@:=^X[=]ZSS*SUG6M6N,7Q[9R/(.GQ>H?'&;RE:1=OVB M7']S<;(3U'[@/7:;0 TZD!")?HQ*4"$1"5B;*<@@+&IY"LK$783"/[M9&4,X*

*M7P^]K$G4M:+]AIRMX8)E(F:[L+8_K5\'N#\B:0X-P]P\VK5%R5&['K]<3<%L MU@8*5=^37OUL4_*.ZX&-9;W&+9K MW--*

*Q6JUWEWW7PR8VF4S+3HUQNTQ24ERCN%{';Y,#:/'-[,?V1^W2ZIO1N!'> M5X6\?I,FC&BB)WR*LM/[8GC9>OQ\6KY>R7'NQTH.VAD9*,*

*[Y;AOS/&'PT23L MAIL6\E<6_88HG5+WL-YP/-I:.2U5=*N])I?":F7]>;H<;S>]+\]31MJOVZAO M-RN[]CF&6W-)1K/U*EM[05]"M,4(R>ZXV??2QF]-*

*+I:*GMT'!?O(_?Y99&$ M:Q;<[K &M_V)YK>MEFX^5.D/MWJSK2^#AC"[_MYW]YVY'[OI #]CT7!5. 9Q*

*MLNR/IF!1;0V>%Q%4)OA7YG+8EFO:Z]C>73X&/-ML8EO/XWFHW95[M7Z*E<.Q6/C1E[-K94ZLTK,;3L"7;UZ&X)^_]6SZ1E5CS[W MT2?R,RX?*

_\CU7:^?^/?O%[.,]6F5M#!H.MZ%O]I/$)LBK(T-_=#*1EVUR; M.'G5ID_*#VY5Q2O)D]'D!^1 BY)775E[BP"=--EHTIL,R0/2'HM8A7"#$%"G MRN^;;1Y/%

<@FA;9.IYXO!'LT"]F#M_&]XO1M$:'8DP:V RC5OL4IF XLCAB:SEQC>Y]KWPV)[X\"=L ML'^WG:Q_G!K?

*1U9'3GGN(9G)M/=R>6X1/%PY;D27F\DT8YS955I72$5B#*7T8B4@9-C;%".$*N M+Y(\<6GD=9/GO]+MHEUB^UI7JFZ?"TGTD%*

Q5,:.]2B"$8&!49,"=2]JE; SI:?PAJ!E*C$%TC3_JLD?_XH]_K?8; M5.=7G5]U?L_O_+++V(5(-H@K&;AD#1A91N!18PWUGLO8<7X^*2LM.LQDC"_;

*M51TZ/RT@B&Q"<"S8V-D6T@_G1^E0*C94D@]Y\7]],.V*N[V12_^XTAQERMK M(_X!EONRY=^%LJLN010(QYIJ96GI)'(@I<>!! H%2 D0JY5W*

,UV2EOJ#^_MIYD>,;12#C'0&LH*NW79HW]AQT_-YNG%J.S)FTP7J<8?/?*#=Y>N'I]/Y_Z M/*C"]YA\],2@CZ5G2;G01>9CP:)X'FK !#F B. M!\:Z&J?*

*%=XKO%=XOU,##:.L7RIX MB!BVUZ6*YIU*^\+)ZCX["B*V>V0TU]V^$;G>?J6',<:?9<9D=3Q]=3SLC!6S MC]-E"0*KZWF@H [>^=P<6[@8G!568F!*

-0CO!/C %0883 2>0LI)[Z)M5D]B M"SZ4V@ZYI$-+;A]YWQ,3/4377%&^5RI44;ZB?#/2G3@6(@,?-:(\HC5XFQD8

M'Z1FWG'APG645X)S0PT'Q@VBO)8)G,!+D)R]0B;-O!3]1'DY9%(,B2!#U>&<,,_MTA&_-7X"_]5FO?]^U>&!G1_V@LH?

*XX.B#MN9YTBH\Y2T"01**,!P6BF049)-MH\M1,+63KJ;X(*,:.7.HN[_/II-IZ>C=S+1M.UOOH+_U2\>IG48:#_@W M_CRX%-3@JJ1ZT.?ZEZ:K:3,G==K\[W*

PP9/=Y2.?7WWDMCOP?-EVO2[]4']Y M_>['=C[UL97'^L5?375L6^_0W5^?]+B\'K M8API?G<[C%1%Z+\BW#YZ;?#;]%/;:/)R6$:#.RNLV?

KL[TH/ZV9"]'^>M[.^ M5I-&7[^[G#1:K@)$]VO"W+OTO@'JS1R^5X-?/Y;Q9BO81<1L?]4T@5X?_68T M#^/'.%PK^-@__R X(XB+H/96\?

4C';?/%SC_%8(WK8%7\V/;]_M?(91QFS4 M3/:39?O/PS2Y$/Q)G'K&HWOFZ,NX@U"&;TP7\E@-5EM-8ITC!=:/4&94X^"*

M'=5^_*V??;Z+%28IJ/^QV694=;.EOMS>HXTD1E2QA24^6GEH%E:7*S>;.O) M:0VJRNG<6N_O?YW,\+-)[2HI'_L--EF4:0#OS10S;L0]X#-ZX<>_-*

-@/LR M[6R!8-8.=T-".8FMC.8?-E,/\%E'S0R&Q6Q:J$!YBB[.3-J#86)#[>+W[9 M\GT]D+OK**\.DBM3.]HA=.7!RJ"Y(L1V:L/*0Y?*

1!=OBF+;2NM,AMQRH3&Z M^F6KHSYL?-X,-+H%GQ$86LRU_<+6S=\'Z:A^UG2&RF+D)W@UM-%RL*

M)JBLYEYN8ZZ_6%L,=]FXLR\7'<0T/S>3V>C%6*^GZ7"P,N9[CW^X_UF;L-H MTN:$FJ17BQ[-W,TR8A)->SQJ?M4.?;DR>O/+V]=IXX+^6L]$\CIJ4T>X!*

M53X=4)N)H>>7F-K.!5U=]PK;MJ<$=],M^H*C==[D$Y&'Y^COF33XR M=TE9R)H%";FTZQ#X)S@E)%"K>&
(Y$YO24W*7[J_%EU>O$;0;G'D]B;^/W>1M M_F>:O4^S2Y?XM#E+YCAF\DW1$_*SP49:#2@7>15<;R56:>TCWJS!Z/U^_LS
MR#U]_5W*Z&G]\'8R^*>;A0\#L0YKMYE;XS*;V+,$IY.O&DM+LWY'9S3X<31M M#T#R.%_.UP>\6_IAX>AG)6W\!IW+9]>D@6<8W*^&CT_*1/(R@'%|
=//96SX M?.GGHS@J1!%OJ?HO-QMMDD+=ZZ]S1,V@QX8LKG/9#HGS:AYK&=TX&*=%PYH; M#O9Z^;YD$:AO?GF+\^6L3$%9"-\[OTO[WI5S CGGT:?
UL1T=8/R[BLI#FZ5XG,&[?W1 M[]^WOM&6A#9?LXU^EN>K58LRK;ZEYRBQ_RK#*E?GX15C.\"W_'.6IGFXF;.W M"7R:5:;58,C5C:;_Y,^;\O37W[19D+?
>MVF#.W;FN77CMG#:VZ^.,9I'Z=%MBNB_AV5 Z>'3&R_3X-]NBG.?(,&=5UB0'(B@B@(C"HF+C!RL]DA<FM-QXCP:!$8@
MB$,7:YVZD<)&"!V6MM3'W M&Y8Y7[!Y-R_IZC9M6^[MMF8=MP_8&9+;8R,VR0>FH@5)>0*1,&+QV1+PQFNJ MLM"2VNM&S @E.IH
+CJ/1!PE.&856(GNT)5]>IE7(WZ4$;<*|':M0*U>;PPY M_???C8N&]DV+HF?:464AQ)"+1B# :VL@:Q\C0Y.TB3|%BY]XMS7EC27__"4@ MH+U/?
Q1JB3]T%EI7EY#'X0\P$"YB(MN*(^Y4&V;Y[9TL]Z V5_C&2@*#1@37 M^$8S(;Q5L+@L&4Y$3<2@4=R](7F/;'G>DIR8FK30FMTTB6G\=^] VS7=+#A;
M;E%F;8:T(;_E F]6U[N,*.X#SFV&]NI[M7"]FECS]6]7[JQ]R0;E5U+"^Z'\)VT"]?)^'U=!4>'BY^>SZ9=1*91!X?;_M-EW*RF]TKNC0+(4F'FQ"LU-
,)269H4&1Z[9)=41:9@AD*24(Z@T8Y0D#*MLZTC>HMN?#;,,#K_=;)RI#^52H T0X^XN&B\ ?K[B,>@ 9<$KGO
M%=,%MFV[_*X&)>9,],AR_[;6S0[!OZYWS3)'7FXFS+?CP$>7]P=[@)V3B"4+ M]OBIF\5V*'KAH]/9?#-C_0H!;6AOJ0!<3MQD]'&ZG!>,/6\6 >,-
&-2E&;8SMR43._J1GXY1U"=EVM]J(-C>U?N>Z] MV,^&V'@^^#A%#[`2MC0/LY%O.,_)GU)R]Y+5*HE^4PQ[R]N-&O(Y-;Z\&U0\,%]?
2W%UXO[/N/_H:>7/!=G M@R+602-75)X2 SZJ7.\]JWK]SBYC +I.[?W'R/G1N*U86HDJE@32E@0;7/^C M;!%I5OQ_+)A^=Q7]7;*[924]*JV--
AQRL23!$MJ/4!*2$%3(["01G>TO3S*\ M5A:O)W%+$FM!O)UL7AL/^&TZF:W_V0CASU+X];0UJSUIV-/]3<:0=OJYR>\V MY6^KQ,+\2G&\T@:;DQ'7%8?
C+<4)..6 N:B@)\N%7 C^J94K)+3L11+K*I7 MQNE3&J_9RM;I*T9I5I82+@;+>5LB'E-AW>A\6GK=`#9_U>=5M9WM>?F_UMNG
MVJ+%;C^#9@%_M9I>G]MC9[M7>5Y(R;OVVO M_Z]>N2T ^/XKI(SQAYYYN-.LV?4""+YWR,O\]C3ZNO6USW,U[VR=;';,,9\ MM=?D37AZ9S.9^\]A?
NC>]UW-5'[NK>]5 E>&G5-QWVGG.V]6=133SM^E\T6; M ^"DS0$\]JZ=X,3SPX3&QW;7>T[HV*7>?_MK61Z8+N<8F\R_V]O.'Q$.LPK#
M#U?'KS=Y]\A;&5*US/U8YC^:3!6MMEEML]IF+VV35=NLMEEMLY>VR:MMOF@V MX8X.W3W+M/:B\\&]E/ERX7,/H'DPS5AWC9K]:!O:-\]:I5)-
IRD\E4HUG6HZ MU72JZ533Z;F2'\U4'A>$WG>T[*Z'1-W/>@]^3M2_W&Q6FA2LBW0O!C!XEYIM MS3\^1KU/>JS(*ATY@=.$M-HXTCVBF6@%*A0=
R@#EI 50%:0+#0#EWQOQ12YCA M2H*ERH-0M#0U2!2RH*5?$0TYY!I''Q5Z/ZVF:D?I,/9\Z6QVB.GL9D?,=L>)
MZGO[Z'M[,QC[0+SO2RFR/KY%7(1&-8+"0%D:4!2YT%X;6)A"H==">RUMQS M$72$1,HPC.P<.,)\9*"4(=4::0&MF^]@P?
#NWC7\OK6&?]]%74WSO!.];MZ]- M<|>"]DUSZ^O6USV%USW,SI"'W]BE2] VS7U2.Y W*;QZYM*E9V[MW6]523;X]0M+M@LICZY;
fNNZ'Z,=^B+WG0'JTUZ$?D+CS?0Q4,.=L4$'% MDR"DTN H]Q"%Y3$0([C+G0X!*2)6D@#"1X7GZ(3GX!^"6^8ST=QRM=]}#'3_ MVQ@.9H-
"!=6C5XP*JD>VS[6"2P67ODBE@DL%EPHN%5PJN!P4N-S2,,[ZY"++ MP!S%T,XF UX2#M$IC.J,DC:XZ^@=@TU9SKP402BT(`9M><1IRR/Q8*@.U-1P\
M&%#M12_6FBFM<\4.RC7VLA]ZWUC5R;9!ERY]:D,&950&(10%@SX37$K>"$XD ML^2Z5Y4F6%L\<2*4@XC:@%4Y SU<-HJGI&T$1:4$080 PXR$:
(6/U%*=#:GA\I'!=B^J>N\]_^R! MN>HZ-*QZW.>R^]K;?!?R.E+W2VR*R9D(QO*,[C<*\(H2\,RHJ+BRUG9:FUOK M:>*6
W<,7789.>;=%4"T]%I9(Q33>W>_DO?,_1Y\<_.*XCU2GXKBIXGBO4@ M52BK4%:AK$)9A;(*917**I2=/)3=4@EFK;$D$U"6)Q I,S")6B!&)^ZMXEFS
MZ[%U2#DR(EP)P T(]R@X)S6P2+7@"2/N'J2V:VS]G,GMS>"PE8Q_6WY,LU'M?\?1I^,>)];+HR73_*8]_SS0QK\-/V(]|UH2(_^83Y8=1_=3I\7*)B/YHO! M-
\6>,JZ[GNP*@[?#IR\ .Y=.E^L)[*09B**&+A)W#]E=?,#V\[O#%09#0*_MPX?!YS1+" 4(P/@F";\X'?
AT68H.8>SF\U$>X:]&D_EBAHJ)5ST;X/OAB:YS2;X\F+SRE-5N^*-UNU0QXVC[>60%S.T+B;QY_@;0]J[E]<^N&---MH(&]7?\WT'SW 5_WB>83&-:?
QI4AO+KE2[\3[/V\N45 M\!_R.'V!.)JE!MS*$+GEQ\D/<30_'[N+5^6W'4PZDZ-6 =;K4?C/E3FM;]><
M"/A>/YQ/YZ/FRK,T=HO1I[0]OVH#;5_NB5]WV]_M1O&T-KM/,PMZM?=N@VZ; M[_9AL\"W>OK19(S: ?.%FZUF_UW]!.YHLL'-
+;8W^&=RA>+%@5L,"O4;--QO@)V@S]26,X:B/W1H7O9_IY/ M^8R7:+NFNUQI2X)DALB) (6.8U9.&U4#HH+3J5'(XYSVS@0!2-((@4X SA
MR'FY)-3X9+7IT-TUM=T2P/K]WTXV;]N\!'],IGZ>9\!*H?!UK7T_+"[7RZ2I^/Q]'/C=-NYK2@%>O11EW#UON0AON1A
M#DZ\V;L=TMR3*H'+D;*DCGYY^,",]2[[-8.\V-<0F!{)MPZ4K0-E7T"4=:#L M 6/$+M7Q*?V?CTRL?>-'U7R/4\^>P7P?U93HR,1:S;>:[Z&9[U[`N?=(IGL?
M.[*#9GH[VH_8XR6UVS[(CV[L)B$-NR4-M5RR'^62>U>P'I5'"FF9HY'$Z* R M1&,4")$2.*42,!-"3$[2$#M31;BDA 41P.0H2\,
{!3X3'Y/R::]6FL[5BO4)PA>##AF#)5,XN4-_% M4X5EB*0F!TC2,YM5XE)V!SM%1P1Q$CPE&H0)$1Q/ 9B7G'\C;;QH""X%RU7
M*@I7%,Z+5'H*ORP*6NMWTDNCWRC<@U! M!X/"O6AJ50 QR6)8_B[Z_X].LU\[@*$PD'A,L&C!*Q(@$TZC\2I8)7?E MWV\IQ[^GV6@:?
YT$]!'S]":U_WM_?S_'+X9_ZW\&K)=H<#\2_JARK&>#A7WN MGZY>IW]=ZG6VO(X(E'HI"62:&0A*.9A)##NO>1:,\<[V^]8X90Q1< 3AI&H
M8Q2\YPXXT=XQ=$O(^G^@\U>PD%U.]7M5+=3WHE'#S1[=02NOV5T'6WV=ZXD"6%G7OL9EB";_A;P/VDVW6HIVRO?W!N+[3=9[U$3Q^H4JE,X M'J?
-,5"& O<<@HBT3+M13@@,@2B;58R=F:\,!V\)I:!UCZ#4-R"098-Q@0? M710IE:QC;YU")V+3K&_K4[TQV>H5]E>H7N'DO$(RB=)D"'"IR^!-Y\ I2TO=
M8G#2]*QTIY]!R$@\)PQL*-4,Q##P5 ;\(P86><#M6*\4 MF=[<<74T+^U443J(WV6- D45RA%M*]5U_=9PF>;IZ;5^Z9/\,=+W!U\1N#M
MEK9^&*69FX4/%TTK]VO/@_+Z<+6W_&4[=M=Y[<;5T]V\^U&\IFI\+HCV,7 M_H)WX<-TC&>\;31E\#O"0CG@G]L8QNMW6<[Q@$]N-IHN2^/ZC5H-
\9W#>%E@ M=/#MZ+L;I'>]U?[K-^_PK&]'>'#ZDF9A-$^#<[SE=7$WQS0'G:>P*/WO\?EO M..,3UB&?]J4;>/.)BC2^W?
[=;#3_"_(LE6IBO%2;+P:ES>J5OO4[[<#L5"H[M9]&E*ZM >(S:T%?Q;X MA$6RS^F\?3SP.U2VTUY"Q&7Q8*1D5PW0.0)83EN:<_#IS\,MZ<]7#//>\^
MJ#V51P?64UE2]MA.O.+%^_"]QSYK?<53><7#[!IZ^(VT]@1]*[&G=0+<1>'(MD0FX;T9Z8CT!537DAQOR3IJH'9E\3[XK^N@I5 Y3>UTW"?
T+"RFFJ^+VF^ M=?=O6)4='WA>0]",,=4)NH0J2,%+S6'!AGS$N& MN,MC9X^I]-PDFT!$8D%H(<_+CF!KE:$619=H/]"5GU%6T;6B:T77BJY[0=><
MB%)O#'I7%,Z+5"

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|0f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|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|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|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|\XUK.:O)(=B8%,7AE1?D3YYX?RHQTP/#L@%WF>_I*3 ME!NP X0"B2'S0/)V Y7SV.)E]4_/_],9&C?U'=?Y^@7X< MZ_[H49C.#-9(,7NC,*.0'H7R$]+H?F!9['+.7]%PQ*@GC M .C"904IF >0\|*IS.N,436$",S5]'Y5! (8^2@0F'2,P3XM11Y1_0B@_V@$_ MX B&9P9EZS$&^!LEV!7]9L11EN4_#ZC)S-:3?//F5ZS-/U?_6U\@5UXD=]H; M,*+@OF=D6C9SXJ=1$XCW/D,Q_+9IY M&2|!AXC'D&;NZ_FKN!#L$[]B\1$UC6L[\SK]M?@5NOF%##K20XBB7C.8J$*P7C MN ^!%(fUUXI=2FZ<|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~LN2(:/:IE'$#MUVA@=0E=\N>*,"N2$\%>/_5>=5$MGU9>]BL\L*#1O(5R02N^'*IG'R] MI@9"V?*&%>ZL6\>K7Y ZQK^W7< MYC9=0@=XN9=Z^D5?-]]^~LN2(:/:IE'$#MUVA@=0E=\N>*,"N2$\%>/_5>=5$(\$)) M1@HN-2FT4UE01:K53L&.2HWBQDEB"YD#FW=D[fW,&&C*^)O7GJM@ =UD5HB"JF(RC6%#55.*6.H4KO- M_0+EL3*6&P\|+RC@GF@5.LMQ(;FB #_?>W&^ "WI%'.Z*P-SC@\O1#?7D0T'H M>G[?#5ZI/11OJ;*U@$/,"Q) MBB)C9$1Y3TFJ.I8[941AS#8S::8 *RPG:48=$:D41*L4.$ISF5)E?)&&K'6:R M]IXMIOYIV,\SG]!<[1AG^=:'3,.X:[[C.ZBS_ ,OT[AP)\2# ^1_#M>?U\ Y M@Z:5!Q"W>K4NK>&R9HFNW=()XRU)#(8.7AL@9 I63S,| M$\@W/OZ$YOWR.9+ ^.<#T+YN7CV7;=G;*3?7*[V][=?7*WG49/9?[7')1K^^4 M;'P>U+GA#?!P A99M0#;JOSJW:OV=@6@\<_]\1:Q_;SO+QM_KFN_7E0.'M O?1/^S*T+\|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|)B992M6CTS('MY;]:4#)C.^JV\2584/I621?W M2OQ[EN0L\,\!6DP-807ODW+;H=QHVT?'T^'Q>0@+/#2]Z3FNRI__+?L<% [@AW>D_@9@]BQG_>M"MQ'KGZB3>;@V($$\>]54%7+,6/M M0"4-I.YMY\>CT8[WJ^,)8]K5#YPP\ES3KNXA_6A_W7":,9E2H0CEVA'!1$J* M-LD"*9]ZKCBJ=\,D_@\E2(O. F&,B)$\$3G4A%F59!4I=;F]-XBI;_]>U', M+|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½,,"XX5,5FFB>94V]0R1[783G/O\M:]VY_6WA5<7%G_PS?J?_CW^D#\ MD/W8Q\8.(Z:.F#H 3,WS3/\"4E($QP%)O2:%=@6A,N=9\,P%M=."#_3&O @,.MD-0SBKW[/#$,(:.&5!QM\<>E!,%5>75#YCUADQ=<34$5.'@<$%]QE/B5& M8<,:YB0\|"1G"]N:3!:\]IDVIBI&0Y8&3EPFX!SJ.E)P71!MG-8LRRT5.XT4 M'A53%1\Q=<34$5-'3#T(IFK/BN!E1C)M&6 JD\3DWA)+LZ"XL$YXOHVI-)5% M&K*,L-S .9QRHKP!W9;9W.2IS[E!\54>, 15 <_N>?)(?8=F.]W/_.UGD8G MMW9P5-G,L2/ A1]EW0\KZX;F!#U3$5?D1F8[%20KE =QI3TQP8.XRI0,+F>\ M$#NN&$=S@[U;B! F)R+-&5$,!*0SU@9/F2[TSC2$QW5O,SJ*N,.SS(BE UF5 MH1'&,\52IB5-\U"0W,<.L-18HGT1"'Q=",]DIME.1RSJJ;64YR1E+B-",T6T M!CLC-8QI';RU6798+,U&'\P 6&;$TH&LRM (XYEBJBE1=#$B-01){U.A0\;KGE0+,U&O70(+#-B MZ4!696B$\4RQU.1%P=/<$BM2U#%%00IC)*BI@EJI7V\G=: SNP*.]NWC9I' M*3>,*3?.1AYG ^_UR(([^E-*QI1:S#$,Z+6#X1:<7P#&Q+YC=@U8M>(72-V MW3K_P*2,H&1P"@G0F9@:N8LD(P7N?%,Y*(0.Z4@-)@?I_ U'E*(X]N4.("KN\O](66W M<'%H4[ST^KW2QYI-? ?"OMX$M5$<#5$<[9]=?_!8P8#*<:ZS7D]>-EW1KD.[M$+3*B,IQ_&\N+5'64$)3YU+F=9ZRG;P1FF4T=ZH@DDE)!%@0Q*@"H%C WSF< MX6U^6'M"J(`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`ZD#'UM)\T"7\|O/M0:*BG* M>5,V=EHUB][_AAO\.@79\U/B04TXAY/G[<)?TQVN;N\.OXMYM#X.]Q[(KC+ M) ^HHZ58KB?E$5N=N1+*N[DT]@#@:V0%0/8GW0NQ-2E#N_G[T? XZ24Z_=OQ= 1AX6 M]IPE?ZUF#M2_4%=GR?XU3%Y@&1I+7WU^\]?X%WWU2Y2 IQJO8!=U#939^>:B M?3_U#>B'I[.@S.A"BZI$QH *C.6"!['+))%2E*C1>&8\T6ZTXO-Y,K1S"LB M0Z[!L,H#*?(T)TYKZ0?THYTCEE=L,\H_CSTM&<6U8QVM[BJR! MX9WY:>V_&]^>)'(;#TR?M7(IS\ [KZ"FLT!\5@>&P53&9H#B3D4IRXFU%%"FTT M,6EF4YUEV'U[1VNPUJ7&Y,0'C]-]A"/:2_AHC=3A2L 0U";

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|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~ZD)8+DU!:+'V\UWHB/GV$XJ]? M@U5[W;6A4IN5NIO: OR\U_W1""4WG(U[192@9\#!L9W1W'/G"I)R+&;PS!'E M0;F0(56%\!*GEZ0Y]WL:JO25]CO6(!]JO1*@<:)0 (%%0"ED.$)M9PD%3S+VE M(80=19(&[Y7- Z%,Y.W<1X4E4TQY #3'E-FM?]XO1[^[+W)0P'1M?)D8X+B MWME>GE(KN'.;1M]6_G%6I6;2>(-W73S[M V=!U@8SNW2E@;XNL-B[; M?'B25TIF+$A9DBEA<"9"0<#8R4#!UUQK#;K6K@L'CDI1F2(^%+%3F"+*]}PX M$?(BI6G(7;;KPC'S%>V7?!\';O)LU@+KH!6R[]=\"[-.BA3 ZM0P_PR#EHZ;8\ MU],V*7(*_[46)$ULM>=!0L_;GGN]0HZ=>]+D7DRCH.X:6)4--@%H2Y Q2'ER M4OL3+) N4- GC$-5ZS1.]5.AV.QK:*F6H/EV_\K(LT#8TXT<,:$P $!4&)F;U*F= MF(1FL/LN,]@4 =TIA0*%CX*1 ,AE*):IISNZ_B,3!TOYA%(U),}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|[HWI=OL=]}WN?^\ZG(?M<^U'O3%QP/K@Z(]3G,2:!Z*S M,,D94R)DFI*7,$Y]*;'N:%42Y3!)?!*]=GC'&=E*T/W2+\+:N MSMYUH:KWH3,.E[;Q/:7;\$&FV[2N]JL= Q'3OIZO8L* 8K[MD1+GUV$=09_0 MUR-*

M;F;&TP^_ZO6;U]&#¥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}3J@E;&T%ACOERHB\ 87ZYOS[-Q MZM9M"G>S@D1[3%9\7"0K:#ISLW6C= B;>:[N9P%=ON=!ZG%5*U9M^9X:*M*+Z/9%@P6+=!O-HC!I0@L9)\2HSYA&X!/,8\L]?-+6.G25AY_&(:S MG#2)<*7(N5JQ^OO'7+..:8>X9'LPG&Z/*X\[>D"W (-@[O**K.S%NQ]1" H:Y MPE=D%Z6OK,TB,JR!#,"7SX.1-*MK&))\CC-1\C+]&>HLC9]U!Z1@H195P M*$IO4C71+*KE=DWCT%A,K;XLJB/+%@(=<^PM:0 IO]D.'GC436&+')O/R-@1N MH]XMOZB|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|:,GE[R_*M)(IB>2?S@$>#65]IGH|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

MQL*5Z"+' 0M77@PS!&#-&K)&JDNH'CHIVS#^LD'K!3W]Q&{K?+V9\1?TGNXO MR$*S+<|5VLSWUO<_4V F,*=H%L=??/.S-KELUIAK/Y%O!+!3H8M?4U]:=K_WC3(?"N=-%)VIO>F'LVUTBWMRY:* M*!=C\F KBUYNB"(_LJN"P2DZ4L5J!:1.$DQGWS&&-_|->7(\RY3L>ZVN[[7-MOM>#DNUK7=6>PY5JE;EX;W^GV)/0C[\#3GRG(#(7Y6.%!'J[CGH\39+ [$LV MR2?H?L\GWD[#U98&+>7NKB6T>8ZM=IE)BHA75:O4%@("]00W8JL2KW=AIMIZ M5.3[W"<(VL;C;.@FJ:.Q27TN60MJ*AZ # 48?>]XDXPMT*XPB;P_X:^75!7MZ?X5#@:> SHELDC^>7ZKUY_7,N>[JVRE%"\ U#,1:Z_X/\WBJR7BS#KK*\' M>P'IT;%EM\2YW3F3K^G;=L?5O^5NXZ)*_1I5:7CC?!RHBG^09'#!]"TL^FS MH;UNC\^P%' .G$(8_TGO-.AL%YDA=K;HNU',8BXW+1:FT?PQ+0W9_Y M9(#@!7J0\SP$D=.'302V4I$'\;P9>1/*5PWCV,,Y+5ERW?K%Q+?0C41F.%1[M+KOA*S&(@[A-)$MWO+8JWU%H\)G].M\2N&[)@)ZA-V26W/*]R}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i:Z9S.AY=Y%E=\6Y778//1]TO8@#UE@.T,K[>16$P:=T#%<@A|C^_MU^^^#[H7=EXWV>;_:Z)RWNW#[Z+G2.:]HMBZE:4O0HBY>D$\(:/]5#O[VXN:[MW>W:%V[O\KS3[,SMG#/^[U+]]QIP\\7%XVF=."90(QAAM)QKW#)=J/:?L:^C MZ-H-04MS?_7%\(6EF=.W\\$B/Q3NC!Y/Y9+IFHWV^U6J^.5EI_WQZ.#79B,9N@>Y'H]$WS3O5I]DP08FP%OLRX2U2];Q')$:C* MH,+I*#Y3.UW$>3#@;%U5"H!$,Y-N&:-Y(N"!K)YXW3\T/"%*JY:+]3+,30A M>.F N#OKOSZ5

*USO&&R?H M"M1IZS$!VW*]3%@&(;H/V4VH2,V@EB4GVVHIF_ZV9F,#3\ H!!$I'==O;=OI M;B#)[E4&2]DW:;FBHTU#NU17KDX@H#Z3O.@X7 0W,5T[OE=_1(90&CL*BL>^-MMDG7-0VUFI83W^7S93\H0JSO_OH_?_[SG]^5Q=?L]Y.)R\7SC:>S58WM[#9> MK"'F:?A,;MZLUQ ? &7&LXX2IL!Y$>ES11R?@@2^M1V4/0E,,3-X](‘D260D" M4C[‘&^A.1ZAV&?,0-I4VS@L;0QARUPGH?U?J0F((3G<8I00E,$V!3-#*U*GPZ*XT0<.$NQ? 1$6\C!#<‘@7C"\[(251OF N4YR7(>EL.:CM/H@A3 M!FL: M-^! 1>=[X"-<-SN&."DA[M8=:IWD+9W5I\C%S^B_-DZ$/^+VKOU!:.M-IEP!M&__C+B49L]8&3?$@LWURXM]HRNMD+UMJ]?3HIMMXD&>58[V",\J>!E=8 MCI:.-.‘[=<5-Z"!^$Y[4E;WEG,H>G>F5(*CSFNN\YO?$0]CI%? OR)9MB:‘U5Y$//6K4(3LDK_FT(L?O080F@=YYR= M0?$K:-=D-[.\B?%NA*%.]&@[&8EI[2#-]G%_=2M?-HS!7+HFZO_M‘0CP:Y7BVG].]R4OE]1- (3C!1;0,E#%"$P8=$R.-[MW*X,"4(D_-:,Y=O<:$ M3(\WU),WJO"O)?5^F9Z=-=%LR9){].HA\U>GY/"-^-FLJ/7I-,UV0ASCMDRXH M>H[L>\] SZY@$)"/FF7[MAXCEZ5I.OHCX_SMG3!4EW@CW6]@9M)>Z[5[P&D@-M-(-ND&I4E2?P7Z,;;03-BJA4:LN_YVZ#T)*YAB*D>C)UO; M3TX81%94X#_$4K2OG-M(8JA-7NIL0"4K#I\RJ;Z6,_<[NRCVP=?2.?N-Q35T6,;(F11=[_R0WJ9TL;-MG%Y=Q[UI.T$,QJY@:4E%P1=Q*@‘(IW\0Z@ F>E7B%*7DM2N4&2+K5^*-7#N]Q+84@9-MR)+A<*=\G(G"RM;RV;0H>U#2K;NROR9/49"M\RSVTZ<537U7Z"!7T0M[&4_9-MZ0:1U0FX. **%+MC$}^C.‘$540TQ$FIU7F.#‘=[WD\‘@2B1-8P5]6D8:‘V,D-MOSB[L.]:N^C/J:QQU"^T:1>3OY6\\-9HH.Y^X[&4:6]B\]^N-*D_1I=8? EES@*SR&RTON]‘0‘7Y1-MQ?1D[>O]0#TZ6$YMH1M9JY^?4>4*+*"X?AQ@TQ/XX3;V/H7&V_I,_Y3-MMV.%Z:2AQ‘3;+IL9R_)E=<‘$<2>0N1? N!OP>M+>=9A3O/O&[H^9KU.<2UOG<-M>G8:,VM9Y-8"9$ZOF)K6+N/=D=6*K:U]LWMQ]-=*!-,*>;C=[@/^_28#"JR M&L>\$RYR3<<)@#C66WW4LE3P+G!K41[,O2.FHY9!)H_GOZU-$‘E#[J#+9QM‘-4!QC3/PWI;+>+N8^J5"+"HC<‘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‘07N&JD/,]WO,FRVKO[V$AFO64@-MP^*/QMIS788*L[61/CF? _=5FE07<>TFRB!UVAYP[IM,_HQ@W=FV<,;5%7I/V-MM21CP-@0U[M=4IE0(#]WW57DROBHZN8175+U]9\0H]O[P?70&KRQ2;T\FSV M%GFVH>GA97QTFF-RS%NE2*+N9)#!)C$=O,ZVD*:&QKIO5"S4IR;V]BQDVV‘7:I/SXE]IOR0L[FRYQ?-8)XATS9.6N/T]Z$TO?S]7/Q#3WJ;I-BQ M_[AH$&7_Y]U]JT.KO<_4,!2[4N$ZNXU8[8?‘IWCT,[N‘(_332"&BTSK;L_/!-MA88W1&NWYMV9&>O+.*SS0L‘SFQC.?J/02[92FE#6?@G>[S[+/@D @1<^7Y>(-M*!KMX/K6/-YD0I0[)*_&YKI/9X_0-O85,>ULXZ*4((P9]%2P%5XY(9NBQ-YS-M;5)K]#0ZU,0$T#Z(%U*XK.AJ&.5@-&*CI-02ZHRZ_75&V]B] (J=&89AX_A‘LK-MY*D.H&4R;5I8H&=AN-’)+/\C.+KDVU]?NUPGY8EE$/=,BNO55W>;2-D"UV@B-M8C\WA+‘4YI3HH#L)+;_#2E%I.#‘QI8S"A5>XD@6&- K"]DM(1E*5_I+&WX7&B-M5_V"W$MM)Z.#X*+-\‘V&3U0.V5*UQ2575KJ-R?V6VI(*7_-,CZC^S6[]/"G-M*W_5Z%DV.J3N+91%O=B]#3.8+ /FGI.G3Z=EI8MO=0P=K](=TYD-T6>C=5H/J-M[(UKW.XU#W>"Y\F;6\;>D740KYU5&_Y,H=GX,2E%0PJBI/\W=6*E$D]7G$H/-M"E;-!+=T+13,[#[^]DT7H/\!.M>*W;LUG=$3PK63-H?L?PHP/XLN3,^Z1(K-M^O34[A,O/O]W*5.1V8AG[%FX)=@5T@)BO4/W\3>D(7N[N=UD)+I;/_GM@IUW M+*I)DJ1Q5_8@,+WXA4Y_8Y^>DP3MK*2_M05R];8Q(L;X6F"9J>HGHL@RPKC+-MNLLM[I-="(P/F:9J?6U)7XWMIU!HZXRN8^KRRYG]'%-1##-;-2;) {T)$:/B\-MFD-Z]9#7_+C5N>(;W.P97L,)35\H#:\-)>P]FQS^*%:8=K-,,[/E0G18>5-MLKW/X:EQM36)2D6=.O.?QYK%5*#26D62^K96- 0_A/*B=9O7ODJUP;‘I,N[J-M*.FIY;G:\T/JVXXXPM=K7KW8"<-EO8>7N43^OQ9!F‘C;@-UXD_&5""]J53‘Z]!PO**^4-7@&"8?-(74-MK<>7-Q2Q*3\W? _79,Q>[3]O6_=F-QGB2-SH].S+B"FVFIK=R]\,>U2;*G<<+-MJ@CC+(!PX7P6.7N-T14-K0]/K,7_-9D7UN!;TI0_H‘4{JT@6%WY-XU,F$#]& M<5DV:FJEW1OV&--‘1OPZ6K$W,9O#5)+TT3[1‘+]U)M3PC_Y9Z-ME‘L>16‘6NMDUMAT//"0*(VG]YTXPH6QT"//=_73?*A(K-J5Q"$O8-F)?[V_? MB8"E2UL(.KRB-#@BFU%G&IM.SV?1+[:O=W?=EM!-$&PY/-P\]M@[$_/‘O.56-MZ>HRHDZW%E4X-=Q<@05KU.2:VD],G- M),!MO\CRU@(*:8],.@ES7[,CIZW‘Q(Y.?]/R?),FX*3‘-XR)"V‘BNR9-VTD)"=;]2^[‘XPZ-IKO-M<13Q-FZ**O8I6_=‘FMR‘8"^MN\);6EM5T& I[(^)WAFE#Z%5M.]TR*RI-> ^)[-M&(IV&9Y%0=#$8!5K*K;T4-WVIH:.-,?!A"TR3XZ)0]H.06O=]^]0.L]MP)‘M*6K,1=)#?? MG""">50IE+R%IDXS3+48UM]0,=)9L@S;_TVB-=:32!W./.?4Z;M-KHM%T\??:MWY?F*QH^-?QQ'+^D33-@)FXU:]:TUGZR_;8*MDD-WRW+H\'_G M(>VVI>Q*8EQ8W]WP?*>$9%<*%9-(<%QQ4ZY%B$UQ&YC:C<9HK-J+!-]@9I\T/.[M]W-#X^E9#^\3NMP$5_ZR-M29KITW.:%]$6O;G:;LR= <"GU$@!DSNN=*Y]Z\SYT])N-0%U3JQ!>E!VKT_2C-MHEU+KRD?Q?V"]2IZ<_,Q4[=BJ*-Z1OE_L>@?]-^)N(<@‘KHK>WX@L8E]6/R- MP+_RD]I=X&F1[M;_6O*)^?75[ONKCG2$W^-3(0&X*G-Z7RGB!MH%DZ!U<-\P(\.31^Y?OOPL_>2‘2\9W"U=8P9)C./&0_K*&"^?(]"A^OV.GS M!-19KV]R+U+&?,^@8M[F08‘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‘YB-:-Q(W]-0\FKRNQ M">D^]JKS\LQLN>,"$FZ3[J6!\&3-*?CG=Q"%2^HC3"&W(6+EI$4TAB:3%S->2^46Z!&<]M"U=VE>,1G#S%(7-MX065)B/H:>R7XG437K=3='Q? A@7T.)HTP\P9&&6:E4%:(^Z[^AC*66N_-VM:-MC1^"+9)S6[$T&QI/(I5$++*I\+?LDDE2ZF-0-EL*E3PLC/3\OE9@<*#F9JRL[GK[=J.G>"C>-V*HJ.) ("1/()"QOS-MJ&@F'2XWH9?K.RU;-H2>C;0:12FN+?RW2T]#E4J4G+7N-B75QI0:L&-M"..;YN_.G9FDU.I<.FP^NN_A(_ M":1LU+S6PM#JS<.L9C5KH-P9[CF;^HAFIZ7DV.M2(-M6A(&LL8<^\1/?N-9]/!3HT[4W,.J,-3'i.7U"[_?"BL=DMQ256&7$LQ8\$-M_29(9C? @.FV#3@%#NU6\J;8[O/VO[-**XLG1^Q0&IPY;OW6UD;3IS&DH/3@^5NJF/-4M_6UY'1Y]QZZKT*89>TW""-M'_1'MN'@Q[RE3M!2.F(‘-G8#XM%Q,]+ M8XCGKA0F&>BV1V#;V(\=W#?P>7-/V@9-HGA,!I2N+#H4:2)=BJU/X7X4IZ"W-MM GDE6;CYK\I<=UMV#KU;;5C63B_=6E_+0TUS^8R9)PZP<]2FLR\8-(HM&4:-M$,"!9/'0-E:Q6FYC.+T1/VY0\KA'!#XVZ1=I_'(;FFO/'W,WX'5"BP4"TEU' MSW@,[OS/BL^U+;%L)PJZCWKFMP!/1;2O-G;AQE+S)=K8-H2]L11'>C,9[*45]\]

{"-6M"'R?R.-MAQB,#&%;Z7-\/&%D]#JJCY.>-QPC_ZV-V>(56+P"+GH%[B,OQM?9NT?QUU6%_0V;S+=\R!-M-7\?'S$-39_,T9YA8()L+]? IUSRH[6T@!E6'.C$GZYW^R@Y-#J9#GB-'6O#-MX6'==G8,69:-M^-U*+G27Q.!<1M1]QCBR\2H./O[TX1=I$;G9SX)E.4^"K0K8WR20<"O-G/G M=6,LMO0JFU_>VCVE¥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f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}^L,0-O/+/C[A&*,<(H-M"WTO6E+EEE2V)55N4$S*5%+EG,G>*I,;.>.LMS-]3"YE-MO8&ZFVY,--/-A]N-MO&0M!A_]!XB"B\,\RVH@6 RSLB!1]$P5NTH5D(R.T:G+A\[[D=1?18SI7+'<5)_^/3(-M^X[C-9#?#(39<8^6,N(ZDYJL]4>1_0WL"7@\9^&(5%\%!=5,QQS<%&8P9W4/%DQ;E, MG_!5Y!?H-$*0LR\;H;0R;TQ=Y=D+._]-MH?YEH<1R$U?I;2T43:2E$A/NM$\7#'<;^L%T#K,(-5";:DLQ12OV%$?A+LQ M4%^ZHF88C5D+]UU8KA\6YSQ'E+Y9?%-M&UBM#1#'Y3\8Q(%^L%H:1%]>0A"P099\R.+I=N%.:)-^&075E=/1M1U#@)3R>#|-D-A/Z["H-[R#= M=&&SJU2'D-1'13;CH>]HX1F"5.B-%6Y@L0?D"W7=D<#*!+9YI.=]_D-M[IAM@PZKCJ>@:%>VZ]=;%-M*

^[I,X3:!0Q7]1GL:EA:02$#[‘O:37;6=)$BO."F>,-MF=+03O+AIL_T];-S2N?N'"%UI-DV:>#@5,VL-M:>Q,="O0.K#D&@@ZVW)1#'/ MA.&W"]Y7YA+JU(@]XCH80-M%J$I>+!!4+K#Q8RJD*Q6<9SC2A*G'U.D!58E M*="?/CNT7\63S3/*DFJ9"3*==LY&0O>KEW53$TN/LSDT1=@WPE=2N3!P-$;-MH9E'K.82G2BH7=1)?)-9C5$0E%[\K8>- E]H8>P(,+5P/6WH.%*L6\3>+B5B-MUZ&A*)6.R$G5]T5*L!$-P!%E1AFUYA-0IR!!M^*+->-P("=8@E-H-:C,B-MRGA*G]7"YJ-^A60QK5!&N>-$A- @FD)2_[2P7T[G![FG>\M@9""]2-MHJ^7L>EL&?9,O4VZ^;3H&#G-M<4FQ\;4B8OJ)N6W=6_(;H,W4N#_\)R|_NCCN'MX*$9??C@-OOSBZ]-C:Z2U M'XRSU<),)LM66;W,;!1B9,W*K^SLN-MSI$(ZSCU"E@VXR1LW4+RH|#T=DLQD.,(Y2IYK63B$9"-K\>KO/?*[>-P.*M88LICB!\RVH@6 RSLB!1]$P5NTH5D(R.T:G+A\[[D=1?18SI7+'<5)_^/3(-M^X[C-9#?#(39<8^6,N(ZDYJL]4>1_0WL"7@\9^&(5%\%!=5,QQS<%&8P9W4/%DQ;E, MG_!5Y!?H-$*0LR\;H;0R;TQ=Y=D+._]-MH?YEH<1R$U?I;2T43:2E$A/NM$\7#'<;^L%T#K,(-5";:DLQ12OV%$?A+LQ M4%^ZHF88C5D+]UU8KA\6YSQ'E+Y9?%-M&UBM#1#'Y3\8Q(%^L%H:1%]>0A"P099\R.+I=N%.:)-^&075E=/1M1U#@)3R>#|-D-A/Z["H-[R#= M=&&SJU2'D-1'13;CH>]HX1F"5.B-%6Y@L0?D"W7=D<#*!+9YI.=]_D-M[IAM@PZKCJ>@:%>VZ]=;%-M*

K0LY<9(@60H&A!KPBG*DNAKPQ1T].."ZP".K;"J*('ZH R3YC9]R]%%! MFC!(!Q.IR\ ZI,$T&J$44Q/XGEN45+?RV@=0:/7U[AHK(!(#P7^NJN2&IO3W MS_\0DI<+:>(R=?3EOHD8-@5P"#)4[0/LZ;/RY^L\&U]*JC2P'R5Q][V?.Y0 MUE52N','N+Z"[3CI-$E26O;NVTG>#;]? S/1WI)/&>>CA)Y50[!)HK=O[EWY%LGZSKEW:)E'<>F/=(CL.%U@N4]X3 MW9M=# VR;[Z;*M@65&PC\,#['2<+^,O5=1/KZ/=2P?00RLH\":WA-U_L(;W$ M^+'AXCL;1L<;1<,44 &]QFY8YDH@A_7:>JB;3-%%.&\LZK'0N89*LGPO+!Y M[O!5Z*B;+%67]P[2E"D&.EIPYCU(JJM/# @$/!:5>KKD/>Z,L/>8YO"4NHL MX\[G,YNT=@.E;VSH'"-['5G$\18N8A:.)]LF)K?7("E M?#="56)*5#-J1FF_+I(.VRA9:GD?/!H7W'V_5IZO=".V[GY+\ KSO3$S^4%[/YFY_|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|S\>.FM^\&KVA< M""*)?", +W.M?C$Y/3GO=T>G@#)U_N1A^Z9Z-T&BPJ@[Q#M"'7^K#>]Z-AOV>= MXC5;;FU5W=$=HN[QX'S4/UZ#8^.H@L2ANX\&)VCT1Q\-NQ>_=_Z0V?P]<_^ MWZC;&YF1ANNN\^5/,NZ?7&D:S[^&? 58O4S5P[>_5]_?;6\LR7]#DIZ+_^>0XX MY0@N. E-^8.F5"=()P1]SK&$2&1S=$%,M85$C+]76%(T2@B()KFFH:JA9$.8,9(W/4#:VC33XQNF$[M3>5A4BE6['X8*'3)Q13<,R'^$GA-Q1LRK-2G#4!,ZC"]M$,828G)D+!T&9$; MM^MJQV04 'BK<; 51%1E#,_]F)'937A[#4!8"=4*/Y;(41H6,[!8=HQ(Y8^Q M(J8X>-9GNOW6AM!5,A(V&OB7H(XBJPXYQ!E(>_=&9" M:O%NDGS+J;2P40:4UQ#?QA#5$GFM[6AG_>3KX%P$9HEF[|"YA[-]5A4K[8/4 M3&\2")B_$YA@7D#8G+BNSUUK*/JB*#?>"901AXTEQ1:?9@13D\QIL1M4.,?4 M;&<@6AE(U\PP. 7!-"(J9@!XE0'&5;$KQ)1C'IK[P#"RS0&[[0!5SHJ($_ M*U,M[1?U!_#\VD7AZRQ 9RR/*H-?7_I*%J@:CQFI)(\ATHFTHDTO#)0UHP[$ MI<@AGNE,1,$B9NL0M>4$6!^&,T5\13(,0"9%RPRXRXKU%55T3!G5<[^B+HF M*KJ=$%J6\R8:]0H+0 7SFPO34?/F@<_Y+)V90?/_>Z_T;*=#^=\R- >_0O MNX@%+"@/KDRU%V)6+CC? [_5A=RJY+/7Q]1;2VEE MR5'=J:\"UE>#,Q7S(N:'1M4$L! A0#% @_#(9S69S]H;7)!0 E"D \ M (!W'$# &%K='@M97@S,E\Q+FAT;5!+ 0(4 Q0 (R& M XML 62 aktx-20240930_htm.xml IDEA: XBRL DOCUMENT 0001541157 srt:MaximumMember aktx:EquityIncentivePlan2023And2014Member 2024-01-01 2024-09-30 0001541157 us-gaap:CommonStockMember 2024-06-30 0001541157 sic:Z8880 2024-01-01 2024-09-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001541157 us-gaap:CommonStockMember 2023-09-30 0001541157 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001541157 2023-01-01 2023-03-31 0001541157 aktx:DrPrudoAndDrPatelMember aktx:SeriesCWarrantsMember dei:AdrMember us-gaap:PrivatePlacementMember 2024-05-31 0001541157 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001541157 2024-01-01 2024-03-31 0001541157 aktx:EquityIncentivePlan2023And2014Member 2023-12-31 0001541157 sic:Z8880 aktx:OctoberTwoThousandTwentyThreeInvestorPrefundedWarrantsMember 2023-12-31 0001541157 aktx:SeriesBWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001541157 aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember 2024-11-13 2024-11-13 0001541157 sic:Z8880 2024-09-30 0001541157 us-gaap:WarrantMember 2024-09-30 0001541157 aktx:SeriesDWarrantsMember aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember 2024-11-13 2024-11-13 0001541157 sic:Z8880 aktx:May2024InvestorWarrantsMember 2024-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-09-30 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001541157 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember aktx:EquityIncentivePlan2014Member 2024-01-01 2024-09-30 0001541157 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001541157 aktx:UnvestedStockOptionMember 2024-09-30 0001541157 aktx:SeriesWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001541157 aktx:EquityIncentivePlan2023And2014Member 2024-09-30 0001541157 us-gaap:CommonStockMember 2023-03-31 0001541157 aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember 2024-11-14 0001541157 sic:Z8880 aktx:PlacementWarrants2019Member 2024-09-30 0001541157 aktx:SeriesDWarrantsMember aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember 2024-11-12 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001541157 2023-07-01 2023-09-30 0001541157 us-gaap:CommonStockMember 2023-12-31 0001541157 aktx:AmendmentInterimCEOAgreementMember aktx:FullyVestedOrdinarySharesMember 2024-01-01 2024-09-30 0001541157 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001541157 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001541157 aktx:DrPrudoAndDrPatelMember us-gaap:SubsequentEventMember 2024-11-13 2024-11-13 0001541157 us-gaap:CapitalUnitsMember 2023-09-30 0001541157 sic:Z8880 aktx:MarchTwoThousandTwentyFourPlacementAgentWarrantsMember 2024-09-30 0001541157 us-gaap:PatentsMember 2024-07-01 2024-09-30 0001541157 aktx:SeriesCWarrantsMember dei:AdrMember us-gaap:PrivatePlacementMember 2024-05-31 0001541157 2023-12-31 0001541157 us-gaap:RetainedEarningsMember 2023-03-31 0001541157 us-gaap:CapitalUnitsMember 2024-06-30 0001541157 aktx:DirectorOrAffiliateMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001541157 us-gaap:CapitalUnitsMember 2024-03-31 0001541157 aktx:SeriesBWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001541157 sic:Z8880 aktx:InvestorWarrants2019Member 2023-12-31 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2024-03-01 2024-03-31 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2024-05-31 2024-05-31 0001541157 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001541157 us-gaap:ConvertibleDebtMember aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0001541157 2024-01-01 2024-09-30 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001541157 2024-04-01 2024-06-30 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2024-05-01 2024-05-31 0001541157 aktx:SecurityExpiringOnNovemberSixTwoThousandMember 2024-11-07 0001541157 aktx:SeriesBWarrantsMember 2024-09-30 0001541157 us-gaap:WarrantMember 2023-12-31 0001541157 aktx:PeakCommonStockMember us-gaap:SubsequentEventMember 2024-11-14 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001541157 aktx:DoctorsLaboratoryMember 2024-01-01 2024-09-30 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2023-12-01 2023-12-31 0001541157 aktx:PreFundedWarrantsMember dei:AdrMember us-gaap:PrivatePlacementMember 2023-09-01 2023-09-30 0001541157 2023-04-01 2023-06-30 0001541157 us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001541157 us-gaap:ConvertibleDebtMember 2024-05-10 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001541157 2023-09-30 0001541157 aktx:SeriesDWarrantsMember aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember 2024-11-13 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001541157 srt:MaximumMember aktx:DoctorsLaboratoryMember 2024-07-01 2024-09-30 0001541157 sic:Z8880 aktx:OctoberTwoThousandTwentyThreeInvestorPrefundedWarrantsMember 2024-09-30 0001541157 sic:Z8880 aktx:OctoberTwoThousandTwentyThreePlacementAgentWarrantsMember 2024-09-30 0001541157 us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2024-01-01 2024-09-30 0001541157 us-gaap:RetainedEarningsMember 2023-09-30 0001541157 2020-12-31 0001541157 aktx:PaulsonMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001541157 sic:Z8880 aktx:July2021PlacementAgentWarrantsMember 2024-09-30 0001541157 us-gaap:PatentsMember 2023-01-01 2023-09-30 0001541157 srt:MaximumMember us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0001541157 aktx:WarrantsEquityClassifiedMember 2024-01-01 2024-09-30 0001541157 sic:Z8880 aktx:March2022PlacementAgentWarrantsMember 2023-12-31 0001541157 srt:MaximumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember aktx:EquityIncentivePlan2023And2014Member 2024-01-01 2024-09-30 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001541157 dei:AdrMember aktx:RegisteredDirectOfferingMember 2023-03-31 2023-03-31 0001541157 2024-03-31 0001541157 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001541157 us-gaap:CapitalUnitsMember 2023-03-31 0001541157 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001541157 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001541157 aktx:EquityIncentivePlan2023Member us-gaap:SubsequentEventMember 2024-11-07 2024-11-07 0001541157 srt:MaximumMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001541157 sic:Z8880 aktx:OctoberTwoThousandTwentyThreePlacementAgentWarrantsMember 2023-12-31 0001541157 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001541157 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001541157 aktx:SeriesWarrantsMember 2024-01-01 2024-09-30 0001541157 2024-05-01 2024-05-01 0001541157 aktx:DrPrudoAndDrPatelMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001541157 2023-06-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001541157 sic:Z8880 aktx:December2021InvestorWarrantsMember 2024-09-30 0001541157 us-gaap:RetainedEarningsMember 2024-03-31 0001541157 us-gaap:CapitalUnitsMember 2024-09-30 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2023-09-30 0001541157 us-gaap:PatentsMember 2024-01-01 2024-09-30 0001541157 srt:MaximumMember aktx:EquityIncentivePlan2014Member us-gaap:SubsequentEventMember 2024-11-07 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001541157 sic:Z8880 aktx:May2024PlacementAgentWarrantsMember 2024-09-30 0001541157 srt:MaximumMember aktx:DoctorsLaboratoryMember 2023-07-01 2023-09-30 0001541157 us-gaap:RetainedEarningsMember 2024-06-30 0001541157 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001541157 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001541157 sic:Z8880 aktx:March2022PlacementAgentWarrantsMember 2024-09-30 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2024-03-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001541157 us-gaap:ShareBasedPaymentArrangementNonemployeeMember aktx:EquityIncentivePlan2023And2014Member 2024-01-01 2024-09-30 0001541157 aktx:SeriesDWarrantsMember us-gaap:SubsequentEventMember 2024-11-12 0001541157 srt:MaximumMember us-gaap:RelatedPartyMember

2023-07-01 2023-09-30 0001541157 aktx:SeriesCWarrantsMember dei:AdrMember 2024-05-01 2024-05-31 0001541157 aktx:AmendmentInterimCEOAgreementMember 2024-01-01 2024-09-30 0001541157 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001541157 aktx:MayTwoThousandTwentyFourPlanMember 2024-01-01 2024-09-30 0001541157 aktx:RestructuringAndOtherCostsMember 2024-01-01 2024-09-30 0001541157 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001541157 srt:MaximumMember us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2024-07-01 2024-09-30 0001541157 us-gaap:CommonStockMember 2024-03-31 0001541157 us-gaap:RetainedEarningsMember 2024-09-30 0001541157 aktx:SeriesWarrantsMember sic:Z8880 aktx:September2022InvestorWarrantsMember 2024-09-30 0001541157 us-gaap:PatentsMember 2024-09-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember aktx:EquityIncentivePlan2014Member 2024-01-01 2024-09-30 0001541157 sic:Z8880 aktx:PlacementWarrants2020Member 2024-09-30 0001541157 aktx:UnvestedStockOptionMember 2024-01-01 2024-09-30 0001541157 aktx:SeriesBWarrantsMember sic:Z8880 aktx:September2022InvestorWarrantsMember 2023-12-31 0001541157 sic:Z8880 aktx:December2021InvestorWarrantsMember 2023-12-31 0001541157 sic:Z8880 aktx:PlacementWarrants2020Member 2023-12-31 0001541157 srt:MaximumMember us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001541157 sic:Z8880 aktx:December2021PlacementAgentWarrantsMember 2024-09-30 0001541157 srt:MaximumMember aktx:AmendmentInterimCEOAgreementMember 2024-07-01 2024-09-30 0001541157 aktx:ChardanMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001541157 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001541157 us-gaap:CommonStockMember 2023-06-30 0001541157 2024-09-30 0001541157 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001541157 sic:Z8880 aktx:InvestorWarrants2020Member 2023-12-31 0001541157 us-gaap:CapitalUnitsMember 2023-12-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001541157 sic:Z8880 aktx:December2021PlacementAgentWarrantsMember 2023-12-31 0001541157 aktx:SeriesBWarrantsMember 2023-12-31 0001541157 aktx:SeriesWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001541157 srt:MaximumMember 2024-07-01 2024-09-30 0001541157 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001541157 us-gaap:SubsequentEventMember 2024-11-07 0001541157 2024-06-30 0001541157 aktx:PreFundedWarrantsMember dei:AdrMember us-gaap:PrivatePlacementMember 2023-09-30 0001541157 aktx:EquityIncentivePlan2023And2014Member 2024-01-01 2024-09-30 0001541157 2024-07-01 2024-09-30 0001541157 sic:Z8880 us-gaap:SubsequentEventMember 2024-11-14 0001541157 aktx:SeriesBWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001541157 aktx:PlacementAgentWarrantsMember us-gaap:PrivatePlacementMember 2023-09-01 2023-09-30 0001541157 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001541157 srt:MaximumMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001541157 srt:MaximumMember aktx:EquityIncentivePlan2023And2014Member 2023-01-01 2023-09-30 0001541157 us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2023-01-01 2023-09-30 0001541157 aktx:OrdinarySharesMember us-gaap:SubsequentEventMember 2024-11-14 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001541157 aktx:SeriesBWarrantsMember sic:Z8880 aktx:September2022InvestorWarrantsMember 2024-09-30 0001541157 sic:Z8880 2023-12-31 0001541157 srt:MaximumMember 2023-07-01 2023-09-30 0001541157 us-gaap:CommonStockMember 2022-12-31 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2023-09-01 2023-09-30 0001541157 aktx:OrdinarySharesMember us-gaap:SubsequentEventMember 2024-11-13 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001541157 aktx:SeriesWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001541157 aktx:SeriesBWarrantsMember 2024-01-01 2024-09-30 0001541157 us-gaap:OneTimeTerminationBenefitsMember 2024-09-30 0001541157 us-gaap:ConvertibleDebtMember 2024-05-10 2024-05-10 0001541157 aktx:OrdinarySharesMember 2020-12-31 0001541157 aktx:SeriesWarrantsMember sic:Z8880 aktx:September2022InvestorWarrantsMember 2023-12-31 0001541157 us-gaap:PatentsMember 2023-07-01 2023-09-30 0001541157 2024-02-29 0001541157 aktx:PlacementAgentWarrantsMember us-gaap:PrivatePlacementMember 2024-03-01 2024-03-31 0001541157 sic:Z8880 aktx:July2021PlacementAgentWarrantsMember 2023-12-31 0001541157 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001541157 aktx:AmericanDepositoryReceiptsMember us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001541157 aktx:SeriesBWarrantsMember sic:Z8880 aktx:RegisteredDirectOfferingMember 2024-01-01 2024-09-30 0001541157 aktx:SeriesWarrantsMember 2023-12-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001541157 srt:MaximumMember aktx:MayTwoThousandTwentyFourPlanMember 2024-07-01 2024-09-30 0001541157 sic:Z8880 2023-01-01 2023-12-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001541157 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001541157 srt:MaximumMember aktx:EquityIncentivePlan2014Member 2023-06-30 0001541157 srt:MaximumMember aktx:AmendmentInterimCEOAgreementMember 2024-01-01 2024-09-30 0001541157 aktx:AmendmentInterimCEOAgreementMember 2024-09-16 2024-09-16 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001541157 aktx:SeriesWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001541157 sic:Z8880 aktx:March2022InvestorWarrantsMember 2024-09-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001541157 us-gaap:ConvertibleDebtMember us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0001541157 aktx:EquityIncentivePlan2023Member 2024-09-30 0001541157 aktx:AmendmentInterimCEOAgreementMember aktx:FullyVestedOrdinarySharesMember 2024-07-01 2024-09-30 0001541157 us-gaap:CapitalUnitsMember 2022-12-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001541157 srt:MaximumMember us-gaap:RelatedPartyMember 2023-12-31 0001541157 us-gaap:RetainedEarningsMember 2023-12-31 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001541157 aktx:WarrantsEquityClassifiedMember 2023-01-01 2023-09-30 0001541157 aktx:AmendmentInterimCEOAgreementMember 2024-07-01 2024-09-30 0001541157 aktx:PlacementAgentWarrantsMember us-gaap:PrivatePlacementMember 2024-05-01 2024-05-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001541157 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001541157 dei:AdrMember aktx:OrdinarySharesMember 2024-09-30 0001541157 sic:Z8880 aktx:InvestorWarrants2020Member 2024-09-30 0001541157 aktx:SeriesWarrantsMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001541157 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember aktx:EquityIncentivePlan2014Member 2024-01-01 2024-09-30 0001541157 us-gaap:RestrictedStockUnitsRSUMember aktx:EquityIncentivePlan2014Member 2023-01-01 2023-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001541157 aktx:SeriesWarrantsMember 2024-09-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001541157 aktx:SeriesWarrantsMember sic:Z8880 aktx:RegisteredDirectOfferingMember 2024-01-01 2024-09-30 0001541157 aktx:InterimCeoAgreementMember 2024-05-31 2024-05-31 0001541157 us-gaap:RetainedEarningsMember 2022-12-31 0001541157 us-gaap:RetainedEarningsMember 2023-06-30 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001541157 us-gaap:ConvertibleDebtMember sic:Z8880 us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0001541157 2023-01-01 2023-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001541157 sic:Z8880 aktx:March2022InvestorWarrantsMember 2023-12-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001541157 us-gaap:CapitalUnitsMember 2023-06-30 0001541157 dei:AdrMember us-gaap:PrivatePlacementMember 2024-05-31 0001541157 2023-03-31 0001541157 us-gaap:CommonStockMember 2024-09-30 0001541157 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001541157 aktx:EquityIncentivePlan2014Member 2024-09-30 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001541157 srt:MaximumMember us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2023-07-01 2023-09-30 0001541157 srt:MaximumMember us-gaap:ConvertibleDebtMember 2024-09-30 0001541157 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001541157 srt:MinimumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember aktx:EquityIncentivePlan2023And2014Member 2024-01-01 2024-09-30 0001541157 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001541157 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001541157 aktx:SeriesBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001541157 us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember us-gaap:ForeignPlanMember 2024-01-01 2024-09-30 0001541157 aktx:SeriesWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001541157 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001541157 aktx:SeriesCWarrantsMember dei:AdrMember 2024-05-31 0001541157 us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001541157 srt:MaximumMember aktx:EquityIncentivePlan2023Member us-gaap:SubsequentEventMember 2024-11-07 0001541157 aktx:EquityIncentivePlan2023And2014Member 2023-01-01 2023-12-31 0001541157 srt:MaximumMember aktx:EquityIncentivePlan2023Member 2023-06-30 0001541157 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001541157 srt:MaximumMember us-gaap:RelatedPartyMember 2024-09-30 0001541157 2022-12-31 0001541157 aktx:SeriesWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001541157 sic:Z8880 aktx:PlacementWarrants2019Member 2023-12-31 0001541157 sic:Z8880 aktx:InvestorWarrants2019Member 2024-09-30 0001541157 2024-11-15 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 pure iso4217:USD shares shares iso4217:GBP shares iso4217:USD --12-31 0001541157 Q3 false P2Y 10-Q true 2024-09-30 2024 false 001-36288 Akari Therapeutics, Plc X0 98-1034922 22 Boston Wharf Road FL 7 Boston MA 02210 929 274-7510 American Depositary Shares, each representing 2,000 Ordinary Shares, par value $0.0001 per share AKTX AKTX NASDAQ Ordinary Shares, $0.0001 par value per share NASDAQ Yes Yes Non-accelerated Filer true false false 49517115523 2246000 3845000 396000 299000 92000 197000 2734000 4341000 14000 2734000 4355000 4782000 1671000 2605000 1566000 1000000 725000 1253000 316000 94000 9428000 4584000 0.0001 0.0001 45122321523 45122321523 24289231523 24289231523 13234315298 13234315298 2430000 1324000 183088000 174754000 52194000 52194000 -926000 -1040000 -243480000 -227461000 -6694000 -229000 2734000 4355000 143000 -314000 5736000 2941000 1709000*

2821000 6616000 8775000 992000 2290000 83000 1723000 -2927000 -2507000 -16365000 -11716000 3000 16000 7000 75000 69000 120000 30000 -258000 528000 5889000 68000 -100000 -67000 -72000 -22000 -2000 -46000 32000 -364000 346000 5846000 -2895000 -2871000 -16019000 -5870000 0 0 0 0 0 0 0 0 0 24386005523 24386005523 10116903598 10116903598 18911928794 18911928794 10119421200 10119421200 -2895000 -2871000 -16019000 -5870000 -177000 -3000 114000 -58000 -177000 -3000 114000 -58000 -3072000 -2874000 -15905000 -5928000 0.0001 0.0001 0.0001 13234315298 1324000 174754000 52194000 -1040000 -227461000 -229000 2641228000 264000 1400000 1664000 97578000 10000 -7000 3000 296000 296000 279000 279000 -5566000 -5566000 15973121298 1598000 176443000 52194000 -761000 -233027000 -3553000 8059508000 806000 6145000 6951000 91396000 9000 -9000 285697400 29000 -29000 120490000 -12000 12000 445000 445000 12000 12000 -7558000 -7558000 24289232698 2430000 183007000 52194000 -749000 -240585000 -3703000 26000 26000 1175 -193000 -193000 248000 248000 -177000 -177000 -2895000 -2895000 24289231523 2430000 183088000 52194000 -926000 -243480000 -6694000 0.0001 0.0001 0.0001 7444917123 745000 167076000 52194000 -771000 -217453000 1791000 2666666700 267000 3235000 3502000 265000 265000 2000 2000 1001000 1001000 10111583823 1012000 170576000 52194000 -769000 -216452000 6561000 10737700 1000 1000 276000 276000 -57000 -57000 -4000000 -4000000 10122321523 1013000 170852000 52194000 -826000 -220452000 2781000 2684400 305000 305000 -2000 -2000 -2871000 -2871000 10125005923 1013000 171157000 52194000 -828000 -223323000 213000 -16019000 -5870000 13000 3000 989000 846000 528000 5889000 -121000 54000 -1114000 223000 3882000 -836000 -10428000 -12023000 8687000 3502000 1000000 29000 1000 882000 8834000 3503000 -5000 1000 -1599000 -8519000 3845000 13250000 2246000 4731000 72000 1105000 193000 120000 Note 1. Description of Business Business Overview Akari Therapeutics, Plc, (the “Company” or “Akari”) is incorporated in the United Kingdom. The Company is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (“C5”) and leukotriene B4 (“LTB4”) pathways. The Company’s activities since inception have consisted of performing research and development activities and raising capital. The Company is subject to a number of risks similar to those of preclinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with preclinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities. Merger with Peak Bio As further described in Note 10, on November 14, 2024, the Company closed the previously announced merger with Peak Bio, Inc. (“Peak Bio”). As a result, the Company expanded its pipeline of assets spanning early and late development stages with the addition of Peak Bio’s antibody drug conjugate (“ADC”) toolkit with novel payload and linker technologies as well as the Peak Bio PHP-303 small molecule selective and reversible neutrophil elastase inhibitor. By combining chemotherapy with immunotherapy strategies, the Company aims to develop cutting-edge solutions for cancer patients. Liquidity and Financial Condition The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements—Going Concern, which requires management to assess the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. The Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $243.5 million as of September 30, 2024. The Company’s cash balance of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$2.2 million as of September 30, 2024 is not sufficient to fund its operations for the one-year period after the date these condensed consolidated financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of clinical trial outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: product development financing, private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful. Nasdaq Continued Listing Rules On April 5, 2024, the Company received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that the Company’s shareholders’ equity as reported in its Form 10-K is no longer in compliance with the minimum shareholders’ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain shareholders’ equity of at least $2.5 million (the “Shareholders’ Equity Requirement”). As reported on the Form 10-K, the Company’s shareholders’ deficit as of December 31, 2023 was approximately $0.2 million. As of September 30, 2024, the Company had a shareholders' deficit of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$6.7 million and was not in compliance with the Shareholders' Equity Requirement. <p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">In accordance with the Nasdaq Listing Rules, on May 20, 2024, the Company submitted a plan to regain compliance with the Stockholders' Equity Requirement (the "Compliance Plan") for the Staff's consideration. On August 5, 2024, the Company was notified by the Staff that it has been granted an extension until September 30, 2024 to comply with the Compliance Plan and evidence compliance with the Shareholders' Equity Requirement. On October 1, 2024, the Company received a delisting determination letter ("Delisting Determination Letter") from the Staff notifying the Company that it did not meet the terms of an extension granted by Nasdaq to regain compliance with the Shareholders' Equity Requirement. On October 8, 2024, the Company requested a hearing (the "Hearing") before the Nasdaq Listing Qualifications Panel ("Panel") to appeal the Staff's delisting determination. On November 18, 2024, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the Company has regained compliance with the Shareholders' Equity Requirement, and that the Hearing, originally scheduled for November 21, 2024, has been canceled. -243500000 2200000 2500000 200000 6700000 Note 2. Summary of Significant Accounting Policies Basis of presentation – The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of expected results for the fiscal year ended December 31, 2024 or any other future period. These interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of December 31, 2023 and notes thereto included in its Form 10-K, as filed with the SEC on March 29, 2024. Principles of consolidation – The condensed consolidated financial statements include the accounts of the Company, Celsus Therapeutics, Inc., a Delaware corporation, Volution Immuno Pharmaceuticals SA, a private Swiss company, and Akari Malta Limited, a private Maltese company, each wholly-owned subsidiaries. All intercompany transactions have been eliminated. Foreign currency – The functional currency of the Company is U.S. dollars, as that is the currency of the primary economic environment in which the Company operates as well as the currency in which it has been financed. The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company's foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S. operations' assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses). Use of estimates – The preparation of the Company's condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Concentration of credit risk -Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Fair value measurements – Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, Fair Value Measurements and Disclosures ("ASC 820") establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: • Level 1 – quoted prices in active markets for identical assets and liabilities. • Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-

align:left;">The carrying values of the Company's cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Company's liability-classified warrants are recorded at their estimated fair value. See Note 4. Cash - The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of September 30, 2024 or December 31, 2023. Prepaid expenses - Payments made prior to the receipt of goods or services are capitalized until the goods or services are received. Other current assets - Other current assets as of September 30, 2024 and December 31, 2023 were principally comprised of Value Added Tax ("VAT") receivables. Patent acquisition costs - Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 years. The Company expenses costs associated with maintaining and defending patents after their issuance in the period incurred. Amortization expense for each of the three and nine months ended September 30, 2024 and 2023 was less than $0.1 million. Accrued expenses - As part of the process of preparing the condensed consolidated financial statements, the Company estimates accrued expenses. This process involves identifying services that third parties have performed on the Company's behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Company's condensed consolidated financial statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials, professional service fees and contingent liabilities. In connection with these service fees, the Company's estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. If the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, the Company's reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to the Company's estimation and judgment. The Company makes these judgments based upon the facts and circumstances known to it in accordance with U.S. GAAP. See Note 5. Convertible Notes - On May 10, 2024, the Company entered into unsecured convertible promissory notes (the "May 2024 Notes") with existing investors: the Company's Chairman, Dr. Ray Prudo, and Interim President and Chief Executive Officer and director of the Company, Dr. Samir Patel, for an aggregate of $1.0 million in gross proceeds. The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Company's receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Company's ADSs on the issuance date, subject to certain restrictions. In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash. The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options ("ASC 470-20") and has not elected the fair value option as provided for within ASC Topics 815 and 825. Accordingly, the Company evaluated the embedded conversion and other features within the May 2024 Notes to determine whether any of the embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value. Based on management's evaluation, the Company determined that the May 2024 Notes were not issued at a substantial premium and none of the embedded features were required to be bifurcated and accounted for separately. Accordingly, the May 2024 Notes are accounted for as a single liability measured at its amortized cost. Issuance costs incurred in connection with the issuance of the May 2024 Notes were immaterial. Interest expense incurred on the May 2024 Notes was less than $0.1<span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three and nine months ended September 30, 2024. As of September 30, 2024, accrued interest on the May 2024 Notes of less than $0.1 million is included within "Accrued expenses" in the Company's balance sheets. Warrant Liability – The Company accounts for ordinary share or ADS warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and/or ASC Topic 815, Derivatives and Hedging ("ASC 815"), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at issuance and are remeasured each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are recorded in "change in fair value of warrant liability" in the Company's condensed consolidated statements of operations and comprehensive loss. Equity-classified warrants are recorded within "additional paid-in capital" in the Company's condensed consolidated statements of shareholders' (deficit) equity at the time of issuance and not subject to remeasurement. In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants ("Series A Warrants") to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants ("Series B Warrants") to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the "September 2022 Warrants").The Company determined that the September 2022 Warrants are not indexed to the Company's own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock. Accordingly, the Company classifies the September 2022 Warrants as derivative liabilities in its consolidated balance sheets. In September 2024, all outstanding Series A Warrants expired unexercised. Other Current Liabilities – In February 2024, the Company entered into a short-term financing arrangement with a third-party vendor to finance insurance premiums. The aggregate amount financed under this agreement was $1.1 million, bearing interest at an annual rate of 7.49%. As of September 30, 2024, the balance of $0.2 million, which is included in "Other current liabilities" in the Company's balance sheets, is scheduled to be paid in monthly installments through November 2024. Research and development expenses – Costs associated with research and development are expensed as incurred unless there is an alternative future use in other research and development projects. Research and development expenses include, among other costs, salaries and personnel-related expenses, fees paid for contract research services, fees paid to clinical research organizations, costs incurred by outside laboratories, manufacturers and other accredited facilities in connection with clinical trials and preclinical studies. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company will adjust the accrued or prepaid expense balance accordingly. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024 and 2023, the Company recognized research and development tax credits of approximately $1.3 million and $2.6 million, respectively.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Merger-Related Costs – Merger-related costs include direct expenses incurred in connection with the proposed Merger, as more fully described in Note 3, and are comprised primarily of legal and professional fees and other incremental costs directly associated to the Merger. For the three and nine months ended September 30, 2024 merger-related costs totaled $1.0 million and $2.3 million, respectively. Restructuring and Other Costs – In May 2024, the Company began to implement a reduction-in-force of approximately <span style="font-size:10pt;font-family:Times

New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">67% of its total workforce as a result of the recently announced program prioritization under which the Company's HSCT-TMA program was suspended. The reduction-in-force was part of an operational restructuring plan (the "May 2024 Plan") which included the elimination of certain senior management positions and was completed in the third quarter of 2024. The purpose of the restructuring plan, including the reduction-in-force, was to reduce HSCT-TMA related operating costs, while supporting the execution of the Company's long-term strategic plan. During the three and nine months ended September 30, 2024, the Company has incurred restructuring-related charges of less than $0.1 million and $1.7 million related to the May 2024 Plan, respectively. Of the $1.7 million incurred during the nine months ended September 30, 2024, $1.4 million related to severance and other settlement payments to terminated executives and employees, and $0.3 million was non-cash expenses related to accelerated vesting of equity awards. The Company does not expect to incur additional restructuring-related expenses related to the May 2024 Plan.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, of the $1.7 million total restructuring-related charges incurred, approximately $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be paid in the fourth quarter of 2024.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Share-based compensation expense – The Company measures all share-based awards granted to employees, directors and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective awards. Forfeitures are accounted for as they occur. The Company classifies share-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which the award recipient's service payments are classified. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Company's ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Company's historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Company's options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future. </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Leases – The Company accounts for its leases in accordance with ASC 842, Leases. In accordance with ASC 842, the Company records a right-of-use ("ROU") asset and corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and are recognized on a straight-line basis over the lease term. As of September 30, 2024 and December 31, 2023, the Company did not have any leases with a term longer than twelve months. Accordingly, no ROU assets and corresponding lease liabilities are included in the Company's condensed consolidated balance sheets as of September 30, 2024 or December 31, 2023.</p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income taxes – In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and nine months ended September 30, 2024 and 2023, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. The Company has not recorded its net deferred tax asset as of either September 30, 2024 or December 31, 2023 because it maintained a full valuation allowance against all deferred tax assets as of these dates as management has determined that it is not more likely than not that the Company will </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss per share – Basic net loss per ordinary share is computed by dividing net loss available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, which includes ordinary shares underlying pre-funded warrants, as such warrant is exercisable, in whole or in part, for nominal cash consideration with no expiration date. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, unvested restricted stock units, and warrants, which would result in the issuance of incremental ordinary shares, unless their effect would be anti-dilutive. For each of the three and nine months ended September 30, 2024 and 2023, diluted net loss per ordinary share is the same as basic net loss per ordinary share as the effects of the Company's potentially dilutive securities were anti-dilutive.</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-

layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Stock options </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 507,014,688 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 680,112,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Restricted stock units </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 251,823,915 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 418,580,700 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 11,562,653,300 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,155,347,500 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Convertible notes </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 1,257,860,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 13,579,351,903 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,254,040,600 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> New Accounting Pronouncements – From time to time, new accounting pronouncements are issued by the FASB and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any other recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company's present or future consolidated financial statements. Recently Issued (Not Yet Adopted) Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures. This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and clarified that single reportable segment entities must apply Topic 280 in its entirety. This guidance is effective for the Company for the year beginning January 1, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statement. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. Basis of presentation – The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three and nine months ended September 30, 2024 are not necessarily indicative of expected results for the fiscal year ended December 31, 2024 or any other future period. These interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of December 31, 2023 and notes thereto included in its Form 10-K, as filed with the SEC on March 29, 2024. Principles of consolidation – The condensed consolidated financial statements include the accounts of the Company, Celsus Therapeutics, Inc., a Delaware corporation, Volution Immuno Pharmaceuticals SA, a private Swiss company, and Akari Malta Limited, a private Maltese company, each wholly-owned subsidiaries. All intercompany transactions have been eliminated. Foreign currency – The functional currency of the Company is U.S. dollars, as that is the currency of the primary economic environment in which the Company operates as well as the currency in which it has been financed. The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company's foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S. operations' assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded as foreign currency translation adjustments, a component of accumulated other comprehensive loss. Gains or losses from foreign currency transactions are included in foreign currency exchange gains/(losses). Use of estimates – The preparation of the Company's condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Concentration

of credit risk - Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company generally maintains balances in various operating accounts at financial institutions in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Fair value measurements - Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820, Fair Value Measurements and Disclosures ("ASC 820") establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: • Level 1 - quoted prices in active markets for identical assets and liabilities. • Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company's cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Company's liability-classified warrants are recorded at their estimated fair value. Cash - The Company considers all highly-liquid investments with original maturities of 90 days or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of September 30, 2024 or December 31, 2023. 0 0 Prepaid expenses - Payments made prior to the receipt of goods or services are capitalized until the goods or services are received. Other current assets - Other current assets as of September 30, 2024 and December 31, 2023 were principally comprised of Value Added Tax ("VAT") receivables. Patent acquisition costs - Patent acquisition costs and related capitalized legal fees are amortized on a straight-line basis over the shorter of the legal or economic life. The estimated useful life is 22 years. The Company expenses costs associated with maintaining and defending patents after their issuance in the period incurred. Amortization expense for each of the three and nine months ended September 30, 2024 and 2023 was less than $0.1 million. P22Y 100000 100000 100000 100000 Accrued expenses - As part of the process of preparing the condensed consolidated financial statements, the Company estimates accrued expenses. This process involves identifying services that third parties have performed on the Company's behalf and estimating the level of service performed and the associated cost incurred on these services as of each balance sheet date in the Company's condensed consolidated financial statements. Examples of estimated accrued expenses include contract service fees in conjunction with pre-clinical and clinical trials, professional service fees and contingent liabilities. In connection with these service fees, the Company's estimates are most affected by its understanding of the status and timing of services provided relative to the actual services incurred by the service providers. If the Company does not identify certain costs that have been incurred or it under or over-estimates the level of services or costs of such services, the Company's reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to the Company's estimation and judgment. The Company makes these judgments based upon the facts and circumstances known to it in accordance with U.S. GAAP. See Note 5. Convertible Notes - On May 10, 2024, the Company entered into unsecured convertible promissory notes (the "May 2024 Notes") with existing investors: the Company's Chairman, Dr. Ray Prudo, and Interim President and Chief Executive Officer and director of the Company, Dr. Samir Patel, for an aggregate of $1.0 million in gross proceeds. The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Company's receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024.<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Company's ADSs on the issuance date, subject to certain restrictions. In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash. The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options ("ASC 470-20") and has not elected the fair value option as provided for within ASC Topics 815 and 825. Accordingly, the Company evaluated the embedded conversion and other features within the May 2024 Notes to determine whether any of the embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value. Based on management's evaluation, the Company determined that the May 2024 Notes were not issued at a substantial premium and none of the embedded features were required to be bifurcated and accounted for separately. Accordingly, the May 2024 Notes are accounted for as a single liability measured at its amortized cost. Issuance costs incurred in connection with the issuance of the May 2024 Notes were immaterial. Interest expense incurred on the May 2024 Notes was less than $0.1 million for the three and nine months ended September 30, 2024. As of September 30, 2024, accrued interest on the May 2024 Notes of less than $0.1 million is included within "Accrued expenses" in the Company's balance sheets. 1000000 The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Company's receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. 0.15 0.17 Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Company's ADSs on the issuance date, subject to certain restrictions. 1.59 125000 406236000 203118 750000 100000 100000 100000 Warrant Liability – The Company accounts for ordinary share or ADS warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and/or ASC Topic 815, Derivatives and Hedging ("ASC 815"), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at issuance and are remeasured each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are recorded in "change in fair value of warrant liability" in the Company's condensed consolidated statements of operations and comprehensive loss. Equity-classified warrants are recorded within "additional paid-in capital" in the Company's condensed consolidated statements of shareholders' (deficit) equity at the time of issuance and not subject to remeasurement. In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants ("Series A Warrants") to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants ("Series B Warrants") to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the "September 2022 Warrants").The Company determined that the September 2022 Warrants are not indexed to the Company's own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock. Accordingly, the Company classifies the September 2022 Warrants as derivative liabilities in its consolidated balance sheets. In September 2024, all outstanding Series A Warrants expired unexercised. 755000 17 755000 17 Other Current Liabilities – In February 2024, the Company entered into a short-term financing arrangement with a third-party vendor to finance insurance premiums. The aggregate amount financed under this agreement was $1.1 million, bearing interest at an annual rate of 7.49%. As of September 30, 2024, the balance of $0.2 million, which is included in "Other current liabilities" in the Company's balance sheets, is scheduled to be paid in monthly installments through November 2024. 1100000 0.0749 200000 monthly installments through November 2024. Research and development expenses – Costs associated with research and development are expensed as incurred unless there is an alternative future use in other research and development projects. Research and development expenses include, among other costs, salaries and personnel-related expenses, fees paid for contract research services, fees paid to clinical research organizations, costs incurred by outside laboratories, manufacturers and other accredited facilities in connection with clinical trials and preclinical studies. <p style="font-size:10pt;margin-top:12pt;font-family:Times New

Roman;margin-bottom:0;text-align:left;">Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Company's vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company's estimate, the Company will adjust the accrued or prepaid expense balance accordingly.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024 and 2023, the Company recognized research and development tax credits of approximately $1.3 million and $2.6 million, respectively.</p> 1300000 1300000 2600000 2600000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Merger-Related Costs - Merger-related costs include direct expenses incurred in connection with the proposed Merger, as more fully described in Note 3, and are comprised primarily of legal and professional fees and other incremental costs directly associated to the Merger. For the three and nine months ended September 30, 2024 merger-related costs totaled $1.0 million and $2.3 million, respectively.</p> 1000000 2300000 <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restructuring and Other Costs - In May 2024, the Company began to implement a reduction-in-force of approximately 67% of its total workforce as a result of the recently announced program prioritization under which the Company's HSCT-TMA program was suspended. The reduction-in-force was part of an operational restructuring plan (the "May 2024 Plan") which included the elimination of certain senior management positions and was completed in the third quarter of 2024. The purpose of the restructuring plan, including the reduction-in-force, was to reduce HSCT-TMA related operating costs, while supporting the execution of the Company's long-term strategic plan. During the three and nine months ended September 30, 2024, the Company has incurred restructuring-related charges of less than $0.1 million and $1.7 million related to the May 2024 Plan, respectively. Of the $1.7 million incurred during the nine months ended September 30, 2024, $1.4 million related to severance and other settlement payments to terminated executives and employees, and $0.3 million was non-cash expenses related to accelerated vesting of equity awards. The Company does not expect to incur additional restructuring-related expenses related to the May 2024 Plan.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, of the $1.7 million total restructuring-related charges incurred, approximately $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be paid in the fourth quarter of 2024.</p> 0.67 100000 1700000 1700000 1400000 300000 0 1700000 500000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Share-based compensation expense - The Company measures all share-based awards granted to employees, directors and non-employees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective awards. Forfeitures are accounted for as they occur. The Company classifies share-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which the award recipient's service payments are classified.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Company's ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Company's historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Company's options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.</p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Leases - The Company accounts for its leases in accordance with ASC 842, <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-

content;">Leases. In accordance with ASC 842, the Company records a right-of-use ("ROU") asset and corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet and are recognized on a straight-line basis over the lease term. As of September 30, 2024 and December 31, 2023, the Company did not have any leases with a term longer than twelve months. Accordingly, no ROU assets and corresponding lease liabilities are included in the Company's condensed consolidated balance sheets as of September 30, 2024 or December 31, 2023. Income taxes – In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and nine months ended September 30, 2024 and 2023, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. The Company has not recorded its net deferred tax asset as of either September 30, 2024 or December 31, 2023 because it maintained a full valuation allowance against all deferred tax assets as of these dates as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of September 30, 2024 and December 31, 2023, the Company had no uncertain tax positions. Net loss per share – Basic net loss per ordinary share is computed by dividing net loss available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, which includes ordinary shares underlying pre-funded warrants, as such warrant is exercisable, in whole or in part, for nominal cash consideration with no expiration date. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, unvested restricted stock units, and warrants, which would result in the issuance of incremental ordinary shares, unless their effect would be anti-dilutive. For each of the three and nine months ended September 30, 2024 and 2023, diluted net loss per ordinary share is the same as basic net loss per ordinary share as the effects of the Company's potentially dilutive securities were anti-dilutive. The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Stock options </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 507,014,688 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 680,112,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Restricted stock units </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 251,823,915 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 418,580,700 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 11,562,653,300 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,155,347,500 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Convertible notes </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 1,257,860,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 13,579,351,903 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,254,040,600 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.967%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.357%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr

style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Stock options </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 507,014,688 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 680,112,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Restricted stock units </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 251,823,915 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 418,580,700 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 11,562,653,300 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,155,347,500 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Convertible notes </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 1,257,860,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 13,579,351,903 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,254,040,600 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 507014688 680112400 251823915 418580700 11562653300 4155347500 1257860000 13579351903 5254040600 New

Accounting Pronouncements- From time to time, new accounting pronouncements are issued by the FASB and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any other recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company's present or future consolidated financial statements. Recently Issued (Not Yet Adopted) Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures. This ASU modified the disclosure and presentation requirements primarily through enhanced disclosures of significant segment expenses and clarified that single reportable segment entities must apply Topic 280 in its entirety. This guidance is effective for the Company for the year beginning January 1, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statement. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU improves the transparency of income tax disclosure by requiring consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. This guidance is effective for the Company for the year beginning January 1, 2025, with early adoption permitted. The amendments should be applied on a prospective basis, with retrospective application permitted. The Company is currently assessing the impact of this guidance on its consolidated financial statements and related disclosures. Note 3. Agreement and Plan of Merger Agreement and Plan of Merger On March 4, 2024, the Company entered into an Agreement and Plan of Merger with Peak Bio and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari ("Pegasus Merger Sub"), as amended by that certain side letter dated August 15, 2024 (the "Merger Agreement"), pursuant to which, on November 14, 2024, Pegasus Merger Sub merged with and into Peak Bio (the "Merger"), with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the "Effective Time"), each issued and outstanding share of Peak Bio common stock, par value $0.0001 per share (the "Peak Common Stock") (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Pegasus Merger Sub or any direct or indirect wholly owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement)), was converted into the right to receive the Company's ADSs representing a number of Akari ordinary shares, par value $0.0001 per share (the "Akari Ordinary Shares") equal to 0.2935 (the "Exchange Ratio"), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The Exchange Ratio was calculated in accordance with the terms of the Merger Agreement, such that the total number of shares of Akari ADSs issued in connection with the merger was approximately 48.4% of the outstanding shares of Akari ADSs on a fully diluted basis. The board of directors of each of Akari and Peak has unanimously approved the Merger Agreement and the transactions contemplated thereby. On November 14, 2024, the Company closed the business combination contemplated by the Merger Agreement, as more fully described in Note 10. 0.0001 0.0001 0.2935 0.484 Note 4. Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents information about the Company's financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> (In thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> Liabilities </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Warrant liability - Series B </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">725</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">725</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> (In thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"> Liabilities </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-

*align:top;padding-bottom:0in;"> Warrant liability - Series A </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant liability - Series B</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,238</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,253</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">— </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,253</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's Level 3 liabilities consist of the Series B Warrants as of September 30, 2024 and the Series A and Series B Warrants as of December 31, 2023, which were determined to be liability-classified instruments. There were no transfers between Level 1, Level 2, and Level 3 during the nine months ended September 30, 2024 and 2023.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the nine months ended September 30, 2024:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Warrant Liability</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(In thousands)</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Series A</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Series B</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance, December 31, 2023</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 15 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,238</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1,253 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Change in the fair value of liability </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(15 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (513 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (528 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Balance, September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.512%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series B </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series A </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series B </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Stock (ADS) price </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.95</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.12 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.12</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercise price</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected term (in years) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected volatility </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 80.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 85.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 95.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Risk-free interest rate </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.6 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.1 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.9 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected dividend yield </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> </table> The following table presents information about the Company's financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">(In thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> Liabilities </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Warrant liability - Series B </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">725</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Total liabilities </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt

double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="14" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> (In thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"> Liabilities </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Warrant liability - Series A </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant liability - Series B</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,238</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,238</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 1,253 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 1,253 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 725000 725000 725000 725000 15000 15000 1238000 1238000 1253000 1253000 The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the nine months ended September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Warrant Liability </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> (In thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series A </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series B </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Balance, December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1,238 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1,253 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Change in the fair value of liability </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">(15 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (513 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (528 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Balance, September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 725 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 15000 1238000 1253000 -15000 -513000 -528000 0 725000 725000 Below are the assumptions used for the fair value calculations of the Series B Warrants as of September 30, 2024, and Series A Warrants and Series B Warrants as of December 31, 2023: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.512%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series B </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Series A </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Series B </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Stock (ADS) price </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.95</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.12 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.12</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercise price</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected term (in years) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected volatility </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 80.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">85.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 95.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Risk-free interest rate </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.6 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.1 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.9 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expected dividend yield </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> </table> 2.95 3.12 3.12 17 17 17 5 0.7 5.7 80 85 95 3.6 5.1 3.9 Note 5. Accrued Expenses Accrued expenses consisted of the following as of September 30, 2024 and December 31, 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.813%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> December 31, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> ($ in thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td>

<td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Employee compensation and benefits </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">624</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 187 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> External research and development expenses </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 589 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 635 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Professional and consulting fees </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 861 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 669 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Restructuring </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 450 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Other </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 81 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 75 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total accrued expenses </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,605</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 1,566 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued restructuring expenses of approximately $0.5 million as of September 30, 2024 relate to one-time termination benefits payable to former employees, including an executive, which are payable in the fourth quarter of 2024. See Note 2.</p> <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued expenses consisted of the following as of September 30, 2024 and December 31, 2023: </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.813%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.843%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">($ in thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Employee compensation and benefits </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">624</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 187 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> External research and development expenses </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td>

<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 589 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 635 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Professional and consulting fees </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 861 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 669 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Restructuring </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 450 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Other </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 81 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 75 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total accrued expenses </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,605</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 1,566 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 624000 187000 589000 635000 861000 669000 450000 81000 75000 2605000 1566000 500000 Note 6. Shareholders' (Deficit) Equity Ordinary Shares On September 30, 2023, the Company's shareholders approved an increase to the number of authorized ordinary shares, par value $<span

style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001 (the "Ordinary Shares"), the Company can issue by 35,000,000,000 ordinary shares in addition to the number of shares outstanding on June 30, 2023. Accordingly, as of September 30, 2024 and December 31, 2023, the Company was authorized to issue up to 45,122,321,523 ordinary shares. Currently, each ADS represents 2,000 Ordinary Shares (the "ADS Ratio"). All ADS and per ADS amounts in the accompanying condensed consolidated financial statements reflect the ADS Ratio. May 2024 Private Placement In May 2024, the Company entered into a definitive purchase agreement with certain investors, Dr. Prudo and Dr. Patel, pursuant to which the Company sold and issued in a private placement an aggregate of 4,029,754 ADSs, and Series C Warrants (the "Series C Warrants") to purchase up to 4,029,754 ADS, at a per unit price of $1.885 per ADS and Series C Warrant for aggregate gross proceeds of approximately $7.6 million (the "May 2024 Private Placement"). The Series C Warrants have 3-year terms ranging from May 31, 2027 to June 21, 2027 and have cashless exercise provisions in limited circumstances. The Series C Warrants (other than those issued to Dr. Prudo and Dr. Patel) have an exercise price of $1.76 per ADS. The Series C Warrants issued to Dr. Prudo and Dr. Patel have an exercise price of $1.79 per ADS. Net proceeds from the May 2024 Private Placement were approximately $7.0 million after deducting placement agent fees and other expenses. At close of the May 2024 Private Placement, the Company issued to Paulson Investment Company, LLC ("Paulson"), as placement agent for the May 2024 Private Placement, warrants to purchase 332,380 ADSs at an exercise price of $1.885 per ADS and a term expiring on May 31, 2029 (the "May 2024 Placement Agent Warrants"). The estimated fair value of the May 2024 Placement Agent Warrants on the issuance date was approximately $0.4 million. The Company determined that the Series C Warrants and May 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the May 2024 Private Placement, each of the Series C Warrants and May 2024 Placement Agent Warrants were recorded as a component of additional paid-in capital. March 2024 Private Placement In March 2024, the Company entered into a definitive purchase agreement with certain existing investors, pursuant to which the Company sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million (the "March 2024 Private Placement"). Net proceeds from the March 2024 Private Placement were approximately $1.7 million after deducting placement agent fees and other expenses. At close of the March 2024 Private Placement, the Company issued to Paulson, as placement agent for the March 2024 Private Placement, warrants to purchase 132,061 ADSs at an exercise price of $1.85 per ADS (representing 125% of the purchase price per ADS sold in the March 2024 Private Placement) and a term expiring on March 27, 2029 (the "March 2024 Placement Agent Warrants"). The estimated fair value of the March 2024 Placement Agent Warrants on the issuance date was approximately $0.2 million. The Company determined that the March 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the March 2024 Private Placement, each of the March 2024 Placement Agent Warrants were recorded as a component of additional paid-in capital. December 2023 Private Placement In December 2023, the Company entered into purchase agreements to sell, in a private placement, to existing investors, Dr. Ray Prudo and Dr. Patel, (the "December 2023 Private

Placement") an aggregate of 947,868 ADSs at $2.11 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the December 2023 Private Placement were approximately $1.8 million after deducting placement agent fees and other expenses. September 2023 Private Placement In September 2023, the Company entered into purchase agreements to sell in a private placement to existing investors and directors, including Dr. Prudo and Ms. Rachelle Jacques, the Company's then President and Chief Executive Officer (the "September 2023 Private Placement") an aggregate of 551,816 ADSs at $3.30 per ADS, and pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 48,387 ADSs at a purchase price per Pre-Funded Warrant of $3.10, for aggregate gross proceeds of approximately $2.0 million. The Pre-Funded Warrants are exercisable at an exercise price of $0.20 per ADS and will not expire until exercised in full. The September 2023 Private Placement closed in October 2023 resulting in net proceeds of approximately $1.7 million after deducting placement agent fees and other expenses. At close of the September 2023 Private Placement, the Company issued to Paulson, as placement agent for the September 2023 Private Placement, warrants to purchase 42,550 ADSs at an exercise price of $4.13 per ADS (representing 125% of the purchase price per ADS sold in the September 2023 Private Placement) and a term expiring on October 6, 2028 (the "October 2023 Placement Agent Warrants"). The estimated fair value of the October 2023 Placement Agent Warrants on the issuance date was approximately $0.1 million. The Company determined that the Pre-Funded Warrants and October 2023 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the September 2023 Private Placement, each of the Pre-Funded Warrants and October 2023 Placement Agent Warrants were recorded as a component of additional paid-in capital. March 2023 Registered Direct Offering On March 31, 2023, the Company entered into securities purchase agreements with certain accredited and institutional investors, including Dr. Prudo (the "March Registered Direct Offering") providing for the issuance of an aggregate of 1,333,333 ADSs in a registered direct offering at $3.00 per ADS, resulting in gross proceeds of approximately $4.0 million. Net proceeds from the March Registered Direct Offering were approximately $3.5 million after deducting placement agent fees and expenses. Warrants In connection with various financing transactions, the Company has issued warrants to purchase the Company's ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement. See Note 2 for further details on accounting policies related to the Company's warrants. The following table summarizes the Company's outstanding warrants as of September 30, 2024 and December 31, 2023: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:41.4%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.88%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.88%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.56%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.56%;box-sizing:content-box;"></td><td style="width:14.24%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td><td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Warrant ADSs </td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td><td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td><td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> December 31, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Weighted-Average </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #fffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise Price </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"> Equity-classified Warrants </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> 2019 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> - </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 59,211 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">7/1/2024</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2019 Placement Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,881</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 57.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 6/28/2024 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> 2020 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 139,882 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 139,882 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Feb-Mar 2025</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2020 Placement Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,481</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,481</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 51.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Feb-Mar 2025 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> July 2021 Placement Agent Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 19,919 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 19,919 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46.40</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">7/7/2026</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 2021 Investor Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">107,775</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">107,775</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 33.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 1/4/2027 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> December 2021 Placement Agent
  Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 8,622 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 8,622 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 35.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 12/29/2026 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-

*top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> March 2022 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 186,020 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 186,020 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">3/10/2027</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">March 2022 Placement Agent Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,882</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,882</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 30.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 3/10/2027 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> October 2023 Investor Prefunded
  Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 48,387 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 48,387 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.20 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> None </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> October 2023 Placement Agent Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td>*

<td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 42,550 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 42,550 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.13</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">10/6/2028</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">March 2024 Placement Agent Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">132,061</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1.85 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 3/27/2029 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> May 2024 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,029,754 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1.77 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> May-Jun 2027 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> May 2024 Placement Agent Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 322,380 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.89</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5/31/2029</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,074,713</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">658,610</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability-classified Warrants</p></td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">September 2022 Series A Investor
  Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">755,000</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 9/14/2024 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> September 2022 Series B Investor
  Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 755,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 755,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 9/14/2029 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 755,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 1,510,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total outstanding </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,829,713 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 2,168,610 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:center;"> </td> </tr> </table>   The following table summarizes the Company's warrants activity for the nine months ended September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.799999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;">   </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Number of </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;">   </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;">   </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Weighted-Average </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;">   </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;">   </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">   </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Warrant ADSs </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;">   </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise Price </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 2,168,610 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 21.97 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Issued </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,484,195 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1.78 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Exercised </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expired </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (823,092 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 20.52 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,829,713 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 6.65 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Capital Redemption Reserve In December 2020, for the purpose of changing the nominal value of the Company's ordinary shares from £0.01 to $0.0001 the Company issued 3,847,331,913 deferred shares (the "Deferred Shares") of $0.01315. The Deferred Shares were created for technical reasons of company law and did not increase the aggregate value of share capital. Also in December 2020, the Deferred Shares were purchased by the Company in accordance with their terms of issue for aggregate consideration of $0.01 and immediately cancelled. The aggregate nominal value at cancellation was $50.6 million. Amounts transferred from share capital on the redemption of the Deferred Shares of $50.6 million, along with the resulting foreign currency effect of the redenomination of Company ordinary shares of $1.6 million, are classified as "capital redemption reserve" within the Company's condensed consolidated balance sheets and condensed statements of shareholders' (deficit) equity. 0.0001 350000000000 45122321523 45122321523 2000 4029754 4029754 1.885 7600000 P3Y 1.76 1.79 7000000 332380 1.885 2029-05-31 400000 1320614 1.48 2000000 1700000 132061 1.85 1.25 200000 947868 2.11 2000000 1800000 551816 3.3 48387 3.1 2000000 0.2 1700000 42550 4.13 1.25 2028-10-06 100000 1333333 3 4000000 3500000 The following table summarizes the Company's outstanding warrants as of September 30, 2024 and December 31, 2023: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.4%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.56%;box-sizing:content-box;"></td> <td style="width:14.24%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Warrant ADSs </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> December 31, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Weighted-Average </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise Price </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Expiration Date </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"> Equity-classified Warrants </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:center;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> 2019 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> - </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 59,211 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td>

<td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">7/1/2024</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2019 Placement Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,881</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 57.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 6/28/2024 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> 2020 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 139,882 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 139,882 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Feb-Mar 2025</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2020 Placement Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,481</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,481</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">51.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Feb-Mar 2025 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> July 2021 Placement Agent Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 19,919 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 19,919 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46.40</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">7/7/2026</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 2021 Investor Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">107,775</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">107,775</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 33.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 1/4/2027 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> December 2021 Placement Agent
  Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 8,622 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 8,622 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 35.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">12/29/2026 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> March 2022 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 186,020 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> 186,020 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">3/10/2027</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">March 2022 Placement Agent Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,882</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,882</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 30.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 3/10/2027 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> October 2023 Investor Prefunded
  Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 48,387 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 48,387 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.20 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> None </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> October 2023 Placement Agent Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 42,550 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 42,550 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.13</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">10/6/2028</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">March 2024 Placement Agent Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">132,061</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1.85 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 3/27/2029 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> May 2024 Investor Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,029,754 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1.77 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> May-Jun 2027 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> May 2024 Placement Agent Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 322,380 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.89</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">5/31/2029</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,074,713</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">658,610</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability-classified Warrants</p></td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">September 2022 Series A Investor
  Warrants</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">755,000</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">17.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> 9/14/2024 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> September 2022 Series B Investor
  Warrants </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 755,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 755,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 1,510,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Total outstanding </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,829,713 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 2,168,610 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-

top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> </tr> </table> The following table summarizes the Company's warrants activity for the nine months ended September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.88%;box-sizing:content-box;"></td> <td style="width:1.8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.799999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Number of </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> Weighted-Average </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Warrant ADSs </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise Price </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 2,168,610 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 21.97 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Issued </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 4,484,195 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 1.78 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Exercised </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-

color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expired </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (823,092 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 20.52 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 5,829,713 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 6.65 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 0 59211 60 0 8881 57 139882 139882 44 22481 22481 51 19919 19919 46.4 107775 107775 33 8622 8622 35 186020 186020 28 14882 14882 30 48387 48387 0.2 42550 42550 4.13 132061 1.85 4029754 1.77 322380 1.89 5074713 6586100 755000 17 755000 755000 17 755000 1510000 5829713 2168610 2168610 21.97 4484195 1.78 823092 20.52 5829713 6.65 0.01 0.0001 3847331913 0.01315 0.01 50600000 50600000 1600000 Note 7. Share-Based Compensation 2023 Equity Incentive Plan On June 30, 2023, the Company’s shareholders approved the 2023 Equity Incentive Plan (the “2023 Plan”), which provides for the grant of stock options, both incentive stock options and nonqualified stock options, stock, with and without vesting restrictions, restricted stock units (“RSUs”) and stock appreciation rights, to be granted to employees, directors and consultants. The Company is permitted to issue up to 980,000,000 ordinary shares under the 2023 Plan, plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Equity Incentive Plan (the “2014 Plan”), to the extent such awards are forfeited, cancelled, or expire unexercised. As of September 30, 2024, the Company had 498,903,915 ordinary shares underlying outstanding equity awards under the 2023 Plan, consisting of stock options and RSUs, and 569,501,522 ordinary shares remained available for future grants under the 2023 Plan. The 2023 and 2014 Plans provide that they be administered by the compensation committee of the board of directors. The exercise price for stock option awards may not be less than 100% of the fair market value of the Company’s ordinary shares on the date of grant and the term of awards may not be greater than ten years. The Company determines the fair value of its ordinary shares based on the quoted market price of its ADSs. Vesting periods are determined at the discretion of the compensation committee. Awards granted to employees typically vest over two to four years and directors over one year. 2014 Equity Incentive Plan Under the 2014 Plan the Company was authorized to grant stock options, RSUs and other awards, to employees, members of the board of directors and consultants. Upon effectiveness of the 2023 Plan no further awards were available to be issued under the 2014 Plan. As of September 30, 2024, the Company had 259,934,688 ordinary shares underlying outstanding equity awards under the 2014 Plan, consisting of stock options. Stock Options The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the nine months ended September 30, 2024: <span style="white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.287%;box-sizing:content-box;"></td> <td style="width:1.112%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.541%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.539%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.051%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.939%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> ($ in thousands, except share and per share data) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Stock
Options </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise
Price </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average
Remaining
Contractual Life
(in years) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic
Value </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 651,237,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.5</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Granted </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 205,080,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Exercised </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Forfeited </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> (304,302,712 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.01 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expired </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (45,000,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 0.02 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at September 30, 2024 (1) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 507,014,688 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 2 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Exercisable at September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 425,181,355 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.0</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> _____ (1) Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.   The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s ordinary shares for those options that had exercise prices lower than the fair value of the Company’s ordinary shares. The weighted-average grant-date fair value per ordinary share of options granted during each of the nine months ended September 30, 2024 and 2023 was less than $0.01. <span style="color:#000000;white-space:pre-wrap;font-

weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option Valuation The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Expected volatility </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 82.6 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 99.2 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Risk-free interest rate </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.8 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Expected dividend yield </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Expected term (in years) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 5.1 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 6.0 </td> <td

*style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> </table> Restricted Stock Units The 2014 Plan provided, and the 2023 Plan provides, for the award of RSUs. RSUs are granted to employees that are subject to time-based vesting conditions that lapse between one year and four years from date of grant, assuming continued employment. Compensation cost for time-based RSUs, which vest only on continued service, is recognized on a straight-line basis over the requisite service period based on the grant date fair of the RSUs, which is derived from the closing price of the Company's AD5s on the date of grant. The following table summarizes the Company's RSU activity for the nine months ended September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.64%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> Time-based Awards </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> ($ in thousands, except per share data) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Shares </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average
Grant Date
Fair Value </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Nonvested shares at December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 385,954,925 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Granted </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 731,393,807 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Forfeited </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> (<span style="color:#000000;white-space:pre-*

wrap;min-width:fit-content;">482,249,417 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Vested </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (383,275,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Nonvested shares at September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 251,823,915 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The fair value of time-based RSUs that vested during the nine months ended September 30, 2024 and 2023 was approximately $0.5 million and $0.2 million, respectively. Share-Based Compensation Expense The Company classifies share-based compensation expense in the statement of operations in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> Three Months Ended </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> Nine Months Ended </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> September 30, </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> ($ in thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Research and development </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 42 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 105 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> General and administrative </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 221 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 263 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-

align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 621 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 741 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Restructuring and other costs </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> – </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 285 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Total share-based compensation expense </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 305 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">989</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 846 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> During the nine months ended September 30, 2024, 276,000,000 ordinary shares underlying unvested time-based RSUs held by a former executive upon termination of employment were accelerated, resulting in additional stock-based compensation expense of $0.3

million. As of September 30, 2024, total unrecognized compensation cost related to unvested stock options and time-based RSUs was $0.2 million and $0.2 million, respectively, The Company expects total unrecognized compensation costs related to unvested stock options and RSUs to be recognized over a weighted average period of 1.7 and 1.8 years, respectively.
980000000 855637300 498903915 569501522 1 P10Y P4Y P1Y 259934688 The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the nine months ended September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.287%;box-sizing:content-box;"></td> <td style="width:1.112%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.541%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.539%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.051%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.178%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.939%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> ($ in thousands, except share and per share data) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Stock
Options </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-
Average
Exercise
Price </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average
Remaining
Contractual Life
(in years) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate
Intrinsic
Value </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 651,237,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8.5</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Granted </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 205,080,000 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Exercised </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Forfeited </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> (304,302,712 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.01 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Expired </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (45,000,000 </td> <td style="padding-top:0in;white-

space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 0.02 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Outstanding at September 30, 2024 (1) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 507,014,688 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 2 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Exercisable at September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 425,181,355 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.01</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.0</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> </table> _____ (1) Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.   651237400 0.01 P8Y6M 205080000 0 304302712 0.01 45000000 0.02 507014688 0.01 P6Y4M24D 2 425181355 0.01 P6Y 0.01 0.01 The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.343%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Expected volatility </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 82.6 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 99.2 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Risk-free interest rate </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.7 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 3.8 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Expected dividend yield </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Expected term (in years) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">5.1 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 6.0 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> </table> 0.826 0.992 0.037 0.038 P5Y1M6D P6Y P1Y P4Y The following table summarizes the Company's RSU activity for the nine months ended September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.64%;box-sizing:content-box;"></td> <td style="width:1.42%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"> </td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> Time-based Awards </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> ($ in thousands, except per share data) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Number of Shares </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average
Grant Date
Fair Value </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Nonvested shares at December 31, 2023 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 385,954,925 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Granted </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 731,393,807 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Forfeited </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> (482,249,417 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> <span style="min-width:fit-

content;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Vested </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> (383,275,400 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 0.00 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"> Nonvested shares at September 30, 2024 </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 251,823,915 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.00</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="margin-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> 385954925 0 731393807 0 482249417 0 383275400 0 251823915 0 500000 200000 Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, was as follows:<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands) </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:center;">2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"> </td> <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Research and development </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 42 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 105 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> General and administrative </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 221 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 263 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 621 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"> 741 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Restructuring and other costs </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> 285 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> Total share-based compensation expense </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 305 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"> </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"> $</p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">989</p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"> 846 </td> <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 27000 42000 83000 105000 221000 263000 621000 741000 285000 248000 305000 989000 846000 276000000 300000 200000 200000 P1Y8M12D P1Y9M18D Note 8. Related Party Transactions The Doctors Laboratory The Company leases office space for its U.K. headquarters in London from The Doctors Laboratory (“TDL”) and has incurred expenses of less than $0.1 million plus Value Added Tax (“VAT”) during each of the three months ended September 30, 2024 and 2023, and approximately $0.1 million plus VAT during each of the nine months ended September 30, 2024 and 2024. David Byrne, a former non-employee director of the Company, is the Chief Executive Officer of TDL and Dr. Prudo is the non-Executive Chairman of the Board of Directors of TDL. The Company received certain laboratory testing services for its clinical trials and other administrative services provided by TDL and incurred expenses of less than $0.1 million during each of the three months ended September 30, 2024 and 2023 and less than $0.1 million and approximately $0.1 million during each of the nine months ended September 30, 2024 and 2023, respectively. The Company recorded payable balances owed to TDL of less than $0.1<span style="color:#000000;white-space:pre-

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of September 30, 2024 and December 31, 2023. Interim CEO Agreement On May 31, 2024, the Company and Dr. Patel entered into an Interim Chief Executive Officer Agreement, effective as of May 1, 2024 (the "Interim CEO Agreement"). Pursuant to the Interim CEO Agreement, Dr. Patel serves as the Company's Interim President and Chief Executive Officer as an independent contractor on an at-will basis. The Interim CEO Agreement can be terminated by the Company immediately for any reason. As the sole compensation for services provided under the Interim CEO Agreement, Dr. Patel was to be paid $50,000 per month in the form of fully vested ordinary shares. On September 16, 2024, the Company entered into an amendment to the Interim CEO Agreement (the "Amendment"), effective July 1, 2024, to revise Dr. Patel's compensation in connection with the services as Interim President and Chief Executive Officer. Pursuant to the Amendment, in lieu of receiving the stated monthly compensation of $50,000 in the form of fully vested ordinary shares, Dr. Patel shall be paid in the form of fully vested non-qualified stock options to purchase ordinary shares ("NQSO"), with the number of ADSs underlying each such monthly NQSOs grant to be equal to two times the number determined by dividing (i) $50,000 by (ii) the closing price of the Company's ADSs on the Nasdaq Capital Market on the last day of each month (or partial month) Dr. Patel serves as the Company's Interim President and Chief Executive Officer. During the three and nine months ended September 30, 2024, the Company recognized approximately $0.1 million and $0.3 million, respectively, in non-cash share-based compensation costs pursuant to the Interim CEO Agreement, as amended, pertaining to (i) NQSOs granted to Dr. Patel to purchase 87,540,000 ordinary shares at an exercise price of less than $0.01 per ordinary share with a grant date fair value of approximately $0.2 million, and (ii) 91,396,000 fully vested ordinary shares granted to Dr. Patel. 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000 50000 50000 Dr. Patel shall be paid in the form of fully vested non-qualified stock options to purchase ordinary shares ("NQSO"), with the number of ADSs underlying each such monthly NQSOs grant to be equal to two times the number determined by dividing (i) $50,000 by (ii) the closing price of the Company's ADSs on the Nasdaq Capital Market on the last day of each month (or partial month) 50000 100000 300000 87540000 87540000 0.01 0.01 200000 200000 91396000 91396000 Note 9, Commitments and Contingencies Leases The Company is currently party to a short-term lease for its U.S headquarters, which currently expires in May 2025, and a short-term lease with TDL for its London offices, which currently expires in July 2025. The Company is not party to any material lease agreements. For each of the three months ended September 30, 2024 and 2023, the Company incurred lease costs of less than $0.1 million. For each of the nine months ended September 30, 2024 and 2023, the Company incurred leases costs of approximately $0.2 million. Employee Benefit Plans The Company adopted an employee benefit plan under Section 401(k) of the Internal Revenue Code for its U.S.-based employees. The plan allows employees to make contributions up to a specified percentage of their compensation. Under the plan, the Company matches 100% of employees' contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations. The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law. During each of the three months ended September 30, 2024 and 2023, the Company charged less than $0.1 million to operating expenses related to the Company's contributions to employee benefit plans. During the nine months ended September 30, 2024 and 2023, the Company charged $0.1 million and $0.2 million, respectively, to operating expenses related to the Company's contributions to employee benefit plans. 100000 100000 200000 200000 Under the plan, the Company matches 100% of employees' contributions up to 5% of the annual eligible compensation contributed by each

employee, subject to Internal Revenue Code limitations. 0.05 The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law. 0.10 100000 100000 100000 200000 Note 10. Subsequent Events Conversion of May 2024 Notes In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and all accrued interest into Company ADSs, resulting in the issuance of an aggregate of 406,236,000 ordinary shares represented by 203,118 ADSs. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash. November Private Placement On November 13, 2024, the Company entered into a securities purchase agreement with certain investors, including Akari's Chairman, Dr. Ray Prudo, and a director and Interim President and Chief Executive Officer of the Company, Dr. Samir R. Patel, pursuant to which the Company agreed to sell and issue in a private placement (the "November Private Placement") an aggregate of 1,713,402 unregistered Akari ADSs, each representing 2,000 of Akari Ordinary Shares, and Series D Warrants (the "Series D Warrants") to purchase up to 1,713,402 ADSs, at a per unit price of (i) $1.70 per ADS and Series D Warrant for all investors other than Drs. Patel and Prudo, and (ii) $2.385, which is equal to the consolidated closing bid price of the ADSs on The Nasdaq Stock Market on November 12, 2024 plus $0.125 for Drs. Patel and Prudo, for aggregate gross proceeds of $3.2 million. The November Private Placement is expected to close shortly following the closing of the Merger, subject to the satisfaction of customary closing conditions.   The Series D Warrants have a term of three years from the closing date of the November Private Placement and have cashless exercise provisions. The Series D Warrants have an exercise price of $2.26 per ADS, which is equal to the Nasdaq official closing price of Akari's ADSs on the Nasdaq Capital Market on November 12, 2024. The Series D Warrants issued to Dr. Patel and Dr. Prudo are immediately exercisable and the warrants issued to each of the other investors will be exercisable six months after issuance.   Akari paid Paulson and Chardan Capital Markets, LLC ("Chardan") (i) with respect to Paulson, a cash fee equal to 7.0% (or 3.5% for any investor that is a director or affiliate of Akari), and (ii) with respect to Chardan, a cash fee equal to 3.5%, in each case of the aggregate purchase price for the ADSs and Warrants sold in the November Private Placement. Merger with Peak Bio On November 14, 2024, the Company completed the previously announced strategic combination contemplated by the Merger Agreement, pursuant to which, Merger Sub merged with and into Peak Bio, with Peak Bio surviving the Merger as a wholly owned subsidiary of Akari. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the Effective Time, each issued and outstanding share of Peak Common Stock (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Merger Sub or any direct or indirect wholly-owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement), was converted into the right to receive Akari ADSs representing a number of Akari Ordinary Shares equal to 0.2935 (the "Exchange Ratio"), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The Exchange Ratio was calculated in accordance with the terms of the Merger Agreement and is such that the total number of shares of Akari ADSs issued in connection with the Merger is approximately 48.4% of the outstanding shares of Akari on a fully diluted basis. At the Effective Time, each warrant to purchase capital stock of Peak Bio ("Peak Warrant") that was outstanding immediately prior to the Effective Time was converted into and exchangeable for warrants to purchase a number of Akari Ordinary

Shares or Akari ADSs, as determined by Akari (each, an "Adjusted Warrant"), on substantially similar terms and subject to substantially similar conditions as were applicable to such Peak Warrant immediately prior to the Effective Time, except (i) for terms rendered inoperative by reason of the transactions contemplated by the Merger Agreement, (ii) as provided in the following sentence and (iii) such amendments to the terms of the Adjusted Warrants as are necessary to comply with applicable Law (as defined in the Merger Agreement). The number of Akari Ordinary Shares (or the number of Akari Ordinary Shares underlying Akari ADSs, as applicable) subject to each Adjusted Warrant is equal to the number of shares of Peak Common Stock issuable upon exercise of such Peak Warrant immediately prior to the Effective Time multiplied by the Exchange Ratio, with any fractional Akari Ordinary Shares or Akari ADSs rounded down to the nearest whole Akari Ordinary Share or Akari ADS, as applicable, and the exercise price with respect to each Akari Ordinary Share (or each Akari Ordinary Share underlying Akari ADSs, as applicable) underlying such Adjusted Warrant equal to the exercise price of such Peak Warrant immediately prior to the Effective Time divided by the Exchange Ratio. At the Effective Time, each option to acquire shares of Peak Common Stock ("Peak Option") that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, was assumed and converted into an option to purchase a number of Akari ordinary shares or Akari ADSs, as determined by Akari (each, an "Adjusted Option"). The number of Akari Ordinary Shares (or the number of Akari Ordinary Shares underlying Akari ADSs, as applicable) subject to the Adjusted Option is equal to the product of (i) the total number of shares of Peak Common Stock subject to such Peak Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, with any fractional Akari Ordinary Shares or Akari ADSs rounded down to the nearest whole Akari Ordinary Share or Akari ADS, as applicable, and the exercise price per share of each Adjusted Option equal to the exercise price of such Peak Option immediately prior to the Effective Time divided by the Exchange Ratio. The issuance of Akari Ordinary Shares, which are represented by Akari ADSs, in connection with the Merger were registered under the Securities Act, pursuant to a registration statement on Form S-4 (File No. 333-282127) filed by Akari with the SEC and declared effective on October 11, 2024. The parties to the Merger Agreement have agreed that the November Private Placement satisfies the conditions set forth in Sections 7.2(e) and 7.3(e) of the Merger Agreement. Authorized Shares On November 7, 2024, the Company's shareholders approved certain proposals such that the Company's directors or any duly authorized committee of the directors be generally and unconditionally authorized to (i) allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of $14,444,680 in connection with the Merger for a period expiring (unless previously renewed, varied or revoked by resolution of Akari) at the conclusion of Akari's annual general meeting in 2025, and (ii) allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of $5,546,667 for a period expiring (unless otherwise renewed, varied or revoked by the Company at a general meeting) on November 6, 2029. 2023 Equity Incentive Plan On November 7, 2024, the Company's shareholders approved an increase in the number of shares available for the grant of awards under the 2023 Plan by 7,800,000,000 Ordinary Shares to an aggregate of 8,780,000,000 Ordinary Shares, plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Plan, to the extent such awards are forfeited, cancelled, or expire unexercised. 125000 406236000 203118 750000 1713402 2000 1713402 1.7 2.385 0.125 3200000 P3Y 2.26 0.07 0.035 0.035 0.2935 0.484 14444680 5546667 7800000000 8780000000 855637300 false false false false

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|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

M^;JB.C>K%1C&(=0U'XSDHQ$YW $R&NS*H\6:$488+GV$UQ&F6H<|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{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{K}{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{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

MV 3!AZI8'9R\".D#!\L8!6QJ;V-/"/_P.9)'R,,. (H/R8#N5G-1=3QV'^X M:X'\&S-UT__;6TIE<|-MTQ]YV<$A'WSN#,[B-2#R]$B@3'X]BZ+/(\^F=BR,4U7G_!'Y:+969!*GO]I) M!_LCC1YC9_WDNTXPX(E4R5ARGF7VCO^?O3=KCATW\D>_"L/WQKWM"+5]SNGV M3/?|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{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|. MD<^\6;=2MFR^=,TWXF+W@B%)%?K]P M(8K6X+^C14P&&3R%D8D%)A|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{H6O0H%C.YI5 >2|+?@*/',,_UN!R7+'G= MWW5"GE_L2],G=@K0JN#K&P0-+*+.PF S^<)8 !I0 $(U0$,5DV) AX\XH5+2 MAIDC>&?3A8=?>$'V/DUD.7U=4-0SQV6?8NAG-,A<=%9]A@/V: (8:7Z0("^+ MDQECSN=BF9X*RZVP)P[_ZHS!Z7F*?1"!6IL@/QA4VH0H,Z26"8Q(!6D F;68M92E M?0DJ*\-$&+!Q_U_'1RM\,WG$^ 1$Z2?9%.1-:\HL4!KO4?(2> ,K]PD8 MDWR|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{(%Q,.- %,9P$?VF6!9 M?= #)C>L4*I*+JU!D4Y? GH#BS@3]H^^$/!.29>5XS,L>%F/;3P9;(6&@R:,A M:=G=\M.LA&I+LL61WQ=6J>V1ADKXO2#UX6O3A[%-33<_;-6G?074EWUE'L"? M'"G8B"5X@M3MT/2+)OGSZ\GF0T@\#.&Q4)QIV3V@8G*YU!19P13+"K MJ*CT&:2X*4VC:(?L5#HPF.^$\IYD[--G0F<)!W]@\W&^8S/Z(];F+!47$#R"G#4%5U2>4O2(4 7Y7G-!*CWE<$.)\9>[A/U(H M?YXAW=@2\&=VT.KIW7&WV_"=EZ?W<9\T"SQGQ2ZF-+^8*B%)*:A$6(&"?[_ M?0>'X(\4W0"B[{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|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|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|'5*I^>24OK/')O5=SO3?>*0@KT& M<<>'N2RK,.->"6/]NYLX0\[/DSO#1B0OE-,U"WYZ/9^&)\L4R2@W<80VVS!^ M1VC8DUV6T%)\AE@0^8=FN_HG);SDJB6Z9IQ,[UPOYRW1=.'EZCP(H05;X%"R MF$DHT)YOM=[_AAS0<;S^> G)ISMXEHF59&/78^D.W'8U_><=O'"Z<> F6Z=-MJ?D@J[K-=WR4\Z'JA]^EI$HBJX4(UW*$,JJ%Y2F3SO>./\]>N<=/G6 5>"X6 M=N70,%"E1;BA8\)D6(,_]Q^TLHOM&;:\"-JH2MWMFP+%64)(.F5]$MR>.]MQ?^7/.1",,#HJ,#E2T0O]_B$YJQ.7.9^[U@I*E=.2U;Q*9FQ 4)AV*;I-T3AW^#2)9] M);.D-K)P$)3C"9&+;O+D-VX1(KF(F$!NUNP+3%N^P@N#$X=EGAP#?W2*PBHI M-"$6=B8?>@:HW2({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|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|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|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|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

*M]6>;]OO."DY+G\\|7]V6I(DUVMQ**6)Z%JZ#3N35-XFU_Y%/PRJL=C[%UC)+ MRWHELJZ)T4?"OFX,JQNACN)*

=C%EE8YFQ5)T)'M;B"K,~98SYSVI:@PWAUT-MWGWO2U!E*YR"6Q9NJB'W8*.9\DCXUXUC.A;1HV%A;S3OA1D=NLI*

*ML"*LXY#>C=!N4#\V9G6^#C3.XJC,LU*HZ3"LQ45R%!M-6V[)1=:H8?%9C!?" M)N9T$%D-KJ))6&7;/NJH?W5U3!T%#[7/HIZC:PKT(.ME?;>7IM*5-*

@6WK-MA MW4ZICM_N2#99QVMR&G"J/;T?FYR21\&FH>K[!YMZV!.^F 4"3;\W]+]:5?P9 M98'GYN$O^Y'R<; QR(*A$2_/,B&S]8E/[A8E!!2J/4!.3

M]R_DMY-3ZV$/&5=INM,G@;6V9_KJ$EU:76RY'?K9J;6.VH<;7(^#]5-]%,,] MT3C'!@9VL_W2\G0L@+>

*MVHNW398EP=.N@TBYAYA]MBV*X%BCFPW^EA!P&2V]DIQ_@.[%=$0^ M^5=(3[O_SUU*H@.TR.W(QG&GF8#"'! (C*SUG+SE*U-K=3J%"*

*(UF=Q2D)!6.11 M6[)C>S^3NFQUS_$=U$*43D]C9.&9%%)(04"YC;FIXON)[P\Z'[8[6OC?WL_@ M,7]!5!K1B1'4<_P;Y3E7-#>84),BK(=!Q/TY>D%AO(79,?*

*XJ MS]-<^A:(\%;Q(&MI,O..'_FVG<2SKSQ4ZA[F,I!0&((+%45X*B$^*0M_$T2D MZ B41&@^8)J=C1%WZ08),7L(EO-OR$UW^)6TC.X V#?!\S]UTR]*

(^"^5]%C ME" WA)?^5S>(&G;C2(,;8P['4,U9;4'\#D19XE.R_;)55[5M_>U8;&)LW# ,CY% ZU

*MIYBWO*U9;4.IF38I$^I.UJS#>1#N,N5Q4+6V[V'1]4%ACH1_8 'SC)FX>,'S M6C/4SN6J9K5L.B'=QK"-5+:+=/U,74>QT>*

]0W=Y@B3U^9#MK+;IN/AOE4;CK M6HR1)?:W& Z.+>S@[U09&\%;SX29FF;]LJQORKCV5&<2FT;>SF0MM%>=R3; MS<#]HVU%G"2,P;8

RSXWBD0L'C:3>@K%!OOGJ&S[F;(M0FLP-G$N%Z24=?B M>B3)V!U.J,8^/8HHHU[G=2Q;^%%PN-?![F)0/PHN=CG:%1O\<23;]CO(';P$*

*M1Y%#VO=]4G-#' 6W.AQ*A=?C*_)&>QW--E_+47!NP ;+W3F3)/_9QJA>6ZQ] M=QUVQF2'W=71535)[J1M>VXX^]3N+\;*

*40OW!3,#M0SSC&FCUO+;9Z:-9C%E MC!VU N ^,I;1O,Z,O8B<5Q,,;)VC_0J(M*ME%M?0>W?CS2CG+;K:@E- M5>IXT?*

*#$[\7I^E$X+#%$6RJQ5O0RG1I'W,Q5N79G,<;-XA4$5;2MC:D@7]# MM)RP*G"ETL[\QL&*:?>B?SI]S9/&"M VTT ;F9NL9CB710%;"D3?QIW?W,>L*

MS>9XN?$(G>+L:I"(0MNT"OYBUJ,ZO0U6 B7;2X0UGR'M,K:M'SD3]->7<7*/DI? ZW6NZF-84VFK<>D4C6U;)Q$YH_=" MJ08Q>%_QB-?T(59<1-S/@*

*C" SY2+L,GQD]]C[S6,*U$1-XAZEI%C#!*]!WR MXG5$1E;>@//.PLZ]):>PSP93C&0;V41L559P\>HF_M=$G1G6;RP;#AB+-GB(M'|RW?P39,SP-*

*\/Q!#G19^2$C&E;EX4#CR0VCO]=0 JQ_LVA[JHNV%C'65,!] M\L]:F:G?/<_C%*UP'W4ZS51?VY_DV[TT.O[Z^4?3LJZ'V>+7SW^QQ(>A-E)K*

M0@2/ZK384M4F/EGVY%%HAM^).P;+0(CXU&J\5B'O\Q7@D.2F=+,[E M(UBVYQ[Z71+;KZ4#6%D@MUOSC IUM/W'"ECLN

*MUK1K2>U^E",IB:;O#$A\-$>1H3%H5]6\04<1/ZT/OT/7=3$?!N.$23.(0.8[(M>NTMI_*%'0671!EZ@UVV)D(>JR;W?]W%!'Y(VQ;E4OC**

*+RAU\K#5[!HXC. M[WSZN5L7CR(8OXLYI*MWP!D,N$ZW"=KB)YX<,W_(2.;"]W9;O(_@G+DAEU_7]!=M M1U2KZ\@+Q6J;.L*

LPMQDAW\+=F*M'4Q&9PZCJSL,=!'1&XG=3:_N_6UV'H7 MJ\[X5;2*DPU5+[L?HE?', $P3-$^(P4#P<%C>W]S :^=TKCL2A11ZVFW+KOH*.*

*5DDO2@&M5UMO MTQIL9-7@?O>4>DFPI49VKFO)_)%2RL.!WX]OB"LS:,)G:,GU=%OZF%N3^7G MDWHQ(_\?;I*X>!L(\0S+Y"QT R4,4+)]^PJ*

M=,N6'K;=,1-<+!*:<>Q$?8-,4$_1CY*L%S"6DOP O)'+H!O0S=2L6"TX:CUQNLWT-C42#>,$-M!MHYT M^GH]S6^D ZQBJUC,9>)C<9Z\$];+"D-*

ZCK9QC&F14<-z>SV3^5&@T7:6;6]+_"@&'83;?JF_TG0W/;,>YI>A2D0V_;4G).?KX#IJ,MY]C'8Z&3RR_GV\>CH8_7,6??

QZNAFU\S9]S'HT';RYKS[./AT-G7 MF_/NXP4QS'N<6WP_'A-Z?NJ<81]O!@VG>,ZMCZ="#X][SKU1WPT65E'IN=ND M\0"<9Q\O!_T0@IQI'\^&

7$).1=G>#W8GQCX0% +<\9^I 4."Z*\]YZ1OPNA M<<#!4!EV=(\Q++V!U#Y3&8[(*C0&6XPQL7R)$[Q0("X@JUF2!-YO(]PM4;SQ03";HHXMKU_-

*W46D/.%NEE7N6$?M=?#]] /=!8E]> M&[9*_C*Z Q'!3,4W<93P?Y)8;ZW+?H(/F6=:,PEDSH]1_)2BY 6F?A5AB0F^=3(R41R%9O%.&C67'+=&*

*],B(Q^\HU,7>C![U MR!Z%BJG+ZH&R8+Y\"(L*Y.RC[G,@97*$MU"M<$M'\T7K '8]1WZ8_!X_D\$NKW>SC MR?^H>2.7'-*8+K+L-+ K77A9\,+%?*

0<1TG=@JYC"EESQZB:^_'?0\'EH[3\ MW@P:\!&KF%5:./AMNMAESU@V_@QYC_CP)PO)$;P]/WB^25>D*+:,)/#0G1NM*

*MA^^PX1^V@*F/T0M*L00A$:N!AW\B)@#Q&09;>Q6%X&2>P6SINN7ZC6L",B\TV MC-\1ND?)"UXO^.0 IP(O#$F7?G*

M%$5H%33'!8\QH@5L.&="!D]5YLGNR(NHUE_L5JA4"G+_8N!'Q6W,;=>-!C M2#ONT([%UP9+EJ-X-/5F:@_Y=\3/G]X,[2CIC@+EL3IEP1;

*M^A(XW:5!A-+T'&5N$,ZK :MB_F3SPU]'5QG;5.M.Z?0P6(4 TEJ1ST/<%YZW MV^S(>X_Y^!5WM4;'<8E*DTP@"/^K(;_XU=B*_F&-D\HJ"M(J.7J,HA<+-*

[=,)]ZFV]YG+$MJS"VR,[<)'G'DH/$2"I(U^L[=@)L+0+D M#N'_T'P-:6)K8X?1:YQLL-S%M$O"L=AG_8?X\JN [!S7D4W;NJ[O\._<"?9 M]*

*>.;*XL"+Y^L(/<(P5^Z?4Q*RVV$%O*&-BM=_/H]X!?Z;Z6(36\ T:J&5% M!0Y8C@YZT';U/OP;JA4?M^_IX0KZJ'X6_7 M0YRRR!+9,+&BZ1F3_OPEAY3M-*

*J%U\%*9370Z6D?6:?O#_BS$GM M:@./Z7B*_JCV=/L\Z%.)0_)>F,1T'F=NN(>&X8&XPLRN;,*\/-Q@0);Z"L_A M#5PM5VFZRWU7+89-K:*

*[F+"$MLVLT;FIV'MFV5MU7C7X =6-S%IQAQP@+_9W: M?#/*V!,OF-+^*6]H;*'RK-XBC[W14JAN_V$BK^*#CI&Q<59Z*8IOGF0+V6Q*

M3@^#60:2;/O[Q\;]TMS'H$9U>-"FA=8+ MMO1,&>ZN[2.XEM M+X?4)]OHE6< M;)A->0]- K;IC+4'=SP'C8&,O5 YY< MBC5($!A-U&AT'#UK>

V)#UAZGP<)\K+E"LMR+/34IJ26'G-&@S::KVT/8^^= M]SY!POOP';][2M'O.SRGBQ<6"= @>52M;9I^\SE5MC=K2=UYV0[.(CAD&PE0

MM1[Y]'YSW0>XX?G>)>ZD?_PBGGU?AGO$OBB6L)HI/I D.DPF]Z;$61?S=] MIY-+3>7]:/SA?_('R\'[IGY]^^NE3E8/X]V%8[L9*

*M"/E&3T*YS0=,D%*F-W)1WM;HU_,P$]202%LN4_E[74T M XU1[" 7_JNGJ)&&)G-5/83\E(;)E-08U5.IH8F4IC5H MZ&)$>*F)C+)+S:_%E&-*

*XQ\T\&7S]"*W86ESRIGK-G)DJ40MCG9(@!\#[]) M\55WB5RL/.NMB,XX]#PFD M5=)(2(-2>>XXB,%G[I:5R.+GJ.WJ-NIAC PN^EC9#.74JZV.3Q=?*

F?!Z/=LE MB1K+0]'8X%L Z_)TXYY3BP=Y^-$-?8->R9_4#P,MSE.@9=>_2GY#Y"F/#51- MO^\HHWO(4ZRQ>X#1>8Y>4!C37&?WC0+@26?=VL?81N(?

*V?QYBF(:2:],LN M2$EHDUC03[&9.@PP_D(4%C_,6>%;(%P@!N]F|_:\>HVIM-)+\)@ /DQ0*9 MBJ98LI&&M\.">H;/Q5HI%:1-1UZR(F1.8V(Z/;;*

*<4NP;C]'6#?S6'5)N/;K] M#5_Q;N0AO ^7V3,6<2C+0B2\^.3"4J/;V F*_&A@A0MB4^@M3\X.9M)#_ LB*

*M0*K+%0U#)86'Y=FFO0:R(_"V1SRE&'W;.4[Q4!,,*I$ ZDC&4NQR4\S@H7-*_M/])00$1NCO@[\#2?@9 7FK#NAPT(UQ+M5RH6H(ZL._2SV1*1EQ]*

(G2"Y@]Y6 M;75;;B;|\^PI]C&$K-4,81'QZ&^2;>'?,.U1CK6\IIE2N2A;Z0/(."[@8 [M6;T.E7|:5]3J?I,&]AZTW!IH->D=)'O0]!

*<]SJZ\AN7!8JET/Y6UF.4CWT&- MQ[(M7/HH4%-:PZPESH:2789SZ4\'=SD.4"X:7#A3[*K]X%;C893&RA]^^]MIS:.3<&R0]MZ++>!L>HO'[NKQ7!8VEFC*

MLNL =E9C$A#CV:]];+$6DV)IBXW*K@/88DT)6HQE_ZQPUJ#/DI[,%2&'=P> M:\Z?8RS\Z6//Z7IH KFO8\?*/.DFU$V#9+S[<>/L-

*IQ=K81+;I+\9_/C45+E9GOF->?= MJ(^2?>===GU1OI[I/>))(-N%X6>>B(E<(;.\&8Q68)KL4X0V4IXLL0J_,6;;1S!H=&!=)7V,5?=N5R;1GQT>5M;J@)\%*KI*

M2H("!V;9^%CC3=ZIN4_&"UM]U'-)?OU6Q U5W,I_?VCFLOJ>TN. M_J_7QQQ^.@3^"T8"676 YK8&D<_(N_S63;)WW7)[S7U&WBFWR/WM-(C5HK'<

MX.4CPVE?#J>^IKVKW/LBTX&:\9L-G%$9#4^#,N$AAT12"-NL5;)>8V>MLF$ MQJHRZAX3R .!>\URH=[P $O-J0X;O"/AS+0)4'G#L4L:TJN:G^6+-*

-^\9!.0= M/#OQCB_IM[))=NI_Q+5'FC9#RQ;8:>&I.6?Y&J$D?0ZV5Q$\ M@@PA?'B.0Q^W::XI,.;PEB56-AD\1 > PJQPZ- #'VAZ.EQJM#GE1E:Y&>+

*M(2W;\//*EH6#QJGXP,^KN2MT+10E8 "Y'>#098R6#2&7-15]I*\WT@>NH.VX M@M9LE6X&#0C(@(85XM#W6X;-*

*HAPTTRBR#IU;C09K*6"$_#%RZ'S2TYX5)]JF# MAE#]!3Y]F*SHIP8IS','S:GN=UP/V^%!<[",_%N\8QI?A(<*,;;-)=U+8#[M,9-AU)=ND!"#R3?*

DPK])5/Y>ADOGE)R^YS_^-4)) 2^7T,Z8(.[6K.S,?>Z M=)GJ.VT,7NLVANF 474M/WGYC?=-->!^Q2$_S]!;!?=.(KM M#W^5_YK[Z>Z]IGIGG7.A?

*-6DWFJXIS$Z5[GW-1223C1E"QYD)3$\^D?0)*M M%T @@P!)-U6Q#1+\V&SV.XB=8@\IH9U@'3\/X] MC?*

=YAGY.8A_U\OKB0I6_QCQ@)_[:N82"-7E:%_,3(1BGA`'^S(VBY/50?M@.P-@)B<)Q^0LD;^^'@']Y'DR:E]@%9'1$68O'5Z=-IEU MWU2[{(WQ1CO,

*G+;8>,J(CG5:^J.X>6]=6F24ZP^48FSAZQG@S3'Z+BIFQM M9H.PC 6"'CE-IQ8>A)N%6X7*CAXY+^H;1TQB4_C4HX(LO1O3)HATGS\ZS""SB/H;@TG,|*

*;*T>4N MG9:M6436C7I:*]6&\6XFM2Z>YM%_ 4&.[WY<^5GXBJ9^&Y=LYDC+3L;<++$:.MUL5JK,E6^I\<#2W$=/-:-*

XEUF#/+#R#X%//3E3Q(4L9)0IZEV#G"'?Y=YZ"83 ML(E5]'((X$G+$$LZN6WZD:+,7R2Y;NFX6"W,2'+6TMB'Z+'@2M0_#_.PC+> M[1RTUAQ-7W^V1-

=97,W26J&<]=-">\A6QW([XM]IC(/9E;JYK(^:!'Y9:'@ MCC G9[N;+')V>I7M-9R-SR)[I-]Y&?"'[6_IU9L%])9Z]*S#R;Z]SU^8YN7# ML$Q:18J/%BI%*

(;]>QX']GHH5.I-V9)KI4P]"FP0>FUUZD9!'8I'GN-FJQ#B MMEC<%D:F6'T:?"THAC]=(PZ5>7% @KZ.VY]P+L9.\7I8,TD

*MKM\!],.TN)B9F^LETM/AGEL<0&,X@+3L)+ HZ) =^7N"Y1HL!TKM M:GK?Q<-$!8O4*)3GG)UNUDSH(4R_WT" U RD8($T>_ RN:EQ'F#-)*M:=QL*

*MZ9?Y2'2T0_E0*_M_)"TC[EA^ M&.GNYNG8=0^]I.[K?^;18?.6;%Z2/$7+C_;DY@V]\U#\NXY!O[=5]A'6+(&-_M;DO!K?X_IV'B)WB-*

*ZZW#R#+8;R.BYLJQ7>\P%.L62S-[E>5B[.*X]R+-@C, MY!5 .2;.[*MY$$44MQ".&/8,.U3BQ>TM;=#2K'[8Y2>WSH8SABR_>.XDS&7R MTO?*

4<1L.]A+!H-[;)ZT(31V\L4^=^3JEM;NX)HO>GG5 M,P0L$9O'-M] =^YDKXH^@^#8=IRIWQQ]!FC]AB0=MTEWP#,9.[#R?9B# ,^V M. 7I8[[;>?"

]XVOG#V,36.=O0#(W+Z, MF?1T,DU@PO.0FH!@UJ8'=?%PCZ&-PNCNA1R0YCP+.+SZ_)I>?15S$(.2X*

M1\HLXID'P=9WA(T7TNP:G"9I!DWWE/F"78(X7A 9'B$<7*B[_IZ&9L.-L2T\.8& MH[+;F],G8K)=P#;(,.8[(Y* .6&=?5VLY'$/O<$V@MUM6-

*B[BJPHYJL#!SL M S@Y4Z:D<6I#E.SE7K/0G@6/U3IR')BG3F$R)X2LNC?U$D&#U!8I MECAUZM-W/GS66V3>*J<>J6GPDD1HFND58OA^F!6A!U-*

4"1^SQ/!^<2#Q',7GO,?^6AD'HP<.C=QP:1]ECMU<[A11FM>&C3Z>AHP]?-YA&UMO;. A? MPR#W(LJ0V>W,#A77FR?,!>_OX3{37*-*

*:U<3%>RJ8P3C<*S/YOTBZ/C9)3$93<'Z5WGVDL#P/R!@38#3 M0W6H:+H/(;CT]F'F13=Y"S^?,G>Z)S6BL=U#P%^/@CZ"XJPFBH>T16\AWF0*

MX/@M>(\V>1O0>$:NIXA$]@.IAE5>16S^' M& Z+H(""^_ &_>Z>\',4JC$19(04,L/\L10Z24._I*D6](_5?TF2P,:\F'*

*M/L6\WE4_DT1TKD[[:5R.P^3V35,%GW YK16/BVK9JB1,0FNT\0GT4CS.V_@5 MI*AQ_W(R6FIC2#)GDBVGT3U,? ""] 8F.\Q D+P/3D5:F=8V;B?*

*5&Z:B_=4S M^D=_1N*U5STV 'WLMGI&\V_KA_^"6Q]68Z&.NR!CU(\HPHO/ENBM+*S M<*F'G;/9X0KQ4 8Q"W?7DMC7U7^JPJ?*

>S;$IMD4UJ7IW.RJ5/D;>N MMDA(N0)![F MDW8^88RP!%$[''F';7\G\R6G5\&_\C3#.]E76>#W,<>[O0.YN(D@VIODX_ M%L?*

*F==%A/BINN\%QB724S4/0[^FV$MVB8@)'0'XTJ4-]+!Z=.4="GOD)L%'0DU'[>%P M9SY2UPR+-U/?N8XOO?0E FE**I5Q9R7Q&,4SJ8[J9OC%*

*RBC;Q&^2ZQBL=FA\ MOA=?@7V2AEG5C#=EAL9GVCY9>,(>0_"*BX;*2&NJ59+55K62K(S9+G I[/14 M)QFMW0ACX*QO3,);)6#S*

M"69;C6;KX_(6+R6FE;T7'QY709KB4YD^5-E'V:7H'4ARY!JASOU:(K.G MZKLGO/=PE^\J.CCA=^WY+W\D\'LA(M$61+2K1E+Z/8GR'?*

@#8#X&@M4K@.AK M\[I:UQTX-%"]=S7!R8O$%@Z!SVNN6K>3Z[PIBKY QXS1LP ^WCC-;=2;AL@LUF7 MV:]R;6(CQ&932-*

U7$A!/_EENBI!/SZI"Q,M\F73ZC+X.N MVHT2R6N3IRZ11++[EC#E)[:-ND]UY\?A]%II:?-1+C\(RW M(T5)99I-?*

1,.34EKW##$S8$VFCFMO28^&F"\@CTP>,%407K)(HN-76XN,F(M#4&?E_HW\4-C4%6%4_5T3E[B3,A+Z\Y"9I]DI(6T,ZH*'9%CYG-.&CE)6QC'*

*M(#3URP+E![1"";DZ(+.(XTL?CZ)IQ_/"38COT],/9W&)B*097U()FOJMD-HY M6STC;A;WL/3RML&)[CK@LY#)]6;$4QPE#2->R*6_J*

MM]H.X/B\D@Q3ATN,R8L4AYC%)5LR_(I5J6(60$DHW72W[]0ODCY+,F5HV].^ MIDU8U^XK:C(GM,0LJ]P2*[. 2U+ XL1 C7*)NWG"ZI$8!E?

&T7)YHFW4)K,Y M:15YIDYC0]4=>B14B=9?IXJ6\,$H7BI)!V1.[T)&N:99X#3L;&R38PG5WV:[M"Z4+;>E

S#KBMRC#)>)CFN87C*CRG;;X6C^MA5IZK M@}[VW4QLDPH4PJO@FH7AIY^N>DKM56A-6_$4ETFXU?PJL&:N)4@7%JQP4ZHK MN"SZ#JQ96.&H5(5PC_ZDRA]643U331F1/#_/+<)8P3G9$'9)'&5*/5;8339(M5@R[\XI+5B#.7&WH*659H;3H#*SBFA5",U<31$M^5G#-7$^0JCU:839S=4&\ ML&D%V,Q]"D+U52NL%EU L(AK%2T[}10(0>FK6T:V FAQ!@PH;%N!MW@'Q(OE M5!@MHKQ$P=X*M$6R/[MF< 7EH(@)H+5!{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|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|_#]13FA);$UHW2S9TG8)AS1%>$\]P9YI&8HAQ$5P6YKTO5!.)V*K33L6;9,OY\1%C93@M[60&71,>6&&\-E\Z,&1-(0=W+P>2J:1 O^'Y^3U M1Q_GB8KCJPU=A9 MU*F1D$"DF.+4G;/JY9$>S6?FU-CG0!JR&+. 5!FA]E&F6K\OOKO5JBS1A6:XX=/ [%'V!:^T!PQC))SX (G /&,QG*A/](L]+G3'/9$EV H#QAU M*%0/= F$ZW=$OTE97IV<)W<) ^A5)T$F$AO9,JC !9G:(R%PP1H'1R9I) M8+#+[T]% T=QH?\+9A-7F50IJ1=TX:4X@/#4@)/BKN55JF^#;8_Q'B: (8V4' M'!B9H2'AVIH;!VL0G)7O@]SQ&.8EQRJ>ZX]1/(I28*W,(K08!%7]N+G\%L$ MBI^$Z9_S"- V+^H<'<56K]

H5AR<1|V99!@_\KKTV,=%.IJ[<2XIC3! MSE.>G'E3X9E,"!UL.=O H^39YNKG[O91<@" >&J+]>1:[]CM%;/|/SR(KT M MJ8G<%XT.&1!01R?
2PV#0,25C[O&II_0BKX]!FWO\BJ28$!TT5^!;G\6=UM9- MZU^OI' T^#%.;YN5;C%#ELSQWM"B! \81Q#B&;/T0N2\04M\)RD^MVW&2\SB
MQ=4)9$A)GY5K1(NHG,S:J*7%EG8-6.?CPI M)VS .F94URYM6N+VIAFW=X,I#\DDKS@"-_/B9TSGJS0%67IQ^.+]*X&$17),
M63)/L'&:IR'BVX>YUA_9\QKNN:M7F1 ZVU\Q*_A0_C\DG%(E]W>KBEP5XG7 M8QK3,$]8CUX$T*F)Y2),I^MMK1X&=U8"'94GVC[C? H(@JL0 C]:,[<
EQ]B M6Q%[>AC-P!Z4>]TAY_I\"LJ_I>#?..YI^UKZX7FWYC%:VS1\/MTSVI[L_!?/L MB*AJN9\5=<4BC\^#6*T5,YXOWF'SEFQ>DCSUXF#SAC
[W"0YQ&]D,Q^!7G96 MJ!BY$(CWSB\STOC=]+%/SCN1T[]>4,F@4^#_\)R_IB&?C%>]$<-R=#_^G^_ M_OKK3VT$C]^;BSGW,GQ>*C)BCVB ;W]
M%*5C\V?MXTL"LPV .VS\ZQ/;J&WM&3I_,1BMW1Z^>0+2DP/C M!M&GCYBW]PPN@(?9R$WX3D@;0,1<'A!O%SE[!9YBQW3Q_V*2'&EH,AW9!R!(
MB^B?AH# 4A0Y/8Q-_[_]-L:'%)80[KT#R4?BK &G@R63J!,UD7V"$_$+38K[M ,7'!'[S52$,U%_+'+%@)TN6HD;FA$36V^(;'%YV
SPD%HFMB,AS)OR:8SW M,/0!2V 1[V]TBJ?1E$/$QT[V3K!^3<_@;38?8E'"%V1=L^[B/
M^HXN7@]CTZA8W_4[ODF"Q4C:K8P/%QV9.+BHN,.!!3BCL4&;@]B%=PP#A%!G
M'96WNV\EWQ!^6@4QLX8_]"G*0P=2)+'[N*+G%7@%45*DC'OO15E"ZJA[^Q@C MI*KLXF6R^Q;&Q64E?G']2XAO@B&9W9=)RE0U)1Z@?
B%.MAR$;.U=F+G@&-V[M'"OOZ^U]4@PGO8["'1XE$2$1W90B&F/-E#W>#NO8)=H7STRN0&VJ>,E.0;," M Q/IH9.DRG<\Q7LO#'HII-E:N?$*'?%>[-
$A^0^HD>0945*6ZGQT9FE0#?5 M6>K5UD "%PXR*DYYLG<02)OD=T *UZZW15 YN=2-GE<_Z$%NIA'.M8B84(+A M@-
CK>F*"=)"O(XCQ$@['A$U$!Q&082$^PPI%K MB$0).PI%WSU'S1!>1R?9.A0ID;YDOJ= 6\?G.3"3KE$(KQG:.S4@<[C@2D ; MZDL5X?!V)R 0/NBYD-1S?
D*,U\,XD%&IJB\U0Z*0.CDSO\H7%"JA# M-(/(9IBT4@[;=*0#DK^X13EE(I#-2&@E#KK=2 <,+@);S9#HI-"&8 M'7#\S7H*X>42VHR(JO.%&HZ@
Y!?'2,1?J.F#H1 ^LQ8AT6Q0+88!^R.X!N?5 M;D'*?HN;1#JJ%H3LM[&(9[-J VK!0[[50/1_&$M\-@K%@],5-;"D^7"<7\BM!;GB/VRL4Q.M1:(!6*
MU2=N:P'0?IF9GC^M!0Q[Y6.AG'(MF-@K#/?FL6O!PUY!6#Q_7@LP]DK&YZ3K MNWBMV^H9 K+BB ;P9V"]_0+0OH C7N3&&D)G?1H5,'H[F:M-BH-
@J(-[6XW M?EOS19O+&RZ3W3Z)22ZJ0.%F:A]C4VF-AEQ_F-[6EAL)^@K'+_?]"#*:-0R0 ML P/A3[/KG5,;;?<))-]_8+.).Y-,HW?
EYMDG+M)IM0Y[5V8'40OXN#W4;R% M[X'W_2),V'NWV6"YYV82]]R@DWF7Q&2;(C);P\(+3ZIB5%9'U@X7Z&E>VG+Y
MB@SJYN=>E,'N8=LTAO,]75=G8/96HVD^'^PVG.]OWNO^ #X0%KU8@/-01.VB"E^NM L@>_D5 KK#+KMQC]"7#9CHY$; MCE/78H0PU#,VRA0*
RG8'N>8:FV&3L/N&3/W>K0R.<(PC%!1;+0*+])KSY7% M70PGO?%"2+3H+\##GTD0\9EAHV=[=X^#^AQZW\((X8 MM61\P3I^ 'X.<43X
MA9>&Z5.GDE?-285*VO,N865S@;7A"L\M>8!^SB MG:\B*J@2?:U5O38 M24I[NZ8@$@!*[6&>^ A_2\G._YD;KL?KH?S.35K5X&YP!;6=.4B1P=
[F*>;B4&,V-Y"H%?Y:[,QA]C0_+=K0!'EON^ M>T@&R-P!BPO4_K.* M_/'Q#E#O[U;[JN([(\P>^FH!VE3/^B;:A>U,=[H7/3@&)IUHSZ_?1?0)#CJZ)6?
A:^HBG=QB71':=N35C.FF#\/SD:7)BAQ7JM MR=_=*GTLNZS@4\R;K+D#%8J3$7B"74[X)8[ ),%)*4.52D>/=-M:G/0XAX:I/)2LT%]>_:.(A-
VLO$W7H]HY3BPEH@3=BR MK"$MEK W&8/5"NV=`1EZ^H06]R:\QV:77N3G47'B'3KA&OS+PX()C(^,@/\0Q+ZE'&)MH>R2]]R5P.E@SB>MW)-Z'
M:7$S(#?F7Z2G-=/JN8J#V=RJ"0PD+ETEK=VTRK9Q(N3Z>X+%%"RO29$\O>]B M-:6"12KLR+.53C=K)O00IM]O(#57;P/7B8W-K49$:#?
U2;,\2)PI["X6\ZT&"C?BNQ=? MR^)K,Z>@!5Y!4@(4ZUK\=_C4X"Z)8#9']&PRKY9LB5L8/\&5^"UC,-A6>&ENUL%_YC.2P;T
M_\RCP^8MV;PD>8I00R2|>4/O/!3_KF/0[Z*2?80U2V"CKT=PA5R ?^Y%&P1F\@J@',]B]M4\YB*D M47A'#'N&^[Y"S8H$U;FH1=;VV@:|>",'>2-'),
[IN"_E;,;<<(=8YS 8KI[/VGPUW$SGN-Y-4EW5@ M\A,=<5)_,$8]/D+ +'MW-[7R]AT,,]HX%N[J^)^>N! M&H,J"?X2Z0@UZREOI[1Z.&O?
E6'ZC=N"97BJS4JYL.(YX!1I7K';PYUM!DE MY.ME#74P^AFCU6@(6;0$C^,Z+!P,'<&#E^N@$A W,AX$MLU0_LL\OES4D$B@ M\4L2H05(K]!+_3
K["96ZDJEG?8Q2_SO?-_M_%L:!J$'#X_><6@-(K(.#G9^"?>;Y!HGF=#O"AWRA&E/S[S.L\3>VA)[6^-!=]X._4GJ M_WL^.=MXLQ'H:&Q2]S!\18K0?
>3Y1%WE&CD8C4=E 9=)CNW+>P]F!XPF@Q=3 MFXTZT >PSZ'_XJ5@]0P!P:L]*";7$N\|O2F99[F/&2)R/,!"F+U,=OLD)CE% M'%&%V\?85%JCX;
(I>EO%D9QK&(0Q%NBPZL)TZ:V,WV"$18N/@\^=+]N[BM#8O M3]1/!Q%9HM->,;3W$&"(0-"?-L5JJGA$5_>YD&"&"/Z"Z$0L4?$;JIX1_@
M.4QQ0$MPA0C+S];,+:C?0-H=6$\/@V2(R(C4F0^NB FZ"-LI]N\=>./>[B/8 M>0KU/24) ;7\($\,M5ZJ,..O%/F&% 5!G\FRL99\Z%.F4724R2J;I@_^JG-:
M*QX7U5)6B9-DH6CC$^BE>)RW\2M(4>/^Y62TU+.;91BZ+:.S\'B8^_$%Z Y,= MWGU(X@2G2B9,ZQVWD^H-4]''^ZAE?7]$O8/#:JQX;@#YZB?
>,YM^HU[C>KA_^M"6Q]68Z&.NR!CU(\HPHO/ENBM+*SDH6'?>1(/T(\E$',PMVUG$J7HJ=2NZ'B MT5RG6;C#2N6IE-R6OI%H0Y3H;9I,N&Z)9AN[F#
(LG#^%;56&,3<[VC6I;4W] MESILZOTLFU);9),.5Z>S<[TA2(B^]* +!-MQ;%BOV5#*9>_Q%-M*@W=,I^/W]SN6H#?
Y)YT2>,$98@:H5UTV%Z*:KZ8*U9X'<$\A4XR M;2YBQ>WB8'0=Y\A@/LCPK=YGV> EN?<@$M"PF3X@*]/#N$1ZJN9AZ-<4A^9> M(F)"1P
N*KV!'E:/KKSR2LA-@H^$FH[:P^',?*2N&19OIKYS'5]ZZ4L$TI34 M$.#.2N(QBF=2'=7-F(<'L$?_(LZ%\%W'8+5#X_,]^ KLDS3,JF:T*9WU/-7V MR<(3]P
"4%3C+>/>]59)5EO53B: Y$ (2N=%8>2F>IAH[488"T\6$NRDV@?[M_ S!,V):=PE,_HG*,LKH&,4B)6^H@CU-VQ>H=B21OPV1@2^,)@P S >
[MIXLG%%MLD%X#-)YAM-9JMC\M;O)285O9> M?'A 52'X;D0&B$3O=KBJLM3>N_A+M]5='#"[]KS M7_Y(X/="1*(MB&A7C;3T>Q+E._ 'P'P,!*M7 -
'7Y#C!61+HF=C[V^=1/,^! MND3#(ZPPS%YV(O]09I=(FT)CP11#QH']-5BX#0-B)VJ,D:P-5X!4 M_C)SF^]X@0AKCYT:*%ZZFN'DQ.(+!D4#G]=O7"""?7
M/<5H.6\\G]Q61%7R!SQFC)@!]O'&:VZEW#9 9G.W& 0WJY5>_8&20VIS1O: M:@_,+-D&
(,QL5)OAX%CD)+]FRVC,228&.@,%B(4K1F!+O$$J8K.\61EJBU4CT"8]]+QJ;.3)/&\6_F)CL]U>*K8D0:D4@BMADN(/P5-)FQ<,#(=4>0XQ7@ M,@/=I
ZGOJ)##9U00/BS&A(Y5LTU&'"S0AT%85 5BR/;YJ6B6@V(G!3'2E.E M:("-]]J"-3>X\',G'44@S.*:QTQ8>;NVGSIAFKC(L?49#,,RNTB0KG3CB,B
M;GH7S+R>!AY"#)2>V6WS+32ZW!#R$K[-*(W+2.KICHZCTLM,!B?W3P,8";[2 MJ1E@_5-VKR;;&G>9CCT\ ]>]0;'T1#C&R)E(J8!A!"?
8%6CL/E:,QV;"MVC M93,*NN6+,524$;$05E'Z*HI, PF(A;(0$Y7DB7MYG&HA(J*>=XD$Z$/B;130A7;IH
M&H#TD02CQ)&.R?]J$37(E$O2@<5OKF#1K+*DQ3=@8]B!:'DF+8#8Y#W24?E) M"VC66E-;D++1_L$N1:4% NM47(&:5U] L%%WZ:F7I04'
MF^1UL6);6F"P25"5KNBE!1$;Q=6!1<"T.*)M%&&%*H5I0<,Z^?7L.F1:8+). M8AU4S$P+_#:)L0JJHVG!R"8!MJ?*FI;Y6R>]TBNZ;9F[30*K;
4Y+4#8)+%* M%:G3@H9-@]MX;3LM4-@DL0H5S],2^&2C7-I?>T\+%-8)I>SB?EKF;YVT*5U(M4 LL-DF:4F4'M:!AG4PI7-10"QS6B9AG5DS4
I)ULJC&PHM: +1)AJ457]0R M;9M$U?Z:CUH@L$Y$'51<4DM,KDUR:W^U2BT0V"2OBM6[%(/AOWYLH8#>^+WV M,^77!DC@/0-QK;!T
X6WM[&L7[#WZR^[$],_ICYKTG<;([_$@P.?E+ M",GCLP+]]JU_+D,G:S*I97X$,;8'T3U;=>M)9+Y'K34Z=[+K"I1'/*C*1 MHH-
=D^#Y@K%FW\=GMU4^#5KV--@]K'V%2X->A:4Z"W M55QLNIU]]_&G#[^)7_Y<:VUZGU)JV]&W9[VADD&GP/_A.7G],0W]8KSHC],P MT8>O__?
KK[_^U!K5Z?LQRH?7#FWJ7:"WN_>?\I?AMZ/P. M(Z_LY1#[QBQL+]Y9R_IVDOY9"]QNJ&>%9:_%^DVQFI78O?B-P&<>JB^HZ3" M0NSHX#4W?
78X>%VB\''^\2>9X_S86C^Q\;&:ZYX9/_,(IRU/\AR!*%^RF^C M\IES\7O%SRB!7AK'*8NK<%_E!P/T7]#7'V4.?WX772.4/[Q$.BH>[=K/$O38
M6BGEHHXRID&_"K!]] 1JG<;N),YZWIASDUV=X0_305^=8=PD.1Q$?(C#FBP&KBO#6+4>/5Y-LQ)AW*88Q?G''\;/_SV(;-0>0XP6!O>B" MZV5R'
%%QA@SF?TC)D0,U4%/'B;'"WT.WBIZ$1@QOT$,_3%?GN/E"\6@$'$5 M.E[*4!Z(\>EBQ$P&43FKQ\WI>B%#21C&)XDQBQ@*7GE\EJO6]9J%"C R0$36
M">I#O<>NES 40T?(%SVI-*''?+?SX.&8L'ZT"J_\+'S%Y<4-)PV1D5]XB#KP M"$&
<>@59H4$^$W*],)R;E+7V5F\>##H:6COUX/P'FTNU.%73[YM%RIH&+U=) MW?/-031T>>^2N*A46&R0VSC-8%Y4<#S9@HO,;-64)?/])*G=/
M'7*SS91V(BFQVXFN'^&%4P+Q^GT?PN):ZO& K+]4<2!AJY)(T]I;S89NS7G0 M(T:
<09&K/W3PK=XCCILL^/"!M[L[&]*I3HYM^'35"0*.Q{]HPG<4*=)JZ)